Infection and early vascular disease in childhood. by Charakida, M.
REFERENCE ONLY
UNIVERSITY OF LONDON THESIS
Degree ^  i \  O  Year 0 ^ 0  0  G> Name of Author
C M A r ^ / V ^  i O / \
COPYRIGHT ^
This is a thesis accepted  for a Higher Degree of the University of London. It is an 
unpublished typescript and the copyright is held by the author. All persons consulting 
the thesis must read and abide by the Copyright Declaration below.
COPYRIGHT DECLARATION
I recognise that the copyright of the above-described thesis rests with the author and 
that no quotation from it or information derived from it may be published without the 
prior written consent of the author.
LOANS
T heses may not be lent to individuals, but the Senate H ouse Library may lend a copy 
to approved libraries within the United Kingdom, for consultation solely on the 
premises of those libraries. Application should be m ade to: Inter-Library Loans, 
Senate House Library, S en ate  H ouse, Malet Street, London WC1E 7HU.
REPRODUCTION
University of London th e se s  may not be reproduced without explicit written 
permission from the S en a te  H ouse Library. Enquiries should be addressed to the 
T heses Section of the Library. Regulations concerning reproduction vary according 
to the date of accep tan ce of the thesis and are listed below as guidelines.
A. Before 1962. Permission granted only upon the prior written consent of the 
author. (The S en ate  H ouse Library will provide ad d resses where possible).
B. 1962 - 1974. In many c a se s  the author has agreed to permit copying upon 
completion of a Copyright Declaration.
C. 1975 - 1988. Most th e se s  may be copied upon completion of a Copyright 
Declaration.
D. 1989 onwards. Most th eses  may be copied.
This thesis comes within category D.
I I This copy has been  deposited in the Library of  L v C
j j This copy has been  deposited in the Senate H ouse Library, Senate House,
Malet Street, London WC1E 7HU.
C:\Documents and Settings\lproctor\Loca! Settings\Temporary Internet Files\OLK8\Copyright - thesis (2).doc

Infection and early vascular disease 
in childhood
Thesis presented for the degree of Doctor o f Philosophy 
in the Faculty of Medicine, University o f London 
Marietta Charakida
Vascular Physiology Unit, Institute o f  Child Health 
University College London 
34 Great Ormond Street, London 
WC1N 3JE, UK 
T e l:+44 20 7813 8223  
F a x :+44 20 7813 8532  
Email: m.charakida@ich.ucl.ac.uk
UMI Number: U591669
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U591669
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
ABSTRACT
Endothelial dysfunction and inflammation are thought to be key events in the 
initiation and progression of atherosclerosis. Infection is one of the most common 
inflammatory stimuli. This thesis sought to evaluate methods for clinical assessment 
o f vascular dysfunction in the young and explored the impact of infection and its 
modifiers on pre-clinical arterial disease.
The reproducibility of three non-invasive methods known to measure nitric oxide 
mediated endothelial function was assessed in children and young adults. O f the three 
methods FMD appeared the most reproducible in our hands especially in children. In 
addition both FMD and pulse wave analysis following salbutamol inhalation were 
sensitive to detect acute endothelial changes induced by an extrinsic inflammatory 
stimulus, typhoid v accination. T he i mpact o f a cute c ommon i nfections a nd c hronic 
HIV infection on endothelial function and structure was assessed. Acute infections 
resulted in endothelial dysfunction, which subsequently recovered to normal. In 
contrast, chronic HIV infection in children was associated with more pronounced 
long-term functional and structural arterial changes. These abnormalities were more 
evident in children receiving antiretroviral treatment and those with a history of more 
advanced H IV d isease. Host m odulators o f t he v ascular r esponse t o i nfection w ere 
studied by investigating the role of mannose binding lectin (MBL). Children with 
allelic variations of the MBL gene, consistent with low MBL levels, had aggravated 
endothelial response to  acute infection. In  vitro work demonstrated the key role o f 
MBL as a modulator of the inflammatory response to specific infectious stimuli. This 
work provides evidence that infection may act as an important mediator of vascular 
dysfunction in early life and that endogenous factors that alter the host response to 
infection have potential to modify the effect of infection at a vascular level.
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CHAPTER 1
GENERAL INTRODUCTION
1.1 EPIDEMIOLOGY OF ATHEROSCLEROSIS
Cardiovascular disease (CVD) is the leading cause of death in developed countries[l]. 
The vast majority of these deaths, numbering more than 15 million per annum 
worldwide are due to complications of atherosclerosis. In the Western world 
however, public awareness of risk factors for CVD and improvement in medical 
treatment has led to a significant reduction in associated mortality (Figure 1.1a) but 
this prolongation in life is often associated with disability [2].
Currently around 2.7 million people in the UK have coronary heart disease, the most 
common form of CVD, which is responsible for one in five deaths in men and one in 
six deaths in women (Figure l.lb)[3]. This noted difference in death rate between 
sexes diminishes with increasing age.
The main pathological process responsible for arterial disease is atherosclerosis. 
Although atherosclerosis was initially considered as an inevitable progressive 
degenerative condition occurring as a result of increasing age, it is now well 
established that this disease has a long preclinical phase [4]. In the young, the 
accumulation of lipid laden cells beneath the endothelium is the primary feature [5]. 
Later, the progression to atheroma formation is characterised by asymmetric focal 
thickenings consisting of inflammatory and immune cells, connective tissue elements, 
endothelial and smooth muscle cells together with lipids [6].
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Figure 1.1: Death rates from cardiovascular disease.
a) From 1990-2003 a significant reduction in cardiovascular death rates has 
been noted in both sexes [2].
b) Coronary heart disease is responsible for the majority o f  cardiovascular 
deaths [3J.
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1.2 EVIDENCE FOR EARLY ATHEROSCLEROSIS
Although the clinical manifestations of atherosclerosis usually present in middle and 
late adulthood, early histopathological changes can be found in the large systemic 
arteries by the first decade of life (Figure 1.2). Indeed in 1953, Enos et al 
demonstrated the presence of coronary atherosclerotic plaques in 77% of young US 
soldiers in their teens and early twenties who died in action in  the Korea w ar [7], 
More recently Stary et al observed macrovascular fatty streaks in 40% of young 
Americans dying of non cardiac causes as well as evidence of lipid rich deposits in the 
coronary arteries of most children by the age of 13 years [4].
Figure 1.2: Atherosclerosis begins in childhood.
This is an intravascular ultrasound o f  the coronary artery o f  a 17 year old boy, who 
died o f non cardiac causes. The black arrows highlight the distinct wall thickening o f  
the coronary arteries already present at this young age [8].
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Similar findings to these pathological studies have recently been demonstrated by 
intravascular ultrasound. In a group of subjects dying of non-cardiac related causes, 
who were providing the donor hearts in a transplantation programme, atherosclerotic 
lesions were observed in 17% of those less than 20 years of age with a steep increase 
in incidence over the next 3 decades [8]. Furthermore, evidence of fatty streak 
formation during fetal development in the context of maternal hypercholesterolaemia 
highlights the importance of prenatal influences in atherogenesis [9; 10].
The development o f atherosclerosis is a well recognised result of the interaction 
between intrinsic characteristics and exposure to risk factors. The latter present early 
in life and impact on preclinical arterial atherosclerotic changes measured in 
adulthood. For instance, in the Bogalusa Heart study, both low density cholesterol 
(LDL) and body mass index (BMI) measured in childhood were independently 
associated with intima media thickness (IMT) measured in the carotid arterial wall in 
adulthood [11]. In addition, increased blood pressure in childhood was associated 
with increased arterial stiffness [12]. In line with these findings, the number of 
cardiovascular risk factors measured in childhood was associated with the occurrence 
of preclinical carotid atherosclerosis in adulthood and with decreased arterial 
elasticity in the Young Finns Study, in Muscatine and the Atherosclerosis Risk in 
Young Adults (ARYA) study [13-16]. The consistency of these observations suggests 
that early identification and treatment of risk factors might be the best investment 
strategy against future cardiovascular events.
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1.3 ATHEROSCLEROSIS: PATHOLOGY AND MECHANISMS
1.3.1 The response to injury' hypothesis of atherogenesis
Many cellular events occurring during atherogenesis are now well characterised. I n 
1858 Virchow was the first to suggest that low-grade injury to the vessel wall caused 
an inflammatory reaction, with subsequent infiltration of leukocytes and other plasma 
constituents into the arterial intima [17], Later in 1973, Ross and Glomset formulated 
a “response to injury” hypothesis of atherogenesis, which incorporated many of 
Virchow’s ideas. This hypothesis has since been modified to incorporate most of the 
known events o f atherogenesis [18].
The proposed initial step in atherogenesis is endothelial damage (Figure 1.3). A 
variety o f insults including hypercholesterolemia, diabetes and hypertension may 
cause injury to endothelial cells. Once the injury is established, alterations in the anti­
thrombotic and permeability barrier functions of the endothelium along with impaired 
local vasodilatory capacity and/or increased release of vasoconstrictors then set in 
motion many of the cellular processes that initiate lesion formation [19]. Furthermore 
the dysfunctional endothelium and activated inflammatory cells produce growth 
factors t hat s timulate sm ooth m uscle c ell growth a nd p roliferation t hus h aving k ey 
role throughout the progression of atherosclerosis (from fatty streaks to the more 
advanced fibroproliferative plaques) [18].
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Figure 1.3: The response to injury hypothesis o f  atherosclerosis.
The atherosclerotic process begins with injury o f endothelial cells by a variety o f  
factors. The endothelium then becomes dysfunctional and adopts proatherogenic 
properties. In the vascular wall macrophages accumulate lipids and become foam  
cells. Foam cells, T cells and smooth muscle cells eventually form the fatty streak. 
This step also includes platelet adherence and aggregation. As fatty streaks progress 
to intermediate and advanced lesions, they tend to form a fibrous cap. Rupture or 
ulceration o f the fibrous cap may rapidly lead to thrombosis (adapted from Ross et al 
[20]).
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Endothelial
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1.3.2 Pathology of atherosclerosis
Insights into the pathology of atherosclerosis are mostly derived from animal studies 
or pathological specimens. The lesions of atherosclerosis are subdivided into fatty 
streaks and fibrolipid plaques.
The fatty streaks present from very early in life, are visible with the naked eye and 
consist of lipid laden macrophages and foam cells within the intima [5]. Whilst many 
fatty streaks regress spontaneously, pathological studies suggest that, a t predilected 
sites and in the presence of risk factors, some early lesions may develop through a 
series of intermediate lesions into raised fibrolipid plaques [4;21 ].
Fibrolipid plaques are the main atherosclerotic lesions, which tend to emerge during 
the second and third decade o f life [6 ]. They consist of a fibrous cap below the 
endothelium which overlies a lipid rich pool typically containing debris derived from 
necrotic foam cells. However, a number of morphological variants have also been 
described ranging from a densely fibrous lesion with a thick cap and small lipid pool 
to lesions with a large lipid pool separated from the lumen only by a thin cap depleted 
of connective tissue [5]. In many advanced lesions the media is thin and an 
inflammatory infiltrate may extend into the adventitia. The development of vessel 
wall remodelling allows the incorporation of large lesions without impeding flow. In 
other cases, plaque may protrude into the lumen and limit blood flow resulting in 
tissue ischaemia. Complications such as plaque rupture or erosion stimulating local 
thrombosis are the basis of the vast majority of clinical events.
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1.3.3 Risk factors for atherosclerosis
A number of classical risk factors for atherosclerosis have been identified over the 
years. These include hypercholesterolaemia, hypertension, smoking, diabetes and 
family history for cardiac disease. Studies performed in adults have demonstrated 
their value in cardiovascular risk prediction. However although these might present in 
early life, they are not as prevalent as documented in adults and unlikely to be the 
only determinants of the initiation of atherosclerotic disease. Thus it is important to 
identify other novel risk factors which manifest in early life that are relevant to 
pathophysiology of atherosclerosis.
1.3.3.1 Hypercholesterolaemia
Cholesterol was first postulated to be related to atherosclerosis when it was found to 
be a major component of advanced atherosclerotic plaques. A number of studies have 
now demonstrated a direct association between serum cholesterol levels and risk of 
cardiovascular disease; particularly coronary artery disease [22]. Differences in 
mortality rates between different populations can be largely explained by differences 
in serum cholesterol levels [23]. The association between cholesterol and coronary 
disease is continuous, progressive and concentration-dependent, even at low 
cholesterol levels and appears to be important from childhood onwards [24]. The 
importance of cholesterol levels even in young adult life has been confirmed in a large 
prospective trial [25]. This study demonstrated a strong association between serum 
cholesterol levels in late teenage or early adult life and the cardiovascular event rate in 
middle age [25]. Apart from total cholesterol, low density lipoprotein (LDL) is 
particularly useful in risk stratification. Other lipoprotein particles such as very low- 
density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL) have also
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considerable atherogenic potential. Several studies for instance have consistently 
demonstrated a positive correlation between low density lipoprotein (LDL) 
cholesterol concentration and the later incidence of clinical atherosclerotic disease 
[22;23;26-28]. Subfractions of LDL cholesterol, small dense LDL particles, which are 
rich in cholesterol and more susceptible to oxidation are especially predictive of 
increased atherosclerotic risk [29]. In contrast high density lipoprotein (HDL) 
cholesterol, which has a key role in reverse cholesterol transport, has been associated 
with decreased cardiovascular risk [30-32]. The ratio of HDL to total or LDL 
cholesterol is also an independent predictor of cardiovascular risk [26]. The 
“atherogenic lipoprotein profile” has also been defined to encompass increased levels 
of small dense LDL cholesterol, low HDL cholesterol levels, moderately raised 
triglycerides and increased postprandial lipaemia.
Interventional trials have firmly established the causal link between cholesterol and 
cardiovascular disease. Large randomised trials have confirmed that reduction in 
cholesterol levels is associated with a corresponding decrease in clinical events [33]. 
In particular, with the development of 3-hydroxy-3-methylglutaryl-coenzyme-A 
(HMG-CoA) reductase inhibitors, marked and rapid reductions in serum cholesterol 
levels have been safely achieved. In the Scandinavian Simvastatin Survival Study [34] 
and the West of Scotland Prevention Study [35], reductions in cardiovascular 
mortality of 20-30% have been demonstrated in patients with hypercholesterolemia, 
with and without established coronary artery disease, after as little as two years 
treatment. Further studies have demonstrated that the benefit from cholesterol 
reduction extends to cerebral and peripheral vascular morbidity and mortality and 
benefits may also be derived in subjects at high risk with normal levels of cholesterol.
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1.3.3.2 Hypertension
Hypertension has been shown to be a major risk factor for both coronary and cerebral 
events in both men and women irrespective of age or gender [36]. Both diastolic and 
systolic blood pressure were related in a dose-dependent and continuous manner with 
incidence of stroke coronary and vascular events [37]. The mechanism of damage is 
probably related to alterations in shear stress on the arterial walls, particularly at sites 
o f turbulent flow, such as bifurcations [38]. However, a wide range of environmental, 
pathological and genetic factors are implicated in the development of high blood 
pressure. For example, hypertension is often associated with obesity, abnormal lipid 
profiles and insulin resistance [39-41], which interact synergistically and further 
increase the total atherosclerotic risk. Clinical studies however, have shown as little as 
5 to 6  mmHg reduction in diastolic blood pressure may result into a 42% fall in the 
incidence of stroke and a 14% drop in the risk of coronary heart disease after five 
years of antihypertensive therapy [42].
1.3.3.3 Smokins
A strong epidemiological link between cigarette smoking and coronary artery disease 
has been consistently confirmed in the last decades. Community based cohort studies 
such as the Framingham study have shown that cigarette smokers are at a markedly 
elevated risk of developing cardiovascular events [43]. These studies have also shown 
that smoking cessation can lead to a decrease in the incidence of cardiovascular 
disease [44], Attention has also been drawn to passive smoking [45]. Compounds 
present in environmental tobacco such as carbon monoxide and benzopyrene seem to 
be toxic even at low concentrations and exposure to smoke has been associated with 
as much as a 30% increase in the relative risk of death from ischaemic heart disease or 
myocardial infarction among non-smokers [46-48]. The exact mechanism whereby
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tobacco smoke increases the risk or accelerates atherogenesis is not clearly defined 
but possibilities include endothelial damage, increased platelet adherence and 
aggregation, increased oxidative stress, increased fibrinogen levels and arterial spasm 
[49-51].
1.3.3.4 Diabetes mellitus
Both type 1 and type 2 diabetics have a marked increase in atherosclerosis and its 
complications when compared to non-diabetics [52]. Type-2 diabetics in particular 
also tend to have a higher incidence of hyperlipidaemia and hypertension [53]. 
Metabolic control has beneficial effects on plasma lipids and blood pressure [54]. The 
mechanism by which diabetes promotes atherogenesis is uncertain, but high glucose, 
insulin and lipid levels may alter both endothelial and platelet physiology. Increased 
oxidative stress and reduced levels of endogenous antioxidants have been 
demonstrated in diabetes and may be important proatherogenic factors [55;56]. In 
addition, insulin is a growth factor and may stimulate smooth muscle cell 
proliferation.
1.3.3.5 Family histon-senetics
The important contribution of genetic make up in the atherosclerotic process has long 
been recognised [57]. Identification of single gene disorders such as familial 
hypercholesterolaemia or apolipoprotein B deficiencies, where an increased 
cardiovascular event rate was noted within families, has enormously increased our 
understanding of atherogenesis [58]. In the absence of overt conventional risk factors, 
a clear association between family history o f premature coronary disease and 
endothelial dysfunction has been reported, further supporting the importance of 
genetic background [59;60].
33
However it is unlikely in the majority of cases that a single gene is responsible for a 
disease with such a high prevalence. Thus it is more likely that common 
polymorphisms lead to alteration in the expression or activity of an encoded protein 
(ie endothelial nitric oxide synthase (eNOS)) and in the presence of additional adverse 
environmental or genetic influences, this alteration may contribute to the development 
of the disease [61]. For instance, our group have recently shown that a Glu298Asp 
substitution in the eNOS gene modifies flow mediated dilatation in pregnancy and in 
cigarette smokers [62;63]. Nevertheless the impact of polymorphisms in genes 
regulating endothelial biology, such as the eNOS gene, or others including those of 
the renin-angiotensin system, inflammatory cytokines, nicotine adenine dinucleotide 
phosphate (NADPH) oxidase and the bradykinin receptor have provided interesting 
data for our understanding of atherosclerosis [64].
1.3.3.6 Other novel risk factors
It is well recognised that the above mentioned cardiovascular risk factors are not 
prevalent in childhood where the origin of the atherosclerotic disease lies. It is thus 
possible that prenatal and postnatal influences which commonly occur in childhood 
are important trigger factors for the initiation of atherosclerosis. Research in this field 
over the recent years has highlighted the contribution of birthweight and early growth 
and nutritional strategies. In addition, since atherosclerosis is an inflammatory 
process, sources of inflammation presenting from an early age are a relevant focus of 
interest. These include infections which are the most common inflammatory stimuli 
occurring in childhood and obesity which is of increasing prevalence, especially in the 
Western world.
34
a) Early growth and nutrition
In 1989 Barker [65] reported a continuous inverse relationship between birthweight 
and also w eight at one year and the later incidence of cardiovascular disease. This has 
subsequently been confirmed in other large cohorts where low birth weight has been 
associated with impaired glucose tolerance, type 2  diabetes, and higher blood pressure 
both in childhood and adulthood [66;67]. These associations might reflect the 
aggregation of genetic, economic and environmental risk factors in the pathogenesis 
of atherosclerosis.
Apart from low birthweight, catch up growth has also been associated with adverse 
cardiovascular outcome. Erikson et al documented that in 3641 men who participated 
in the Helsinki study the highest death rate from coronary heart disease occurred in 
those who not only had low birthweight but whose weight caught up in the first 7 
years of life [6 8 ]. As a result o f this accelerated growth, these people had average or 
above average body mass by the end of the first decade of life [6 8 ]. More recently 
Barker et al demonstrated that the pattern of growth is important for cardiovascular 
health [69]. Thus, adults who had been small at birth and thin at two years of age 
having put on weight thereafter w ere at increased risk of developing insulin resistance 
in later life and also presented w ith increased incidence of coronary events [69].
It is not known why catch-up growth maybe detrimental for cardiovascular health. 
One possibility is that alterations in body composition related to catch-up growth may 
be responsible for these adverse outcomes. For instance babies who are thin at birth 
lack muscle and accelerated catch-up growth may lead to disproportionately high fat 
mass [70]. Moreover catch-up growth may reflect persisting changes in secretion of 
hormones including insulin like growth factor 1 and thus indirectly influences both
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childhood growth and coronary heart disease [71]. This growth acceleration 
hypothesis as a denominator of cardiovascular health is intriguing because it provides 
a window, in the early postnatal period, where interventions can be implemented. 
Indeed, compelling data suggest that the trajectory of vascular disease risk is 
potentially modifiable by early post natal nutritional strategies which can limit the rate 
of catchup growth in small for dates infants [72].
c) Infection
Histopathological studies have now demonstrated that atherogenesis represents an 
inflammatory response to vascular injury. A possible role for infection and systemic 
inflammation in initiation and development of cardiovascular disease has been 
proposed. Viral and bacterial infections are common in children and they may 
contribute to the development and course of atherosclerosis by inducing the 
expression of cytokines and adhesion molecules, stimulating smooth muscle cell 
migration and proliferation, inhibiting apoptosis and increasing lipid accumulation. 
Although t hese b iological p rocesses are fundamental i n t he b iological sy stem, t hey 
have been associated with alterations in vascular responses, which although proving 
beneficial in the acute phase, in the presence of other risk factors they may have a 
long-term detrimental effect. The putative role of infection in atherogenesis and the 
outcome of prevention trials are described in section 1 .6 .
d) Obesity
The prevalence of obesity is increasing rapidly in children. The likelihood that an 
obese child will become an obese adult increases with age and the severity of obesity. 
Obesity is associated with accelerated development of fatty streaks and fibrous 
plaques in childhood and an increased prevalence of coronary artery calcification and
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clinical coronary heart disease in adulthood [73;74]. This is thought to be largely due 
to the metabolic and physiological consequences of obesity which include insulin 
resistance, dyslipidaemia, hypertension and over activity of the sympathetic nervous 
system [75]. Obesity has recently been considered to be an “inflammatory disease” 
characterised by elevation in C-reactive protein (CRP) levels and increased release of 
pro-inflammatory c ytokines or adipokines from adipose tissue including interleukin 
(IL) 6  (IL-6 ), tumour necrosis factor - a  (TNF-a) and leptin.
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1.4 ENDOTHELIUM
1.4.1 Physiology of endothelium
The endothelium is a single layer of cells that lines the luminal surface of blood 
vessels. A rough estimation of the endothelial surface of a man of 70kg is 27,000m2 
which corresponds more or less to the surface area of two football fields and one 
tennis c ourt [ 76]. B ecause o f i ts a natomical 1 ocation, t he e ndothelium d efines i ntra 
and extra vascular compartments. Although it was long thought to serve only as a 
barrier between blood components and the vessel wall, it has become appreciated that 
the endothelium is a metabolically active tissue that can integrate blood borne signals 
and contribute significantly to the functions of different organs. It can regulate 
numerous blood vessel functions including cell adhesiveness, vascular growth and 
coagulation by the generation of local mediators. The endothelium plays a central role 
in controlling vascular tone by producing numerous locally active mediators including 
nitric oxide (NO), prostacyclin, angiotensin II, endothelin and endothelium 
hyperpolarizing factor (EDHF) [77].
1.4.1.1 Nitric Oxide
NO is a freely diffusible gas with a half-life of less than 6  seconds in vivo. The actions 
of endogenously released NO in mammals were first described in experiments using 
isolated blood vessels. Stimulation of rabbit aorta with acetylcholine resulted in 
relaxation that was dependent on the presence of the endothelium. This endothelium 
dependent relaxation was in turn mediated by the release of a labile factor, identified 
as endothelial derived relaxing factor (EDRF) [78]. The identity of EDRF was 
confirmed a s N O i n 1 987 [ 79] a nd i t i s e stablished a s t he active m etabolite w hich 
mediates the smooth muscle relaxant effects of n itroglycerin and other a nti-anginal
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organic nitrates [80]. NO was also found to have diverse functions such as 
anticoagulation, non-adrenergic/non-cholinergic neurotransmission, and cytotoxic 
and cytostatic actions [81].
Synthes i s:  NO is generated via a five electron oxidation of the terminal guanidiniun 
nitrogen on the amino acid L-arginine (Figure 1.4). The reaction is both oxygen- and 
NADPH-dependent and yields the co-product L-citrulline in addition to NO [82;83]. 
This electron oxidation is facilitated by a single enzyme the Nitric oxide synthase 
(NOS) [84]. This enzyme is stereospecific for the L-isomer, since D-arginine is not a 
substrate. Due to the observation that carbon monoxide and other haem binding 
agents inhibit NOS activity, it is believed that the haem component of NOS represents 
the catalytic center. For the activity of NOS a number of cofactors are necessary [85]. 
NADPH acts as a source of electrons for oxygen activation and substrate oxidation. It 
is also believed that the flavin-adenine-dinucleotide (FAD) and flavin mononucleotide 
(FMN) play an analogous role in shuttling electrons from NADPH to the iron haem. 
Other essential cofactors for NOS activity are tetrahydrobiopterin (BH4) and 
calmodulin [8 6 ].
NO may be generated by 3 distinct isoforms of NOS which are coded by different 
genes [87] and named according to their original description; neuronal NOS (nNOS), 
endothelial (eNOS) and inducible NOS (iNOS). n and eNOS are calcium dependent 
while iNOS is calcium independent [8 8 ]. The eNOS is the main NOS iso form 
expressed in the cardiovascular system. It is mostly expressed in endothelial cells and 
plays key role in the regulation of vascular tone and tissue perfusion. A variety of 
other cells also express this isoform [89].
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Figure 1.4: The Nitric oxide pathway.
In response to increase in blood flow, NO is generated from the N-guanido terminal 
o f the amino acid L-arginine and molecular oxygen by nitric oxide synthase enzymes 
(NOS) in the endothelium. In this reaction several substrates are needed including 
tetrahydrobiopterin (BH4) and nicotine adenine dinucleotide phosphate (NADPH). 
NO then diffuses into smooth muscle cells. It increases soluble guanylate cyclase 
which leads to increased levels o f cyclic guanosine monophosphate (cGMP). The 
latter mediates the vasorelaxation o f smooth muscle cells. Oxygen species deactivate 
NO and form peroxynitrite (Adapted from Lloyd-Jones [90]).
Vasodilator activity’ o f  NO
The relative contribution of NO to endothelium dependent relaxation has been studied 
by examining the effects of pharmacologic inhibitors of NOS. The eNOS enzyme is 
located in endothelial cells within caveolae in the plasma membrane bound to 
caveolin [91]. In t he r esting s tate, t he m ajority of e NOS i s i nactive a lthough s ome 
eNOS is active producing a tonic level of NO which is involved in the maintenance of 
vascular tone. Blockade of NOS activity systemically with NG-monomethyl-L- 
arginine (L-NMMA) in healthy human volunteers resulted in an increase in blood 
pressure [92], and blockade of NOS activity in the forearm reduced forearm blood 
flow [93], indicating the importance of basal NO release. Endogenous NO-mediated 
vasodilator tone has been demonstrated in coronary, pulmonary and systemic 
vasculature, indicating its importance in the regulation of flow in many vascular beds 
[94;95].
Physiological and pharmacological stimuli such as shear stress, hypoxia, 
acetylcholine, substance P, adenosine triphosphate and thrombin activate eNOS via 
calcium/calmodulin -dependent mechanisms [96]. Once NO is released by endothelial 
cells it acts both within the lumen of the vessel where it is a potent inhibitor of 
leukocyte adhesion and platelet activation [97], and also on surrounding smooth 
muscle cells and tissues. Within smooth muscle cells, it activates soluble guanylate 
cyclase (sGC). Activated sGC produces cGMP which activates cGMP-dependent 
protein kinase (PKG) and may also activate cyclic adenosine monophospate (cAMP) 
dependent protein kinase [98]. Together NO, cGMP and PKG mediate various 
processes resulting in the decrease in smooth muscle calcium concentration, the
41
dephosphorylation of contractile proteins such as myosin light chain finally causing 
vascular smooth muscle relaxation [99].
1.4.1.2 Prostaglandins
Prostaglandins are produced from arachidonic acid, which is released from membrane 
lipids by phospholipase A2 and metabolised by cyclo-oxygenase (COX) [100]. COX 
has two isoforms; COX-1, which is constitutively expressed, and COX-2 that is 
induced by cytokines and differs by a single amino acid substitution in the enzymatic 
site. NO or its breakdown product peroxynitrite may be involved in upregulating 
COX activity in inflammatory cells, though this process is complex and may be 
isoform and tissue dependent [ 1 0 1 ].
Endothelial cells produce a range of prostaglandins according to their tissue type, with 
prostacyclin and thromboxane A2 being the most important in the vasculature in 
health. Prostacyclin binds to specific receptors and activates adenylate cyclase to 
increase cAMP [102] that, in smooth muscle cells, causes relaxation by protein kinase 
phosphorylation of contractile proteins [103] and, within the lumen, inhibits platelet 
aggregation [104]. By contrast thomboxane A2 is a vasoconstrictor that acts as a 
potent platelet aggregator through a calcium dependent pathway [105]. COX, 
particularly the constitutive isoform, may in certain circumstances also be an 
important source of oxygen free radicals [106].
In healthy individuals COX-1 inhibition with aspirin (and other non-steroidal anti­
inflammatory agents) has been shown to reduce blood flow in human forearm 
resistance vessels [107]. This is suggestive of a role for prostanoids in vascular tone in 
the forearm, a phenomenon that has also been demonstrated in the coronary
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circulation [107]. Anti-inflammatory doses o f aspirin have been shown to prevent 
inflammation induced endothelial dysfunction in the forearm, though a direct local 
effect of prostanoid inhibition could not be demonstrated [108].
1.4.1.3 Endothelium-derived hyperpolarizin£ factor (EDHF)
A number of different studies have demonstrated that endothelium dependent 
relaxation can be resistant to inhibitors of cyclooxygenases and of nitric oxide 
synthases [109]. Therefore the existence of an additional pathway that is involved in 
the smooth muscle relaxation was attributed to a non-characterised endothelial factor 
called EDHF. Following stimulation of endothelial cells with an agonist such as 
acetylcholine or bradykinin, there is a transient increase in the calcium (Ca2+) which 
leads to the activation of Ca2+ dependent potassium (K+) channels and membrane 
hyperpolarization [110]. The mechanism by which this endothelial cell 
hyperpolarization is transferred to vascular smooth muscle cells was attributed to 
EDHF [111]. Following hyperpolarization, the intracellular Ca2+ concentration 
decreases in smooth muscle cells and this will lead to vasorelaxation [ 1 1 1 ].
To date it has been relatively difficult to study extensively the effects of EDHF in 
humans, due to the toxicity of the inhibitors of potassium channels [ 1 1 2 ]. 
Nevertheless from animal experimental studies it has been made clear that the 
contribution of EDHF-mediated responses as a mechanism of endothelium-dependent 
relaxation increases as the vessel size decreases. In the coronary and renal vascular 
bed EDHF also contributes to vasodilatation in conduit arteries [113].
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1.4.1.4 Endothelin
Endothelins (ET) are 21-amino-acid peptides, which are produced by various cells 
including endothelial cells [114]. Originally they were discovered in 1988 [114] and 3 
different isoforms of ET are now known [114]. Endothelial cells produce ET-1 
exclusively [114]. ET-1 is synthesised from its precursor, big ET-1, by endothelin 
converting enzyme-1. Big ET-1 in turn, is proteolytically cleaved from the primary 
ET-1 gene product, prepro ET-1 [115]. ET-1 is produced in response to different 
factors including hypoxia, hyperoxia, pressure, low shear stress, catecholamines, 
thrombin etc [116] and its action is mediated via vascular smooth muscle and 
endothelial receptors [75]. By acting on vascular smooth muscle receptors ET-A and 
ET-B, ET-1 causes vasoconstriction while the same iso form, by acting on the ET-B 
receptors of endothelial cells, induces vasorelaxation [75]. Indeed, ET(A) receptor 
antagonism was associated with coronary vasodilatation and improved endothelial 
function in atherosclerotic patients [117].
ET-1 i s i mplicated i n t he p athophysiology o f a variety o f c ardiovascular d isorders, 
including heart failure, coronary heart disease, pulmonary hypertension and 
atherosclerosis [118]. In these conditions there is evidence of increased plasma ET 
levels, increased ET-1 mRNA in endothelial cells and smooth muscle cells and 
enhanced vascular responses to ET antagonists. Accumulating evidence suggests that 
endothelin does not only act as a potent vasoconstrictor but also as a cytokine which 
plays a significant role in inflammation [119]. Thus it has been shown to be a 
chemoattractant for macrophages and monocytes, to stimulate cytokine production 
and to induce the release of growth factors from endothelial cells.
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1.4.1.5 Angiotensins and kinins
The endothelium also regulates the activity o f the renin-angiotensin system. 
Angiotensin converting enzyme, which converts angiotensin I to angiotensin II is 
expressed on the endothelial cell membrane. Angiotensin II is a peptide that has 
vasoconstrictor, prothrombotic, oxidant and atherogenic properties. Two different 
membrane receptors are known to be activated by angiotensin II [120]. The activation 
of AT2 receptors on endothelial cells leads to secretion of NO and prostaglandin while 
stimulation of smooth muscle ATi receptors leads to vasoconstriction, generation of 
reactive oxygen species and ET-1 release [121].
1.4.2 Endothelial dysfunction
Injury or activation of the endothelium alters its regulatory functions and results in 
abnormal endothelial cell function. This is characterised by an imbalance of 
endothelium derived relaxing and contracting factors. In atherogenesis, endothelial 
injury appears to be a key early event preceding any structural vascular alterations and 
potentially triggers the initiation and progression of atherosclerotic lesions [18].
Several studies performed both in animal models of atherosclerosis and in human 
atherosclerotic arteries, have demonstrated that in the dysfunctional endothelium NO 
bioavailability is impaired [122]. Thereby, vasoconstrictor responses to certain 
substances are augmented. Accumulating evidence suggests that increased vascular 
production of reactive oxygen species plays an important role in endothelial 
dysfunction and accounts for a large proportion of reduced NO bioavailability 
[123; 124]. Increased vascular superoxide production has been demonstrated in 
association with all the known cardiovascular risk factors predisposing to
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atherosclerosis. A number of different vascular sources of superoxide have been 
implicated including NADPH oxidase and xanthine oxidase [125]. Superoxide may 
react quickly with NO, resulting in formation of peroxynitrite [125]. In addition, 
vascular reactive oxygen species promote the oxidative degradation of the critical 
eNOS cofactor BH4 leading to eNOS uncoupling and hence decreased NO production 
and increased free radical generation. Enhanced LDL cholesterol and particularly 
oxidised LDL play also important role in endothelial dysfunction [126].
A number o f other factors may also affect eNOS function at post-translational level. 
For instance, experimental evidence suggests that hypercholesterolaemia can 
contribute to decreased NO production by upregulating caveolin abundance and 
promoting caveolin-eNOS interaction [127]. Protein kinase B dependent 
phosphorylation of eNOS also plays a critical role in eNOS activation and endothelial 
function [128]. Abundance of endogenous eNOS inhibitors, such as asymmetric 
dimethyl-arginine as well as deficiency of cofactors required by eNOS may also alter 
eNOS activity at post-translational level [129].
In addition to changes in vasoactive function, the dysfunctional endothelium acquires 
a proinflammatory and procoagulant phenotype [130]. It increases the expression of 
adhesion molecules on the abluminal surface, which facilitates the binding of 
monocytes and their migration into the intima. It enhances the release of growth 
factors including platelet derived growth factor, which promotes smooth muscle 
migration and proliferation and also favours the production of factors that induce 
coagulation instead of fibrinolysis (ie tissue factor, plasminogen activator inhibitor-1 ).
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Thus endothelial dysfunction may promote local thrombus formation at the site of a 
plaque.
Therefore endothelial dysfunction is probably important across the entire spectrum of 
atherosclerotic disease; in the development of the cellular interactions resulting in 
lesion progression and in the behaviour of advanced plaques and their propensity to 
cause arterial occlusion [131].
1.4.3 Methods to assess endothelial function in vivo
Several techniques may be used to assess arterial endothelial function in vivo ranging 
from the biochemical to the physiological. No single measure describes all aspects of 
its varied function. A number of bioassay methods are now available that can quantify 
the activation of the vascular endothelium [von Willebrand factor (vWF), platelet 
activating factor inhibitor- 1 (PAl-1 ), tissue plasminogen activator (t-PA) and 
thrombomodulin]. However the endothelial regulation of vascular tone is the most 
widely studied functional aspect of the endothelium in clinical studies with 
endothelium-derived NO playing a central role in this process. Endothelium 
dependent vasodilatation can be assessed invasively and non-invasively in the 
coronary and peripheral circulation.
1.4.3.1 Invasive assessment o f  the peripheral and coronan3 endothelial function
Invasive p harmacologic testing o f a rterial function c an b e p erformed following t he 
insertion of a thin cannula into the brachial or femoral artery, or during cardiac 
catheterisation [132]. Venous occlusion plethysmography, and quantitative coronary
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angiograpy a nd D oppler F low W ire t echniques are u sed t o m easure p eripheral a nd 
coronary vascular responses, respectively [132; 133]. Local infusion of endothelium- 
dependent pharmacologic probes such as acetylcholine, bradykinin or substance P is 
used to assess endothelial vasomotor function. For comparison, endothelium- 
independent vasomotor capacity can be similarly explored by infusion of nitrates, or 
other agents that act directly on smooth muscle such as calcium-channel antagonists. 
Similarly, the contribution of NO to basal and stimulated vasomotor function can be 
determined by using antagonists of NOS such as L-NMMA to block NO synthesis 
[134].
Although these invasive methods are quite safe and have been widely used in research 
to unravel early mechanisms in the atherosclerotic process, ethical and practical 
limitations restrict their use to a limited group of patients and healthy subjects. These 
issues make such techniques particularly unsuitable for use in studies involving 
children. Given these limitations it is necessary to use non invasive tools for the 
assessment of vascular function in the young.
1.4.3.2 Non-invasive assessment o f  peripheral endothelial function
Peripheral endothelial function can be assessed non-invasively using high resolution 
ultrasound. The rationale for studying endothelial function is to assess arterial 
diameter before and after a known stimulus. The most suitable arteries for study are 
the large superficial arteries such as the brachial, femoral or carotid arteries. Images of 
coronary or renal vessels tend to have lower resolution because they are at a greater 
depth. Although the brachial artery is not directly clinically relevant to atherosclerotic 
disease, study o f this artery is justified as endothelial dysfunction is a diffuse process 
which is observed throughout the vascular tree.
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Flow mediated dilatation (FMD) of the brachial artery is a technique that was 
developed and validated in our department. It uses haemodynamic shear stress 
induced by reactive hyperaemia to stimulate endothelial release of NO [135]. FMD is 
repeatable, reproducible, relevant to  the underlying disease process, correlates with 
coronary vascular endothelial function, and is now in widespread use as a clinical 
research tool [132; 136; 137]. The physiology and protocol of this technique is 
described in section 2 . 1 .
Endothelial dysfunction as measured by FMD has been noted in children with familial 
hypercholesterolaemia f rom t he first d ecade o f  1 ife a nd i n o ther c onditions s uch a s 
hypertension and type I diabetes [59; 138; 139]. Moreover, inflammatory conditions 
such as Kawasaki disease or polyarteriitis nodosa impair the vasoreactivity of the 
endothelium, an effect which is sustained long-term [ 140; 141]. The identification of 
factors that induce preclinical atherosclerotic changes is important not only because it 
gives u s f urther i nsights i nto t he p athophysiology o f t his complex d isease b ut a Iso 
because it has the potential for reversibility.
Early changes in endothelial reactivity have been shown to be modifiable by both 
physiological and pharmacological interventions. Regular physical exercise for 
instance improved endothelial dysfunction noted in overweight teenagers [142]. 
Nutrient supplements and administration of pharmacological regimens in high risk 
children also improved endothelial reactivity [143; 144]. Although promising, whether 
these interventions will translate into long-term benefit needs further 
confirmation[145].
Wilkinson et al and Hayward et al tested the hypothesis that pulse wave analysis 
(PWA) combined with provocative pharmacological testing with inhaled salbutamol,
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which can stimulate release of NO from vascular endothelial cells, might provide an 
alternative method of assessing endothelial function [146; 147]. In these studies, 
inhalation of 400 pg of salbutamol led to a 12% reduction in the arterial augmentation 
index (AIx), consistent with an increase in arterial compliance. Previous studies have 
shown that salbutamol induces potent release of NO (approximately 50% increase in 
local flow, similar in magnitude to the effect of acetylcholine) in response to intra- 
arterial infusion [148]. In both studies, this effect was blunted in subjects with clinical 
conditions associated with endothelial dysfunction and was also effectively inhibited 
by L-NMMA a selective inhibitor of NO production. These data support the view that 
endothelial release of NO is responsible for the observed change in the pressure 
waveform with salbutamol and also that this technique has relevance to biology and 
can be used in clinical trials. Apart from applanation tonometry 
photoplethysmography has also been used in a similar way to assess endothelial 
function.
1.4.4 Risk factors and endothelial dysfunction
Several studies have shown a significant association between endothelial dysfunction 
and the presence of coronary risk factors in persons with no clinical evidence of 
coronary disease. The classical cardiovascular risk factors (hypercholesterolaemia, 
cigarette smoking, diabetes and hypertension) have been consistently associated with 
disturbances in normal endothelial physiology even among young subjects 
[50; 139; 149]. In addition the risk factor score, a reflection of the total number of risk 
factors, has been associated with endothelial dysfunction [150].
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1.4.5 Endothelial dysfunction and prognosis
Evidence suggests that loss of endothelium dependent vasodilation is characteristic in 
the development of atherosclerosis and has adverse consequences. Endothelial 
vasodilator function has been used to assess the impact of multiple environmental and 
genetic influences on the vasculature and as a potential surrogate marker of 
atherosclerosis.
Endothelial dysfunction is considered to be a generalised phenomenon affecting both 
the coronary circulation and the distal peripheral vascular beds. Studies performed at 
the time of cardiac catheterization, although some limited by small number of studied 
patients or by the lack of a thorough multivariable assessment of other potentially 
important independent predictors of risk, clearly demonstrate a direct association 
between endothelial dysfunction and event rates [ 133; 151; 152]. The prognostic 
importance of the non-invasive assessment of the peripheral endothelial function was 
confirmed by most but not all studies [153]. Chan et al demonstrated that FMD was 
associated with outcome in a cohort of coronary patients enrolled in an intensive 
cardiac rehabilitation program [154]. On the other hand Fathi et al documented that in 
444 patients who were at risk for coronary events, FMD did not predict cardiovascular 
outcome in a period of one year [155]. More recently Witte et al in a meta-analysis of 
2 1 1  articles reported that following risk factor stratification the relationship between 
FMD and risk factors remained only in the group regarded as low risk in the 
population [156]. This analysis although not assessing cardiovascular outcome, 
indirectly questions the predictive value of FMD.
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1.5 INFLAMMATION IN ATHEROSCLEROSIS
The inflammatory nature of atherosclerosis was first described in the 1850s. Since 
then a number of studies have demonstrated that a specialized chronic inflammatory 
response precedes migration and proliferation of arterial smooth muscle cells during 
atherogenesis. The primary event in the initiation of atherosclerotic process is the 
accumulation of lipids and lipoprotein particles in the subendothelial space. This 
event is followed by attachment, adherence and migration of peripheral blood 
monocytes and T-lymphocytes at sites throughout the arterial tree, particularly at 
branches and bifurcations. Multiple interactions between monocytes, platelets and 
lymphocytes together with endothelial and smooth muscle cells in concert with LDL 
cholesterol will lead to the development of atherosclerotic lesions.
1.5.1 Monocytes/macrophages
Monocytes/macrophages are important both in the initiation and progression of 
atherosclerosis. Recruitment of monocytes into the arterial wall is one of the earliest 
events in atherosclerosis. Insults to the endothelium, such as hypercholesterolaemia, 
stimulate the production of leukocyte chemoattractant molecules, which activate 
receptors on monocytes leading to integrin dependent firm adhesion to the 
endothelium and facilitate subsequent diapedesis to subendothelium [157],
Once circulating peripheral monocytes migrate from the vascular to extravascular 
compartments, they develop into macrophages [158]. The latter are important 
mediators of inflammation in atherosclerotic lesions through production of cytokines, 
oxygen free radicals, proteases and complement activation.
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Macrophages are important in cholesterol homeostasis. They usually respond to 
excess of free cholesterol, as a result of the intracellular turnover, by down regulating 
their receptors for LDL cholesterol. However macrophages are also exposed to large 
amounts of cholesterol derived from cell debris or lipoprotein material [159]. This 
chemically modified LDL is recognised by different receptors, called scavenger 
receptors that are not down regulated in the same way in the presence of cholesterol 
[159]. Once the amount of intracellular oxidised LDL exceeds the amount that can be 
mobilised from macrophages, it accumulates as cytosolic droplets. This affects 
cellular viability and function leading to the formation of macrophage derived foam 
cells [160](Figure 1.5).
Further studies implicate macrophages not only in the initial but also in the late phases 
of atherogenesis where the atherosclerotic lesion is already established. Experimental 
studies have described constitutive expression of metalloproteinases by the 
macrophage foam cells within atheroma o f hypercholesterolemic rabbits [ 161-163]. 
Macrophage related proteolysis within atheroma contributes to weakness of the 
protective fibrous cap of the plaque. This process promotes the propensity of those 
plaques to rupture and trigger thrombosis which typically leads to unstable angina, 
myocardial infarction and stroke [162].
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Figure 1.5: The recruitment o f monocytes and the formation offoam cells
Modified LDL activates endothelial cells to express monocyte chemoattractant protein -1 (MCP-J), which attracts monocytes from the vessel 
lumen into the subendothelial space. Once resident in the intima the monocytes acquire characteristics o f tissue macrophage and internalize 
modified LDL particle. These processes give rise to the arterial foam cell (the first step in the atherosclerotic process). Finally the foam cell 
secretes pro-inflammatory cytokines, growth factors and metalloproteinases (Adapted from Ross [18])
1.5.2 B & T lymphocytes
Macrophages are not the only cells contributing to atheroma formation. T cell 
adhesion to dysfunctional endothelium has also been demonstrated. T cells of both the 
helper (CD4+) and cytotoxic suppressor types have been detected in human atheroma 
and have been shown to be immunologically activated [164]. Compelling evidence 
exists for the role of these cell types in the orchestration of the disease process [165]. 
Natural killer T cells, a T cell subpopulation, are prevalent in early lesions. They 
recognise lipid antigens and their activation increases lesion progression in many 
animal models of atherosclerosis [166].
Binding to adhesion molecules facilitates the T cell entry into the intima. Once in the 
arterial intima, T cells may become activated. Then they respond directly either by 
attacking the antigen, or indirectly by stimulating B-cells to produce antibodies 
against the antigen or enhancing the inflammatory response by secreting
i
cytokines[160].
1.5.3 Adhesion molecules
Adhesion molecules are important components of the inflammatory process. They 
belong to three distinct families including selectins, integrins and the immunoglobulin 
gene superfamily [167](Figure 1.6). These adhesion molecules have received much 
attention, not only for their participation in normal physiological processes, but also 
for their potential roles as modulators of cell-cell interactions [167]. They contribute 
to vascular dysfunction and tissue injury and have been associated with different 
vascular diseases including atherosclerosis [167].
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Figure 1.6: The multistep process o f leukocyte recruitment
Selectins mediate the initial leukocyte-endothelial cell interaction that is manifested as leukocyte rolling. This transient binding results in further 
leukocyte activation and subsequent firm adhesion and transendothelial migration o f leukocytes both o f which are mediated by interactions 
between members o f the integrin and immunoglobulin superfamily o f CAMS.
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a) Selectins
Selectins are transmembrane glycoproteins containing an amino-terminal calcium- 
binding lectin domain, and epithelial growth factor-like domain and between two and 
nine complement regulatory repeats [168; 169]. They have received their name from 
the cell type on which they were originally identified; L-selectin on leukocytes, E- 
selectin on endothelium and P-selectin on platelets [167]. L-selectin is constitutively 
expressed on the surface of leukocytes whereas P and E selectin are only expressed 
following activation of platelet and endothelial cells respectively. In the presence of 
inflammatory cytokines including TNF-a, IL-1 and reactive oxygen species, the 
endothelium responds by upregulating genes that code for and induce expression of 
adhesion molecules[170]. Once selectins are produced they ligate glycoprotein 
moieties on circulating neutrophils and platelets and they are responsible for the 
leukocyte rolling and their transient binding to endothelial surface [18].
b) Integrins 
\
Integrins are heterodimeric molecules consisting of a and P subunits that mediate 
both cell-cell and cell-extracellular matrix interactions [171]. They are subdivided into 
subgroups on the basis of their P subunit [167; 168]. They mostly recognise and tightly 
bind to cellular adhesion molecules of the immunoglobulin superfamily and to large 
extracellular matrix proteins, including fibronectin, vitronectin and fibrinogen. 
Although there are large numbers o f variations, three groups are most important in 
atherogenesis (P1-P3 ) [172]. The “very late appearing antigen” intergrins, pi family, 
are the group expressed on endothelial cells and primarily mediate cell adhesion to 
extracellular matrix proteins such as collagen and laminin. Although expressed only 
on leukocytes, P2 intergrins are involved in the migration of leukocytes to sites of 
inflammation. The endothelial ligand is dependent upon the a subunit, either being a
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member of the immunoglobulin family or other large matrix proteins [173]. The P3 
integrins are found on platelets and are involved in platelet adhesion [168].
c) Immunoglobulin gene superfamily
The immunoglobulin gene superfamily includes a broad range of molecules with 
multiple Ig-like domains. Among them the most studied in relation to atherogenesis 
are the intercellular adhesion molecule-1 (ICAM-1), the vascular cell adhesion 
molecule-1 (VCAM-1) and platelet-endothelial cell adhesion molecule-1 (PECAM-1). 
ICAM-1 is found on a number of cells, including endothelium and leukocytes. 
VCAM-1 is also found on endothelial cells but can also be expressed by other cell 
types like macrophages, myoblasts and dendritic cells [167]. PECAM-1 is expressed 
on leukocytes, platelets and endothelial cells. The CAMs act as endothelial ligands for 
integrins expressed by leukocytes and platelets and are involved in cell-cell 
interaction and signal transduction [167]. Levels of soluble adhesion molecules have 
been shown to correlate with various cardiovascular risk factors such as smoking 
[174; 175], hypertension [176; 177] and hypercholesterolaemia [178; 179] and have 
been used as prognostic markers of future cardiovascular events. In the 
Atherosclerosis Risk in Communities (ARIC) study sICAM-1 was associated with 
future cardiovascular events even after controlling for other potential confounders 
[180]. These results were further confirmed in the Physicians Health Study [181]. 
Thus, study of cell adhesion molecules may prove useful in the understanding of the 
pathophysiology of atherosclerosis and plaque instability and they are likely to prove 
useful tools in stratifying atherosclerotic disease severity and prognosis.
1.5.4 Cytokines in the pathogenesis of atherosclerosis
Interestingly, cytokines differentially affect atherogenesis with distinct cytokines 
directing pro- and anti- atherogenic processes, modulating plaque characteristics and
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clinical outcomes. The classical pro-inflammatory cytokines, IL-1 and TNF-a, 
stimulate the production of adhesion molecules, procoagulants and other mediators 
and typically mediate pro-atherogenic processes whereas anti-inflammatory cytokines 
IL-4, I L- 8  and IL-10 mediate anti-atherogenic pathways and diminish experimental 
atheroma [182],
Recent work has also demonstrated overexpression of the immunoregulatory molecule
CD 154 (CD40 ligand (CD40L)) and its counterpart CD40 in experimental and human
atherosclerotic lesions [183]. These molecules can be expressed by macrophages, T
and B lymphocytes, endothelium, platelet and smooth muscle cells in atherosclerotic
lesions. A number of atheroma associated functions such as production of adhesion
molecules, chemokines, proinflammatory cytokines, growth factors,
metalloproteinases and coagulation are mediated by CD40/CD40L interactions [183].
Experimental studies showed that CD40/CD40L is involved in both in the early and
late stages of atherosclerosis. Indeed, interruption of the CD40 signalling 
\
significantly reduces atherosclerotic lesions in LDL receptor deficient mice and 
improved plaque stability in ApoE-deficient mice [184].
Laboratory studies identifying cytokines as mediators of atherogenesis stimulated 
clinical investigations into the potential role of cytokines as diagnostic and prognostic 
tools. Studies of serum IL-ip, TNF-a and CD40L demonstrated elevated levels in 
patients with hypertension, acute myocardial infarction and stable angina [185-187]. 
Finally, cytokines and cytokine inducible inflammatory markers have been associated 
with future cardiovascular events [183; 188].
1.5.5 Heat shock proteins in atherosclerosis
Heat shock proteins (HSPs) are present in most cells and play a role in cell protection
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from damage in response to stress stimuli such as infections, oxidants and cytokine 
stimulation. There is a risk of autoimmunity associated with HSPs due to high 
interspecies sequence homology throughout the range from bacteria to humans. They 
are divided in families according to their molecular weight and are highly expressed 
in cardiovascular tissues. Among them HSP65 and HSP70 and HSP60 are the ones 
that have been most extensively studied in atherosclerosis [189].
Immunisation of normocholesterolaemic rabbits with recombinant mycobacterial 
HSP65 leads to atherosclerotic lesion [190]. Cholesterol fed mice when immunized 
with HSP65 develop aggravated atherosclerotic lesions [191]. In humans, antibodies 
against mycobacterial HSP65 are associated with both carotid and coronary 
atherosclerosis [192-194]. Berberian et al reported for the first time the elevated 
expression of HSP70 in human atherosclerotic plaques [195]. Then other groups 
showed that heat shock proteins predominate in central areas of more thickened 
atheroma around sites of necrosis and lipid accumulation [196]. Back in 1993 
Kleindienst et al demonstrated that HSP60 was found on the endothelium, smooth 
muscle cells and mononuclear cells [197], The intensity of HSP60 expression was 
also closely associated with the severity of atherosclerotic disease [192]. Human 
HSP60 antibodies have been associated with both the presence and the severity of 
coronary artery disease [198]. Likewise the soluble form of HSP60 has been found to 
be elevated in the circulation of persons with carotid atherosclerosis [199]. In addition 
to the antigenic properties of HSP60, bacterial HSP60 may have direct 
proatherogenetic effects by stimulating human vascular cell and macrophage 
functions. Thus bacterial and human HSP60 have been shown to induce expression of 
adhesion molecules and matrix degrading metalloproteinases as well as secretion of
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pro-inflammatory cytokines by human vascular endothelial cells, smooth muscle cells 
and macrophages [2 0 0 ].
1.5.6 Triggers for inflammation in atherogenesis
Clinical and experimental evidence suggest that classical and novel risk factors for
atherosclerosis may trigger inflammation in atherosclerosis, thus providing further
evidence for the central role of inflammation in the pathophysiology of
atherosclerosis[201]. For instance, it is well documented that dyslipidaemia, which for
years was regarded as prerequisite for progression of atherosclerosis is closely linked
with inflammatory processes [202]. Lipid subfractions once retained in the intima
undergo oxidative modification and acquire pro-inflammatory actions [203]. These
modified lipoproteins can induce the expression of adhesion molecules, chemokines
and pro-inflammatory cytokines both in inflammatory cells and in vascular wall cells
[201]. The apoprotein fractions of the lipoprotein particles may also undergo
modification in the artery wall and are able to elicit antigen-specific immune 
*
responses [ 204]. A part f rom d yslipidaemia, h ypertension h as a Iso b een 1 inked w ith 
inflammatory processes in atherogenesis. Angiotensin II produced by endothelial cells 
is a prooxidant but also a proinflammatory molecule, increasing the expression of pro- 
inflammatory cytokines and adhesion molecules from smooth muscle cells [205;206]. 
The production of pro-inflammatory c ytokines and other inflammatory pathways in 
vascular endothelial cells is enhanced in diabetes and obesity [207;208]. In particular, 
adipose tissue is an important source of cytokine production thus promoting 
inflammation and atherogenesis.
However t he m ost c ommon p ro-inflammatory st imuli a re i nfections. T hus s tudy o f 
different infections might give us insights about the pathophysiology of 
atherosclerosis.
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1.6 INFECTION & ATHEROSCLEROSIS
The contribution of inflammation and immune responses in the initiation and 
progression of atherosclerotic lesions has been well documented [201]. Infections are 
the most common inflammatory insults and there is now evidence to suggest the role 
of specific infectious agents or multiple infections in the initiation and progression of 
the atherosclerotic process.
1.6.1 Acute infections and atherosclerosis
Death rates from cardiovascular disease, particularly acute myocardial infarction, 
have a higher prevalence in winter months [209]. Although many factors can account 
for this seasonal variation, the greater number of respiratory infections in winter 
months might also be responsible. This possible association is further supported by 
the documentation that death rates from cardiovascular disease increases during 
epidemics of influenza[2 1 0 ].
irf 1998 Meier et al [211] documented the results of a population based study in UK 
where the association between acute myocardial infraction and recent or acute 
respiratory infection was explored. The study population consisted of 1922 people 
who h ad a first t ime d iagnosis o f a cute m yocardial i nfarction ( AMI) f  rom 1 994 t o 
1996 and had no history of clinical risk factors and 7649 controls matched for age and 
sex. The information was retrieved from the general practice research database in UK. 
For all subjects the date of the last respiratory tract infection either before the index 
date or before an arbitrary chosen date was documented. The authors concluded that 
acute respiratory tract infections are associated with increased risk for AMI for a 
period of two weeks. Recently Smeeth et al confirmed these findings in population 
study of similar setting in which they included people with prior myocardial infarction
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and ischaemic stroke [212]. These authors documented also that urinary tract 
infections to a lesser extent are associated with a transient increase in the risk for 
vascular events. The risk for event was higher for the first three days after exposure to 
infectious stimulus and decreased slowly in the following weeks. In children, acute 
infections have been shown to increase the presence of oxidised LDL and have been 
associated with a greater carotid intima medial thickness on ultrasound three months 
later[213].
Other inflammatory insults including sepsis and surgery have also been associated 
with short term increases in the risk of atherothrombotic disease [214;215].
The specific mechanisms explaining the association of acute infections with increased 
cardiovascular risk remains debatable. One possible explanation could be that during 
acute infections there is alteration in the properties of inflammatory cells within 
atherosclerotic plaques to favour rupture. Another contributing factor could be 
vascular endothelial dysfunction, which is associated with impaired vasodilatation and 
weakening of the anti-inflammatory and anti-thrombotic properties of the vessel wall. 
Furthermore, adverse alterations in the lipid profile known to occur following acute 
infections may also contribute. Finally changes in homocysteine metabolism 
accompanying infections could all combine to increase the risk of acute coronary 
events following an acute infection [216]. Further information about the pathogenetic 
mechanisms of infection is included in section 1.6.4.
1.6.2 Chronic infections and atherosclerosis
A number of infectious agents have been reported as triggers or mediators of the 
inflammatory response in atherosclerosis [216]. Even in childhood Pesonen et al 
showed in a necropsy study a correlation between infectious diseases at the time of
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death and intimal thickening, which could be a precursor to atherosclerosis[217]. 
These data are particularly important considering that most of the viruses including 
the herpesvirus, human cytomegalovirus (CMV) and the gram negative bacteria, 
chlamydia pneumonia {C.pneumoniae) and helicobacter pylori (H.pylori), are 
ubiquitous presenting in more than 50% and some of the times up to 80% of the 
population especially in older ages [218].
To investigate the link between infection and atherosclerosis the researchers have 
elaborated different clinical and experimental approaches. These range from 
seroepidemiological studies of groups of patients with and without atherosclerotic 
disease, detection of the infectious agent or parts of it in the atheromatous lesions, 
experimental studies in animal models and in vitro experimental studies in cell 
systems with the aim of identifying the implicating mechanisms.
1.6.2.1 Bacteria and atherosclerosis 
\
Among the bacteria, C.pneumoniae and H.pylori are the ones that have received most 
of the attention as possible infectious agents that may play a role in atherosclerosis. 
This is because they are prevalent in the general population.
a) Chlamydia pneumoniae
C.pneumoniae is an obligate intracellular gram negative bacterium which is 
responsible for community acquired pneumoniae but also for pharyngitis, bronchitis 
and sinusitis [219], It has a unique morphological cycle involving 2 morphological 
forms, the elementary body and the reticulate body. The former is the infectious form 
which is adapted to extracellular survival whereas the latter is the metabolically active 
and dividing form which is adapted for intracellular multiplication. In addition, the
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organism may evolve into a persistent body, an intracellular metabolically inactive, 
non-replicating but viable form that allows it to maintain chronic infection and 
thereby a state of chronic inflammation that may contribute to the atherosclerotic 
process. The antibody prevalence for C.pneumoniae by the age of 20 is around 50% 
and can increase up to 70-80% between the ages of 60-70years [220].
Serological evidence
In 1988 Saikku et al were the first to provide evidence of association between 
antibodies against C.pneumoniae and atherosclerosis in  a group o f 40 Finnish men 
admitted for AMI and an equally sized matched control group[221]. The same group a 
few years later documented that patients with chronic chlamydia infection as assessed 
by antibody titers had twice the risk of a cardiovascular event compared to those 
without. The association remained even after adjusting for the classical coronary risk 
factors [222]. In addition, they were able to demonstrate that if low grade 
inflammatory response as measured by CRP was taken into consideration then the 
coronary risk was almost doubled [223]. Since then a number of groups have 
investigated the association between C.pneumoniae seropositivity and coronary risk 
[224]. In 1997, Danesh et al published a meta-analysis of 18 seroepidemiological 
studies [225]. In this meta-analysis the presence of a possible association between 
C.pneumoniae infection and coronary risk was stated. However it was highlighted that 
the result should be interpreted with caution as there seems to be a great heterogeneity 
in the studied populations and the clinical endpoints. In addition, the interpretation is 
made difficult by the lack of standardisation for serological assessment. For instance, 
most of the studies have used microimmunofluoresce, which has been critisized for 
interlaboratory variation and poor reproducibility and variable cutoff points for IgG 
and IgA antibodies were introduced in diffferent studies[226].
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Apart from case control studies, prospective studies have also been performed to 
explore further the association between serological evidence for chlamydia infection 
and coronary events. A meta-analysis of the majority of these studies has shown that 
the overall risk of coronary heart disease in the presence of seropositivity for 
C.pneumoniae is lower to what it was previously suspected by the cross sectional 
studies [227].
The implicating mechanisms that may account for a possible link between
C.pneumoniae and atherosclerosis are unclear and not possible to define by
serological studies. The presence of serum antibodies does not necessarily indicate the
persistence of active infection at any site nor informs us of the temporal exposure of
the coronary arteries to any type of insult. In the case of C.pneumoniae the picture is
even m ore c omplicated because t he a ntibody t iters m ay f all s ubstanstially w ithin a
few years of seroconversion and may increase substantially if re-infection occurs thus 
\
being less reliable indicators of persistent respiratory infection [225].
Analytical documentation of the cross sectional and prospective epidemiological 
studies associating C.pneumoniae with atherosclerosis and its complication is 
included in the appendix A.
Histopatholo2icaI evidence
The presence of C.pneumoniae in atherosclerotic plaques was first described by Shor 
et al [228]. The organism was identified by electron microscopy and chlamydia 
immunoperoxidase staining. This group was able to demonstrate the presence of the 
organisms in all the post-mortem atheromas but in none of the control cases. Since 
then a number of other studies provided positive and negative results about the 
presence of the bacterium in atherosclerotic lesions [229-247].
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For histopathological studies a number of different techniques have been elaborated 
with v ariable s ensitivity. A lthough d irect c ulture o f  t he o rganism i s considered t he 
gold standard, the cell culture has proven extremely difficult and successfully 
performed only in a few laboratories. Therefore other techniques have been used for 
C.pneumoniae identification. These included polymerase chain reaction (PCR), 
immunocytochemical staining, immunofluorescence and in situ hybridisation. Overall 
although C.pneumoniae seems to be more prevalent in atherosclerotic lesions, the 
percentage positive varies considerably between different methods [232].
b) Helicobacter pylori
H.pylori is a Gram negative bacterium which has been identified in 1983 and
colonizes the gastric epithelium and causes life-long infection. It appears from
childhood and persists until older age. By the age of 50 years, 40% of the population
will have antibodies against H.pylori [225].
Serological evidence 
\
In 1994 Mendall et al provided evidence of an association between antibodies against
H.pylori and coronary heart disease [248]. Since then a number of epidemiological 
studies cross sectional, retrospective and prospective in design have been performed 
providing conflicting results about the role of H.pylori in atherosclerosis. Danesh et al 
for instance in a large cross sectional study including 1 1 2 2  survivors of suspected 
acute myocardial infarction and equal number of age and sex matched control group 
without previous history of coronary heart disease were able to demonstrate a 
moderate association between coronary heart disease and H.pylori seropositivity 
which could not be explained or accounted by other known cardiovascular risk factors 
[249], Other groups have also confirmed these results and in most studies stronger 
associations were noted when the more virulent H.pylori strain such as those bearing
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the cytotoxin associated gene-A (CagA) was taken into consideration [250]. A recent 
prospective study has correlated the evolution of the carotid plaques with 
seropositivity to the virulent strain of H.pylori CagA while no association was found 
with the non virulent strains infections [251]. However not all studies are consistent 
[252-254]. In the ARIC study for instance a prospective evaluation over a period of 3 
years has reported a negative association between H.pylori infection and clinical 
coronary heart events[255]. Although unlike other bacteria, high IgG antibodies for
H.pylori are fairly reliable indicators of chronic gastric infection, the lack of 
appropriate adjustment for cardiovascular risk factors or socio-economic class, which 
is highly related to H.pylori infection, might partly explain some of the discrepancies 
in published studies. Appendix A contains detailed information about the 
epidemiological studies linking H.pylori infection and CVD.
Histopatholo2ical evidence
The identification of H.pylori in atherosclerotic specimens has also been 
controversial. DNA from H.pylori has been found in half of the atherosclerotic 
plaques obtained from carotid endarterectomy specimens, while none was found in 
any of the autopsy control atherosclerosis free carotid samples suggesting that there is 
a tropism of this bacterium for atherosclerotic lesions [256]. In contrast, Blasi et al 
failed to detect H.pylori when 50 atherosclerotic plaques from aortic aneurysms were 
tested [257]. Similarly in another vascular bed Danesh et al failed to show the 
presence of H.pylori genomic material when 39 carotid atheroma samples were tested 
[258]. Thus while there may be an association between H.pylori and coronary heart 
disease there is no evidence that it is pathogenic.
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c) Chronic periodontal infections
A potential association between periodontal disease and atherosclerosis was first 
proposed in 1963 by Mackenzie and Millard [259]. Since then studies in animals and 
humans have explored this hypothesis and the degree of association varies from 
strong to negligible or no association [260]. In some studies it appears to be a 
correlation between the severity of the dental disease, in terms of alveolar bone loss, 
and the degree of coronary atherosclerosis [261], however most of the results are also 
confounded by variation in social class [262].
The mechanism of any association is not clear. Deshpande et al in 1998 showed that
bacterium porphyromonas gingivalis can infect endothelial cells and lead to
endothelial activation [263]. Further studies in humans have shown an association
between chronic severe dental disease, an inflammatory state and impaired endothelial
function [264]. A possible role of autoimmunity has also been suggested. Further
information is included in section 1.6.4 
\
1.6.2.2 Viruses and atherosclerosis 
a) Herpesviridae
Infection with herpes simplex virus (HSV) and CMV in the general population are 
mostly chronic and asymptomatic. Positive antibody titers against HSV-1 and CMV 
are detected in more than 80% and 60% of adults older than 65 years old 
respectively[265]. Since the first experimental evidence of a possible direct role of 
herpesviridae in the induction of atherosclerosis in chickens by infection with Marek’s 
disease virus [266] numerous studies have been performed to explore the association 
between these pathogens and cardiovascular disease.
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Seroepidemiolozical evidence
Many e pidemiological s tudies h ave s hown m ore t han t wo-fold i ncrease in v ascular 
disease in cytomegalovirus seropositive subjects [265;267]. In 2000 Muhlestein et al 
documented that in the presence of an underlying inflammatory process as measured 
by CRP, CMV seropositive individuals are at least twice as likely to develop CVD 
over seronegative subjects [268]. To further support the association, Nieto et al 
provided evidence of a graded response between the odds of intima media thickening 
and the levels of antibodies for CMV, an association which remained after adjusting 
for the known cardiovascular risk factors [269]. More recently, herpesviridae 
infections were implicated in plaque instability, acceleration of atherosclerosis and 
development of cardiovascular events [270]. However, negative studies have also 
been published. Adler et al documented that prior infection with CMV is not a major 
risk factor for angiographically demonstrated coronary artery atherosclerosis [271]. In 
the Physicians Health Study no association was detected between CMV or HSV 
antibodies and AMI or stroke over a 12-year follow up period [272]. Overall the 
association between herpesviruses and atherosclerosis from epidemiological studies is 
not very convincing although the results may be indicative of a relationship in a 
subgroup of patients in particular those undergoing interventional 
procedures[273;274].
Histopatholozical studies
The p resence o f C M V  a n d HS V v iral a ntigen o r n ucleic a cid i n a theromatous a nd 
non-atheromatous blood vessels has also been investigated. However, the 
interpretation is difficult as there seems to be great heterogeneity on the anatomical 
site of the studied vessels and also on the methodology used to demonstrate the 
presence of viruses. For instance, in one study DNA from CMV was detected in 90%
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of the samples using polymerase chain reaction whereas by using dot blot for antigen 
detection, t he p ositivity rate d ropped t o 2 5% [ 225]. In a n a ggregate a nalysis o f  2 0 
studies the differences between diseased and normal vessels are small (47% compared 
to 39%) [225]. The reported negative findings do not necessarily argue against the 
possible role of CMV in the development of atherosclerotic lesions [275]. The 
infectious agents may have been present and initiated the lesion at an earlier stage and 
subsequently may remain latent and possibly undetectable when studied with less 
sensitive methods.
Apart from herpesviridae, other viruses that have been associated with atherosclerosis
including hepatitis A, Epstein-Barr, Coxscackie and human immunodeficiency virus
(HIV) [276;277]. For the latter the findings are particularly relevant considering the
increasing rate of spread of the virus worldwide. In addition with the introduction of
new antiretroviral therapies, HIV is regarded as a chronic disease rather than a life
threatening disease. Constans et al demonstrated that atherosclerotic plaques occurred 
*more often in HIV patients than in controls and also another group documented the 
presence of advanced atherosclerosis in coronary arteries of HIV seropositive patients 
in the absence of cardiovascular risk factors [278;279]. More recently it was also 
reported that carotid intima media thickness is significantly greater and progresses 
more rapidly in HIV patients compared to controls further supporting the link between 
chronic infectious status and atherosclerosis [280].
1.6.2.3 Pathogen burden in atherosclerosis
Given the discrepancies for the association of single pathogen candidates with 
atherosclerosis, Epstein and colleagues introduced the idea that pathogen burden (the 
sum of infectious exposures) might be a better prognostic marker of cardiovascular
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risk[216]. Initially a panel of 5 pathogens was tested and was associated with 
angiographic coronary artery disease in a cross sectional study and with 
cardiovascular events in a prospective study [281 ;282]. Subsequently in the 
Atherogene Study a panel of 8  pathogens was tested and by following a structured 
statistical analysis it appeared that most of the documented association was driven by 
viruses and less by the most commonly studied bacteria ie C.pneumoniae and H.pylori 
[283].
This was also confirmed in the Heart Outcome and Prevention Evaluation (HOPE)
Study where a modest association between cardiovascular events and total pathogen
score was found [284]. In the latter study, seropositivity to viruses but not to bacteria
(C.pneumoniae and H.pylori) contributed to the overall risk [284].
Concurrently other investigators provided mechanistic insights about the potential
link by which pathogens may contribute to atherogenesis. They demonstrated in a
group of 375 patients undergoing coronary angiography that increased pathogen 
\
burden was associated with increased systemic inflammation, endothelial dysfunction 
and increased severity of coronary artery disease [285].
1.6.3 Experimental evidence for the role of infection in atherosclerosis
The seroepidemiological and histopathological findings are corroborated by the 
results of animal experiments. Animal models provide an ideal tool to study the role 
of pathogens in the development of vascular disease for obvious ethical reasons which 
make human studies impossible. Another advantage to animal models is the ability to 
focus on specific parameters in atherosclerosis while controlling for additional risk 
factors.
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Marek virus was the first etiologic agent found to induce atherosclerosis [286] in 
chicken. Apart from chickens genetically altered mice prone to atherosclerosis have 
been widely used to study the effect of different pathogens in the lesion formation. 
Burnett et al demonstrated that CMV infection of ApoE knockout mice accelerates 
the development of atherosclerosis in the absence of a high fat diet [287], a finding 
which was further confirmed by other groups [288]. Intranasal inoculation with 
C.pneumoniae has been found to cause a systemic spread of infection in cholesterol 
fed mice [289]. However, other studies produced contradictory results depending on 
the age of the animals, their sex and the specific strain of the organism chosen by the 
investigators.
Rat m odels o f carotid artery b alloon a ngioplasty have a Iso b een a u seful m odel t o 
study the effects of CMV on restenosis. In this animal model, Zhou et al demonstrated 
a 40% greater neointimal formation in CMV infected animals when compared with 
controls[290]. Later experiments demonstrated that CMV aggravates intimal 
hyperplasia in rats by stimulating smooth muscle cell proliferation [291]. This 
vascular effect was noted irrespective of the presence of the virus in the vascular wall, 
suggesting that inflammatory and immune mediated responses to CMV are more 
important in aggravating the response to vascular injury rather than the virus itself. 
C.pneumoniae infection increases intimal thickening and atherosclerosis in New 
Zealand white normocholesterolaemic rabbits [292;293].
Furthermore animal models provided evidence that infectious agents may initiate the 
atherosclerotic process by inducing autoimmunity against cell wall components. This 
is supported by the observation that immunisation of mice with endogenous (32
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glycoprotein-I (a ligand recognised by anti-phospholipid antibodies) [294] or 
HSP60/HSP65 increased atherosclerosis [191]. Similarly normocholesterolaemic 
rabbits have increased atheroma formation when immunised with HSP60, and HSP60 
expression is detectable within the plaques [190; 192].
1.6.4 Pathogenetic mechanisms
Infectious agents may trigger atherosclerotic process via direct and indirect 
mechanisms. Direct effects of microbial infection on vascular cells include cell lysis, 
transformation and lipid accumulation. Indirectly infectious agents may stimulate 
systemic responses (ie antibodies, cytokine production, acute phase reactants) that 
could predispose to atherosclerosis. In addition autoimmune reactions resulting from 
molecular mimicry may also contribute to the development of atherosclerosis.
1.6.4.1 Direct effect o f  infectious agents on vascular cells
a) Cell lvsis and transformation
Endothelial cells and smooth muscle cells are the main constituents of the normal 
vessel wall. Infection and lysis of these cells may represent the first step in the 
alteration of the vascular wall homeostasis. In particular the lysis of the endothelial 
cells may allow the migration of leukocytes into the vessel wall and the initiation of 
the inflammatory process. Apart from immunological clearance, infection of 
endothelial cells results in a number of other direct cellular physiological 
modifications that are accociated with the development of atherosclerosis.
• Endothelial activation 
Infectious agents can alter endothelial cells from a phenotype that is normally 
anticoagulant to one that is procoagulant. This is supported by enhanced tissue factor
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and PAI-1 expression in endothelial cells following infection with HSV-1 and 
C.pneumoniae [295;296]. Moreover, HSV-1 infection has been shown to increase 
thrombin generation and reduce thrombomodulin expression and plasminogen 
activator activity [297].
Infectious agents can also induce proinflammatory changes in endothelial cells. For 
instance CMV and C.pneumoniae infection increases endothelial expression of 
adhesion molecules (VCAM-1 and ICAM-1) which significantly enhances 
transendothelial migration of inflammatory cells [298]. Herpesviridae have been 
shown to increase endothelial P-selectin expression and H.pylori infection of 
endothelial cells induces upregulation of ICAM-1, VCAM-1 and E-selectin[299;300].
• Endothelial dysfunction
Infectious agents also seem to interact with NO mediated and non-NO mediated 
pathways and may lead to endothelial dysfunction. Thus, individuals infected with 
xCMV have been shown to have impaired endothelium mediated coronary vasodilatory 
responses [216]. However other studies provided contradictory results. Prasad et al 
reported that subjects seropositive to H.pylori had reduced coronary vasodilator 
response to acetylcholine whereas Clarke et al reported that the response to forearm 
endothelial function was attenuated in young diabetic patients with CMV 
seropositivity but was not affected by positive serology for H.pylori or C.pneumoniae 
[285;301]. Finally Khairy et al reported that no association was found between 
chronic infection with C.pneumoniae, CMV, or H.pylori and FMD in the brachial 
artery in healthy young men [302].
• Smooth muscle cell growth
Proliferation and migration of smooth muscle cells from the media into the neointimal 
space is a hallmark of atherosclerotic lesion formation. A number of studies have
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shown that pathogen-mediated acceleration of vascular disease may also involve 
enhanced accumulation of smooth muscle cells in the lesion [303].
A reduction in apoptosis of smooth muscle cells could lead to accumulation of these 
cells at sites of vascular injury. Although apoptosis is an intrinsic cell process it can 
also be modulated by environmental signals [304;305]. Both CMV and C.pneumoniae 
have been shown to reduce the apoptotic rate of infected cells [306]. In particular, the 
immediate early gene products of CMV can bind and cytoplasmically sequester the 
tumor suppressor gene 53 which induces apoptosis [307-309]. Indeed, Tanaka et al 
demonstrated that overexpression of these genes from human CMV (IE 2-84) 
protected human coronary artery smooth muscle cells from p53-induced 
apoptosis[310].
Apart from reduction in apoptosis, increased proliferation is equally important for the 
enhanced smooth muscle cell growth at the site of vascular injury. A number of 
studies demonstrated that C.pneumoniae and CMV infection of endothelial and 
smooth muscle cells not only induces the release of growth factors and cytokines from 
these cells but also increases their ability to respond to these stimuli [311]. Thus, 
CMV infection of endothelial cells increases e xpression of fibroblast growth factor 
and p latelet d eri ved g rowth f actors w hich a re p otent s timuli i n s mooth muscle c ell 
proliferation [303;312]. Furthermore CMV infection upregulates the expression of C- 
C chemokine RANTES in smooth muscle cells and fibroblasts [311 ;313]. In the 
presence of these chemokines CMV infection induces migration of smooth muscle 
cells towards production sites of these chemokines. The increased migration is also 
promoted by expression of the viral chemokine receptor US28 [314].
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b) Lipid accumulation
The accumulation of cholesterol in both intracellular and extracellular sites is well 
recognised as one of the characteristic events in the atherosclerotic process. In 
addition it is widely believed that as LDL becomes oxidised the rate of its influx into 
the v essel wall i ncreases. T he o xidative 1 ipoproteins c ontribute t o t he formation o f 
foam cells in the vessel wall during atherogenesis but they may also activate 
endothelial cells and macrophages to release cytokines. The latter may participate in 
smooth muscle cell mitogenesis or enhance the binding of oxidised LDL to vascular 
cells [315].
One of the first observations supporting a causal role for pathogens in atherosclerosis
was the finding that arterial vessels from Marek virus infected chickens showed
increased lipid deposition [286;316]. Both C.pneumoniae and CMV alter the lipid
metabolism of the infected smooth muscle cells and macrophages [317]. Specifically 
\
CMV infection of monocytes increases their expression of scavenger receptors thus 
enhancing lipid deposition [318]. C.pneumoniae infection causes increased LDL 
uptake in murine macrophages with a subsequent increase in foam cell 
development^ 17].
Hajjar et al demonstrated that HSV infection of human smooth muscle cells decreases 
lysosomal and cytoplasmic cholesterol ester hydrolytic activity thus providing a 
possible mechanism linking infectious agents with lipid accumulation [319]. In 
addition, C .pneumoniae i nfection o f endothelial cells releases a cellular components 
that convert LDL to its proatherogenic form and reduces its resistance against 
oxidation[320]. Furthermore Chlamydia HSP60 has been reported to colocalize with
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human HSP60 within the cells of the atheromatous plaque, to induce autoimmunity in 
atherosclerosis and to be involved in LDL oxidation [321],
1.6.4.2 Indirect effect o f  infectious agents that could predispose to atherosclerosis 
Systemic inflammatory response
Atherogenesis is believed to develop and progress in response to a sequence of events 
triggered by the response to vascular injury. In this process cytokines have primary 
role in orchestrating the attraction and adhesion of inflammatory cells to the vessel 
wall.
Infectious agents can induce pro-inflammatory cytokines from vascular cells. For
instance, endothelial cells have been shown to produce IL- 6  in response to CMV
infection and IL- 6  and IL- 8  in response to H.pylori infection [300;322]. In addition,
both CMV and C.pneumoniae infection upregulate endothelial cell expression of
chemokines (namely IL- 8  and MCP-1) which promote leukocyte chemotaxis 
\
[323;324]. Thus by augmenting the adherence and infiltration of inflammatory cells 
C.pneumoniae and CMV are capable of promoting vascular disease.
There is now evidence to suggest that infectious agents may precipitate plaque 
instability and rupture by enhancing inflammation in the atherosclerotic plaque 
area[325]. For instance bacterial endotoxin and cytokines released during bacteremia 
might activate the vascular cells and leukocytes resident within the atheroma and 
precipitate thrombosis on a preexisting atherosclerotic plaque. Chlamydia HSPs have 
been shown to stimulate the secretion of matrix metalloproteinases, enzymes which 
weaken the fibrous cap of atheromatous lesion and thus predispose to plaque 
rupture[326].
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Finally acute phase reactants may also be involved in the atherogenesis. Infections, 
mostly bacterial induce a systemic inflammatory response. CRP is considered as a 
very reliable systemic marker of inflammation and its resting level associate strongly 
with the host aggregate pathogen load [281]. Numerous studies have demonstrated 
strong associations between CRP levels and cardiovascular events and others 
provided multiple potential pathogenic mechanisms, which could support its 
instrumental role in the development of atherosclerosis [327]. For instance increased 
levels of CRP can increase atherothrombosis by stimulating changes in both the 
coagulation system and the phenotype of the endothelium and mediate greater 
myocardial injury by increasing complement dependent cell lysis [328;329]. 
Advanced periodontal disease has also been shown to be associated with an elevation 
in CRP and a reduction in FMD, relative to healthy controls [264].
1.6.4.3 Molecular mimicry/ autoimmunity 
\
Molecular mimicry has been proposed as a mechanism responsible for the 
development of autoimmune diseases, and compelling evidence suggests its role in 
atherosclerosis. A number of infectious pathogens contain peptide sequences 
homologous with host proteins. In this case, the immune response although initiated 
by the invading pathogen can be sustained and converted to an autoimmune attack 
against host tissues containing the cross reacting peptide sequences. A number of 
association studies support this hypothesis however direct evidence for the role of 
autoimmunity in atherosclerosis is lacking [330;331].
For instance, there seems to be high homology between HSPs expressed in infectious 
pathogens and host HSPs. A number of studies have shown association between 
antibodies against human HSPs and atherosclerotic or proatherosclerotic
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changes[199;332]. However, only limited information exists about the direct 
contribution of infection in this process. Schett et al demonstrated that elevated levels 
of specific salivary IgA antibodies against mycobacterial HSP65 were found to be 
significantly increased in patients with gingivitis [333]. Mycobacteria HSP65 is 
highly homologous to human HSP60. The investigators speculated that the pathogens 
causing gingivitis expressed HSP which then stimulated an IgA antibody response in 
the host, which they suggested may serve as cross-reactive autoantigen. This 
autoimmune reaction may contribute to a link between infection and 
atherosclerosis[333].
Autoantibodies to certain cytokines have also been detected in apparently healthy 
individuals [334]. It is also known that CMV and Epstein Barr virus contain peptide 
sequence homologous to chemokine receptors and to cytokines respectively [216]. In 
addition Zhu et al demonstrated increased susceptibility to coronary artery disease in 
\vt>men who had a humoral rather than cellular response to CMV infection [335]. This 
finding is consistent with the possibility of autoimmune antibody mediated reaction 
against infection.
1.6.4.4 Host-Patho2en interaction
One other hypothesis explaining the pathophysiologic link between infection and 
atherosclerosis in some cases is the host pathogen interactions. Thus infectious agents 
may only be proatherogenic in the presence of an appropriate metabolic environment 
ie dyslipidemia, diabetes etc. Furthermore, the differences in the documented 
atherosclerotic risk of infection may reflect differences in the host’s response to 
infection ie type of inflammatory response humoral or cellular but also the magnitude 
of the inflammatory response. For instance Zhu et al demonstrated that increased
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prevalence of coronary artery disease was noted in people seropositive for CMV but 
only in the presence of elevated levels of CRP [336]. Furthermore, experimental 
evidence implicates altered control of inflammation by innate immune defenses that 
include pattern recognition molecules such as Toll-like receptors and mannose 
binding lectin (MBL) in the pathogenesis of atherosclerosis [160]. The role of the 
latter in the initiation of atherosclerosis is one of the central interests of this thesis.
Mannose binding lectin
MBL is part of the humoral innate immune system. It is an acute phase protein which
is found in normal serum at low levels but is also produced in increased amounts
during the acute phase response [337]. It is a calcium dependent sugar binding protein
and its resting levels in the body are largely genetically determined. Deficiencies in
MBL can be caused by 3 single nucleotide polymorphisms within exon 1 of the MBL
gene on chromosome 10: allele B at codon 54 (G54D), allele C at codon 57 (G57E) 
\
and allele D at codon 52 (R52C) which result in aminoacid substitutions that 
compromise assembly of functional oligomers. In addition to the exon 1 mutations, 
there are four polymorphisms in the promoter region of the MBL gene, including the 
H/L and X/Y systems, and one of these variants (X/Y) influences profoundly 
expression of the protein [338]. There is strong linkage disequilibrium between the 
promoter region polymorphisms and the exon 1 variants of the MBL gene. MBL 
binds to mannose residues, which are accessible on many bacteria but are covered by 
other sugar groups in the carbohydrates on vertebrate cells (Figure 1.7). Most of the 
information about which microorganisms may interact with MBL comes from 
epidemiological observations and the study of experimental infections of MBL- 
knockout animals [339].
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Figure 1.7: MBL binding to bacteria.
MBL binds to microbial surfaces and is able to promote opsonophagocytosis. It can 
activate the complement by the lectin pathway. This is mediated by serine protease 
MASP-2 and results in the formation o f  the C2 convertase C4b2a, which mediates 
cleavage o f  C3 and the formation o f C3b fragments which are recognized by the CR1 
receptor on the phagocytes. MBL can also promote inflammation by modulating 
cytokine (TNF-a, IL-1/3 and IL-6) release from monocytes (original picture from  
Turner et al [340]).
Decreased levels of MBL have been associated with an increased number of 
infections. A number of studies have presented evidence that MBL deficiency 
increases the susceptibility of an individual to infectious diseases and in particular to 
organisms causing acute respiratory tract infections during early childhood [341 ;342], 
Other studies have demonstrated that MBL deficiency is related to increased 
susceptibility by specific pathogens including HIV, plasmodium falciparum, 
Cryptosporidium parvum, neisseria meningitis and mycobacterium tuberculosis [343].
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Epidemiological studies demonstrate an association between deficiency in MBL and 
increase in cardiovascular events or thrombotic events in people with systemic lupus 
erythematosus [344;345]. The theoretical basis of an increased risk of CAD due to 
low levels of MBL is that inflammation can initiate atherosclerosis and insufficient 
MBL can increase the risk and duration of the inflammatory response to infections. 
However MBL is an acute phase protein and studies have demonstrated that elevated 
levels of MBL may enhance tissue damage during acute injury. Indeed, its inhibition 
with monoclonal antibody, reduced myocardial complement deposition and ischemic 
injury in an experimental model of reperfusion injury [346].
1.6.5 Infection in atherosclerosis. Is there a causal link?
Despite the numerous experimental and epidemiological studies exploring the role of 
infection in atherosclerosis, the data remains conflicting. One approach to clarify the 
discrepancies and confirm whether there is causal association between infection and 
atherosclerosis would be to treat infections and estimate whether this will impact on 
risk reduction for the development of cardiovascular complications. Given the relative 
preponderance of data for C.pneumoniae, and to lesser extent H.pylori, antibiotics 
against these agents have been investigated primarily.
Experimental work in rabbits and mice models of atherosclerosis have provided some 
encouraging evidence for the role of macrolides in treating C.pneumoniae induced 
atherosclerotic complications [347;348]. Unfortunately, the results from human 
studies have not been supportive. Although several pilot studies have demonstrated 
significant positive clinical effects, these findings were not subsequently confirmed in 
large randomised clinical trials which have in the most part shown no benefit from 
antibiotic therapy [348-351].
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The ROXIS (Roxithromycin in Ischemic Syndromes) study was the first randomized 
antibiotic trial in acute coronary syndromes. In this study, 202 Argentine patients with 
unstable angina or non-Q-wave MI were randomised to roxithromycin or placebo for 
30 days [352]. The endpoints measured at the end of the treatment period were the 
rates of recurrent ischemia, myocardial infarction and ischemic death. Although in the 
antibiotic treated group there was a trend torwards lower events, this did not reach 
statistical significance perhaps because of the limited power. The Azithromycin in 
Acute Coronary Syndrome (AZACS) study studied approximately 1,450 patients 
[353]. Patients were entered in the study regardless of serology to C.pneumoniae. 
Treatment was given for only 5 days, and duration of follow-up was 6  months. In this 
study no important benefit from this short term antibiotic treatment was noted. In the 
ACADEMIC (Azithromycin in Coronary Artery Disease: Elimination of Myocardial 
Infection with Chlamydia) trial of azithromycin, the authors showed a reduction in 
inflammatory markers without any change in the clinical outcome in the 2 -year 
follow-up [354]. Using clarithromycin as the treatment, the Clarithromycin in Acute 
Coronary Syndrome Patients in Finland (CLARIFY) study showed a trend towards a 
reduction in cardiovascular events and a significant fall in the secondary endpoint of 
cardiovascular events and stroke [355]. Larger antibiotic trials provided disappointing 
results.
The Weekly Intervention with Zithromax for Atherosclerosis and Its Related 
Disorders (WIZARD) suggested a potential benefit for longer-term antibiotic 
regimens [356]. In this study, 7000 patients with a history of myocardial infarction 
and seropositivity to C.pneumoniae were randomised to azithromycin 600mg or 
placebo for 1 2 weeks. After 1 4 months, there was no significant reduction for a ll­
cause death. A trend towards therapeutic benefit was seen in male diabetics and
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smokers but not in those with high baseline antibody titers of C.pneumoniae. At 6 
months, the secondary endpoint of death/MI was reduced and the reduction in the full 
composite endpoint was almost significant, but the differences between treatment 
groups gradually diminished. The Azithromycin and Coronary Events Study (ACES), 
sponsored by the National Institute of Health, studied 4012 adults with documented 
stable coronary artery disease [357]. Patients were recruited from 256 clinical centers 
in United States between 1999 and 2000 and were randomised to treatment with oral 
azithromycin 600mg once a week for a year. Four years after, there was no difference 
between the groups with regard to the composite primary outcome (death from 
coronary heart disease, nonfatal myocardial infarction, hospitalisation for unstable 
angina and coronary revascularisation). Finally, PROVE-IT TIMI 22 (Pravastatin or 
Atorvastatin Evaluation and Infection Therapy Thrombolysis in Myocardial 
Infarction) was similar in concept to ACES, but tested a quinolone antibiotic, 
gatifloxacin which is bactericidal and therefore should be more effective at clearing 
residual persistent infection [358]. The study was initially set up to compare intensive 
versus moderate lipid lowering treatment in 4162 patients following the occurrence of 
an acute coronary syndrome. To investigate further the role of C.pneumoniae in 
cardiovascular risk, patients within each treatment group were randomised to receive 
placebo or gatifloxacin 400mg/day for 10 days per month beginning on Day 15. At 30 
months of follow-up, there was no difference in the primary endpoint of the trial 
between the two treatment groups [358]. In addition, no difference was observed in 
the main secondary endpoint of all-cause death or myocardial infarction. The antibody 
titers for C.pneumoniae at baseline did not predict outcomes and antibiotic treatment 
did not reduce the levels of high sensitivity CRP (hsCRP) or C.pneumoniae antibody 
titers.
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1.6.6 Unanswered questions and future directions
By t aking i nto c onsideration t he n umber o f  c onflicting o bservations for t he r ole o f 
infection in the atherosclerosis it is reasonable to question the importance of 
infectious pathogens in driving the atherosclerotic process.
Lack of serological association however does not disprove lack of a role of implicated 
pathogens in atherogenesis. It is widely accepted that persistent infection may not be 
distinguishable from resolved infection in the presence of persistently raised antibody 
levels. In that respect future studies focusing on the pathogen burden may be 
improved by using assays which will reflect the extent of ongoing chronic infection. 
Furthermore expanding serology panels appears promising for future research. In 
contrast, persistent serological response may actually identify individuals who are 
more immunologically active rather than more infection burdened. Immune reactors 
may be at an advantage in an environment where infectious risk is prevalent but at a 
disadvantage where atherosclerosis dominates. Where infection is not clinically 
evident the presence of both seropositivity and inflammatory markers may better 
define r isk a ssociated v ascular i nfection. C linically m easurable c irculating p roducts 
marking active infection would be useful to be evaluated further [359].
Finally although the disappointing results of the antibiotic trials disqualify the long 
term antibiotic treatment (at least with the current antichlamydial therapies available) 
in the management of coronary artery disease they do not exclude the important role 
of infection in the atherosclerotic process. Almost all antibiotic studies were 
performed in the advanced stages of atherosclerosis for secondary prevention and 
little information is available on primary prevention. On this basis one could speculate 
that infection might have a relatively minor role in the late stages of the disease where
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a number of cardiovascular risk factors have already accumulated. In contrast, the 
situation might be different in initiation and progression of atherosclerosis.
1.6.7 Why study children?
Evidence demonstrates that atherosclerosis begins remarkably early. It is an accepted 
belief that research addressing the mechanisms responsible for the early evolution of 
disease should be directed in childhood and early adult life. Studies in children give 
us the opportunity to understand the latency period of disease onset, as well as the 
association with and interactions between other risk factors which may prove 
important for primary prevention. However, one should also bear in mind that the risk 
factor profile in childhood is different to that seen in adult years and changes through 
puberty and adolescence.
The study of infection in initiation of clinical atherosclerosis has a number of 
advantages. In children the incidence of infection is high while the incidence of 
classical cardiovascular risk factors is relatively low. Thus in this young age we have 
the unique opportunity to separate the effects of infection from the other well 
established cardiovascular risk factors. It is also possible to measure the response of 
the host to infections, which can be determined or modified by sex or the genetic 
make up, and thereby consider their propensity to lead to atherosclerosis [335].
Non-invasive methods are now available that allow us the study of the vascular 
biology of atherosclerosis. With the use of these methods a small number of groups 
have provided evidence for the role of both acute and chronic infection in early 
atherosclerosis. Pesonen et al investigated in autopsy material taken from 175
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children aged 0-15 years the relationship of clinically evident infection prior to death 
with intimal thickening of the coronary arteries [217]. He demonstrated that infections 
in general and viral infections in particular, seem to be associated with intimal 
thickening, which may predispose coronary arteries to atherosclerosis [217]. Liuba et 
al f  rom t his g roup s uggested t hat a cute i nfections i n c hildren w ere a ssociated w ith 
enhanced oxidative modification of LDL and by decrease in HDL-C [213]. Lately 
Volanen et al measured C.pneumoniae-specific IgG and IgA antibodies in 199 healthy 
children followed-up annually from 7 to 11 years of age [360]. They demonstrated 
that children with persistent C.pneumoniae seropositivity had increased aortic intima 
media t hickness s uggesting t he i mplication o f t his o rganism i n t he i nitiation o f  t he 
atherosclerosis. However further studies are required to explore the impact of 
infection in early atherosclerosis.
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1.7 SUMMARY AND AIMS
Cardiovascular disease is a major cause of morbidity and mortality that typically 
becomes prevalent from the fourth decade of life. The pathophysiological processes 
that underlie atherosclerosis however, begin much earlier even by the first decade of 
life. Endothelial dysfunction is thought to be a key event in the initiation of 
atherogenesis. A number of risk factors such as hypercholesterolaemia, diabetes, 
smoking etc have long been described for their detrimental effect both on the 
endothelium but also in other aspects of atherosclerotic process. However these risk 
factors are not prevalent in the young. Therefore, the identification of novel risk 
factors is necessary. Among them infection is the interest of this thesis. Exposure to 
viral and bacterial infectious agents is frequent in everyday life in all ages. Little 
clinical information exists in the literature about their role in the initiation of 
atherosclerosis whereas their role in triggering cardiovascular events has been 
extensively studied but remains controversial.
\
1.7.1 Aims of this thesis
1. To evaluate methods for assessing endothelial function non-invasively in 
childhood a nd a Iso a ssess t heir s ensitivity t o d etect t he v ascular e ffect of a cute 
inflammatory stimuli.
2. To examine the impact of common acute infections on vascular endothelial 
function in a population based cohort.
3. To examine the role of chronic infections using as a model HIV infection, on 
vascular function and structure.
4. To determine whether MBL can influence the vascular consequences to infection 
(in vivo and in vitro).
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CHAPTER 2
GENERAL METHODS
A. IN VIVO LABORATORY MEASUREMENTS
2.1 FLOW MEDIATED DILATATION
Studies performed in the 1980s indicated that large arteries (conduit vessels)
responded to alterations in blood flow by increasing vessel diameter and that this
phenomenon was endothelium dependent [361 ;362]. Early techniques were aimed at
the assessment of the coronary artery endothelial function and were necessarily
invasive and difficult to repeat over time. In 1989, a non-invasive ultrasound
technique was developed to assess endothelial function in peripheral conduit vessels
[362]. This technique is based on the observation that conduit vessels respond to an
increase in flow (or more precisely shear stress) by dilating [363]. This phenomenon
is designated flow mediated dilatation and has been shown to correlate well with
invasive testing of endothelial function in the coronary circulation [137]. FMD of the
brachial artery has been used to study endothelial dilator function in patients with a
variety of cardiovascular risk factors (hypercholesterolaemia, hypertension, diabetes, 
\
smoking) and has been used in large clinical studies as a surrogate marker for 
cardiovascular risk [ 134; 135].
Several patient related factors such as age, sex and ethnicity have also been shown to 
affect FMD results. Thus, FMD is decreased in older subjects and increased oxidative 
stress is a possible responsible mechanism [364]. Females have better endothelial 
function compared to males of similar age and smaller vessel size as well as 
oestrogens may account for these observations [365]. African-Americans have been 
shown to have lower FMD values when compared to healthy white subjects possibly 
reflecting the increased incidence of hypertension and vascular disease in the 
former[366;367].
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In addition, a number of environmental and lifestyle factors can influence FMD and 
should be taken into consideration when interpretating FMD results. For instance, 
colleagues i n o ur d epartment h ave p reviously d emonstrated t hat F MD i ncreases b y 
0.24% per °C difference in temperature [368]. Others demonstrated that a single high 
fat-meal can impair FMD within 2 to 5 hours, and increased oxidative stress and 
asymmetric dimethylarginine (ADMA) may be the responsible factors [369;370]. 
Similarly coffee intake 2 hours prior to FMD measurements has been associated with 
endothelial dysfunction; an effect mediated by caffeine as decaffeinated coffee 
consumption did not have similar detrimental effect [371]. Furthermore brief episodes 
of mental stress, similar to those encountered in everyday life, may cause transient 
endothelial dysfunction lasting up to 4 hours in h ealthy young individuals possibly 
through an increase in the endothelin activity [372].
To assess flow mediated dilatation in humans it is possible to study the brachial, 
radial, femoral and tibial arteries; however the vast majority of studies to date have 
assessed FMD in the brachial artery. The non-invasive nature of FMD allows studies 
to be conducted among children, adolescents and young adults, which can broaden 
our insight into the causes, development, and pathophysiological mechanisms of 
cardiovascular disease.
2.1.1 Physiology of FMD
FMD r elies o n t he p rinciple t hat b lood v essels d ilate i n r esponse t o an i ncrease i n 
blood flow. Increased blood flow is generated after a period of distal cuff occlusion, 
which induces reactive hyperaemia on cuff release. The increase in conduit arterial 
diameter in response to this high flow stimulus is measured using ultrasound and the 
magnitude of this dilation is taken as a measure of the bioactivity of the NO pathway. 
However, it has to be noted that the precise mechanism for the acute detection of the
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hyperaemia-induced increase in shear stress and the subsequent signal transduction to 
modulate vasomotor tone have not been fully characterised. Possible mechanisms 
involved in this process are Ca2+-activated K+ channel opening, hyperpolarisation of 
the cell membrane, protein kinase B mediated phosphorylation and Ca mediated 
activation of eNOS [128;373-375]. Once NO is produced from the endothelial cells it 
diffuses to vascular smooth muscle cells and activates sGC. This results in the 
generation of cGMP and the activation of cGMP-dependent protein kinase (PKG). 
The latter activates various pathways which result in reduced smooth muscle cell 
calcium concentration, dephosphorylation of contractile proteins and ultimately in 
smooth muscle cell relaxation [376;377].
It has been suggested that vascular endothelial cell hyperpolarisation, due to shear 
stress-induced K+ channel opening, results in Ca2+ entry to the cytoplasm [373] and 
activation of eNOS [374]. The subsequent generation of NO appears to account for 
FMD [378]. It has been demonstrated that endothelial denudation in vitro or 
administration of NOS inhibitors in vivo abolishes FMD in a variety of arterial vessels
[363]. In humans it is unknown whether other mediators, such as prostaglandins or the 
putative EDHF mediate FMD [379].
2.1.2 Experimental technique
2.1.2.1 Subject preparation
All FMD studies were performed in quiet temperature controlled rooms (24 to 26°C). 
All subjects were rested for at least 15 minutes while the procedure was explained 
step by step to reduce stress and ensure cooperation. The subject lay supine on a 
couch to minimize the effect of the orthostatic stimulus which will lead to an increase 
in flow mediated dilatation [380] and the right arm rests on a cushion as shown in 
Figure 2.1
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Figure 2.1: Experimental set up for FMD.
The experimental set up used to record FMD demonstrating stereotactic clamp and 
micrometer adjustment screws.
\
It is well established and emphasised by the guidelines of the International Brachial 
Artery Reactivity Task Force that a number of factors including fatty meals, caffeine, 
smoking, may affect FMD measurements [363]. Thus, extra care was taken to 
minimise the confounding effect of the above mentioned factors. Thus, all adult 
studies were performed following 8 hours fasting and none of the participants was a 
smoker or receiving vitamin supplements or vasoactive medications. Studies in 
children were performed in non-fasting state to increase recruitment and facilitate 
cooperation. However detailed documentation of any meals or beverages taken prior 
to the study was made to include this information in the analysis. Finally, none of the 
children followed any strenuous exercise programme prior to study nor were receiving 
any medications.
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2.1.2.2 Imase acquisition
High-resolution vascular ultrasound is used to image a straight, non-branching 
segment of the brachial artery above the antecubital fossa in the longitudinal plane. 
Ultrasound images rely on the principle that the sound waves transmitted through the 
tissues are reflected from interfaces between adjacent structures that have different 
acoustic impendances. The higher the frequency of the transmitted pulse, the shorter 
the wavelength and therefore the better the resolution.
Anterior 
Wall of 
Brachial 
artery 
Posterior 
Wall of 
Brachial 
artery
Figure 2.2: Stable image o f  a longitudinal section o f  the brachial artery.
Once a stable clear image is obtained (Figure 2.2), the ultrasound probe was securely 
fixed using a stereotactic clamp and micrometer adjustment screws (Figure 2.1), 
which permit adjustment in the coronal and sagittal plane to maintain a constant, 
focused image of the vessel being studied. Depth and gain settings were adjusted to 
enhance the contrast between the arterial lumen and vessel wall. Brachial artery 
images were recorded on to Super VHS videotape. In this thesis, studies in chapters 4 
and 6 were performed using an Aloka 5500, Japan, 7MHz linear probe while studies
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in chapter 3 and 5 were performed using a standard Acuson XP ultrasound system 
(Acuson, USA) also with a 7MHz linear probe.
2.1.2.3 Inducing high blood flow in a conduit artery
In order to determine FMD in the brachial artery, high blood flow is generated by 
inducing reactive hyperaemia. Colleagues in our department have previously 
demonstrated that duration of cuff occlusion affects the peak and duration of reactive 
hyperemia and the degree of vessel dilatation (Figure 2.3). Following these 
experiments occlusion time has been optimised to 5 minutes to achieve maximal 
dilatory response [381].
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Figure 2.3: The effect o f duration o f cuff occlusion on %FMD.
Cuff occlusions o f less than 1.5 minutes were not followed by significant dilatation, 
whereas with increasing cuff occlusion times up to 4.5 minutes, flow mediated 
dilatation increased linearly. No further increase in maximal dilator response was 
seen when the cuff occlusion time was extended further to 4.5 minutes (original data 
from Leeson et al[381]).
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In addition to occlusion time, cuff position is an important determinant of FMD 
response. Proximal occlusion leads to a greater dilator response, but this dilatation is 
thought to result from a combination of increased flow and ischaemia of the conduit 
vessel. The latter is a complex signal which is mediated by the release of local factors 
in addition to NO [382;383].
For the previously described reasons, for all the studies described in this thesis a 
blood pressure cuff (7cm wide) is positioned 1-2 cm below the antecubital fossa 
(Figure 2.4).
Ultrasound
probe
Pneumatic
cuff
Figure 2.4: Distal blood pressure cujfplacement to induce reactive hyperaemia.
The blood pressure cuff is inflated to supra-systolic pressure (standardised at 
300mmHg for adults and 200mmHg for children), causing forearm ischaemia, for five 
minutes, the optimal occlusion period to achieve maximal dilation [381]. Following 
ischaemia, vasodilatory metabolites (ie K+, adenosine, ATP) are produced and 
changes in pH occur that lead to a decrease in peripheral resistance while the brachial 
artery pressure remains normal [383]. As a result a rapid, transient increase in blood 
flow in brachial artery occurs which lasts approximately 90 seconds, with peak flow 
observed within 30 seconds following cuff release (Figure 2.5).
97
0 . 0  ■! 1 1 1 1
0 25 50 75 100
Time (Seconds)
Figure 2.5: Blood flow  /  time profile.
VTI: velocity -time integral
Increased blood velocity results in increased wall shear stress, which stimulates the
endothelium to release vasodilators (predominantly NO). This causes relaxation of the 
\
vascular smooth muscle and results in a measurable dilation of the vessel 
approximating to 5-10% of the baseline diameter measure [384].
a) Measurement of blood flow
Blood flow velocity was measured using pulsed wave Doppler. The Doppler signal is 
the velocity-time profile for a single cardiac cycle and is displayed as a spectral 
Doppler curve. The area under the curve of the velocity-time profile is the velocity­
time integral (VTI), and approximates to the average distance, measured in metres, 
travelled by a pulse of blood during one cardiac cycle (Figure 2.6). The resting VTI is 
0.01-0.05m.
98
VASCULAR LAB, GREAT ORMOND STREET HOSPIT P G .l 
PT: , A300T6.9801
S/s INVERTEp , CAL = . 50m/fS , , . 31
2 2 - J A N - 0 1  
0 4 : 2 2 : 1 1 A M
10 5MH
BRACHIAL A 
GENERAL
30dB - /  1 / - /D  
1 .5mm/l 
PW D= 19nm
177=0 403 m
Figure 2.6: Calculating the velocity time integral.
VTI = Velocity (m/s) x time (seconds)
VTI = [Distance (m) / time (seconds)] x time (seconds)
VTI = Distance (m)
Volume flow is the volume of blood that passes a point in a specified period. This can 
be calculated based on the assumption that we can approximate the segment of the 
studied artery to a cylinder (Figure 2.7). Blood flow volume can be calculated as 
follows
Figure 2.7: Approximation o f  an artery to a cylinder
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Volume /  cardiac cycle = artery cross-sectional area x average distance travelled by 
pulse = nr(t)2 fv(t) dt,
r(t) = the measured instantaneous vessel radiusy 
v(t) = the instantaneous blood velocity.
The Doppler signal is measured at an angle of approximately 70° to the axis of the 
blood vessel, giving f v(t) dt = cos 70° x measured VTI, and thus:
Volume / cardiac cycle = cos 70°.nr(t)2. VTI
Volume per minute is calculated by multiplying this value by heart rate (HR). 
Volume / min = HR cos 70°.nr(t)2. VTI.
VTI can be considered proportional to volume flow per minute if heart rate, the 
Doppler angle of incidence and arterial diameter (2 x arterial radius) remain constant 
during the period of study. Measurement of the radius for the period of peak flow (up 
to 30 seconds after cuff release) shows that Ar «  (tends to zero, compared with) 
baseline radius, i.e. there is no significant change in arterial radius (and diameter) 
during the period of peak flow (Figure 2.8). In addition during the same time period 
heart rate and Doppler angle are also constant, and thus it can be concluded that peak 
volume flow following cuff release coincides with peak VTI.
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The most significant error in the assumption that the volume flow per minute is 
proportional to VTI is due to variation in the radius. To calculate this error, the square 
(^ f the radius at time t, r(t)2, was expanded as follows:
r(t) = r(t=0) + Ar
r2(t) = (r(t=0) + Ar)2
r2(t) = r 2 (t=0) + 2r(t=0)Ar + A r2
= r2 (t=0)|l+2Ar/ r(t=0) + Ar 2/ r2 (t=0)|
In the above formulae, r(t=0) is the arterial radius at the time when the blood pressure 
cuff is released and it is equal to the radius of the artery prior to forearm ischaemia 
[baseline; r(baseline)]. Now as A r«r(t=0), we can ignore the last term, and the error 
in volume is:
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Volume / min = HR(t=0) cos 70°.nr(t=0)2. VTI [1 + 2Ar/r(l=0)J
So fractional error is typically (2Ar / r(t=0)), and thus varies with dilation. From figure 
2.8, the maximum error occurs at t~60s (time of maximum dilation and thus Ar) and is 
typically -6% . For the majority of the period of interest (30 seconds following cuff 
release), however, this is negligible, as arterial radius remains almost constant and 
approximately equal to r(t=0). Consequently the following formula can be used to 
calculate peak volume flow per minute during reactive hyperaemia:
Volume /  min (peak) = HR(at time o f peak VTI) cos 70°.nr(t=0)2.VTI(peak)
2.1.2.4 Analysis o f  FMD measurements 
a) Measurement of arterial diameter
hi the original description of the technique, the image of the vessel was recorded in 
M-mode [135]. Arterial diameter was measured using manual on-screen callipers, 
which were placed at the M-lines of the anterior and posterior walls, at a single point 
in the artery. This method is extremely labour intensive and is subject to significant 
observ er error and hence may be inappropriate for measurement of the brachial artery 
diameter response to increased flow which is generally on the order of 0.2-0.4mm and 
is even smaller in the presence of impaired endothelial function. In order to optimise 
analysis time, researchers have identified specific time points of interest (baseline, 
peak dilation and recovery of baseline) rather than the complete study. To overcome 
the limitations of this method, quantitative ultrasound techniques, using B-mode 
images, have been developed. In addition artery diameter is measured at the same 
time in the cardiac cycle. This is achieved by using electrocardiographic (ECG) gating
102
during image acquisition [363] (Figure 2.2). The onset of the R-wave is used to 
identify end diastole and the peak of T wave reproducibly identifies end systole. Peak 
systolic diameter is larger than end systolic diameter, because the vessel expands 
during systole to accommodate the increase in pressure and volume generated by left 
ventricular contraction. The magnitude of this response is affected by the vessel 
compliance and it may be reduced by factors such as aging and hypertension[363]. To 
minimise this confounding effect, ultrasound end-diastolic images of the vessel over 
3-second interval are acquired. These images are subject to 8 bit analogue to digital 
conversion. Proprietary commercial digital edge detection software (Brachial Tools, 
Medical Imaging Applications, Iowa City, Iowa, USA) is used to calculate the 
internal diameter of the artery (Figure 2.9).
Figure 2.9: Region o f  interest box during automatic diameter measure.
Initial calibration allows the observer to convert the image size on the computer, 
measured in pixels, to the actual diameter of the artery (mm). This is performed by 
drawing a line on the screen between two marks on the ultrasound image that are 
known to be 1cm apart. Finally the vessel region of interest (ROI) is used by the
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operator to select the most stable portion of the artery for automatic diameter analysis. 
Depending on the size of the ROI chosen by the observer 200-400 individual pixel 
columns are used to create the overall diameter for each frame. This method of 
analysis allows continuous and comprehensive description of the changes in vessel 
diameter that occur over time in response to a flow stimulus and would be expected to 
increase the precision of the measurements.
Once the study has been analysed a text file is generated and then by using an 
appropriate macro, a graph of the arterial diameter against time is created. The arterial 
dilator response can be expressed as absolute change in vessel diameter, or as 
percentage change in diameter from baseline. It is also possible to plot the whole time 
course of the dilatation and calculate both the peak dilation (the average of three 
highest measurements) and the area under the curve for the whole dilation profile 
(Figure 2.10).
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Figure 2.10: Area under the curve o f  diameter / time profile.
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2.1.3 Experimental protocol
All FMD studies described in chapter 4 and 6 were performed in 4 clinical rooms in 
the O Id C hildren’s H ospital i n B ristol U niversity as p art o f  t he A von Longitudinal 
Study of Children and Parents (ALSPAC). The FMD studies described in chapters 3 
and 5 were performed at the Vascular Physiology U nit, Department of C ardiology, 
Institute of Child Health, University College London.
Longitudinal ECG gated end diastolic images were acquired every 3 seconds using 
customised software and arterial diameter over 1 -2cm segment was determined for 
each image, using an automatic edge detection algorithm (Brachial Tools, Iowa USA). 
Pulse wave Doppler was used to measure blood flow velocity expressed as the 
velocity time integral (VTI) for a single cardiac cycle. Brachial artery diameter and 
VTI were measured for 1 minute (baseline), during 5 minutes of reduced blood flow 
(induced by inflation of a pneumatic c uff to 300mmHg for adults or 200mgHg for 
children placed at the forearm, immediately below the antecubital fossa, distal to the 
segment of brachial artery being analysed), and for 5 minutes during reactive- 
hyperaemia after release of the blood pressure cuff. The blood flow stimulus was 
expressed as the ratio of peak to baseline volume flow per minute. Dilation was 
expressed as peak percentage dilatation.
2.1.4 Accuracy and reproducibility of the technique
In any measuring technique, there are a number of potential sources of error. Ideally, a 
measure should be accurate and reproducible over both time and between observers. 
The problem of potential measurement inaccuracy in FMD was addressed in our 
department by Sorensen et al[ 136] using high resolution ultrasound to record the 
absolute dimensions of ‘phantom’ arteries of known diameter (mock blood vessels 
with the same ultrasound characteristics as the original embedded in a block of latex).
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These investigators recorded the observer’s ability to distinguish between small 
differences in phantom vessel diameters. Different observers were able to discern the 
absolute diameter correctly to within 0.04 mm and were able to distinguish between 
pairs of phantom arteries with diameter differences 0.1 mm in 61% of cases using this 
technique [136]. These data suggest that the technique is accurate.
In addition, it is also important to establish reproducibility of this technique over time 
(intra-observer variation) and between observers (inter-observer variation). Sorensen 
et al. have assessed inter-observer variability using the technique of FMD in a study, 
in which four independent observers recorded arterial diameter. They reported that no 
measurement was more than 0.1 mm from the measure made by the other 3 observers 
and the coefficient of variation was 1.8% [136]. However coefficient variation up to 
50.8% has been stated in the literature, depending on the site of measurement and 
protocol used [385]. Our reproducibility measurements are incorporated in chapter 3.
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2.2 ENDOTHELIUM INDEPENDENT DILATION
To assess endothelium independent dilatation, glyceryl-trinitrate (GTN) is given 
sublingually and arterial dilation is recorded. GTN supplies NO directly to vascular 
smooth muscle and causes relaxation, which is independent of the endothelial cell 
layer. Nitrovasodilators produce NO which activates sGC which produces cGMP and 
thereby activates PKG [386]. Following PKG activation either by inducing 
repolarization or by having a direct effect on Ca2+ channels the outcome is the 
decrease in Ca2+ and thus vasodilatation [376]. This test has been used as a 
comparator for FMD to determine whether any observed differences in FMD are a 
consequence of endothelial dysfunction rather than a reflection of differences in 
underlying smooth muscle function.
The degree of dilatation following GTN administration is dependent on the dose. 
Increasing doses up to 200pg of GTN are related to linear increase in arterial flow and 
in arterial dilatation. Maximal arterial dilatation is typically achieved at doses less 
than 400pg. Originally conventional anti-anginal doses of GTN (400pg) were used to 
measure maximal smooth muscle dilatation in experimental protocols [381]. This had 
two major disadvantages; firstly administration was commonly associated with 
headache, which though short lived and self-limiting is undesirable and secondly the 
dilator response of the conduit vessel to large doses of GTN was far in excess of that 
following reactive hyperaemia (which usually are around 5-10%). This meant that it 
was possible to miss subtle differences in intrinsic smooth muscle function because of 
the excess of NO applied to the system. Cross et al demonstrated that a smaller dose 
of GTN (25 pg) can induce a conduit vessel dilator response of similar magnitude to
107
the one induced by a flow stimulus in a cohort of chronic renal failure patients [387]. 
Subsequent work by Kharbanda et al confirmed these observations in healthy 
volunteers [388]. Peak vasodilation in response to GTN occurs 3-4 minutes following 
GTN administration.
In studies in this thesis, a 25 pg GTN dose was administered sublingually to test the 
intrinsic function of the vascular smooth muscle in the brachial artery in adults and 
also in diseased children. Brachial artery diameter was measured, as described above, 
for 1 minute, after which GTN was administered. Brachial artery diameter was 
measured for another five minutes following GTN administration. Dilation in 
response to GTN was expressed as peak percentage dilation (Figure 2.11).
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Figure 2.11: A typical readout o f endothelium independent response to GTN.
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2.3 PULSE WAVE ANALYSIS
The first quantitative recording of the arterial pulse was made in 1860 by Etienne 
Jules Marey who developed a mechanical sphygmograph which reproduced the 
arterial pulse waveform on a paper display.
2.3.1 Physiology of PWA
Viewed from the heart there are 2 apparent reflection sites, one in the lower body and 
one in the upper body. O’ Rourke introduced the asymmetric T tube model to describe 
these 2 reflection sites. When the heart beats it generates a direct pressure pulse which 
travels forward in the arterial tree. At various points in the arterial tree the pressure 
waves are reflected creating backward travelling waves in the arterial system, which 
summate with the direct forward travelling wave. The pressure pulse at any point of 
the arterial tree is hence the summation of a direct wave and reflected waves from the 
periphery [389;390]. The reflected waves have their origin at points where the flow 
and pressure waves are not perfectly m atched. Common reflection s ites are branch 
points, constrictions or areas of turbulence [391]. The pulse pressure increases 
markedly as the wave travels toward the periphery due to increases in arterial stiffness 
and wave reflection amplitude so that these pressure components are greater in 
peripheral arteries than in the ascending aorta. The degree of amplification is related 
to the difference between elastic moduli of the respective arteries and distance to 
reflection sites [392].
2.3.1.1 Applanation tonometry’
Applanation tonometry is a non-invasive technique for measuring arterial pressure. A 
piezo-resistive transducer is applied over an artery. When the piezoelectric crystal is 
deformed by arterial pressure transmitted through the overlying superficial tissue and
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skin, its resistance changes. This change in resistance is directly related to the pressure 
applied on the crystal. There are now different ways of accommodating the 
piezoelectric transducer. It can be mounted on the tip of pen-type probe (Millar 
micromanometer, Texas US) or an array of transducers can be strapped around the 
wrist (Colin wrist probe, Japan). Applanation tonometry requires the artery to be 
flattened against a hard surface such as the head of the radial bone (radial artery) or 
the vertebral column and ligaments in the neck (carotid artery). With knowledge of 
the normal waveforms and frequent use it is relatively easy to obtain optimal traces. 
Applanation t onometry has b een v alidated a nd t he r adial a rtery p ressure w aveform 
obtained is very close to that obtained using invasive intraarterial measurements of the 
radial artery pressure waveform.
2.3.1.2 The Millar probe
The radial and carotid artery pressure waves and amplitude were recorded non- 
invasively with a pencil type probe (at the base of the neck for the common carotid 
artery and over the right radial artery). The probe incorporates a high fidelity strain- 
gauge transducer at the tip, which has a small pressure sensitive ceramic sensor area 
with a frequency response of >2kHz that is coplanar with a longer area (7mm 
diameter) of flat surface in contact with the skin overlying the arterial pulse (Millar 
instruments). The probe’s technology is based on the principle of applanation 
tonometry.
2.3.1.3 Augmentation index
Indices to characterise the pressure pulse can be derived from the contour of the pulse. 
The feature of the pulse contour, which has received the most interest, is the peak (or 
shoulder) that occurs in systole due to reflected waves. Murgo et al [393] studied the
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contour of the pressure pulse in detail and were the first to define the AIx. AIx is a 
measure of the increase in BP caused by the return of the reflected wave during 
systole. AIx will depend on the characteristics of the reflected wave such as its timing 
(large artery stiffness) and its amplitude (related to peripheral vascular tone).
Carotid and radial pulse pressure waveform
The contour of the pulse pressure waveform differs according to the site of the 
measurement due to the propagation and reflection of pressure waves throughout the 
vasculature[394-396]. There is however little difference between the carotid pulse and 
the aortic pulse because the distance between the two arteries is relatively small. The 
carotid pulse has a short sharp incisura denoting aortic valve closure and the end of 
ventricular systole as does the ascending aortic pulse (Figure 2.12). Also the carotid 
pulse shows the same type of late systolic augmentation in middle aged and older 
adults as does the ascending aortic pulse. Carotid pulse AIx has been shown to 
correlate with and to be an independent determinant of left ventricular hypertrophy.
Caroti<^ pulse Sharp incisura
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Figure 2.12: Carotid pulse pressure waveform.
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Although the carotid pulse is easily accessible, it can be a challenge to obtain accurate 
recordings. The carotid artery is sited deeply in the neck and is poorly supported 
laterally. Thus it is difficult to obtain consistent records from the carotid artery. In 
addition, the assumption is made that systolic and pulse pressures are the same as in 
the brachial artery. Application of the probe to the carotid artery can lead to cardiac 
slowing which is attributable to baroreceptor stimulation or to gagging and coughing 
due to pressure on the neck near the throat, thus being relatively unpleasant for many 
people.
By contrast, the radial pulse is easily accessible and the artery can be applanated 
against the radial bone without difficulty. The shape of the radial pulse is very 
different from the aortic pulse. The propagation, timing and reflection of pressure 
waves in the vasculature cause the peripheral pressure pulse to differ from the central 
pressure pulse [396]. Mechanical and elastic properties of the arterial tree distort the 
direct and reflected waves during their propagation and, especially in young subjects, 
the peripheral pulse pressure is increased compared to central pulse pressure [397- 
399]. In the radial waveform, the reflected wave usually causes a shoulder on the 
down-slope of the systolic part of the radial pressure pulse (Figure 2.13).
Radial pressure waveform
Figure 2.13: The radial pulse pressure waveform.
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It is increasingly recognised that important information relating to arterial wave 
reflections can be derived from the contour of the aortic pulse. In the past AIx was 
obtained from invasive aortic pressure recordings. More recently there has been much 
interest in the estimation of the aortic waveform from the more accessible peripheral 
arteries (carotid and radial). Synthesis of the aortic wave from the radial or carotid 
pressure wave assumes a generalised transfer function (the relationship between 
pressure waves at different sites). Use of generalised transfer function assumes that 
properties of the arterial system between two sites are similar in all persons and under 
all conditions [400]. Although this does not seem to be the case, the results using a 
generalized transfer function approach 90% accuracy in estimating central systolic 
blood pressure however controversy exists for the accuracy in estimating aortic 
AIx[401]. Millasseau et al [402] in studies performed in young subjects observed that 
there is a close correlation between the aortic AIx derived by application of a transfer 
function to the radial waveforms and the radial AIx calculated directly from the radial 
waveform without use of transfer function. The correlation between these indices was 
greater than that between values of aortic AIx derived from radial and carotid 
waveforms by using the transfer function approach. The authors concluded that radial 
AIx may provide an equally good measure of central pressure reflection.
Factors that affect AIx
Ageing has been associated with increase in AIx [403]. With increasing age the 
arterial wall becomes thickened and stiffer (Figure 2.14). There is hyperplasia of the 
intima and in the media the elastin is reduced and replaced with collagen. As a result 
of these changes with increasing age there is a progressive increase in late systolic 
pressure peak in both radial and carotid arteries t ogether with disappearance of the
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secondary diastolic pressure wave. Changes are similar at both sites but at any age the 
late systolic pressure wave is lower in the radial artery than in the carotid.
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Figure 2.14: The effect o f age on peripheral and central pressure waveform.
Original data from Nichols[404]. Solid thick arrows identify the peak o f the reflected
wave and solid thin arrows indicate the beginning o f the reflected wave
Apart from age, differences in body height affect the AIx [405;406]. The shorter the 
height the higher the AIx, possibly as a result of the early reflection of the pressure 
wave. The differences in body height can also explain the differences in augmentation 
index observed between males and females. Heart rate also affects AIx. The faster the 
heart rate the lower the AIx. More specifically AIx increases by 0.24% for lbeat/min
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decrease in the heart rate [407]. This inverse relationship can be explained by the fact 
that when the heart rate is fast the duration of the ventricular ejection period is 
decreased, therefore the reflected waves are more likely to arrive in diastole. The left 
ventricle has to work against a smaller pressure and there is greater perfusion to the 
coronary arteries which results in the summation of the incident and reflected wave. 
Lifestyle factors such as smoking and caffeine intake (Figure 2.15) have also been 
shown to alter the arterial wall properties both acutely and chronically [408]. This 
might possibly be mediated by the antagonism of endogenous adenosine or due to 
increased catecholamines following caffeine intake or through endothelial dysfunction 
that has been demonstrated for both factors.
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Figure 2.15: The effect o f  caffeine on radial and aortic pressure waveform.
(original data from Vlachopoulos et al [409]).
A number of cardiovascular risk factors including hypertension, diabetes and 
hypercholesterolaemia have been associated with an increase in AIx. Hypertension is 
associated with increase in arterial stiffness and by itself may cause pressure wave 
changes (increased amplitude of the secondary systolic pressure wave) which are 
comparable to the ones seen because of the ageing process. Diabetes mellitus has also
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been thought to increase the arterial stiffness of elastic arteries [410]. This again 
causes early return of the reflected waves to the ascending aorta and increases aortic 
AIx. Dyslipidemia, another risk factor for the development of atherosclerosis has been 
associated with alterations in the elastic properties of the aorta. In patients with 
heterozygous familial hypercholesterolaemia increased aortic stiffness was found 
compared to age-matched normolipidemic siblings and reduction in nitric oxide 
bioavailability and endothelial dysfunction may be the implicating 
mechanisms[411 ;412].
Changes in AIx occur due to changes in amplitude and timing of wave reflection as a 
result of increased stiffness of the large elastic arteries with little change in muscular 
arteries. Vasodilator drugs such as the ACE inhibitors, nitrates, NO, salbutamol etc 
decrease arterial stiffness and pulse wave velocity and thus alter reflected wave 
characteristics through their action on smooth muscle cells in the arterial wall 
[147;413-416]. This mechanism delays return of the reflected wave from the 
periphery to the heart and decreases its amplitude and duration (Figure 2.16).
Before nitrate 9 min after nitrate
Figure 2.16: The impact o f GTN on radial pressure waveform.
Original data from Jiang et al [414].
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23.2 Experimental technique
All subjects were studied supine. The blood pressure was measured non-invasively 
using Omron automated sphygmomanometer recordings on the contralateral arm. 
Immediately after blood pressure measurement, the radial artery pulse was felt and the 
pencil probe was positioned on top of the point where the strongest pulse was felt. 
Extra care was taken to ensure that the arm holding the pencil probe was comfortably 
positioned so that the elbow or the wrist was resting against a solid surface to 
minimise interference from operator movements.
sphygmoCor
Millar pmbe
Figure 2.17: Set up for PWA measurements in the radial artery.
Once a satisfactory signal has been obtained (pressure waves are completely 
consistent beat to beat, amplitude is optimised and the pulse wave measured has the 
same character as one would expect in the artery) from at least ten consecutive pulses 
then the recording was taken to determine heart rate and AIx. The radial arterial 
pressure waveform was recorded directly onto a laptop computer running proprietary 
waveform analysis software (SphygmoCor Px Version 6.0, ATCOR, Sydney 
Australia).
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2.3.2.1 Analysis ofPWA measurements
The SphygmoCor analysis software automatically averages approximately 10 
waveforms and calculates AIx on the averaged waveform. From the measurements in 
the radial artery both the aortic AIx (using transfer function) and the peripheral AIx 
were calculated. For studies performed in children the peripheral AIx was used for our 
calculation as the secondary wave is more easily detected by the automated software, 
it provides accurate information about central pressure reflection and also the inbuilt 
transfer function has not been validated for children and is therefore inapplicable to 
the studies described in this thesis.
Quality control
Differences in the timing and amplitude of reflected waves will alter the pressure 
pulse contour, and explain the differences in the pressure pulse contour measured at 
different site. Reasonable confidence is gained about the quality of the measurement if 
the pressure waves are highly consistent beat to beat, if amplitude is the greatest that 
can be achieved and if the pulse wave measured has the same character as one would 
expect in the artery ie sharp upstroke, straight rise to the first systolic peak, a definite 
sharp incisura, and near-exponential pressure decay in late diastole [417]. The best 
quality is usually achieved by placing the tonometer probe on the point where the 
strongest pulse is felt and also both the patient and the technician have to be very still. 
The software has an inbuilt control system to ensure optimal quality in the waveform 
as defined by the manufacturer, ie mean pulse height >100mV, pulse height 
variability and variability of diastolic points as a percentage of the pulse height <5% 
(Figure 2.18). Apart from AIx a number of other relevant parameters can also be 
derived from PWA measurements.
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Peripheral T1.T2. AIx 106m. 302m. 25% Aortic AIx (AG/PP)@HR 75 -38%
CENTRAL HAEMODYNAMIC PARAMETERS 
Heart Rate. Penod 56 bp«. 1078 m  PI Height (PI • Dp] 31 mHg BuckbergSEVR (Ad/As) 152*(2441/1803)
Ejection Duration 375 ms. 35X Augmentation -9 mmHg MP. (Systole. Diastole) 77,52 mmHg
| Aortic T1.T2.Ti 121.272.173 m  AIx (AG/PP, P2/P1] -23%. 71* End Systolic Ptem«e 69 rrtnHg_________
Figure 2.18: PWA analysis report.
Good quality signal is obtained when all the parameters in the quality control box 
(red circle) are in green.
Central systolic and diastolic pressures are peak and trough of the aortic wave 
respectively. The first pressure peak (PI) is caused by left ventricular ejection, the 
second (P2) is caused by wave reflection. The height of the reflected wave measured 
from the level of PI is central augmentation pressure. It can be positive, if P2>P1 or 
negative if P2<P1. In the latter case P2 occurs later and is on the declining part of the 
pressure curve. Ejection duration (ED) and time to P2 are the distances from the 
beginning of the pressure wave to the dicrotic notch and to the peak of reflected wave 
respectively; their ratio (TP2:ED) characterizes the type of wave reflection. Further 
parameters are central mean systolic and diastolic pressures which are the mean 
pressures during systole and diastole respectively (Figure 2.19). Central systolic and 
diastolic pressure-time indices are the areas under systolic and diastolic parts of the 
curve, respectively multiplied by heart rate.
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Figure 2.19: Radial and derived aortic pulse waveform obtained from pulse wave 
analysis.
Radial pulse wave is calibrated on blood pressure measured conventionally 
(peripheral systolic a nd diastolic b loodp ressure, PSP, PDP), a orticp ulse wave is 
calibrated on mean pressure, obtained by integration o f  radial pulse wave, assuming 
that mean pressure is identical at two sites. CSP, CDP, central systolic and diastolic 
pressure; ED, ejection duration; PI, P2, first and second pulse pressure peak, 
respectively; CAP, central augmentation pressure -  increase o f  pressure over PI due 
to wave reflection; TP2, time to the peak o f reflected wave. Original data by 
Filipovsk}' [417].
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2.4 PULSE WAVE VELOCITY
Arterial stiffness has been implicated in atherosclerotic disease progression. An 
increase in arterial stiffness will lead to increased central systolic and pulse pressure- 
as well as left ventricular afterload- and decreases coronary artery perfusion pressure. 
The pressure pulse takes a finite time to propagate along the aorta.
An increase in aortic pulse wave velocity (PWV) with age and blood pressure was 
recognised as early as 1934-1936 by Hallock and Haynes et al. Since then a number 
of studies demonstrated that pulse wave velocity is associated with cardiovascular 
mortality [418].
2.4.1 Phvsioloev of pulse wave velocity
Pulse wave velocity is a well-established technique for obtaining a measure of arterial 
stiffness between two locations in the arterial tree, as the velocity of the pulse wave 
along an artery is directly dependent upon the stiffness of that artery. PWV can be 
measured using the Bramwell-Hill (PWV=VAPV/AVp where APV/AV=relative 
volume elasticity of vessel segment, p=density of blood)[419]. But a more practical 
approach is to measure transit time, the time the arterial wave takes to travel from one 
point to another point. The assessment of PWV then relies on the determination of the 
pulse transit time (TT) over an arterial segment of length and the measurement of the 
arterial pulse at 2 different sites.
2.4.2 Experimental technique
As with the pulse wave analysis the SphygmoCor system was used to assess arterial 
stiffness. It uses a 3-lead ECG in conjuction with a tonometer to measure the pressure 
pulse waveform sequentially in the two peripheral artery sites. As with the pulse wave
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analysis, the brachial blood pressure is taken just prior to performing the SphygmoCor 
measurement to allow calibration of the radial pressure waveform. The three ECG 
leads a re a ttached t o t he s ubject a nd t he h eart b eat i s c ontinuously recorded. M ost 
commonly, pulse wave velocity measurements are performed between the carotid and 
femoral artery sites, so as to measure specifically the stiffness of the aorta. For the 
studies described in this thesis the radial to carotid recordings were used to calculate 
pulse wave velocity. The choice of the arterial sites was principally based on the fact 
that these arteries are easily accessible and also to  minimise the emotional distress 
related to groin exposure in children. The tonometer is placed on the wrist directly 
above the right radial artery. The waveform is recorded on the computer. The data 
collection screen allows the operator to see the peripheral signal and display of the 
last 10 seconds of data. Recordings were taken when a reproducible signal was 
obtained with high amplitude excursion. Then another recording from the carotid 
artery is made. The subject is asked to extend their neck so that the carotid artery will 
be flattened against the muscles of the neck. Sometimes to improve the recording the 
subject was asked to breathold on expiration to minimise the often marked respiratory 
variation seen in young subjects.
2.4.2.1 Analysis o f PWV measurement
The Sphygmocor device uses successive measurements of pressure waveforms and a 
simultaneous ECG. For each measurement site, the delay from the R-wave of the 
ECG t o t he f oot o f t he pressure p ulse i s d etermined. S ubtraction o f t he R-wave t o 
pulse foot time at the proximal and distal sites provides the transit time (Figure 2.20). 
PWV is then calculated from the arterial length and transit time using the intersecting 
tangent algorith. This algorithm uses the point formed by the intersection of a line
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tangent to the initial systolic upstroke of the pressure waveform and a horizontal line 
through the minimum point. The distance travelled by the pulse wave was measured 
over the body surface with a tape measure. PWV was calculated as the distance: 
transit time ratio and is expressed as meters per second.
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Figure 2.20: PWV acquisition page.
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2.5 DIGITAL VOLUME PULSE (DVP)
In the 1930s Alrick Hertzman described a photoelectric plethysmograph, a device 
which takes advantage of the fact that the absorption of light by a transilluminated 
tissue varies with its blood contents [420]. This device illuminated the skin and back- 
scattered light was measured by a photocell.
2.5.1 Physiology of DVP
By transluminating tissue, one can measure the light absorption in  the finger. This 
technique is widely used in oxymeter devices to determine oxygen saturation in the 
arterial blood. Oxygen saturation is measured from the ratio of absorbance of the red 
(usually 660 nm) and infra-red (usually 940nm) light, the red light being mainly 
absorbed by deoxyhemoglobin and the infra red light by oxyhemoglobin [421].
The DVP is formed by the pulsatile component of the infra-red light transmitted 
through the finger pulp. Variations of the digital intra-arterial pressure during the 
cardiac c ycle d istend t he a rterial wall a nd s o i ncrease b lood v olume i n the a rterial 
segment and downstream vessels and thus generate the DVP [422].
The light absorbance can be divided into a constant component and a pulsatile 
component, which gives the arterial volume pulse. Reduction in blood perfusion in the 
finger tip (for example in subjects with cold hands or Raynaud syndrome) results in a 
smaller constant and pulsatile components but pulse contour remains similar.
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Figure 2.21: Principle for DVP measurements.
Original data from Millasseau et al[423].
The DVP and the pressure pulse are related by a generalised transfer function 
independent of individual variation and interventions. So, the DVP contains the same 
information as the pressure pulse and it is thus most likely that the DVP is influenced 
like the pressure wave transmission and reflection. Like the pressure pulse the first 
peak of the DVP will then correspond to a direct wave travelling from the heart to the 
finger and the second peak to a wave reflected from the lower body. The amplitude of 
the reflected wave will depend on the amount of reflection. The time delay between 
the direct wave and the reflected wave will be determined by the speed of wave 
propagation [423] (Figure 2.21).
2.5.1.1 DVP vrobe
Of the two wavelengths used in pulse oxymetry, infra-red light is absorbed most by 
the finger pulp, and provides the pulsatile signal of the greatest amplitude. For this 
reason the DVP was measured using a modified pulse oxymetry probe (Nellcor, 
California, US) (Figure 2.22). It consists of an infra-red light emitting diode and a 
photodiode mounted on a finger clip. The pulsatile (AC component) part of the signal 
measured by the photodiode is the DVP. The signal from the photodiode was filtered
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and amplified and the DC component removed by an electronic circuit (Micro 
Medical Ltd, Gillingham, UK).
\ \
DVP probe
Figure 2.22: Pulse trace system (Micro Medical).
2.5.2 Experimental technique
The subject lay supine for at least 15 minutes before the initiation of the studies in a 
temperature controlled room 25-27°C. Skin temperature measurements were taken to 
ensure that fingers were warm and the hand was resting on the bed. The DVP probe 
was placed in the terminal phalanx of the left index finger in a way that embraces the 
whole pulp. To minimise the occurrence of poor signals from vasoconstricted and 
poorly perfused subjects a unique control system maintains the light transmission at 
the optimum level to accurately follow blood volume changes, independent of the 
subjects’ finger size to obtain an extremely accurate and noise free signal. The 
technique is well tolerated by the subject.
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2.5.2.1 Analysis o f DVP signal
The signal from the modified Nellcor probe was sampled at 100MHz using a 12-bit 
analogue to digital acquisition board (PC30F Series Board of Eagle Technology) and 
stored on a PC using custom-built software. The software allowed continuous 
recording o f t he D VP waveform for f urther a nalysis s uch a s t he c alculation o f t he 
second derivative, transfer function or indices characterising the contour of the pulse. 
The algorithms to calculate the average pulse and the contour indices were first 
developed with Matlab (Mathworks, US) and then implemented as embedded 
software in desktop unit (Figure 2.22) (Pulse Trace, Micro Medical Ltd, UK). In this 
unit, the signal is digitalised at 100 Hz and sampled with 8-bit resolution. Pulses are 
ensemble averaged and contour indices are derived from the average DVP. It averages 
the digital volume pulse waveform over a 1 min period. It rejects waveforms with low 
amplitude, artefact or noise and rejects ectopic and arrhythmic waveforms. The total 
number of waveforms identified and the total number of waveforms used in the 
calculations w ith t heir st andard d eviation i s t hen d isplayed. T he p oints u sed i n t he 
calculations are marked as systolic peak, systolic inflection point if present and 
diastolic inflection point. The machine has a colour liquid crystal display (LCD) 
screen giving real time blood volume pulse waveforms; signal averaging with 
advanced rejection/acceptance criteria. The pulse trace measurements may be printed 
at the time during the test or saved and printed at a later time from the system 
memory. The unit can also be connected to the serial port of a computer running pulse 
trace utilities software that allows the database including the waveforms to be 
uploaded to a computer for viewing, storage, report generation and data trending.
From the DVP measurements a reflection index (RI) and stiffness index (SI) is 
generated.
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Derivation of reflection index from DVP
The RI is the height of the diastolic component of the DVP expressed as a percentage 
of the systolic peak. It has long been shown that nitrovasodilators can alter the pulse 
waveform inducing a reduction in the inflection point in the downslope (Figure 2.23).
DVP “
Figure 2.23: Calculation o f the reflection index.
More recently it has been documented that substances which stimulate the 
endothelium to produce NO such as acetylcholine can have similar effect on the 
inflection point of the digital volume pulse [424]. Chowienczyk et al studied the 
factors that influence the RI [425]. They found that locally induced changes in the 
flow as those produced by infusion of vasodilators in the brachial artery did not alter 
the RI whereas systemic administration of the vasodilators had a significant impact on 
the RI [425]. The authors suggested that this effect could be explained by reduction in 
pressure wave resulting from vasodilation of arteries in the lower body as a result of 
the systemic administration of nitrovasodilators. In addition, they found that 
vasodilators that stimulate NO release from the vascular endothelium had a significant 
effect on RI. Thus, they proposed that the response of RI to vasodilators could be used 
as a surrogate endpoint to assess conditions associated with endothelial 
dysfunction[425].
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The RI varies less with blood pressure but does vary with heart rate. In part this is 
because reduced reflection is usually associated with tachycardia. RI is a measure of 
peripheral vasodilatation and it varies between 60-90% in normal subjects.
Derivation of SI index: an index of vascular stiffness from the DVP 
As I have previously mentioned the DVP is formed by the summation of the direct 
wave and reflected wave. The time delay between the direct and the reflected wave is 
determined by the forward and backward propagation time along the aorta and large 
arteries and thus could be used to measure pulse wave velocity [425]. However, it is 
not possible to measure the exact time of arrival of the reflected wave but the peak to 
peak time (PPT) should be a good approximation. This PPT was shown to be closely 
related with the pressure wave transit time from the root of the subclavian artery to the 
aortic bifurcation [425]. The stiffness index is an estimate of pulse wave velocity in 
large arteries and is obtained from subject’s height divided by the time between the 
systolic and diastolic peak of the DVP and is a measure of large arteries stiffness 
(Figure 2.24).
. Subject height
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Figure 2.24: Calculation o f the stiffness index.
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SI is influenced by age and blood pressure in a similar manner to PWV. In addition SI 
shows little change with nitrovasodilators which influence the tone of small muscular 
arteries comparable to the effect seen in the PWV [423].
2.5.3 Accuracy and reproducibility of arterial stiffness measurements
There are differences in validation procedures used for the different techniques 
between different groups. There is no gold standard method for local or regional in 
vivo assessment of arterial stiffness. In general most of the studies have demonstrated 
good reproducibility figures for the aortic AIx with intraobserver variation between 
4.5% to 6.5% and for interobserver variation 5.1% to 8.4%. For aortic PWV Liang et 
al [426] reported intraobserver coefficient of variation of 3.2% while other reported 
coefficient variation of 8.8%. For the DVP as far as the stiffness index is concerned a 
coefficient variation o f 9.6% was reported b y  Millasseau et al. Our reproducibility 
measurements using these techniques are included in chapter 3.
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2.6 INTIMA MEDIA THICKNESS (IMT)
Arterial vessel wall changes occur during a long subclinical lag phase and are 
characterized by functional disturbances and by gradual thickening of the intima 
media. Over the past decade the measurement of carotid artery intima media thickness 
using high resolution B mode ultrasonography has emerged as one of the methods of 
choice for determining the anatomic extent of atherosclerosis and its progression and 
for assessing cardiovascular risk. Measurement of IMT is non invasive, safe and well 
accepted by patients and it has been associated with the presence and extent of 
coronary atherosclerosis [427]. Measurements can be performed serially and 
theoretically it has the advantage of visualizing the arterial wall, in contrast with 
angiographic techniques which provide only an outline of the arterial lumen. Proof of 
validity of this methodology is based on several lines of evidence. Several 
observ ational studies have demonstrated that there is a relationship between ultrasonic 
and histological determination of IMT although in some studies it was demonstrated 
that ultrasound estimation gives a slighter higher IMT reading [428]. This could be 
explained by post-mortem shrinkage of the tissue but also by contraction which can 
occur during histological fixation. Carotid IMT increases significantly with age and 
several studies have demonstrated that is greater in men compared with women. Rates 
of progression in control group have ranged from 0.006mm/year in asymptomatic 
subjects to 0.06mm/year in subjects with coronary artery disease [429;430].
In the Insulin Resistance Atherosclerosis Study it was found that ethnicity may also 
influence carotid IMT, since black participants were shown to have significantly 
greater carotid IMT than the white participants [431]. Moreover other well established 
cardiovascular risk factors have also been associated with increased IMT. Several 
studies have shown that diabetes mellitus is associated with an increased IMT and that
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duration of type 2 diabetes is also an important determinant of increased 
IMT[432;433]. Increased carotid IMT was also found in hypercholesterolaemics[434]. 
Of all the traditional cardiovascular risk factors hypertension seems to have the 
greatest impact on IMT, probably via medial hypertrophy [435;436]. The association 
with the cardiovascular risk factors is evident even in the young ages as it has been 
demonstrated recently in the Bogalusa Heart Study[437]. In addition, recently a 
positive association has been documented between carotid IMT measurements and 
presence of carotid plaques (localised echostructure that encroached into the 
vessel>l mm b eyond t he i nterface b etween 1 umen a nd i ntima) a nd t he F ramingham 
risk score and the carotid IMT, suggesting that different risk factors might have an 
additive influence on IMT [438]. Lifestyle influences have also been shown to affect 
carotid IMT. In the Monitored Atherosclerosis Regression Study dietary cholesterol, 
body mass index and smoking were important determinants of the annual progression 
of carotid IMT [439].
Several prospective studies have demonstrated that carotid IMT is associated with 
cardiovascular outcome [440]. For instance the Kuopio Ischaemic Heart Disease Risk 
factor (KIHD) study in middle aged Finish men demonstrated that IMT of 1mm or 
above doubled the risk for acute myocardial infarction over 3 years period [441]. 
Similar findings were reported for the ARIC study [442]. The Rotterdam Study has 
shown that an increase of 0.16mm in IMT is associated with a risk ratio of 1.4 for 
acute myocardial infarction or stroke for a 3 year period [443;444].
Carotid IMT has also been shown to be responsive to interventions. Therapeutic 
interventions with blood pressure lowering agents, lipid lowering agents as well as 
multi factorial interventions in diabetics can slow the progression or even reduce
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carotid IMT [445-448]. Apart from pharmacological interventions, lifestyle 
modifications such as weight loss and smoking cessation have been associated with 
0.13mm/year reduction in progression of carotid IMT [439]. Although recently 
carotid IMT has been recognised as a surrogate marker by which to evaluate 
therapeutic interventions in atherosclerotic disease [449], the additive predictive value 
of IMT to the commonly used risk factors for estimating or predicting cardiovascular 
events remains a matter of debate.
2.6.1 Experimental technique
2.6.1.1 Imase acquisition
Different ultrasound techniques have been used to measure IMT in the carotid artery. 
Although most groups use the B-mode to calculate the average IMT of an arterial 
segment [450], some others used M-mode techniques to assess IMT at a discrete 
arterial position at a fixed timepoint in the cardiac cycle [451]. More recently, 
echotracking devices have also been used to measure IMT. These devices can 
calculate IMT at a fixed timepoint and also the average IMT during one cardiac 
cycle[452].
A number of different scanning procedures (reference site, arterial wall, direction of 
scanning) have been used to determine IMT. Most of the studies have measured IMT 
in the carotid artery but the best site of carotid IMT measurement is still a matter of 
debate (Figure 2.25). Common carotid artery (CCA) (1-2 cm proximal to the carotid 
bulb) was examined in most studies whereas the internal carotid artery (ICA) and 
carotid bulb were studied less often [453]. The CCA is easier to image as it is 
relatively close and parallel to the skin surface. In contrast IMT measurements in the 
ICA can be shown to be quite challenging [454]. Although atherosclerotic lesions 
appear later in the CCA compared to ICA or bifurcation, changes in all sites seem to
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be equally strongly associated with risk of subsequent cardiovascular 
events[441;455]. Apart from the carotid artery other arterial sites as the common 
femoral, brachial or radial arteries have been proposed for IMT measurements.
Figure 2.25: Schematic representation o f  the CCA, the bifurcation, the ICA, and the 
external carotid artery. Original data from Kanters et al [456].
While the elastic common carotid artery is assumed to represent mainly intimal 
thickening, IMT of the more muscular peripheral arteries represents both a change in 
the intima and /or media layer [452]. There is conflicting information in the literature 
as to whether IMT thickening in the muscular arteries has the same meaning as 
carotid artery IMT thickening. The Angina Prognosis Study in Stockholm (APSIS) 
study showed that IMT of the common femoral artery has prognostic implications in 
patients with stable angina pectoris but is different from common carotid artery 
IMT[457]. Other groups have reported an association between ventricular 
hypertrophy and IMT of both the common carotid and the brachial artery in patients 
with previous myocardial infarction. Another study showed that increased blood 
pressure was associated with increased IMT of the femoral artery but not the carotid 
artery [458]. Overall since there are a number of indications that increased IMT of the 
muscular arteries does not have the same meaning as carotid artery EMT and
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considering that increased medial layer has not been shown to be a marker of 
generalized atherosclerosis, the carotid artery has been suggested as the preferred site 
for IMT measurements [452].
Discrepancies exist also as to which arterial wall should be measured. Different 
scanning directions have been implemented in some studies for IMT measurements 
(anterolateral/ lateral/ posterolateral) so as to get better view of wall-thickness 
eccentricity [459]. Most studies have measured IMT on the far wall, while others 
averaged these measurements with those of near wall [460]. Reliable IMT 
measurements can be obtained from the far wall whereas near wall measurements are 
not equally reliable. This is due to the different order in which the interfaces of the 
intima-lumen and media-adventitia are exposed to the incoming ultrasound beam, 
generating different B-mode images of the near and far wall. In general, good image 
of the near wall depends strongly on the gain settings, and is more difficult to 
standardize. Measurements from the far wall are more reproducible than those of the 
near wall.
2.6.2 Experimental protocol
The subject lay supine in a temperature controlled room. Both the right and left 
carotid arteries were scanned using a 5-10 MHz linear array transducer (Acuson, 
Aspen) in order to detect vessel wall changes and to measure common carotid IMT. 
The proximal part of the carotid bulb was identified, and the segment of the common 
carotid artery 1 cm proximal to the bulb was scanned as this region has been 
demonstrated to provide the most reproducible results when measurements are 
performed in more than one direction. The transducer was manipulated such that the 
near wall of the carotid artery was parallel to the transducer footprint and the lumen 
maximised i n t he 1 ongitudinal p lane. T he i mage w as f  ocused o n t he p osterior ( far)
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wall and the resolution box function was used to magnify the arterial far wall. Since it 
has been shown that IMT of the carotid artery changes during the cardiac cycle 
(decreases during systole due to the larger vessel diameter and increases during 
diastole), the optimal longitudinal image was acquired on the R wave of the 
continuously recorded electrocardiogram and videotaped on Super VHS tape for 5 
seconds to minimize variation.
2.6.2.1 Analysis o f IMT measurements
Differerent measuring procedures have been used in different studies. IMT can be 
determined by visual assessment of the leading edges by the ultrasonographer and 
measured using electronic callipers. Automated computerized edge tracking method is 
also available [449]. The latter method provides the opportunity to measure EMT over 
a longer arterial section and thus generate a mean value. However at present and with 
the available software, well standardized manual measurements are probably as good 
as automated measurements. For the manual method of analysis different measuring 
protocols have been used (ie mean of several maximum measures 2-12, or mean of 
randomly selected measures 3-5 or mean of measures over 1cm) [456;461]. 
Measurements can be performed on a video image or on a digitally frozen image. Off­
line analysis has the advantage of separating data acquisition from data interpretion, 
making patient examination more efficient.
In studies described in chapter 5, measurements of the far wall of the common carotid 
artery were made from stored images using electronic calipers. IMT was calculated as 
the distance between the first bright line (lumen-intima interface) and the leading edge 
of the second bright line (media-adventitia interface) (Figure 2.26). Six 
measurements, the three maximum measurements of the right common carotid artery
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in three different frames and the three maximum measurements of the left common 
carotid artery in three different frames were averaged.
Figure 2.26: Image acquisition and analysis o f  the IMT measurement.
IMT is measured between the first bright line and the leading edge o f the second
bright line (shown by the blue arrows) in the far wall o f the common carotid artery.
2.6.3 Reproducibility
Phantom studies have shown that distances similar to the intima-media thickness of 
the carotid arterial wall can be measured with B-mode ultrasound system with an axial 
resolution of 0.2 to 0.4mm at a precision of about 0.03 to 0.05mm [462]. 
Intraobserver variability of carotid has been reported between 2.4% to 10.6 % in 
different studies and interobserver variability varies from 3.1% to 18.3% [463]. In 
general reproducibility of IMT measurement was better in studies limited to the 
common carotid artery far wall than in studies including multiple measurements at 
different carotid sites. In addition variability is less when mean IMT is measured 
compared to maximum IMT and also when measurements have been performed in 
more than one direction [456]. Recently the studies with an automated computerized 
IMT measurement rather than a manual cursor placement reported the best 
reproducibility [456].
137
B IN  VITRO EXPERIMENTS
2.7 ENDOTHELIAL CELL CULTURE
As it has been previously mentioned endothelial cells have key role in vascular 
homeostasis. Abnormalities of endothelial cell structure and function may contribute 
significantly to initiation and progression of atherosclerosis [18]. The role of 
endothelial cells however can be better defined if these cells are isolated and cultured 
for in vitro study. A wide variety of sources, including different anatomical sites and 
different species can be used as a primary source of endothelial cells. Depending on 
the source of origin endothelial cells have been shown to be heterogeneous in their 
response to specific stimuli [464]. Human umbilical vein cells (HUVEC) are an ideal 
source of endothelial cells, since they are cheap and readily available.
Collagenase type II Gibco BLR 17107-015
DMEM with L-glutamin 
4500mg/L/D glucose Invitrogen 41965-039
Attachment factor TCS Cell Work ZHS-8949
Cell fix Becton-Dickinson 3401181
Accutase PAA labs LI 1-007
Fungizone (Amphotericin B) Invitrogen 15290-026
Penicilline/Streptomycin Invitrogen 15140-114
RPMI1640 with L-glutamine, 
HEPES Invitrogen 22511-026
MCDB 131 Invitrogen 10372-019
Plastic filling tubes Avon Medicals
TC 24 well plates Coming 3527
Table 2.1: Materials fo r  HUVEC culture.
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Phosphate-buffered Saline (PBS) 
-Prepared using one tablet of PBS 
(Oxoid) per 100ml double distilled 
water
137 mM NaCl 
2.7 mM KC1 
8 mM Na2H P04 
1.5 mM KH2P 0 4
Puck’s A Saline
0.4 g/L KC1 
8 g/L NaCl 
0.35 g/L NaHC03 
1 g/L glucose 
0.2 % EDTA 
10% FCS
0.005 g/L phenol red
FACS Wash/Buffer
lx PBS
0.02% Sodium Azide 
5% FCS
Table 2.2: Buffers used for endothelial cell culture.
2.7.1 HUVEC Growth and Culture Media
HUVEC are particularly difficult to grow compared to other cell types, requiring 
media rich in amino acids, vitamins, carbohydrates and salts, and high concentrations 
of foetal c alf s erum ( FCS). O ver t he 1 ast d ecade c ompanies h ave d eveloped m edia 
specifically for endothelial growth. For the purpose of experiment described in this 
thesis MCDB 131 supplemented with lOmM L-glutamine, 100 units/ml 
penicillin/streptomycin, 0.25pg/ml amphotericin B and 20% FCS was selected as 
growth media for HUVEC.
Cells were rested on RPMI 1640 media supplemented with lOmM L-glutamine, 100 
units/ml penicillin/streptomycin, and 20% FCS. Once supplements were added to the 
media, it was kept at 4°C for no longer than 1 month. Frequent warming of the media 
to 37°C was avoided by keeping a 50ml working stock solution. Description of 
chemical, reagents and buffers for HUVEC culture is included in Table 2.1 and Table 
2 . 2 .
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2.7.2 Foetal calf serum
Foetal calf serum is important for good yield of HUVEC. A batch from South 
America was used as it was established by Jacobsen (PhD thesis 2005 unpublished) 
that this is the best for HUVEC growth and gives consistent endothelial cell responses 
to inflammatory mediators. FCS was heat inactivated at 56°C for 30 minutes and 
aliquots kept at -20°C until further use. Once defrosted, FCS was filtered through at
0.22pm pore filter and kept at 4°C for no longer than 1 month.
2.7.3 Experimental technique
2.7.3.1 Isolation o f endothelial cells from umbilical cords
Endothelial cells were extracted from umbilical cords. Extraction from umbilical 
cords was performed as previously described by Kotowicz et al. [465]. Umbilical 
cords were obtained from West Middlesex hospital, where consent for the use of the 
umbilical cord for scientific research was obtained at the antenatal clinic. Cords were 
collected in RPMI 1640 media supplemented with 100 units/ml 
penicillin/streptomycin, lOmM L-glutamin and 2.5 pg/ml amphotericin B (referred to 
as Cord Preparation Media) in autoclaved polypropylene bottles, and kept at 4°C. 
Cords were collected twice a week to ensure that extraction of endothelial cells was 
performed no later than 72 hours post delivery. Cords that were heavily meconium 
stained were discarded. All the procedures for endothelial cell extraction were 
performed under aseptic conditions in a Class II safety cabinet. Glassware and metal 
instruments were meticulously washed and IMS sprayed before use. Media, 
collagenase and FCS were pre-warmed to 37°C in a water bath.
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2.7.3.2 Protocol for isolation o f HUVEC
1. The cords were inspected for damage, cuts or needle punctures from cord blood 
sampling. The cords were then spayed with 70% IMS and the blood was squeezed out 
into a waste pot. At least 1cm was cut from both ends to reveal a clean surface. The 
cord was sprayed again with IMS and was placed in a glass bottle containing RPMI- 
1640 medium with antibiotics.
2. The cord was taken out of the glass bottle with a forcep. One end was clamped with 
an artery forcep. In the other end, the vein was identified and cannulated with a sterile 
plastic filling tube (Kwill). The filling tube was secured with an artery forcep.
Umbilical 
v e in ------
Umbilical 
- a rte rie s
Figure 2.27: Identification o f the umbilical vein in the umbilical cord.
3. The vein (Figure 2.27) was slowly filled with warmed RPMI-1640 without FCS. 
Sites of leakage were clamped as necessary.
4. The medium was then discarded to remove excess blood and then the vein was 
filled with 0.1% collagenase II solution.
5. The cord was then incubated at 37°C in 5% CO2 for 15 minutes.
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6. Following incubation, the digest was removed from the cord into sterile glass 
bottles and flushed though with equal volume of RPMI-1640 with 5%FCS. This was 
transferred to a sterile 50ml conical tube.
7. The digest was centrifuged at 1200rpm for 5 minutes at room temperature. The 
supernatant was discarded and the pellet resuspended in MCDB-131 with lOmM L- 
glutamine, 20% FCS and antibiotics.
2.7.3.3 HUVEC primary culture and sub-culture
The digest was transferred to 25 cm2 tissue culture flasks. In general, digest from a 
large cord (enough to take 20-30 ml of collagenase solution) was resuspended in 10 
ml of culture medium and plated into T-25 flask. The flasks were incubated at 37°C 
and 5%CC>2. In two days the medium was changed and the cells were inspected under 
phase contrast microscope (Figure 2.28).
Figure 2.28: HUVEC under phase contrast microscope.
HUVEC were identified as small clusters of oval adherent cells. If cells were 
approaching confluence (usually within 72 hours culture) they were sub-cultured. 
Cells that did not grow or were contaminated with smooth muscle or fibroblastic cell 
overgrowth were discarded.
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2.7.3.4 Endothelial cell splitting 
When endothelial cells were confluent, were washed with either RPMI 1640 or 
accutase. Then 5ml of accutase were added to the flask. Cells were inspected under 
phase contrast microscopy. Within 15 min cells were becoming rounded and 
dislodged, the flask was tapped against the top to aid the detaching of the cell. The 
cells were resuspended in growth medium and seeded into 6, 24 or 48 well plates, 
depending on the experimental design, which were precoated with attachment factor. 
The seeding ration was usually one 25cm2 flask for 1 tissue culture plate. Growth 
medium was replaced every 2-3 days and generally cells were used within one week 
of passaging.
2.7.4 Analysis of adhesion molecule expression on HUVEC
Antibody Company Product Code
Goat anti-mouse IgG 
RPE conjugate antibody Dako R0490
Mouse anti-human CD31 Serotec MCA195
Mouse anti-human 
CD62E (E-selectin) Serotec MCA883
Mouse anti-human CD54 
(ICAM-1) Serotec MCA532
Mouse anti-human 
CD 106 
(VCAM-1)
Serotec MCA907
Table 2.3: Monoclonal antibodies used fo r  HUVEC experiments.
2.7.4.1 Protocol for staining o f HUVEC for adhesion molecule expression
The media was discarded and PUCK’s A saline was added to the cells. The cells were 
then incubated for 20 min in 37°C to help cells to detach. Then cells were scraped 
with a Pasteur pipette and washed with FACS wash and were centrifuged at 1200rpm
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for 5 min at room temperature. The supernatant was discarded and cells were 
incubated for 10 minutes with either CD62E (5pg/ml), CD54 (5pg/ml), CD 106 
(20pg/ml) and mouse IgG2B (5pg/ml) at room temperature (Table 2.3). When the 
incubation period was over, cells were washed with 1 ml of FACS wash and 
centrifuged at 1200 rpm for 5 minutes. The supernatant was discarded and 
Fluorescently labelled Goat anti-mouse IgG (F(ab)2 ) phycoerythrin (PE) was added. 
Cells were left for 10 minutes at room temperature in the dark.
Finally endothelial cells were washed again with 1ml of FACS wash and centrifuged 
at 1200rpm for 5 min. The supernatant was discarded and 300pl of Cell fix were 
added to endothelial cells and stored at 4°C until further use.
2.7.4.2 Flow Cytometry and FACS analysis
Fixed HUVEC were analysed using FACScalibur(BD) or FACScan(BD) flow 
cytometer and CellQuest(BD) software. Flow cytometry is an analytical technique 
that allows the rapid quantification of multiple physical characteristics of cells or 
cellular constituents of heterogenous cell populations. It is being increasingly used in 
various biomedical applications and depends on a combined system of optics, fluids 
and electronics. A laser functions to provide a light signal of uniform intensity and 
waveform.
Flow cytometry analyses cells in a flowing liquid stream as they pass a light source 
and is based on the sheath flow principle [466]. Pressure applied to the sample liquid 
pushes the cells at a steady flow up along the sample line. It is injected into the centre 
of the sheath fluid where it is hydrodynamically focussed into a fine stream of single 
particle width that is then aligned to the focal point of the laser light source to obtain 
measurements. Through the function of analog to digital convertors and amplifiers,
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electronics will then convert the electrical pulses being generated into graphical data 
for analysis.
Endothelial cells were gated as illustrated in Figure 2.29 and 5000 events were 
collected from within this gate. Whilst each FACS instrument will have different 
instrument settings, a sample is given below on Table 2.4.
Detector Voltage Amplitude gain
Forward Scatter E-l 1.00
Side Scatter 347 1.00
Fluorescence-2 (PE) 417 1.00
Table 2.4: Flow cytometry settings for endothelial cell detection.
Activation of endothelial cells was assessed by measuring the % of gated positive 
cells and the mean fluorescence intensity (MFI) which is used to denote how much 
fluorescence a given particle population carries.
2.7.4.3 Verification o f Endothelial Cell culture
Verification of endothelial cell culture was determined by the typical ‘cobble-stoned’ 
appearance of endothelial cells in vitro (Figure 2.28) and by endothelial cell surface 
staining of PEC AM-1 (CD31) detected by FACS analysis (Figure 2.29). PEC AM-1 is 
expressed at high levels by endothelial cells, and hence is a quick and efficient 
method of verifying endothelial cell cultures.
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Figure 2.29: Characterisation analysis o f HUVEC by Flow cytometry (FACS). 
Endothelial cells were identified by FACS using forward and side scatter 
characteristics. Endothelial cells were gated (R3) and cells stained with isotype 
control antibody and anti CD31 (PECAM-1) are shown.
2.8 C.PNEUMONIAE CULTURE AND PREPARATION
C.pneumoniae are intracellular bacteria that have a unique biphasic developmental 
cycle with two distinct morphological forms. The extracellular infectious form 
(0.3pm, diameter) is called an elementary body (EB) and the intracellular replicating 
form (1.0pm, diameter) is called reticulate body. Infectious EBs start the cycle by 
attaching to a susceptible host cell membrane and gain access into the host cell via 
either parasite-specified phagocytosis or receptor-mediated endocytosis. Once inside 
the cell, the C.pneumoniae remain within an enlarging intracellular vacuole, a 
characteristic inclusion, avoiding lysosomal fusion and hence destruction (Figure
2.30).
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Figure 2.30: C.pneumoniae developmental cycle.
During the first few hours, elementary bodies differentiate into metabolically active 
reticulate bodies. By using the host cell energy and nutrient resources, reticulate 
bodies begin to multiply. Following a number o f divisions reticulate bodies start to 
transform back to elementary bodies. Finally the infectious elementary bodies are 
released into the cytoplasm by exocytosis or host cell lysis, to initiate new cycles in 
new host cells. In cell culture conditions, the duration o f the developmental cycle is 
between 48 to 72 hours [467].
2.8.1 Materials
McCoy cells (derived from human fibroblasts) and C.pneumoniae TW183 propagated 
in McCoy cell line (104 inclusion forming units, IFU) were kindly provided by the
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department of Microbiology at UCLH. C.pneumoniae TW183 were stored in small 
aliquots at -80°C in the Virology department at Great Ormond Street Hospital.
Company Catalogue Number
Eagle’s minimum 
essential medium 
(MEM)
Sigma 21575-022
Foetal calf serum Tissue culture services European origin, Cat NO: CF018, Batch 150201
Gentamicin Sulphate Sigma G-3632
Vancomycin Bavid Bull Laboratories 6911A
C.pneumoniae specific 
monoclonal antibody Dako Cytomation M6600
Polyclonal Goat 
Anti-mouse 
immunoglobulins FITC
Dako Cytomation F0479
Table 2.5: Materials used for C.pneumoniae growth and staining.
BUFFERS COMPONENTS
McCoy growth medium (MGM): 500ml of MEM + 50 ml of foetal calf serum
Fluid changing medium
100ml MGM + (1ml Glucose 3M, 1ml 
fungizone 250g/ml, 1ml vancomycin 
1 mg/ml, 1ml gentamicin 1 mg/ml)
Table 2.6: Buffers-Medium used for C.pneumoniae growth.
2.8.2 Replication of C.pneumoniae
Viability of C.pneumoniae was tested prior to experimentation. McCoy cells were 
maintained by weekly passage into tissue culture flasks. Confluent monolayers of 
McCoy cells were prepared on 12mm cover slips placed in sterile shell vials.
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C.pneumoniae were propagated by infecting monolayers, checking for infectivity after 
48 and 72 hrs of incubation and passing further into several more shell vials. An 
aliquot of C.pneumoniae was removed from freezer, thawed and vortexed. This was 
first inoculum. Growth medium was removed from shell vials. 250pl of inoculum was 
inoculated onto cell monolayers in the shell vials. Two uninoculated shell vials were 
used as negative control. The shell vials were centrifuged for an hour at 4.600rpm at 
35°C, to allow the entrance of elementary bodies into the cell. After centrifugation, 
the vials were left undisturbed in the centrifuge for an hour. One ml of fresh media 
containing 1 mg/ml o f cyclohexamide w as a dded t o e ach s hell v ial. T he v ials w ere 
then incubated at 37° C with 5%C02 for up to 72 hours.
2.8.3 Direct immunofluorescence staining
Cover slips from two shell vials and one negative control were examined for 
infection after 48hrs and 72hrs. Medium was discarded from vials. The infected and 
uninfected monolayers on cover slips were washed with 1 ml of PBS (pH7.4), fixed in 
cold methanol for 15minutes and air-dried. Cover slips (monolayers facing up) were 
fixed with glass bond on to glass slides. 15pl of monoclonal antibody was applied 
evenly onto each cover slip. The slides were incubated at 37 0 C in a humid chamber 
for 3 0 m inutes. T hese were r insed gently i n P BS b ath and a ir-dried. 1 5pl o f  FITC 
antibody diluted in 1:10 naphthalene black was used as a secondary antibody and the 
slides were incubated as above.
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Figure 2.31: Steps for direct immunofluorescence staining.
Monoclonal antibody specific for the chlamydia elementary bodies was added to 
McCoy cells. In the secondary reaction FITC conjugated antibody binds to the 
primary antibody. Cells were then assessed under fluorescence microscope for the 
presence o f inclusions.
Finally the slides were washed gently in PBS for ten minutes followed by 5 minutes 
wash in distilled water. These were air dried, mounted and observed at X I000 
magnification using fluorescence microscope. Once it was confirmed that the 
inoculum was viable (by multiplying into the cells) then cells from rest of the shell 
vials were harvested, pooled and 250pl of this was used to infect further McCoy cells.
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Figure 2.32: C.pneumoniae inclusions in McCoy cells.
Characteristic picture o f the chlamydia inclusions shown in green in McCoy cells 
under fluorescence microscope (magnification xlOO).
2.8.4 Determining inclusion forming units (IFU)
Three passages were required before a strong inoculum (90% cells infected) was 
obtained. Small aliquots of these were stored in the -80 freezer. This stock was used 
for the experiments described in chapter 7. Preparing a series of ten fold dilutions and 
infecting two monolayers of McCoy cells as previously described I assessed the IFU 
of the stock. Following 72 hours of incubation, direct immunofluorescence staining 
was performed. Total numbers of inclusions were counted on each cover slip and an 
average taken of the two. The aliquot with 10-50 inclusions was used to calculate the 
strength of the original stock. This was calculated as the number of counted IFU 
multiplied by the dilution factor. For the experiments described in chapter 7 a stock 
solution of 1.8x108 C.pneumoniae IFU was used.
2.9 PURIFICATION OF MANNOSE-BINDING LECTIN
Tris Buffered Saline (TBS), pH 8.0
u Tris 0.02 M
3
00
fi
o
Sodium chloride 0.1 M
Sodium Azide 0.02 % (w/v)
+ *
3WC
3
Tris Buffered Saline with Calcium (TBS4), pH 8.0
Tris 0.02 M
03
Sodium chloride 0.5 M
£ Calcium chloride 0.01 M
Sodium Azide 0.02 % (w/v)
ELUTION BUFFER NO. 1
TBS
EDTA 10 mM
ELUTION BUFFER NO.2
TBS
Mannose 100 mM
COLUMN WASHING BUFFER NO. 1
Sodium borate 
pH adjusted to 10.0 0.1 M
COLUMN WASHING BUFFER NO. 2
Glycine-HCl 0.1 M
All solutions degassed and filtered using a 0.2 pm filter 
before use.
Table 2.7 : Buffers used fo r  MBL purification.
2.9.1 Rationale for choice of purification method
The first purification of MBL was described by Kozutsumi et al [468]. This 
preparation was obtained from rabbit serum applied to a column of mannan derived 
from the Saccharromonas cerevisiae cell wall and coupled to a solid support. In 
subsequent years many more purification techniques have been described for mouse,
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rabbit and human MBL [468-470]. Many of these techniques have used mannan or 
mannose affinity columns for purification, exploiting the carbohydrate binding 
properties of MBL. However several issues have been raised regarding the 
purification of MBL by carbohydrate binding. Firstly, MBL is not the only molecule 
present in serum which binds to mannan and mannose and therefore single step 
purification by this technique often results in contamination with other molecules 
including immunoglobulins. Various recombinant human MBL proteins have been 
described but in several cases their physiochemical properties differed from the MBL 
purified from serum, raising the question of whether recombinant MBL should be 
used in functional studies [471]. In addition, the recombinant protein is not associated 
with MASPs, resulting in the need for these proteases to be added from another 
source if the protein is to be used in functional studies.
After careful consideration of the above issues it was decided to purify human MBL 
using an affinity chromatography method. Three affinity chromatography columns 
were used to achieve purity. Essentially, the sample was twice passed through 
mannan-agarose columns to isolate the protein, and the product was then passed 
through an anti-immunoglobulin column as a safeguard against immunoglobulin 
contamination. The purification set up and the chromatograph of MBL compounds are 
shown in Figure 2.33 and Figure 2.34 respectively.
2.9.2 Experimental technique
2.9.2.1 Source o f MBL
Cold ethanol fractionated pooled human plasma was used as a source of MBL and this 
was provided by the Blood Products Laboratory, Elstree, London, UK. This source
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was convenient as a large volume of starting material was required to obtain a high 
yield of MBL, such that an equivalent volume of serum could not be obtained from 
laboratory volunteers. Specifically, the B+l fraction was provided as a paste and had 
the added advantage that it had been partially purified resulting in significant 
depletion of the albumin and IgG.
2.9.2.2 Protocol o f MBL purification 
Five hundred grams of human plasma paste (B+l fraction) was defrosted overnight at 
+4°C in 2 litres of TBS buffer. The defrosted mixture was then centrifuged at 12000 
rpm for 20 min at +4°C in the Sorvall RC-5B centrifuge and the supernatant decanted. 
Ammonium sulphate was added to the supernatant to approximately 42% saturation 
(130g/500ml supernatant) and incubated at room temperature for 1 hour before being 
re-centrifuged as before.
The supernatant was discarded and the precipitated protein pellets pooled together and 
dissolved in TBS+ buffer to an approximate volume of 900 ml, which was then 
dialysed overnight at +4°C against TBS+. Clotted paste was homogenised manually 
by using a 50 ml syringe and the paste then re-centrifuged as before. Finally, the 
supernatant was decanted and stored as +4°C for affinity chromatography.
A water jacketed XK column (16/20) (Amersham Biosciences) packed with mannan - 
agarose was cooled to +4°C and equilibrated with 30 ml TBS+ at 2 ml min’1 using a 
ACTA™ FPLC. The paste was applied to the column using the ACTA sample pump 
P-920 at a rate of 0.5 ml min'1, and the column then washed with TBS+ at 2 ml min’1 
until the absorbance at 280 nm returned to baseline levels (this and all further steps 
were performed using the P-920 pump). The column was eluted with TBS containing 
EDTA at 0.5 ml min'1. Two millilitre fractions were collected until the elution peak
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was observed. The column was then washed with TBS+ containing 100 mM mannose 
at 1 ml min*1, followed by 0.1 M sodium borate, pH 10.0, and finally 30 ml of TBS+ at 
1 ml min*1 until the eluent absorbance at 280 nm returned to baseline.
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Figure 2.33: Experimental set up for the purification o f  MBL
Both an Amersham Biosciences HR mannan-agarose column (gel volume 10 ml, 
i.d.lOmm) and an HR anti-IgG column (gel volume 5 ml, i. d. 5mm) were equilibrated 
with 30 ml of TBS+ before sequential application of the eluent from the XR mannan- 
agarose column. Recalcified fractions were applied to the HR mannan-agarose 
column with the anti-IgG column off line and washed through with TBS+ until the 
baseline returned to zero. The HR anti-IgG column was reattached and TBS+ + 
lOOmM mannose applied at 0.5 ml/min to elute MBL from the first column. Both 
columns were washed twice with 5 ml of 0.1 M Glycine-HCl, re-equilibrating with 30 
ml TBS+ after each wash before storing at +4°C. The column flow-through fractions
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were pooled and concentrated into PBS + 0.02% NaN3 using a Vivaspin 15R 
(Amicon). The material was then stored at +4°C until required.
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Figure 2.34: Chromatograph of MBL compounds following injection onto a 
chromatography column.
2.9.3 Analysis of MBL
2.9.3.1 Analysis o f MBL purity
The purity of each MBL preparation was determined by performing SDS- 
polyacrylamide gel electrophoresis (SDS-PAGE) under reducing or non-reducing 
conditions, with final detection by silver staining or enhanced chemiluminescence 
(ECL) development of immunoblots [471]. The concentration of MBL eluted from the 
anti-MBL column and further purified using the anti-IgG column was determined by 
an ELISA procedure. The electrophoresis of MBL was performed by Marina Johnson.
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BUFFERS USED FOR SDS ELECTROPHORESIS
10 x Transfer Buffer
Tris 48.0 mM
Glycine 39.0 mM
3.75 ml 10 % (w/v) SDS added to 11 of 1 x transfer buffer before use
SDS-PAGE running buffer
Glycine 190.0 mM
Tris 25.0 mM
SDS 0 . 1  % w/v
2 x Sample buffer
Tris 120.0 mM
Table 2.8: Buffers used for SDS electrophoresis.
• SDS-Polyacrxlamide sel electrophoresis o f  MBL under reducing conditions
For analysis under reducing conditions, 10 % acrylamide SDS-PAGE gels were 
prepared. Samples were diluted with an equal volume of 2 x sample buffer containing 
4% 2-mercaptoethanol (freshly prepared), and heated at 105°C for 3 min. They were 
then loaded onto the gel and electrophoresed at 120 V for 1 hour at room temperature 
alongside rainbow markers (size standards). Immediately after running, gels were 
fixed by incubating in 40% methanol and 10% acetic acid for at least 1 hour. Proteins 
were detected using the Bio-Rad silver stain detection kit according to the 
manufacturer’s instructions. Development of the reaction was stopped by incubation 
of the gels with 5% acetic acid.
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• SDS-Polvacrvlamide eel electrophoresis o f  MBL under non-reducine 
conditions
For analysis under non-reducing conditions 3 -  10% acrylamide continuous gradient 
SDS-PAGE gels were prepared using a Bio-Rad gradient former. Samples and 
biotinylated SDS-PAGE standards were diluted in an equal volume of 2 x sample 
buffer (freshly prepared) and electrophoresed for 600 Vh alongside rainbow markers. 
Proteins to be detected by silver staining were fixed and processed as described 
above. Proteins to be detected by enhanced chemiluminesence (ECL) were transferred 
from the gels to nitrocellulose membranes using a semi-dry transblotter (Trans-Blot, 
Bio-Rad, Hemel Hempstead, UK). Gels were carefully applied to the nitrocellulose 
membranes and sandwiched in between 6  pieces of filter paper which, along with the 
membranes, had been pre-soaked in Transbuffer. Transfer was performed by 
electrophoresis at 20 V for 20 min. The membranes were then incubated in PBS 
containing 2 % skimmed milk for 1 hr at room temperature on a shaking platform to 
prevent binding of any free proteins to the membrane. Membranes were washed three 
times for ten minutes in PBS-Tween before being incubated in 1 pg ml' 1 biotinylated 
anti-MBL in PBS-Tween for 3 hr at room temperature on a roller. Membranes were 
washed three times in PBS-Tween as before and then incubated in a 1 in 1000 dilution 
of Streptavidin-Horseradish peroxidase conjugate in PBS-Tween for 3 hr at room 
temperature on a roller. One final washing step was performed as before and the 
chemiluminescence reaction performed by applying the ECL detection reagents to the 
membranes for 1 min before draining and wrapping in Saran-Wrap. Proteins were 
visualised by exposure to X-ray film initially for 15 seconds, with options of longer 
discretionary exposures determined by the results of the initial exposure.
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Silver stained gels and ECL detected immunoblots were compared to assess the purity 
of the preparation.
2.9.3.2 Analysis o f the concentration o f MBL in the purified preparations
To determine the concentration of purified MBL a symmetrical sandwich ELISA was 
used.
• Rationale o f “double-sandwich " ELISA 
ELISA’s combine the specificity of antibodies with the sensitivity of simple enzyme 
assays, by using antibodies coupled to an easily assayed enzyme that possesses a high 
turnover number. One of the most useful of these immunoassays is the two antibody 
“double-sandwich” ELISA, which is used to measure the concentration of a specific 
compound in unknown samples. This ELISA is fast and accurate, and if a purified 
antigen standard is available, it can be used to determine the absolute amount of 
antigen in an unknown sample. The “double-sandwich” ELISA requires two 
antibodies which bind epitopes on the antigen (compound measured) that do not 
overlap. This can be accomplished with either two monoclonal antibodies that 
recognise discreet sites on the antigen or one batch of affinity-purified polyclonal 
antibodies.
To utilize this assay, one antibody (the “capture ” or first antibody) is purified and 
bound to a solid phase typically attached to the bottom of a plate well. Antigen is then 
added and allowed to complex with the bound antibody. Unbound products are then 
removed with a wash, and a conjugated second antibody (the “detection ” antibody) is 
allowed to bind to the antigen, thus completing the “sandwich”. The assay is then 
quantitated by measuring the amount of enzyme-labelled secondary antibody bound to 
the matrix, through the use of a colorimetric substrate.
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Figure 2.35: Basic principles o f  “double-sandwich ” ELISA.
(A). Antibody is added and allowed to passively attach to a plate well surface (solid 
phase) by incubation in buffer; (B). Unattached antibodies are washed away and 
antigen (compound to be measured in unknown sample) is added; (C). Antigen is 
“captured” by coating antibodies during incubation. Unbound antigen is then washed 
away; (D). Conjugated second antibodies directed against the antigen are added; (E). 
Binding o f the second antibody during incubation completes the “double-sandwich ”. 
Free second antibody is washed away; (F). Colourless substrate is added and is 
converted to coloured product by the antibody-bound enzyme. The colour is then 
quantified in a spectrophotometer.
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Ideally the enzyme substrates should be stable, safe and inexpensive. Substrates are 
colourless and are converted by the enzyme, coupled to the secondary antibody, to a 
coloured product, e.g., p-nitrophenylphosphate (pNPP), which is converted to the 
yellow p-nitrophenol by alkaline phosphatase. Substrates used with horse-radish 
peroxidase (HRP) include 2,2’-azo-bis(3-ethylbenzthiazoline-6-sulfonic acid) 
(ABTS), o-phenylene diamine (OPD) and 3,3’5,5’- tetramethylbenzidine base (TMB), 
which yield green, orange and blue colors, respectively. Figure 2.35 summarises the 
basic principles of the “double-sandwich” ELISA.
2.9.3.3 Experimental protocol
A symmetrical sandwich ELISA was used as previously described to determine the 
concentration of purified MBL. At each incubation step a volume of 100 pi was used, 
dilutions were performed in PBS containing 0.05% Tween-20 (PBS-T) unless 
otherwise stated, and each washing step consisted of three washes with PBS-T using a 
Denley Wellwash stacking ELISA plate washer. Aliquots of diluted purified protein 
were incubated in microwells precoated with monoclonal antibody against MBL. 
Dilutions performed were 1/20, 1/100 and 1/1000 in PBS-T and calibrated against a 
doubling dilution standard curve based on a serum standard pool. The diluted 
samples (purified protein) were incubated at 37°C for one hour, washed and then 
bound MBL was detected using a biotinylated anti-MBL added at 1 pg/ml and 
incubated for one hour at 37°C. The plates were washed and 1/1000 dilution of 
streptavidin-peroxidase was then incubated for one hour at 37°C. After washing, the 
ELISA was developed using 100 pi TMB substrate solution. Adding 100 pi 4N 
H2 SO4 stopped the reaction and the A4 5 0  o f each well was read using a Dynatech 
MRX plate reader (Actema, Aldermaston, UK) with the standards plotted as a 
sigmoid curve (Revelation software).
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2.10 STATISTICS.
All data are expressed as mean±SD unless otherwise stated. A number of parametric 
and non-parametric tests were used in this thesis. Parametric tests were used whenever 
possible (i.e when the data were normally distributed, or could be easily transformed 
to normality). If the data could not be easily transformed, non-parametric tests were 
performed. Normality of the data was assessed by plotting histograms and applying 
the Kolmogorov-Smimov test of normality. Stata version 8 and SPSS version 10 
analysis packages were used for the analysis of the data.
Parametric tests used were independent t-test, paired t-test and one-way analysis of 
variance (ANOVA). In the case of studies where the means of more than two 
variables were compared by t-tests a Bonferroni correction was applied. This states 
that when 3 or more variables are considered the resultant “p value” was multiplied by 
all possible comparisons. For example, if 3 groups were used the outcome of A vs. B 
vs C would be multiplied by 3 (as it would be possible to compare A:B, A:C and B:C) 
and only if the result was still less than 5% it would be considered statistically 
significant. In chapter 3 reproducibility measurements were performed by 
constructing the Bland-Altman plots. In chapters 4, 5 and 6 multivariable linear and 
logistic regression analysis were used. In  all studies significance was defined as a- 
value of less than 5%, indicating that the chance of the null hypothesis still being true 
even though the difference is greater than the critical value was less than 5%.
2.11 ETHICS
All studies presented in this thesis were approved by the Institute of Child Health and 
Great Ormond Street Hospital local research Ethics Committee. Studies described in 
chapter 4 and 6 were also approved by the Bristol Ethics Committee. Ethics 
Committee approval documents are provided in Appendix B.
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CHAPTER 3
ASSESSING VARIABILITY OF NON-INVASIVE 
TECHNIQUES FOR MEASURING 
ENDOTHELIAL FUNCTION
3.1 INTRODUCTION
In clinical practice, diagnosis and treatment of atherosclerotic vascular disease are 
usually instituted late in the natural history, at a stage when plaques are well 
established and clinical complications have occurred. As the process of atherogenesis 
begins in childhood, research has been directed towards detection of early vessel wall 
changes in asymptomatic subjects at increased risk, by non-invasive methods. As 
physiological abnormalities may precede anatomical changes, a test of vascular 
reactivity might detect early disease. Given that endothelial dysfunction is an 
important early event in atherosclerotic process, the validation of non-invasive 
methods to assess endothelial function with the potential to use in clinical practice is 
warranted.
Flow mediated dilatation of the brachial artery is the best validated and the most 
widely used non-invasive method to assess endothelial dysfunction [363]. However 
this technique is technically challenging, time consuming and requires expensive 
equipment. The changes evoked in the peripheral pressure waveform in response to 
the inhalation of salbutamol, measured using applanation tonometry or digital pulse 
contour analysis have been suggested as alternative methods to assess endothelial 
function [146; 147]. These last two methods are technically and financially less 
demanding and the required equipment is cheap and easily portable. However their 
reproducibility has not been confirmed or assessed in childhood where early 
prevention has the greatest potential for long term benefits.
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3.2 AIMS OF CHAPTER
The purpose of the studies described in this chapter is to assess
• the reproducibility of endothelial function testing using FMD, PWA and DVP 
in adults and children.
• the sensitivity of these three methods to detect acute changes in endothelial 
function provoked by inflammatory stimuli.
3.3 SPECIFIC METHODS
3.3.1 Reproducibility of three non-invasive methods to assess endothelial 
function in adults and in children
3.3.1.1 Study population
Sixteen healthy adults (mean age 28yrs range 18-39 yrs) and 16 healthy children 
(mean age 13yrs range 7-17yrs) were recruited from among staff, friends and families 
for the reproducibility protocol. All subjects were normotensive without any history 
of dyslipidaemia or cardiovascular disease. Smokers or asthmatics were excluded 
from the study. Subjects were asked to refrain from ingesting food and drinks 
containing caffeine for 4 hours prior to the study and were also requested to refrain 
from vigorous exercise for a day prior to the study. Height and weight were measured 
and a short medical history was taken. The study protocol was approved by the 
Institute of Child Health, UCL, Ethics Committee. Written informed consent was 
sought from all subjects and parent/guardian and assent from the child was obtained at 
the time of the study.
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3.3.1.2 Assessment o f vascular function
a) Flow m ediated  d ila ta tio n
Brachial artery FMD on the right arm was induced by a 5 minute inflation of a 
pneumatic cuff, to 300mmHg in adults and 200mmHg in children, placed around the 
forearm immediately below the medial epicondyle. The diameter changes in the 
brachial artery were measured using edge detection software (Brachial Tools, MIA, 
USA) from ECG triggered ultrasound images (Acuson Aspen, USA) captured at 3 
second intervals throughout the 11 minutes recording protocol as previously described 
in section 2.1. Brachial FMD was expressed as the maximum percentage change in 
vessel diameter from baseline calculated from the average of 20 images obtained 
during the baseline recording and the average of three readings at peak diameter.
The magnitude of the flow stimulus was recorded continuously by pulse wave 
Doppler and expressed as reactive hyperaemia % (RH) derived from the maximum 
change in flow within 15 seconds post deflation of the pneumatic cuff relative to the 
baseline resting flow.
b) S albutam ol m ediated  endo thelia l function
The average of three baseline readings separated by one minute was taken to measure 
the baseline peripheral augmentation index and reflection index. The peripheral 
pressure pulse waveform was acquired at the right radial artery using a handheld 
applanation tonometer probe (Millar Inc) as previously described in section 2.3. The 
RI% was obtained using a photoplethysmograph (Micro Medical, Gillingham, Kent, 
UK) placed on the index finger of the left hand as previously described in section 2.5. 
Then salbutamol was administered via a spacer device to ensure maximum delivery of 
the drug. Recordings of the PAIx and RI were taken simultaneously 5 minutes post
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inhalation of salbutamol and at 2.5 minutes interval up to 20 minutes thereafter. 
Results are expressed as the maximum change in PAIx and RI calculated from the 
baseline reading.
Thus endothelial function measured by PAIx was expressed as follows:
PAIx s= Max PAIx- Baseline PAIx 
PAIx s: change in PAIx post salbutamol
Max PAIx: maximum reduction in PAIx post salbutamol over the period o f  20minutes 
Baseline PAIx: the average o f  three baseline recordings pre salbutamol.
Similarly endothelial function measured by RI was expressed as follows:
RIs= Max RI- Baseline RI 
RIs: change in RI post salbutamol
MaxRI: maximum reduction in RI post salbutamol over the period o f  20 minutes 
Baseline RI: the average o f three baseline recordings pre salbutamol.
c) E ndothelium  independen t response to g ly c e ry l-tr in itra te  
Endothelium independent dilatation induced by administration of 25pg of glyceryl- 
tinitrate (GTN) sublingually was assessed using three modalities, brachial ultrasound 
imaging, PWA from the right radial pulse and DVP from the left index finger. The 
changes in brachial diameter post GTN were assessed for 5 minutes in the brachial 
artery as previously described in section 2.2. Brachial GTN was expressed as the 
maximum percentage change in vessel diameter from baseline calculated from the
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average of 20 images obtained during the baseline recording and the average of three 
readings at peak diameter following GTN administration.
The PAIx from PWA and the RI from DVP were recorded prior to and for a 
maximum of 20 minutes post GTN administration. Brachial artery diameter change 
was expressed as a percentage change from baseline as previously described. The 
maximum PAIx and RI changes induced by GTN were calculated as the change from 
the three averaged baseline measures respectively and expressed as follows:
PAIx g= Max PAIx- Baseline PAIx 
PAIx G: change in PAIx post GTN.
Max PAIx: maximum reduction in PAIx post GTN over the period o f  20 minutes. 
Baseline PAIx: the average o f three baseline recordings pre salbutamol.
Similarly endothelium independent function measured by RI was expressed as 
follows:
R I g = Max RI- Baseline RI 
RIg: change in RI post GTN.
MaxRI: maximum reduction in RI post GTN over the period o f  20 minutes. 
Baseline RI: the average o f  three baseline recordings pre salbutamol.
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3.3.2 Reproducibility study protocol
The reproducibility studies were performed on two consecutive days for the adult 
studies and one week apart for the children. Consecutive studies were performed at 
the same time of the day for every individual. After 5-10minute period of supine rest 
the study protocol was performed as follows.
The vasodilator response of the brachial artery to a transient increase in blood flow 
was used to determine FMD as previously described in section 2.1.3. In addition, an 
image of the brachial artery was printed and accurate measurements of the position of 
the probe were documented in order to ensure that the same section of the artery was 
scanned on the repeat visit.
Seven minutes after reactive hyperaemia, the baseline PAIx and RI were assessed 
using applanation tonometry and photoplethysmograph as previously described from 
the right radial artery and the left index finger respectively.
The response of the brachial artery to GTN was then assessed. This included one 
minute of baseline recording of the brachial artery by ultrasound machine, then 25pg 
GTN were administered sublingually and finally the response of the brachial artery to 
GTN was continuously recorded for the following 5 minutes as previously described 
in section 2.2. In addition, recordings of the PAIx and RI were made 3, 5, 10 and 15 
minutes after GTN administration. Prior pilot studies (data not shown) have shown 
that a period of twenty minutes is sufficient for the haemodynamic changes and the 
brachial artery diameter to return to normal after GTN administration. After 20 
minutes, a further set of three baseline recordings of the radial pulse waveform and 
the pulse contour from the left index finger were made one minute apart and averaged 
to determine the pre salbutamol baseline of the PAIx and RI respectively. All subjects
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were then given an inhaled dose of salbutamol (Allen & Hanburys) using a spacer 
device and changes in PAIx and RI were recorded over a period of 20 minutes.
The same protocol was followed in the repeat study, one day apart, for adults in order 
to assess the reproducibility of the three methods. This protocol is depicted in a flow 
chart (Figure 3.1).
The children underwent the same procedure as previously described without GTN 
administration, to shorten the study by at least 20 minutes and to improve compliance. 
The studies in children were arranged on a weekend to avoid disruption to school 
attendance and the repeat visit was scheduled for one week apart. The protocol 
followed by children is depicted in flow chart (Figure 3.1).
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a)
Sublingual Inhaled salbutamol
administration of 400pg
25pg GTN
r i
Rest
5-10
mins
FMD
11
mins
PWA
DVP
GTN response 
PWA & DVP & 
U/S 20 mins
PWA
DVP
Post salbutamol 
PWA and DVP 
20 minutes
b)
Inhaled salbutamol
Rest FMD PWA Post salbutamol PWA and DVP
5-10 mins 11 mins DVP 20minutes
Figure 3.1: Study protocol for adults and children.
a) Study protocol for adults in visit 1.
b) Study protocol for children in visit 1.
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3.3.3 Ability of endothelial function testing using salbutamol mediated changes in 
PAIx and RI to characterise the vascular consequences of an acute inflammatory 
stimulus
3.3.3.1 Study population
Eighteen men underwent the adult protocol before and 8 hours after administration of 
a typhoid vaccination. None of the participants were smokers, had any cardiovascular 
risk factors or had received salmonella typhi vaccination before.
3.3.3.2 In flammatory model
Inflammation was induced by the injection of salmonella typhi capsular 
polysaccharide vaccine 0.026mg (Typhim Vi, Pasteur Merieux MSD) into the gluteus 
maximus muscle. This produces a low grade inflammatory response, a transient 
increase in cytokine levels without a systematic haemodynamic response as has been 
previously confirmed by studies performed by my colleagues in our 
department[472;473].
3.3.3.3 Study protocol
Day 1: Subjects came for an initial assessment and endothelium dependent and 
endothelium independent responses were recorded by using the three previously 
described modalities (ultrasound, applanation tonometry and digital volume pulse) as 
described in the reproducibility for adults study.
Day 2: Subjects received the typhoid vaccination injection and 8 hours later, the 
second vascular assessment was performed as previously described. The two studies 
were performed at the same time of the day.The protocol for the typhoid study is 
depicted in (Figure 3.2).
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Day 1
Sublingual Inhaled salbutamol
administration 400pg
of25pg GTN
Rest FMD PWA GTN response PWA Post salbutamol
5-10 mins 11 mins DVP PWA & U/S DVP PWA & DVP
&DVP recordings 20
mins
Day 2
Sublingual Inhaled salbutamol
administration 400pg
of25pg GTN
Typhoid vaccination 
1 r
Rest FMD PWA GTN response PWA Post salbutamol
5-10 11 mins DVP PWA & U/S & DVP PWA & DVP
mins DVP 20 mins recordings
8 hours 20 mins
Figure 3.2: Protocol for endothelial function assessment with three modalities after 
typhoid vaccination.
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3.4 STATISTICS
The data were analysed with the SPSS analysis package version 10. Differences in the 
PAIx and RI from baseline following salbutamol inhalation and GTN administration 
were assessed by ANOVA for repeated measures. Reproducibility of the methods was 
assessed by constructing the Bland Altman plots and reported as mean±SD of the 
differences between the two different visits and by calculating the % coefficient 
variation (CV=SD of the differences /overall mean) between the two different visits. 
Differences in endothelial function after typhoid vaccination were compared by paired 
t-test.
3.5 RESULTS
3.5.1 Reproducibility of flow mediated dilatation in adults
The baseline diameter and the haemodynamic characteristics were similar in the two 
visits as shown in Table 3.1. There was good reproducibility as demonstrated by the 
Bland Altman plots (Figure 3.3). The coefficient of variation was 1.71%.
FMD response was comparable in the two visits (r=0.8, p<0.001) and there was good 
agreement shown by the Bland Altman plot (Figure 3.4). The mean difference 
between visit recordings was 1.21±0.73%. The coefficient of variation was 7.09% 
(Table 3.3).
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VISIT 1 VISIT 2 p value
Baseline diameter (mm) 3.54±0.44 3.59±0.50 0.2
Baseline VTI (m) 0.07±0.03 0.07±0.03 0.6
Baseline HR(beats/mins) 61±6.9 64.5±10.84 0.1
Peak VTI (m) 0.42±0.07 0.44±0.07 0.3
Peak HR (beats/min) 62±7.52 63±7.78 0.6
% Reactive hyperaemic flow 676.3±281.1 625.2±196.3 0.5
Table 3.1: Baseline and haemodynamic characteristics in the two visits. 
Abbreviations: VTI: velocity time integral, HR: heart rate.
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Figure 3.3: Reproducibility o f baseline diameter in the two visits,
a) There was good agreement between the baseline diameters on two separate visits 
one day apart (r=0.95, Pearson correlation coefficient) b) The differences in the 
baseline diameter were plotted against the mean change. Dotted lines represent 2 SD 
o f the differences.
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Figure 3.4: Reproducibility o f endothelial function response as assessed by FMD in 
the two visits.
a ) There was good agreement between the FMD response on the two separate visits 
(r=0.8 (Pearson correlation coefficient), p<0.001).
b) The differences between the two visits were plotted against the mean change in 
FMD in the two visits. Dotted lines represent the 2SD o f the differences in FMD in the
two visits.
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3.5.2 Reproducibility of salbutamol evoked changes in PAIx and RI in adults
There was no significant difference in the baseline values of PAIx and RI in the two 
visits (47.1 ±9.7% vs 45.9±9.2%, p=0.8 visit 1 vs visit 2). A significant reduction in 
PAIx and RI was noted after salbutamol inhalation in the two visits (Figure 3.5, 
Figure 3.7)). The mean maximum change in PAIx (-10.65±4.15% vs -10.13±5.05% 
visit 2-visit 1) and RI% (-16.55±8.02 vs -16.5±6.4 %) after salbutamol inhalation was 
of similar magnitude in the two visits. The maximum reduction in PAIx and %RI was 
noted between 15-20 minutes in the vast majority of cases. The maximum change in 
PAIx and in RI induced by salbutamol inhalation showed no systematic observer bias 
error as shown by the Bland Altman plots (Figure 3.6, Figure 3.8). The coefficient of 
variation for PAIx and RI between the two visits was 11.48 % and 18.18% 
respectively (Table 3.3).
Time (minutes)
Figure 3.5: The impact o f  salbutamol inhalation on PAIx.
PAIx recordings (N=16) at 0 (baseline) and at 5, 7.5, 10, 12.5, 15, 17.5, 20 minutes 
and the maximum reduction in PAIx in both visits after 400jug salbutamol inhalation 
are demonstrated. Values expressed as mean±SE. ***: p<0.001 when compared with 
baseline for every visit.
-— Visit 1
0 5 7.5 10 12.5 15 17.5 20
177
a)
Visit 1
-17.5 -15.0 -12.5 -10.0 -7.5 -5.0 -2.5 0.0
--10
--15
--20
Visit 2
b)
-5.5
-3.0
-0.5
-20 - l C b
- 2.0
--4.5
L-7.0
PAIx (Visit 1+Vis it 2)/2
>
<
Figure 3.6: Reproducibility o f the salbutamol induced responses on the PAIx in the 
two visits.
a) The Pearson correlation coefficient o f the PAIx in the two visits was r=0.77
(p<0.001).
b) Bland Altman plot fo r  the PAIx. Dotted lines demonstrate the 2SD o f the 
differences.
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Salbutamol inhalation was followed by a significant increase in heart rate (56.6±2.2 
beats/minute at baseline vs 63.2±2.8 beats/minute; max increase after salbutamol 
inhalation, p<0.001). However, the observed changes in heart rate were not associated 
with the changes in PAIx or in RI (r=0.05 and r=0.1 respectively) suggesting that 
changes in PAIx and RI cannot be attributed to haemodynamic variations.
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Figure 3.7: The impact o f salbutamol inhalation on RI.
RI recordings (N=16) at 0 (baseline) and at 5, 7.5, 10, 12.5, 15, 17.5, 20 minutes and 
the maximum reduction in RI in both visits after 400pg salbutamol inhalation are 
demonstrated. Values expressed as mean±SE. ***: p<0.001 and **: p<0.01 when 
compared with baseline fo r  every visit.
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Figure 3.8: Reproducibility o f the salbutamol induced responses on the RI in the two 
visits.
a) The Pearson correlation coefficient o f the RI in the two visits was r=0.4 (p=NS).
b) Bland-Altman plot fo r  the RI. Dotted lines demonstrate the 2SD o f the differences 
between the two visits.
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3.5.3 Reproducibility of GTN responses assessed by ultrasound in the two visits
in adults
GTN response was comparable in the two visits (r=0.64, p<0.01). There was no 
systematic observer bias in the GTN measurements in the two visits as shown by the 
Bland-Altman plot. The mean difference between visit recordings was 2.13±2.9%. 
The coefficient of variation was 19.06%.
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Figure 3.9: Reproducibility o f the endothelium independent response as assessed by 
GTN in the two visits one day apart.
a) There was good agreement between the GTN induced responses on two separate 
visits (r=0.67; Pearson correlation coefficient, p<0.01).
b) Bland Altman plot o f GTN responses in the two visits.
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3.5.4 Reproducibility of GTN evoked changes in PAIx and RI in adults
There was no significant difference in the baseline values of PAIx in the two visits 
(50.4±8.5% vs 48.3±9.1% p=0.5, visit 1 vs visit 2) and of RI (68.6±8.6% vs 
66.9±9.6%) in the two visits. GTN evoked a rapid reduction in the PAIx as early as 3 
minutes after the administration of 25 jig of GTN (Figure 3.10, Figure 3.12).
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Figure 3.10: The impact o f glyceryl-trinitrate on the PAIx in the two visits.
PAIx recordings (N=16) at baseline and at 3, 5, 10, 15 minutes and the maximum 
reduction in PAIx in both visits after 25pg glyceryl-trinitrate are demonstrated. 
Values expressed as mean±SE. ***: p<0.001 when compared with baseline fo r  every 
visit.
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Figure 3.11: Reproducibility o f  the glyceryl-trinitrate induced changes on the PAIx in 
the two visits.
a) The Pearson correlation coefficient o f  the PAIx in the two visits was r~-0.3.
b) Bland Altman plot fo r  the PAIx. Dotted lines demonstrate the 2SD o f the 
differences.
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As with the assessment of salbutamol-mediated changes, the maximum response to 
GTN was used to establish the reproducibility o f the method. The mean maximum 
change in PAIx and in the RI after GTN administration from the baseline values was
-10.6±5.1% visit 1 vs visit 2). There was poor correlation between the maximum 
responses induced in PAIx and in the RI after the GTN administration (r=-0.33, and 
r=0.3 respectively p=NS) (Figure 3.11, Figure 3.13). As shown by the Bland-Altman 
plots, the mean difference between visit recordings was 1.67±7.12% for PWA and 
0.79±5.8 for DVP.
Figure 3.12: The impact o f glyceryl-trinitrate on the RI in the two visits.
RI recordings (N-16) at 0 (baseline) and at 3, 5, 10, 15 minutes and the maximum 
reduction in PAIx in both visits after 25pg GTN are demonstrated. Values expressed 
as mean±SE. ***: p<0.001 when compared with baseline for every visit.
of similar magnitude in the two visits (-12.4±5.2% vs -11.4±3.8% and -11.4±4.9% vs
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Figure 3.13: Reproducibility o f  the glyceryl-trinitrate induced changes on the RI in 
the two visits:
a) The Pearson correlation coefficient o f  the RI in the two visits was r=0.3.
b) Bland Altman plot fo r  the RI. Dotted lines demonstrate the 2SD o f the differences.
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3.5.5 Reproducibility of FMD in two visits in children
The baseline diameter and the haemodynamic characteristics were similar in the two 
visits as shown in Table 3.2. The baseline diameter was comparable in the two visits 
(r=0.97, p<0.001). The coefficient variation was 1.5% (Table 3.3).
FMD response was comparable in the two visits (r=0.89, p<0.001) and there was good 
agreement in the FMD measurements in the two visits as shown by the Bland- Altman 
plot (Figure 3.14). The mean difference between visit recordings was 1.1±0.78%. The 
coefficient variation was 6.28% (Table 3.3).
VISIT 1 VISIT 2 p value
Baseline diameter 
(mm) 3.1±0.6 3.1±0.6 0.5
Baseline VTI (m) 0.1±0.1 0.1±0.1 0.5
Baseline
HR(beats/mins) 75±12.5 73±11.5 0.7
Peak VTI (m) 0.35±0.1 0.37±0.1 0.5
Peak HR 
(beats/min) 76±13.9 71±11.0 0.4
% Reactive 
hyperaemic flow 444.4±273.7 354.5±133.9 0.4
Table 3.2: Baseline and haemodynamic characteristics o f  children.
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Figure 3.14: Reproducibility o f the endothelial function response as assessed by 
FMD in the two visits.
a) There was good agreement between the FMD responses on two separate visits 
(r=0.89 p<0.01) one week apart.
b) The d ifferences b etween the two v isits w ere p  lotted a gainst t hem ean c hange i n 
FMD in the two visits.
187
3.5.6 Reproducibility of salbutamol evoked changes in PAIx and RI in children
There was no significant difference in the baseline values of PAIx in the two visits 
(42.8±9.7 % vs 45.5±11.5 % p=0.5, visit 1 vs visit 2) and RI (64.8±11.3 vs 61.2±16.4; 
p=0.5). There was no statistical significant difference in the mean maximum change 
in PAIx and RI in the two visits (-8.0±5.3 vs -9.7±5.6; p=0.5 and -12.5±6.3 vs - 
7.8±8.4; p=0.1). The maximum reduction in PAIx and RI was noted between 10-15 
minutes in the vast majority of cases as shown in Figure 3.15 and in Figure 3.17 
respectively. The maximum change in PAIx and in RI induced by salbutamol 
inhalation showed no systematic observer bias error as shown by the Bland Altman 
plots (Figure 3.16, Figure 3.18). The coefficient variation for PAIx and RI between 
the two visits was 17.14% and 36.34% respectively (Table 3.3).
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Figure 3.15: The impact o f salbutamol on PAIx in the two visits in children.
PAIx recordings (N=16) at 0 (baseline) and at 5, 7.5, 10, 12.5, 15, 17.5, 20 minutes 
and the maximum reduction in RI in both visits after 200pg salbutamol inhalation are 
demonstrated. Values expressed as mean±SE. ***: p<0.001 when compared with 
baseline for every visit.
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Figure 3.16: Reproducibility o f the salbutamol induced responses on the PAIx in 
children in the two visits.
a) The correlation coefficient o f the PAIx in the two visits was r=0.43, p=NS.
b) Bland-Altman plot fo r  the PAIx. Dotted lines demonstrate the 2SD o f the 
differences.
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Unlike in adults, heart rate was not significantly increased at 20 minutes after 
salbutamol inhalation in children and the changes in heart rate were not associated 
with the changes seen in PAIx (r=0.12, p=0.8).
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Figure 3.17: The impact o f salbutamol on RI in children in the two visits.
RI recordings (N=16) at 0 (baseline) and at 5, 7.5, 10, 12.5, 15, 17.5, 20 and max 
***: p<0.001 when compared with baseline for every visit.
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Figure 3.18: Reproducibility o f the salbutamol induced responses on the RI in 
children in the two visits.
a) The correlation coefficient o f  the RI in the two visits was r=-0.11.
b) Bland-Altmann plot fo r  the RI. Dotted lines demonstrate the 2SD o f the differences.
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3.5.7 Summary of the reproducibility of endothelial function with the three
modalities
Coefficients of variation
Baseline
diameter
Baseline
PAIx%
Baseline
RI%
FMD% APAIxs ARIs
Adults 1.71 4.33 3.95 7.09 11.48 18.18
Children 1.57 4.10 5.78 6.28 17.14 36.34
Table 3.3: Coefficient o f  variation for baseline measurements and endothelial 
function measurements with 3 modalities in adults and children.
APAIxs: difference in the PAIx following salbutamol inhalation in the two visits.
ARIs: difference in the RIfollowing salbutamol inhalation in the two visits.
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3.5.8 Ability of endothelial function testing using salbutamol mediated changes in 
PAIx to characterise the vascular consequences of an acute inflammatory 
stimulus
The baseline and haemodynamic characteristics were comparable in the two visits as 
shown in Table 3.4. Eight hours after the typhoid vaccination a significant reduction 
in endothelial function was noted when assessed by FMD or by salbutamol induced 
changes in the PAIx. Endothelial function as assessed by salbutamol induced changes 
in the RI was similar at before and 8 hours after typhoid vaccination (Figure 3.19). 
Endothelial independent response to 25pg GTN before and after typhoid vaccination 
was preserved when assessed by the three modalities (Figure 3.19). The baseline 
recordings of the PAIx and RI were comparable in the two days (p=0.9 for both).
VISIT 1 VISIT 2 p value
Baseline diameter (mm) 3.86±0.4 3.9±0.3 0.1
Baseline VTI (m) 0.09±0.03 0.08 ±0.05 0.5
Baseline HR(beats/mins) 69±8.5 68 ±11.3 0.6
Peak VTI (m) 0.46±0.1 0.38±0.2 0.2
Peak HR (beats/min) 69±7.2 67±10.9 0.8
Reactive hyperaemic flow % 535.5±205.9 567.2±323.8 0.8
Table 3.4: Baseline and haemodynamic characteristics before and 8 hours after 
typhoid vaccination.
Abbreviations: VTI velocity time integral, HR: heart rate.
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Figure 3.19: The impact o f typhoid vaccination on endothelial function.
Eight hours after the typhoid vaccination a reduction in %FMD and also a reduction 
in the absolute change in the PAIx was noted. GTN induced vasorelaxation and GTN 
induced changes in PAIx were similar in baseline and 8 hours post vaccination. 
Values expressed as mean±SE.
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3.6 DISCUSSION
In this study, we have demonstrated contemporaneous reproducibility of 3 non- 
invasive techniques for assessment of endothelial function. Of the three methods, 
brachial FMD appears to be the most reproducible in our hands in healthy adults and 
children. In addition, both FMD and PAIx were sensitive to detect acute short lived 
perturbation in endothelial function mediated by low grade inflammatory stimuli but 
the power to detect this change appears greater for FMD.
Endothelial function assessment by flow mediated dilatation has been widely used in 
clinical practice since the early 1990’s when the method was developed in our 
department. It has been shown to be accurate, to have relevance to biology and to be 
associated with cardiovascular outcome [135-137]. However, it has been criticized for 
being technically demanding and operator dependent. Advances in the methodology 
(use of stereotactic probe holder and analysis software for accurate edge detection 
diameter) have greatly diminished the latter, however the cost of ultrasound machine 
and inherent technical challenges in the method have withheld its use from the clinical 
practice.
Recently the use of PWA or DVP with provocative pharmacological testing with 
salbutamol has been suggested as alternative method for measuring endothelial 
function[146;147]. Changes in peripheral augmentation index and reflection index 
following salbutamol inhalation have been shown to be NO dependent and were able 
to distinguish between health and disease in small clinical studies [147;425]. Both 
techniques have been regarded as operator independent, although for PWA certain 
skill and practice for the placement of the tonometer probe and recording o f the 
arterial pulse is required. In addition the cost of the machinery and software required
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is much less in comparison to the ultrasound, thus more attractive for widespread use 
in clinical setting.
In our study we were able to demonstrate comparative reproducibility for the baseline 
measures of PAIx and RI to the ones reported from other groups [147;402], however 
the reproducibility of salbutamol mediated changes in PAIx was less than previously 
reported in male subjects. In addition, salbutamol mediated changes in reflection 
index was found to be less reproducible in adults and children. Although we have 
used a spacer device to optimize the delivery of the salbutamol we did not measure 
plasma drug levels as the study was planned to be non-invasive. Thus we are unable 
to exclude variations in the inhalation technique, absorption in the lungs or uptake by 
the circulation between the different visits. In addition, measurements of arterial pulse 
from the finger have been shown to be more dependent on sympathetic tone and also 
to environmental changes such as temperature. The influence of the latter was 
minimised in our study since the finger probe has an inbuilt system to keep the finger 
warm throughout the measurements. However we could not account for any 
alterations in sympathetic tone between visits. These limitations may account for the 
less reproducible results noticed when endothelial function was assessed with PWA or 
DVP compared to FMD in both adults and children.
In this study we have also assessed the sensitivity of the three different methods to 
detect a Iterations i n e ndothelial f  unction a ssociated w ith a 1 ow grade i nflammatory 
stimulus, such as the one created by typhoid vaccination. It has been demonstrated 
that a typhoid vaccination can induce short lived conduit and microvascular 
endothelial dysfunction. In this study both brachial FMD and PWA following 
salbutamol inhalation showed a reduction in endothelial function 8 hours after
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vaccination but this effect was not seen by DVP, suggesting that in a study of this size 
this technique is unable to detect a difference. The lower reproducibility of PWA and 
particularly DVP compared to FMD has implications for sample size calculations in 
future endothelial function studies. Formal power calculations are potentially 
misleading as t hey rely on a p articular e ffect s ize ( i.e 2 %) w hich m ay or m ay n ot 
mean the same thing with the different measures. However comparing just 
reproducibility, sample size is proportional to the square root of the within subject SD 
and compared to FMD this is larger for PWA and DVP by 2 times and 6 times 
respectively. Thus studies based on PWA and DVP will need to be substantially larger 
than for FMD to achieve the same power to detect a given effect size.
3.7 CONCLUSION
In t his s tudy w e h ave d emonstrated t hat e ndothelial f  unction m easured by FMD i s 
more reproducible compared to both PWA and DVP in healthy adults and in children. 
Changes evoked in peripheral pressure waveform in response to the inhalation of 
salbutamol and measured using applanation tonometry can also be used as an 
alternative methodology for measuring endothelial function in adults especially when 
financial and technical difficulties do not permit ultrasound measurements. We have 
also been able to show its usefulness for acute mechanistic experiments. However one 
should always balance the cost effectiveness of the machinery and software with the 
larger numbers that would be required to demonstrate clinically significant differences 
between study groups. Thus the findings of this study support the use of brachial 
FMD for assessment of endothelial function in epidemiological and mechanistic 
studies.
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CHAPTER 4
THE IMPACT OF ACUTE COMMON 
INFECTIONS ON ENDOTHELIAL FUNCTION IN
CHILDHOOD
4.1 INTRODUCTION
Infection is the most common inflammatory insult. To date, most clinical studies 
trying to unravel the contribution of infection to the atherosclerotic process have 
focused on the advanced stages of atherosclerotic disease in adults, and have provided 
conflicting results [268;474-476] as has been previously described in section 1.6.
However, the greatest burden of infection occurs in childhood, raising the possibility 
that infection may play a more important role during the preclinical phase of 
atherosclerosis in the absence of unquantiflable risk factor burden usually present in 
older ages. There has been limited clinical investigation into the role of infection in 
children; however one provocative study suggested that a severe infection can 
accelerate the early progression of structural arterial disease [213]. It remains 
unknown whether acute common infections in childhood can affect endothelial 
function.
4.2 AIMS OF CHAPTER
The purpose of this chapter was:
• To investigate the impact of common mild childhood infections on endothelial 
function in a large cohort of children nested within the ALSPAC cohort.
• To assess the long-term effect of these minor infections on endothelial 
function.
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4.3 METHODS
4.3.1 The ALSPAC population
The Avon Longitudinal Study of Parents and Children (ALSPAC) is a population 
based study which is part for the European Longitudinal Study of Pregnancy and 
Childhood. It includes a geographically defined population from the West of England 
in the Avon area with 1 million people and includes the city of Bristol (Figure 4.1).
W A L E S G L O U C E S T E R
B R I S T O L
C H A N N E L
S o u t h  G l o u c e s t e r s h i r e
Br i s t o l  Ci
N o r t h  S o m e r s e t
B a t h  a n d  Nor t h  
E a s t  S o m e r s e t
S O M E R S E T
Figure 4.1: The Avon area in UK.
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It consists of mixture of rural areas, leafy suburbs and moderate-sized towns and as 
such provides a good representation of the general UK population as far as 
socioeconomic status, lifestyle habits, family structure. In addition the frequencies of 
preterm deliveries, disabilities and incidence of infection were similar with that of the 
whole Great Britain.
In this study pregnant women who had an expected day of delivery between 1st April 
1991 and 31st December 1992 were eligible for recruitment. The participation rate was 
85% of the eligible total general population in 3 health authorities in the Bristol UK 
area [477]. From the total of 15,541 pregnant women enrolled in the study a cohort of 
14,062 live bom children has been followed up prospectively. Detailed information 
about the children has been collected from questionnaires administered through 
childhood and clinic measurements have been performed on the entire cohort annually 
since the age of 7 years[477].
4.3.2 The Vascular study population
In 2002 our group started characterizing the vascular phenotype of approximately 
8,000 of these children who continued to come in the annual clinic follow ups.
The population of this study consisted of 600 children aged 10 years. These were 
children bom between February 1992 and June 1992, who were participating in a 
vascular study of the entire ALSPAC cohort, provided that they did not have asthma 
or chronic infections and were not taking antibiotics or anti-inflammatory drugs.
4.3.3 Definition of infection
Prior to study, parents were asked to fill a questionnaire regarding the health status of 
their children. The parents were asked to state whether their child had any current
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infection and to specify the type and severity and duration of infection. In addition 
they were asked whether their child had any infection in the past two weeks from the 
study. Details about medication or vitamin supplements taken by children at the time 
of the vascular assessment or regularly were taken. The commonest symptoms 
described in the questionnaires were cough, cold, fever and sore throat. The presence 
or absence of these symptoms was not confirmed by formal clinical examination, or 
serological evidence. No blood tests were undertaken to document infectious agents 
or state. Children were then classified into three different groups; 1) children who 
reported acute infection at the time of the study (AI group), 2) children who were 
convalescing from an infection in the previous two weeks but were well at the time of 
the study (Conv group) and 3) children without recent illness (Controls). None of the 
illnesses were considered severe enough to warrant medical consultation or 
prescription of antibiotics.
4.3.4 Endothelial function
Following the results of the reproducibility study described in chapter 3, flow 
mediated dilation was considered to be the most sensitive and reproducible method 
for endothelial function assessment in children. Thus we set up 4 clinical rooms in 
Bristol and each child underwent measurement of endothelium dependent vascular 
responses of the right brachial artery by high resolution ultrasound imaging (Aloka 
5500, Japan; 7MHz linear probe and automated vessel diameter measurements, 
Brachial Tools, MIA) in one of the clinical rooms in Bristol. Detailed description of 
the experimental protocol is included in section 2.1.2.
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4.3.5 Potential confounding factors
4.3.5.1 Measures o f social position
Information about the occupation, education, income of the mother and 
fathers/partners was collected from questionnaires in the 32-week antenatal period. 
On the basis of these answers each one (mother and father/partner) were allocated to a 
social class group (which ranged from V=unskilled to I=professional) with the United 
Kingdom Registar General’s occupational coding. A combined variable was derived 
that was the highest socioeconomic class of the mother and her partner.
4.3.5.2 Measures o f  cardiovascular risk factors
At the time of the vascular assessment children’s blood pressure was measured as the 
average of the last 2 seated readings with an automated oscillometric device 
(Dinamap 9301 vital signs monitor) in the left arm. Since it has been recognized that 
BP cuff size is crucial for accurate BP measurements, with smaller cuffs contributing 
to higher BP reading whereas larger cuff underestimate the BP reading, extra care was 
taken to account for cuff size. The arm circumference was measured and when was 
found <25cm a paediatric cuff was used whereas when arm circumference >25cm an 
adult cuff was used for the recordings.
Heart rate was measured as the average of the last 2 readings as recorded from the
same (Dinamap 9301 vital signs monitor) device. Weight was measured to the nearest
0.1kg with SECA scales while the child was wearing underwear, and height was
measured to the nearest 0.1cm with a Leicester height meter. From these
2 •measurements body mass index values were calculated (weight/height , with weight 
in kilograms and height in meters). At the time of the study no blood was collected
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due to time constraints. To account for the background risk factor profile of these 
children blood sample measurements for total cholesterol, high density lipoprotein 
and low density lipoprotein performed at age 7 years were used in our analysis.
4.3.5.3 Measures o f  previous infection and h\>2iene practice
Mothers reported, in four different questionnaires at 15 months, 15-24 months, 24-38 
months and 54 months how often in a normal day their child’s face and hands were 
wiped and also how often hands were wiped before meals. Responses ranged from 
“not at all” to “five or more times per day”. Mothers were also asked how often their 
child was given a bath or shower, brushed their teeth and cleaned their ears. 
Responses ranged from “hardly ever” to “more than once a day”. The score at each 
time point was the sum of six questions giving values 0-18, with higher values 
indicating greater hygiene. From these responses the mean child’s hygiene score was 
derived (ranging from least hygienic to most hygienic) [478].
Similarly, a mean infection score was created from questionnaires for the age periods 
less than 6 months, 6-18 months, 18-30 months, 30-42 months and 59-81 months 
giving values from 0-7. The infection score at each time point was the number of 
infections (diarrhoea, vomiting, cough, high temperature, cold, earache, and ear 
discharge) reported. In addition an “infection seen by the doctor” score was also 
derived with individual questions recoded as seen the doctor with infections versus 
not seen the doctor with infection/no infection. Using the same timepoints, a mean 
antibiotic score was calculated, where the score at each time point was “0” for no 
antibiotic use, “ 1” for only one episode of use and “2” for 2 or more episodes of 
antibiotic use. For all variables, mean values were only calculated if values were 
recorded for at least two timepoints.
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4.3.6 Follow-up study methods
To assess the long term effect of the infectious illness on endothelial function we 
carried out repeat measures. We calculated that forty children from the AI group 
would have the power to demonstrate a 25% improvement in the FMD response 
relative to their baseline measurement in the AI group with 90% power and at 5% 
significance level. To ensure adequate participation, we invited by letter all 135 
children of the AI group and 150 randomly selected Control children to attend for a 
further vascular assessment (12±6 months after the initial evaluation).
4.4 STATISTICS
The data were analysed with the Stata analysis package version 8. All vascular 
function data were normally distributed and are presented as mean and standard 
deviation (SD) for continuous variables or percentages for categorical variables. We 
examined the effect of infection on endothelial function by linear regression analysis. 
Multivariable analysis was performed to adjust for other potential confounders. At the 
follow-up study, t-tests were used to compare the differences in endothelial function 
measures.
4.5 RESULTS
4.5.1 Population characteristics
Of the 600 subjects, 301 children had either an acute infection at the time of the study 
(AI, N=135) or were convalescing from an infection in the previous two weeks but 
were well at the time of study. The 299 controls were healthy children without recent 
illness. The majority of children in both the AI and Conv groups presented with upper 
respiratory tract infections (93% and 94% respectively). The remainder had either ear
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(2% and 2%) or urinary tract infection (5% and 4%). Seventeen children from the 
Control group were excluded from the analysis as their vascular measures could not 
be linked to the main database. None of the children in this study had infectious 
illnesses deemed sufficiently severe to warrant prescription of antibiotics. The clinical 
characteristics and risk factor profile o f the children are shown in Table 4.1. Higher 
socio-economic position was associated with increased incidence of infection, and 
there were more boys than girls in the AI group. No other factors were associated with 
infectious status.
In the follow up study all 43 children who replied from the AI group were studied but 
3 were excluded as they presented with acute infection or with a history of recent 
infection within the last two weeks. Fifty Control children had a repeat study in an 
identical manner. None of those children had experienced a further infection during 
the intercurrent period between the two studies.
4.5.2 Associations between acute infection and clinical characteristics.
Higher socio-economic position was associated with increased incidence of infection, 
and there were more boys than girls in the AI group. No other factors were associated 
with infectious status (Table 4.1).
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AI group
N=135
Conv group 
N=166
Control
group
N=282
p-value
Male (%) 54.1 47.0 40.4 0.01
Social class I and II (%) 67.2 59.7 54.1 0.02
BMI (kg/m2) at lOyrs 16.1(1.8) 15.8(1.6) 16.2(2.2) 0.4
TCHOL (mmol/L) at 7yrs 4.4(0.7) 4.4(0.7) 4.4(0.7) 0.9
HDL (mmol/L) at 7yrs 1.5(0.3) 1.6(0.4) 1.5(0.3) 0.1
LDL (mmol/L) at 7yrs 2.2(0.6) 2.3(0.5) 2.3(0.6) 0.5
SBP (mmHg) at lOyrs 102.2(8.2) 101.5(8.9) 100.7(8.4) 0.1
DBP (mmHg) at lOyrs 57.1 (6.8) 57.1 (7.2) 56.9(7.1) 0.8
HR (beats/min)at lOyrs 71.2(11.9) 73.0(11.5) 71.0(11.3) 0.6
Infection score: Not seen by 
doctor 3.7(0.9) 3.6(0.9) 3.5(0.9) 0.1
Infection score: Seen the by 
doctor 1.4(0.9) 1.3(0.9) 1.3(0.9) 0.3
Antibiotic score 0.8(0.5) 0.7(0.5) 0.7(0.5) 0.1
Hygiene score 9.8(1.8) 9.7(1.8) 9.8(2.0) 0.8
Table 4.1: Demographic and clinical parameters according to infection status in 
children.
Abbreviations: HDL: high density lipoprotein, TCHOL: total cholesterol, LDL: low 
density lipoprotein, BMI: body mass index, SBP: systolic blood pressure, DBP: 
diastolic blood pressure. HR: heart rate.
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4.5.3 Infection and endothelial function
Endothelial dependent FMD was lower in the AI group compared with both the Conv 
and the Control children (p<0.001 for both) (Figure 4.2). In addition, FMD was also 
lower in the Conv children compared with the Controls (p<0.001). Baseline diameter, 
baseline flow, reactive hyperaemia flow and absolute change in flow were similar in 
the three groups (Table 4.2).
10.0 1
7 .5  -
% FMD 5 0 . 
2 .5  - 
0.0
AI Conv Control
Figure 4.2: The impact o f  infection on endothelial function.
This figure demonstrates the differences in endothelial function (%FMD) between the 
acute infection (AI) group, the convalescent (Conv) group and the Controls.
*: p<0.001 when compared with the Control group.
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A Igroup
N=135
Conv group 
N=166
Control group
N=282 P value
Baseline
diameter
(mm)
2.7(0.3) 2.7(0.3) 2.7(0.5) 0.9
% FMD 6.3(2.7) 8.1(3.1) 9.7(2.5) 0.001
Baseline flow 
(ml/min) 8.6(3.7) 8.7(4.1) 9.2(5.7) 0.6
% Reactive
hyperemia
flow
492.2(139.1) 523.2(138.2) 486.0(140.9) 0.6
Absolute 
change in 
flow (ml/min)
31.0(9.4) 31.3(16.23) 32.4(17.6) 0.8
Table 4.2: Vascular characteristics according to infectious status.
Baseline diameter and sex were independently associated with FMD (Table 4.3). 
However based on the data from the literature, we considered all other factors as 
potential confounders and adjusted for them in the analysis. The impact of AI on 
FMD was unaltered after multivariable adjustment for sex, baseline diameter and total 
cholesterol, systolic blood pressure, socio-economic status, BMI, infection and 
hygiene score (Table 4.4).
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P (Cl)
Unadjusted 
p value
Adjusted
p-value
Baseline diameter (mm) -0.9(-1.4, -0.3) 0.002 -
Sex (males) 0.7(0.2, 1.2) 0.01 0.05
Birth weight (kg) 0.1 (-0.4, 0.6) 0.6 0.4
Social class 0.2(-0.3, 0.8) 0.4 0.5
BMI at 10 yrs (kg2/m2) -0.01 (-0.1, 0.1) 0.9 0.6
TCHOL (mmol/L) at 7yrs -0.1 (-0.5, 0.4) 0.7 0.6
HDL (mmol/L) at 7yrs -0.7(-1.6, 0.3) 0.2 0.1
LDL (mmol/L) at 7yrs 0.1 (-0.5, 0.7) 0.7 0.6
SBP (mmHg) at lOyrs -0.02(-0.05, 0.01) 0.1 0.2
DBP (mmHg) at lOyrs 0.01(-0.03, 0.05) 0.6 0.6
Infection score: Not seen by doctor -0.2(-0.5, 0.08) 0.2 0.2
Infection score: Seen the by doctor -0.1 (-0.4, 0.2) 0.6 0.7
Antibiotic score 0.1 (-0.4, 0.6) 0.6 0.7
Hygiene score -0.04(-0.2, 0.1) 0.6 0.6
Table 4.3: Associations between endothelial function and risk factors.
Univariate associations between risk factors and FMD unadjusted and following 
adjustment for differences in baseline vessel size.
% FMD unadjusted % FMD adjusted
AI group -3.4 (-3.9, -2.8) -3.1 (-3.9, -2.3)
Conv group -1.7 (-2.2,-1.1) -1.7(-2.4, -0.7)
Table 4.4. Associations between FMD and acute infection.
Values adjusted for sex, baseline diameter, infection score, hygiene score, total 
cholesterol, body mass index, social class, systolic blood pressure.
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4.5.4 Follow up study
The differences in vascular function between the AI and Control children who 
participated in the follow up study were similar to the findings for the whole cohort. 
Baseline vessel size was similar in both the AI and the Control group at the two visits. 
Baseline and reactive hyperaemia flow measurements were similar in the Control 
group at the two visits (Table 4.5). FMD was unchanged in the Control children in the 
two visits. In contrast, FMD improved substantially in the children in the AI group 
(Figure 4.3), (Table 4.5).
r p=0.06 I
p < 0 .0 0 1
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Figure 4.3: Follow up study.
Flow Mediated Dilatation (FMD) was reassessed in 40 children o f  the acute infection 
(AI) group and 50 o f  the Controls in a mean interval 12±6 months after their initial 
evaluation. The horizontal lines represent the mean values for each group.
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AI group (N=40) Control group (N=50)
Visit 1 Visit 2 P* Visit 1 Visit 2 P* Pt
Baseline diameter (mm) 2.8(0.3) 2.7(0.3) 0.2 2.8(0.9) 2.7(0.4) 0.5 0.9
%FMD 5.0(2.3) 8.2(2.5) 0.001 9.3(2.4) 9.2(2.3) 0.8 0.06
Baseline flow (ml/min) 8.5(2.8) 11.6(6.9) 0.01 10.3(8.7) 10.3(4.9) 0.9 0.3
%Reactive hyperemia flow 499.1(143.2) 432.7(140.2) 0.05 476.8(140.5) 477.8(162.4) 0.9 0.2
Absolute change in flow 
(ml/min)
31.6(8.9) 33.1(13.5) 0.8 34.5(13.9) 33.9(12.5) 0.6 0.8
Table 4.5: Vascular characteristics o f children in the follow up study.
*p: visit 1 vs visit 2
tp: visit 2 o f the acute infection (AI) group versus visit 2 o f the Control group
2 1 2
At follow up study, FMD was lower in the AI group compared to Controls but this did 
not reach conventional statistical significance (p=0.06). Thirty six of the children in 
the AI group had endothelial function values within normal range at follow up. The 
FMD values of four AI children remained two standard deviations below the mean 
value for the Control children. In the control group, two children had FMD values two 
standard deviations below the mean both at baseline and at restudy. There were no 
demographic or clinical features which discriminated this small group of AI or 
Control children from the remaining children. Baseline flow measurements in the AI 
group were higher in the follow up study compared with their index visit. Although 
this baseline difference in flow resulted in lower reactive hyperaemic flow expressed 
as a percentage, the absolute increase in hyperaemic flow was similar to that seen at 
the first visit (Table 4.5).
4.6 DISCUSSION
This study shows that minor infectious illnesses are associated with impairment in 
endothelial function in otherwise well children. Vascular function recovered in most 
but not all children at follow up study one year later.
The data suggest that even mild childhood infections that do not require a visit to the 
doctor or antibiotic therapy, are associated with marked endothelial dysfunction. It is 
noteworthy that the impact on FMD was comparable to that seen in previous studies 
in young adults with risk factors such as diabetes and family history of coronary 
artery disease [59;479]. Within this large representative cohort, there was a range of 
vascular responses to acute infection. This is unlikely to have been due to variation in 
cardiovascular risk factor profile in our population, as there were similarly low levels
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of risk factors in all three groups. In addition, due to size and time limitations of the 
study, blood was not taken at the time of the study. I was therefore unable to define 
whether specific infectious agents are more likely to produce vascular effects. It was 
also not possible to quantify the magnitude of the vascular inflammatory response by 
measuring blood markers of endothelial activation, which have been identified in 
adult subjects at risk of coronary artery disease. Furthermore we did not have the 
opportunity to examine the potential contribution of parental risk factors i.e smoking 
[480;481].
In this study, I was able to examine changes in FMD over an average follow up of one 
year. Endothelial responses in most, but not all the children in the AI group, returned 
to within the normal range. Thus, the effects of AI at this age may be transient and 
recoverable. I was unable however, to determine the potential impact of recurrent 
infections, which might be cumulative as in the animal studies, on the initiation and 
progression of early atherosclerosis [482;483]. The AI, Conv and Control children all 
had similar reported histories of early childhood infections and hygiene practices. 
None of the children experienced an intercurrent infection in the interval between the 
two studies. There were only four children from the AI group in whom vascular 
function remained abnormal at follow up. This did not allow us to study the factors 
which might predispose to persistent endothelial dysfunction after acute infection. It 
remains possible that genetic or environmental factors may influence the long-term 
vascular effects of infection that may take years to become clinically apparent.
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4.7 CONCLUSION
In this study I demonstrated that a minor infection in childhood is associated with 
endothelial dysfunction. Endothelial function recovered in the majority of children 
within 12 months. Acute endothelial dysfunction caused by infection is unlikely to 
result in acute or chronic vascular disease in childhood. However, it is possible that 
chronic infection might accelerate atherogenesis in children which may manifest later 
in life. The impact of chronic infection in childhood is discussed in the next chapter.
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CHAPTER 5
THE IMPACT OF CHRONIC HIV INFECTION ON 
VASCULAR FUNCTION AND STRUCTURE IN
CHILDHOOD
5.1 INTRODUCTION
In chapter 4 I was able to demonstrate that in children aged 10 years an acute 
infectious stimulus is associated with a transient perturbation of endothelial function. 
However, the identification of the long-term effect of infection on the vasculature 
necessitates the study of recurrent infections or chronic infections in childhood. So far 
there is conflicting information in the literature about the role of chronic infections 
such as C.pneumoniae, H. pylori, herpes simplex and CMV in coronary artery disease 
risk in adults as it has been extensively reviewed in chapter 1 section 1.6. In addition, 
the seroprevalence of these infectious agents is low in childhood with seroconversion 
occurring usually post pubertally or in young adulthood.
Therefore to study the effect of chronic infection in childhood I decided to study HIV 
infection. By the end of 2004 almost 2.2 millions of children were living with HIV 
worldwide and the rates of infection are increasing yearly. In addition, life expectancy 
of HIV infected patients has improved considerably in developed countries as a result 
of antiretroviral therapy (ART). With this increase in lifespan an enhanced incidence 
of cardiovascular atherosclerotic disease has become apparent in HIV-infected adults 
and both the virus and the metabolic abnormalities related to the use of combination 
therapy have been implicated [484-486]. Protease inhibitors (Pis), in particular, are 
associated with dyslipidemia, insulin resistance and lipodystrophic phenotype. In 
adults however it has been difficult to separate out the effects of HIV disease itself 
from the drug treatment, or from that of the classical risk factors on cardiovascular 
disease risk.
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5.2 AIMS OF CHAPTER
The purpose of the study was to assess:
• The impact of chronic HIV infection on endothelial function and on arterial 
structure in the absence and presence of ART.
5.3 METHODS
5.3.1 Study Population and Design
We studied HIV-infected children attending Great Ormond Street Hospital (GOSH) 
NHS Trust (London, UK). Children with current opportunistic infections or 
cardiovascular risk factors, including hypertension, diabetes, and renal failure, were 
excluded. Of the 96 HIV-infected children identified as eligible for the study, 83 
agreed to participate. Fifty-nine healthy volunteer children were recruited as control 
subjects from healthy siblings of the HIV-infected children and children of staff 
working at the hospital. No formal matching was used in selecting the control children 
(apart from siblings). None had a current or recent infectious illness, nor were they 
receiving any medication or vitamin supplementation.
All children had a clinical examination, including blood pressure measurements, blood 
sampling, anthropometry, and vascular measurements. Details of past clinical and 
ART history were extracted from the UK Collaborative HIV Pediatric Study (CHIPS) 
database. Children were allocated a Centers for Disease Control (CDC) stage 
reflecting the extent of HIV disease progression (N: signifies no symptoms; A, B and 
C increasingly severe disease and C: AIDS) [487]. The HIV clinic at GOSH does not 
use rigid criteria for initiating ART. However, ART is usually started for persistently 
low or declining CD4% counts and/or clinical deterioration.
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The nature of the ART regime was not based on measures of disease severity. 
Ethnicity data were obtained from the National Study of HIV in Pregnancy and 
Childhood (NSHPC).
Institutional Review Board approval was received, and all parents, caregivers or 
children, when appropriate, gave written informed consent to participate in the study 
at the time of the visit.
5.3.2 Anthropometric Measurements
Weight and height were recorded, and body mass index (BMI; kg/m2) was calculated. 
Values were converted to age- and sex-adjusted z scores with the use of UK reference 
curves [488]. Blood pressure was measured as the average of 3 seated readings with 
an automated oscillometric device (Omron). A pediatric cuff was used when the arm 
circumference was <25 cm and an adult cuff when the arm circumference was >25 
cm.
5.3.3 Blood Sample Analysis
Non fasting blood was taken from all children in heparinized tubes, and 1 mL of 
plasma was stored at -80°C. Lipid levels and inflammatory markers (see below) were 
measured in all subjects, and markers of disease activity were assessed in the HIV- 
infected children.
5.3.3.1 Markers of HIV Severity and Inflammation
HIV RNA viral load was measured by branched DNA assay (Chiron Diagnostics) 
with a lower limit of detection of 50 copies per 1 mL. CD4% was measured by flow 
cytometry. For viral load and CD4% measurements, the most recent measurements
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(within 3 months before the study visit) were used if available. High-sensitivity C- 
reactive protein (hsCRP) was analyzed with an in-house ELISA method in Royal 
Infirmary in Glasgow [489].
5.3.3.2 Lipoprotein analysis
Total cholesterol was measured by enzymatic colorimetry; HDL was measured 
directly in plasma after precipitation with polyethylene glycol (Roche Diagnostics). 
Apolipoprotein B (apoB) and lipoprotein (a) [Lp(a)] were measured by
immunoturbimetry kits from WAKO and Diasys Diagnostic Systems, respectively. 
LDL peak and mean particle diameters were determined by PAGE. All lipid assays 
were performed in Royal Infirmary in Glasgow under supervision of Dr Muriel 
Caslake.
5.3.4 Vascular Measurements
5.3.4.1 Intima media thickness
The right and left common carotid arteries were scanned with a 5- to 10-MHz linear- 
array transducer (Acuson) as described in chapter 2, section 2.6.2.1. The mean of the 
three maximum measurements in the right and left carotid were used to calculate the 
mean IMT.
5.3.4.2 Flow mediated dilatation
Each child underwent measurement of endothelium-dependent vascular responses of 
the right brachial artery by high-resolution ultrasound imaging with an Acuson 5- to 
10-MHz linear probe. Detailed description of the protocol is included in section 2.1.2. 
Doppler derived flow measurements (using a pulsed-wave Doppler signal at a 70° 
angle) were also obtained continuously. Endothelium-independent response to
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glyceryl trinitrate (GTN) was also calculated as a percentage change from the baseline 
diameter after sublingual administration of 25 pg GTN in the HIV-infected children 
only.
5.3.4.3 PWV measurements
Each child underwent pulse wave velocity measurements using the sphygmoCor 
device as previously described in section 2.4.2. Briefly, the pressure pulse waveform 
was recorded consecutively in the radial and carotid artery simultaneously with an 
ECG signal, which provides an R-timing reference. The integral SphygmoCor 
software processes each set of pressure-pulse and ECG waveform data to calculate the 
mean time difference between R-wave and pressure wave on a beat to beat basis. 
PWV is then calculated using the mean difference and the carotid to radial arterial 
length.
5.4 STATISTICS
In descriptive analyses, parametric summary statistics and significance tests were used 
when the data were approximately normally distributed; otherwise, nonparametric 
methods were used. All FMD and GTN analyses were adjusted for baseline diameter; 
GTN analyses were adjusted for weight. Multivariate regression analysis was used to 
examine relationships between vascular measurements and HIV infection status and 
ART exposure with adjustment for potential confounders. Confounders included age, 
sex, ethnicity, Centers for Disease Control (CDC) stage, hsCRP, glucose, and selected 
lipid parameters. Variables that were not normally distributed were loglO transformed 
to reduce the influence of outlying observations.
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5.5 RESULTS
5.5.1 Study population
The 83 HIV-infected children had a mean age of 11.0 years (range, 5.4 to 17.7 years); 
70% were black; and all had acquired HIV from mother-to-child transmission. The 
control children were 1 year older than the HIV-infected children; 80% were white 
and had similar age-adjusted BMI scores (Table 5.1).
Twenty-seven HIV-infected children had never received ART. The remaining 56 
children had taken ART for a median of 5 years (range, 0.2 to 14 years). Of these 56, 
31 had received regimens containing a PI (Table 5.2). At the time of the study, 48 
children were taking ART (23 including a PI), and 35 children were not receiving any 
ART. Of the 31 Pi-exposed children, 8 were on combination therapy that did not 
include a PI at the time of the study visit (median duration since a PI was taken, 1.3 
years; range, 0.5 to 2.8 years). Twenty HIV-infected children (24%) had previously 
experienced a CDC stage C disease [490]; all 20 had been treated with ART (15 
exposed to PI therapy) (Table 5.2).
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HIV-infected children 
(n=83)
Controls
(n=59) p* value
Demographic data
Age (years) 11.0 (3.1) 12.2 (2.8) 0.014
Male % 57 47 0.31
Height z-score [IQR] -0.31 [-1.26,0.27] 0.30 [-0.15,0.94] <0.001
BMI z-score [IQR] 0.04 [-0.78, 0.87] 0.20 [-0.46, 1.04] 0.39
Clinical parameters
Systolic blood pressure 
(mmHg) 104(10) 110(12) <0.001
Diastolic blood 
pressure (mmHg) 61(9) 63(8) 0.09
Heart rate (bpm) 80(13) 72(12) <0.001
Glucose (mmol/L) 4.4 (0.7) 5.1 (0.3) <0.001
High sensitivity CRP 
(mg/L) median [IQR] 0.6 [0.2, 2.3] 0.2 [0.1, 0.6] <0.001
Table 5.1: Demographic data and clinical parameters for HIV-infected children and 
Controls.
Abbreviations: BMI: Body mass index, CRP: C-reactive protein. Values are given as 
mean (SD) unless otherwise stated. *: p-value based on the two sample t-test or 
Wilcoxon two sample test where appropriate.
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PI treated 
(n=31)
Non-PI treated 
(n=25)
Untreated
(n=27)
p* value
Demographic data
A g e  (years) 1 1 .1 (3 .5 ) 11.5 (3 .0 ) 10.3 (2 .5 ) 0 .3 9
M ale (% ) 62 4 4 63 0 .7 2
H eight z -score;  
m edian [IQ R] -0 .5 9  [ -1 .3 5 ,0 .1 8 ] -0 .4 0  [-0 .9 4 , 0 .0 6 ] -0 .2 4  [ -1 .3 2 ,0 .3 8 ] 0 .7 5
B M I z -score; m edian  
[IQ R]
-0 .2 0  [ - 0 .8 1 ,0 .7 5 ] 0 .0 4  [-0 .9 3 , 0 .5 6 ] 0 .6 2  [ -0 .2 5 ,1 .1 9 ] 0 .13
Clinical parameters
S y sto lic  b lood  pressure  
(m m H g) 103 (1 0 ) 103 (8 ) 1 0 6 (1 0 ) 0 .3 7
D ia sto lic  b lo o d  pressure  
(m m H g) 61 (1 2 ) 6 0  (7 ) 6 1 ( 6 ) 0 .9 0
Heart rate (b eats/m in ) 7 9 ( 1 1 ) 79  (1 2 ) 83 (1 5 ) 0 .3 7
G lu co se  (m m o l/L ) 4 .4  (0 .8 ) 4 .3  (0 .6 ) 4 .4  (0 .7 ) 0 .7 9
H igh sen s itiv ity  C R P  
(m g/L ); m edian [IQ R] 1.1 [0 .2 , 2 .0 ] 1.2 [0 .4 , 6 .7 ] 0 .4  [0 .4 ,2 .0 ] 0 .1 4
Clinical parameters 
related to HIV and 
ART
C D C  stage C (% ) 48 2 0 0 < 0 .001
C D 4 %; m edian  [IQ R ] 2 6  [ 2 1 ,3 4 ] 2 6  [1 4 , 29 ] 22  [19, 24 ] 0 .1 8
H IV  R N A  ( lo g  10 
co p ies /m l) 2 .3 0  (0 .9 8 ) 2 .6 8 ( 1 .1 1 ) 4 .0 8  (0 .7 0 ) < 0 .001
E xposure to  A R T  ( y e a r s ) ; 
m edian [IQ R] 5 .3  [4 .7 , 6 .8 ] 3 .8  [2 .3 , 6 .0 ]
E xposure to  P is  (years); 
m edian [IQ R] 4 .2  [2 .7 , 5 .1 ]
Table 5.2: Demographic and clinical parameters in HIV-infected children according 
to ART exposure.
Abbreviations: BMI: Body mass index, CRP: C-reactive protein, CDC, Centers for  
Disease Control and Prevention. ART: antiretroviral treatment, PI: protease 
inhibitors. Values are given as mean (SD) unless otherwise stated. *: global p  values 
based on AN OVA or the Kruskal-Wallis test where appropriate.
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5.5.2 Lipoprotein parameters
Triglycerides, non-HDL cholesterol, apoB, and Lp(a) were significantly higher in 
HIV-infected children compared with control subjects. In addition, HIV-infected 
children had significantly lower HDL cholesterol levels and mean and peak LDL 
particle sizes (Table 5.3).
HIV-infected children
(n=83)
Controls
(n=59)
p* value
Lipid/ Blood results
Total cholesterol 
(mmol/L) 4.1 (0.9) 3.8 (0.7) 0.06
HDL cholesterol 
(mmol/L) 1.2 (0.5) 1.4 (0.3) 0.02
Non HDL cholesterol 
(mmol/L) 2.9 (0.8) 2.4 (0.6) <0.001
Mean particle diameter 
(nm) 28.2(1.0) 29.0(1.1) <0.001
Peak particle diameter 
(nm) 27.8(1.2) 28.6(1.4) <0.001
ApoB (mg/dL) 75 (17) 64(11) <0.001
Lp(a) mg/dL; median 
[IQR] 42 [23, 69] 23 [14,51] 0.02
Triglycerides 
(mmol/L); 
median [IQR]
1.0 [0.7, 1.3] 0.6 [0.5, 0.8] <0.001
Table 5.3: Lipid profile in HIV-infected children and Controls.
Abbreviations: HDL: high density lipoprotein, ApoB: apolipoprotein B, IQR indicates 
interquantile range.
Within the HIV cohort, differences in lipid parameters were observed between those 
receiving different treatment regimens (Table 5.4). Total cholesterol was higher in 
children receiving ART (both with and without PI) compared with untreated HIV-
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infected children. Lp(a), apoB, and triglyceride levels were higher in Pi-treated 
children compared with non-PI-treated and untreated HIV-infected children. HDL 
cholesterol levels were lower in the untreated HIV-infected children compared with 
treated children, and the latter had levels similar to those in the control children.
PI treated 
(n=31)
Non-PI treated 
(n=25)
Untreated
(n=27)
P*
value
Lipid/ Blood results
T otal ch o lestero l  
(m m o l/L ) 4 .6  (0 .9 ) 4 .0  (0 .8 ) 3 .6  (0 .8 ) 0 .0 0 2
H D L  ch o lestero l 
(m m o l/L ) 1.4 (0 .5 ) 1.3 (0 .5 ) 1 .0  (0 .3 ) 0 .0 0 0 7
N o n  H D L  ch o les tero l 
(m m o l/L ) 3 .2  (1 .0 ) 2 .7  (0 .7 ) 2 .7  (0 .7 ) 0 .0 2
A p o B  (m g/d L ) 8 0  (2 0 ) 7 3 ( 1 5 ) 7 2  (1 5 ) 0 .1 3
M ean particle d iam eter  
(nm ) 2 8 .0 ( 1 .1 ) 2 8 .3  (0 .7 ) 2 8 .3  (1 .2 ) 0 .5 2
P eak particle d iam eter  
(nm ) 2 7 .7 ( 1 .2 ) 2 7 .0 ( 1 .3 ) 2 7 .8 ( 1 .3 ) 0 .7 4
L p(a) (m g/d L ); m ed ian  
[IQ R] 5 0  [3 8 , 86 ] 33  [1 7 , 4 5 ] 3 4  [ 2 1 ,6 3 ] 0 .01
T rig ly cer id es (m m o l/L );  
m edian  [IQ R] 1.1 [0 .8 , 1 .4] 0 .9  [0 .8 , 1 .2] 0 .9  [0 .6 , 1.4] 0 .31
Table 5.4: Lipid profile o f  HIV-infected children according to ART exposure.
5.5.3 CRP measurement
hsCRP was significantly higher in the HIV-infected children compared with control 
subjects (Table 5.1). Eight HIV-infected children had markedly increased hsCRP 
values (CRP >10 mg/L); although they did not have clinical evidence of acute 
infection, these CRP levels are compatible with acute inflammation. However, the
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difference in CRP values between control subjects and HIV-infected children 
persisted when the analysis was performed with these 8 children omitted.
5.5.4 Vascular Measurements
5.5.4.1 IMT Assessment
IMT measurements were available for 77 of the 83 HIV-infected children and 45 of 
the 53 control subjects. IMT was higher in the HIV-infected children compared with 
the control subjects (P<0.0001; Table 5.5) in both unadjusted and adjusted analyses.
There was a significant association between IMT and age in the HIV-infected children 
that was not observed in the control subjects (Figure 5.1); for every year increase in 
age, IMT was increased on average by 0.005 mm (95% Cl, 0.0003 to 0.01). There was 
no association between ethnicity and IMT in either HIV-infected or control children.
There was evidence of a treatment effect when the HIV-infected children were 
categorized as ever exposed to Pis, non-PI-treated, and untreated (P=0.03; Table 5.6). 
Exposure to Pis was associated with a higher mean IMT compared with both those 
untreated (P=0.04) and the non-PI-treated group (P=0.01; Figure 5.2). Similar results 
were found when the children were categorized according to their treatment regimen 
at the time of the test.
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Figure 5.1: Age and IMT in HIV-infected children and controls.
Intima media thickness (IMT) was increased with age in HIV-infected children (solid 
line) but not in Controls (dotted line).
There was no association between IMT and CD4% or viral load at the time of the 
study, but more advanced CDC stage was associated with greater IMT. However, in 
multivariate analyses, the higher IMT in children with exposure to Pis could not be 
accounted for by CDC stage or other potential confounders. Notably, there was no 
association between IMT and duration of PI therapy.
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Figure 5.2: IMT in HIV-infected children and controls.
a) IMT in HIV-infected children and controls.
b) IMT according to exposure to treatment. IMT was significantly higher in children 
who had received protease inhibitors (PI).
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5.5.4.2 FMD Assessment
FMD measurements were available for 82 of the 83 HIV-infected children and 57 of 
the 59 control children. Resting vessel size, blood flow, and reactive hyperemia were 
similar in both groups. FMD was lower in the HIV-infected children than in the 
control subjects after adjustment for baseline diameter (P=0.02; Table 5.5 and Figure 
5.3). The relationship remained after adjustment for age, sex, and other potential 
confounders. There was no evidence of an association between age, sex, ethnicity, 
lipids, and hsCRP in the whole cohort.
Among the HIV-infected children, there were no differences in baseline vessel 
diameter, baseline flow, or reactive hyperemia in the different treatment groups. FMD 
was significantly lower in those exposed to Pis compared with non-PI-treated 
(P=0.05) and untreated (P<0.001) children. Similar results were obtained when the 
analysis was performed by current therapy (Figure 5.3). The response to GTN was not 
associated with exposure to ART (Table 5.6). As for IMT, CDC stage C was 
associated with lower FMD. FMD was also inversely related to hsCRP, and this 
relationship remained after excluding the 8 HIV-infected children whose hsCRP was 
>10mg/L. However, the relationship between FMD and ART exposure remained after 
adjustment for CDC stage, hsCRP, and other potential confounders in multivariate 
analysis.
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Figure 5.3: Endothelial function in HIV-infected children and Controls.
a) Flow mediated dilatation (FMD) was significantly reduced in HIV-infected 
children.
b) FMD according to antiretroviral treatment (ART) received at the time o f the study 
visit. FMD was reduced in children receiving protease inhibitors (PI).
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5.5.4.3 PWV measurement
PWV was increased in the HIV-infected children compared with the controls, in both 
unadjusted and adjusted analysis (Table 5.5). A significant association between PWV 
and age was noted in the HIV-infected children but not in the controls (Figure 5.4). 
Increased cholesterol was predictive of increased PWV in the whole cohort. No 
evidence of an association between ethnicity and logCRP was found.
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Figure 5.4: Age and PWV in HIV-infected children and Controls.
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There was evidence of a treatment effect. Children on antiretroviral therapy had 
increased PWV compared to non-treated (Figure 5.5, Table 5.6). This effect was more 
pronounced in children who were exposed or receiving at the time PI therapy. No 
association between PWV and CD4% or viral load was detected.
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Figure 5.5: PWV in HIV-infected children and controls.
a) PWV in HIV-infected children and controls.
b) PWV in HIV-infected children according to treatment.
HIV-infected children Controls p-value
Baseline diameter 
(mm) 2.8(0.5) 2.9(0.5) 0.1
%FMD 7.9(4.9) 9.4(5.8) 0.02
Baseline flow 
(ml/min) 13.9(10.2) 13.5(11.9) 0.8
% Reactive 
hyperemia flow 580.9(259.4) 687.1(386.7) 0.1
%GTN 15.1(5.3)
IMT (mm) 0.6(0.07) 0.47(0.06) <0.001
PWV (m/sec) 7.5(1.3) 7.0(1.1) 0.03
Table 5.5: Vascular characteristics in patients and controls. 
Values expressed as mean (SD).
Untreated No -P I  treated PI treated p-value
Baseline 
diameter (mm) 2.8(0.5) 2.7(0.6) 2.8(0.5) 0.8
%FMD 9.9(5.7) 8.1(5.9) 6.3(5.4) <0.001
Baseline flow 
(ml/min) 13.7(8.8) 15.1(12.1) 13.2(10.2)
0.8
% Reactive 
hyperemia flow 626.6(269.3) 503.1(233.9)
615.9(262.8) 0.2
%GTN 17.2(8.9) 14.0(9.5) 14.5(8.4) 0.08
IMT (mm) 0.58(0.06) 0.58(0.06) 0.62(0.07) 0.03
PWV (m/sec 7.2(0.9) 7.7(1.5) 7.9(1.5) 0.04
Table 5.6: Vascular characteristics according to ART exposure.
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5.6 DISCUSSION
This study demonstrates that structural and functional changes of the vasculature are 
already present in HIV-infected children from childhood. These changes were most 
pronounced in children receiving Pis but were also observed in non-PI treated and 
untreated children. Our findings support a role for both HIV infection itself and for 
ART, particularly Pis, in the pathogenesis of early vascular disease, likely to be 
relevant to future clinical atherosclerosis.
The long-term consequences of HIV infection are particularly important for young 
individuals. With newer antiretroviral regimens, HIV has now become a chronic 
illness in developed countries. Thus, HIV-infected children have the potential to 
survive even to the third or fourth decade of life. As cardiovascular disease is 
emerging as an important health concern at these ages, it is critically important to 
determine the early impact of both the HIV infection and its treatment on the arterial 
wall in these children.
In our study, we measured carotid IMT to assess structural disease of the arterial wall. 
IMT represents the cumulative burden of adverse influences operating from the 
earliest stages of disease. Increased IMT has been shown to reflect conventional risk 
factor burden in children as young as 10 years of age and is an independent predictor 
of adverse cardiovascular outcome [491]. We also assessed endothelial function, 
which is known to be a key event in the initiation and progression of preclinical 
atherosclerosis and pulse wave velocity, a measure of arterial stiffness [20]. Arterial 
stiffness can be an important determinant of the vascular load to the heart and has 
been associated with adverse cardiovascular outcome. With these well validated 
measurements of arterial structure and function I have been able to describe the
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impact of disease and treatment, minimising the effects of exposure to confounding 
risk factors usually present in adults.
Only one other study has examined the vascular changes of long-term exposure to 
HIV in children. FMD was impaired and PWV was increased as in our study but IMT 
was not increased [492]. The more extensive vascular changes in our population may 
be due to older age and more advanced disease. IMT was related to both age (a 
surrogate for duration of HIV) and CDC stage. The observed differences between 
HIV-infected children and controls remained after accounting for differences in the 
baseline characteristics between the groups, suggesting that these changes may be 
related to HIV disease. This study also raised the possibility of a cumulative effect of 
HIV virus with ART or the metabolic consequences of ART. All vascular measures 
were impaired in children receiving ART and this effect was most pronounced in the 
PI treated children. However, these findings must be viewed with some caution. It is 
unclear if the observed vascular changes which appear to be associated with ART are 
driven by changes in the metabolic profile of these children. Insulin resistance and 
metabolic syndrome have been independently associated with vascular disease and 
accelerated cardiovascular disease in HIV adults. Insulin resistance and the full 
metabolic syndrome are prevalent in overweight individuals and there is a suggestion 
that they are increasingly prevalent in high-risk HIV-infected young people, 
especially in African-Americans [493]. In the current study, we did not find major 
differences in BMIz scores between cases and controls and between HIV-infected 
children receiving different antiretroviral regimens. However further studies are 
required to ascertain the vascular effects of ART in childhood and provide insight into 
the mechanisms contributing to vascular disease.
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HIV may promote atherosclerosis by activating the vascular endothelium directly or 
indirectly by systemic cytokine stimulation by the virus [494]. In addition, 
opportunistic agents such as cytomegalovirus or herpes virus, often present in HIV 
may contribute to endothelial damage [269;480]. In this study, HIV-infected children, 
had elevated total cholesterol and cholesterol subfractions. In particular, it is 
interesting to note that Lp(a) levels, which are highly genetically determined, were 
also elevated in HIV children compared to controls [495]. This finding has to be 
interpreted with caution. The average level of Lp(a) is higher in black children than in 
whites so that ethnic differences may contribute to the Lp(a) variability. Furthermore, 
within the HIV cohort, the most pronounced changes in Lp(a) were noted in children 
receiving PI therapy. It is possible that increased synthesis or clearance of the particle 
related to HIV infection and PI therapy can account for the observed differences 
[496]. The disturbances of lipids (increased total cholesterol and Lp(a) and a smaller 
LDL particle size) in our children receiving Pis are similar to those reported in adults 
but did not account for the observed vascular abnormalities [497]. Nevertheless, the 
impact of lipid abnormalities on vascular disease progression in HIV warrants further 
prospective exploration. Other mechanisms may also contribute to the adverse effect 
of HIV and ART on vascular disease, including enhanced expression of macrophage 
scavenger receptors and mitochondrial toxicity [494;498].
5.7 CONCLUSION
HIV infection and ART therapy are associated with an atherogenic structural and 
functional arterial phenotype from early childhood. As death rates among HIV- 
infected children have decreased 5-fold since the introduction of the highly active 
antiretroviral treatment, careful long-term monitoring appears warranted to detect
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emerging cardiovascular disease. Longitudinal studies are needed to understand the 
aetiology of vascular disease and particularly ascertain the contribution of different 
ART regimes. Pharmacological or physiological interventions may be required to 
prevent future vascular events in HIV-infected children.
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CHAPTER 6
MANNOSE BINDING LECTIN: A MODULATOR 
OF THE ENDOTHELIAL RESPONSE TO
INFECTION
6.1 INTRODUCTION
In chapters 4 and 5 I demonstrated that infection may play an important role in 
atherosclerosis by influencing the vascular biology of the atherosclerotic process but 
the implicated mechanisms remain largely unknown. It is possible that viral or 
bacterial infectious agents have an independent direct contribution to atherogenesis or 
this effect is mediated by host inflammatory processes. The importance of the latter is 
confirmed by current evidence demonstrating that the relationship between infectious 
agents and atherosclerosis may be modulated by innate immune defenses that include 
pattem-recognition molecules such as Toll-like receptors and possibly MBL 
[499;500].
MBL, a collagenous lectin, has key role in promoting phagocytic clearance of 
inflammatory agents. The levels of this protein are mostly genetically determined with 
almost one third of the population presenting with haplotypes predictive of low MBL 
levels (further information in section 1.6.4.4). In vivo, it is unclear how much MBL is 
required for optimal function but low serum levels (<l,000ng/L) have been associated 
with increased incidence of certain infectious and inflammatory diseases [340;345]. In 
addition, recent evidence implicates MBL in both clinical and preclinical phase of the 
atherosclerotic process.
Madsen et al documented an early onset and aggressive progression of atherosclerotic 
disease in MBL deficient people compared to immuno-competent counterparts [500]. 
At the other end of the disease spectrum, MBL deficiency has been reported to 
increase the risk of graft occlusion after bypass surgery and variant MBL genotypes 
have been associated with increased carotid artery plaque area [501 ;502]. The link 
between MBL and atherosclerosis is further supported by prospective studies. For
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instance, in the Strong Heart Study, high prevalence of variant MBL alleles, 
predictive of low MBL levels, were independently associated with incident coronary 
artery disease [344]. More recently increased MBL levels were shown to be 
associated with decreased likelihood of acute myocardial infarction, particularly in 
diabetics [503]. Interactions between MBL and specific infectious agents have also 
been demonstrated. For instance Rugonfalvi-Kiss et al reported that the association 
between C.pneumoniae and coronary artery disease is modulated by MBL [504]. 
Negative associations have also been reported [505;506].
Overall, the interpretation of these results is difficult considering that the impact of 
genetic make up can be modified throughout life by environmental influences and this 
potentially confounding effect of lifetime global risk factor burden is difficult to 
quantify retrospectively. I therefore decided to explore the impact of MBL 
polymorphisms during the early stage of atherogenesis.
6.2 AIMS OF CHAPTER
The purpose of this study was:
• To explore the impact of MBL polymorphisms on endothelial function at the 
early stage in atherogenesis.
• To investigate the role of MBL as a modulator of endothelial dysfunction 
during infection.
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6.3 METHODS
6.3.1 Study population
Our study population consisted of 2000 consecutive children aged 10 years nested 
within the ALSPAC cohort who underwent vascular assessment (as previously 
described chapter 4 section 4.2). The protocols were approved by the ALSPAC Law 
and Ethics committee and by the Local Research Ethics Committees. Written 
informed consent was obtained from the parent/guardian and assent from the child 
was also sought at the time of the study.
6.3.2 Definition of infection
Information on the nature and timing of infection at the time of vascular function 
measure was obtained from questionnaires filled by parents/guardians of the children 
as previously described in section 4.3.3. Consistent with our previous analysis in 
chapter 4 children were again classified into three different groups: 1) children who 
reported acute infection at the time of the study (AI group), 2) children who were 
convalescing from an infection in the previous two weeks (Conv group) and 3) 
children without recent illness (Controls).
6.3.3 MBL genetics
6.3.3.1 DNA extraction and senotvpin2 o f  the MBL exon 1 and promoter 
polymorphisms
Genotyping was performed separately for the exon 1 mutations and the promoter X/Y 
polymorphisms by Renata Hamvas and Marina Johnson at ICH. In both cases a 
synthetic DNA molecule (Universal Heteroduplex Generator -  UHG) was constructed 
spanning the region of interest and containing insertions, deletions and/or
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substitutions such as to permit detection of all possible known mutations (kindly 
donated by N. Wood, University of Bristol).
6.3.3.2 Preparation o f  DNA
DNA was extracted from cord blood of the ALSPAC children stored at -80°C using a 
commercial kit (Qiagen, “QIAamp Blood Kit”), and DNA was extracted from 200 pi 
of blood according to the manufacturer’s instructions. DNA was eluted into 200 pi of 
sterile water and stored at -20°C.
6.3.3.3 DNA amplification
Separate PCR reactions were performed on the genomic DNA samples, one to 
amplify the region of the gene containing the Exon 1 mutations, and one spanning the 
region of the promoter polymorphisms. Both of these PCRs were also performed for 
the synthetic UHG. Genomic DNA was PCR-amplified for exon 1 in a 20 pi reaction 
using 5 pi of aqueous DNA (approximately 10 ng pl-1), 0.6 pi each of 50 pM RMBL 
(5’-CCAACACGTACCTGGTTCC-3’) and LMBL (5-CTGTGACCTGTGAGGATG 
C -3’) primers, 2 pi of lOx PCR buffer, 2 pi of dNTP mix (2mM each of dATP, 
dCTP, dGTP and dTTP), 1.2 pi of 25mM MgC12, 0.2 pi of Taq DNA polymerase, and 
sterile water to make the total volume up to 20 pi. The exon 1 UHG amplification was 
carried out in volumes of 2000 pi with all reagents in the same proportions to the 20 
pi genomic reactions except for the UHG DNA where 27 pi were used. PCR reactions 
for the promoter polymorphisms were carried out in a similar fashion to the exon 1 
with the only exception being substitution of the primers for MBLproR (5’- 
CAGGGCCAACGTAGTAAG-3’) and MBL proL (5’-CTAAGGAGGGGTTCATCT 
G -3’). PCR reactions were carried out at 95°C for 5 minutes, followed by 35 cycles 
(for exonl) or 42 cycles (for promoter PCR) of 95°C for 1 minute, 56°C for 1 minute
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and 72°C for 1 minute. These cycles were followed by a final extension step of 72°C 
for 10 minutes. The presence of PCR product was confirmed by running 3 pi of 
product with 1 pi of loading dye on a 2% agarose gel containing 0.5 pg ml-1 ethidium 
bromide in 1 x TBE running buffer for 1 hour. Results were visualised under UV 
light.
6.3.3.4 Heteroduplexins
Following confirmation of amplification of genomic DNA, 10 pi of UHG PCR 
product and 5 pi of loading dye were added to each sample. Samples were 
heteroduplexed by heating at 95°C for 10 minutes and then allowing samples to cool 
to room temperature for 20 minutes. Fifteen microlitres of heteroduplex product were 
loaded onto polyacrylamide gels (20% for exon 1 analyses or 10% for promoter 
analyses) and run for 3 hours at 200 V in 1 x TBE buffer at room temperature (exon 
1) or 4°C (promoter). Gels were stained in 0.5 pg ml-1 ethidium bromide in 1 x TBE 
buffer for 10 minutes before being visualised under UV light.
6.3.3.5 Determination ofhaplotypes and genotypic groups
Each of the three exon 1 structural gene mutations is in linkage disequilibrium with a 
different promoter polymorphism such that the X always occurs with an A allele. 
Thus haplotypes are expressed as YA/YA, YA/XA. The phenotypic expression of the 
MBL exon 1 and promoter polymorphisms was determined by ELISA for MBL in a 
subgroup of the ALSPAC children (N=529) (Figure 6.1).
Thus to account for the differences in MBL levels, the children in our study children 
were classified in 4 groups (Table 6.1) according to exon 1 and promoter X/Y 
polymorphisms.
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Genotypic groups Variant alleles for exon 1 and X/Y 
promoter
Group 1 YA/YAYA/XA
Group 2 XA/XAXA/YD
Group 3 YA/YB+YCXA/YD
Group 4 XA/YB+YC
YO/YO
Table 6.1: Genotypic groups according to exon 1 and XJYpromoter MBL 
polymorphisms.
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Figure 6.1: MBL levels according to exon 1 and XJY promoter polymorphisms in 
ALSPAC (unpublished data provided by Marina Johnson).
6.3.4 Vascular study measurements
Each child underwent measurement of endothelium dependent vascular responses of 
the right brachial artery using high resolution ultrasound imaging (Aloka 5500, Japan,
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7MHz linear probe and automated vessel diameter measurements Brachial Tools, 
MIA, USA) in a temperature controlled vascular room in Bristol. Detailed description 
of the protocol is included in section 2.1.3.
6.3.5 Potential confounding factors
Social class group (V unskilled to I professional) was allocated to mother and father 
using the United Kingdom Registrar General’s occupational coding from information 
obtained from questionnaire at 32 antenatal week as previously described in section 
4.3.5. Blood pressure, heart rate, body mass index were assessed in all children as 
previously described in chapter 4 at the time of the vascular assessment, while 
information about the lipid profile of these children was obtained from non-fasting 
venous blood samples collected from all children at the age of 7 years. Finally 
information about the infectious and hygiene history of these children was collected 
from questionnaires and infectious and hygiene scores were constructed as described 
in section 4.3.5.
6.4 STATISTICS
The data were analysed with the Stata analysis package version 8. All vascular 
function data were normally distributed and are presented as mean and standard 
deviation (SD) for continuous variables or percentages for categorical variables. 
Differences in the baseline characteristics according to infectious status and genotypic 
group were determined by ANOVA for continuous variables and chi square for the 
categorical variables.
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We examined the effect of MBL polymorphisms on endothelial function by linear 
regression analysis. Logistic regression analysis was used to identify the determinants 
of the lowest quartile of FMD in the children who presented with acute infection or 
with recent history of infection. To account for the impact of a number of relevant 
potential confounders, multivariable analysis was performed.
6.5 RESULTS
6.5.1 Population characteristics
Of the 2000 children, 414 children had either an acute infection at the time of the 
study (AI, N=191) or were convalescing from an infection in the previous two weeks 
but were well at the time of study. The 1586 controls were healthy children without 
recent illness. The majority of children in both the AI and Conv groups presented with 
upper respiratory tract infection. The clinical characteristics and risk factor profile of 
the children are shown in (Table 6.2).
6.5.2 Associations between acute infection and clinical characteristics.
Children in the AI group had increased BMI. In addition, higher socio-economic 
class, increased DBP and increased infection score (not seen doctor) was noted in 
infected children compared to Controls. No other factors were associated with 
infectious status (Table 6.2).
247
Variable A1 group Conv group Control group P value
Sex (% male) 45.9 46.4 49.6 0.3
Soc/ class 
(% I/II) 63.6 65.0 61.3 0.01
BMI (kg/m2) 18.3(3.0) 17.7(2.9) 18.1(2.9) 0.01
Tchol (mmol/L) 
at 7yrs 4.3(0.6) 4.4(0.7) 4.4(0.7) 0.4
HDL (mmol/L) 
at 7yrs 1.5(0.3) 1.5(0.3) 1.5(0.3) 0.1
LDL (mmol/L) 
at 7yrs 2.2(0.5) 2.3(0.5) 2.2(0.5) 0.5
SBP (mmHg) 
at lOyrs 103.1(8.8) 102.5(9.3) 102.2(8.6) 0.2
DBP(mmHg) 
at lOyrs 58.9(8.1) 59.0(7.5) 58.0(7.5) 0.03
HR (beats/min) 72(10) 72(11) 72(14) 0.9
Infection score 
Not seen doctor 3.6(0.9) 3.7(0.9) 3.5(0.9) 0.02
Infection score 
Seen the doctor 1.3(0.9) 1.3(0.9) 1.2(0.9) 0.4
Antibiotic score 0.7(0.5) 0.7(0.5) 0.7(0.5) 0.6
Table 6.2: Baseline characteristics o f the children according to infectious status.
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6.5.3 Associations between MBL genotype and clinical characteristics
Genotypic information existed for 1719 children. Among the 281 missing (50 were in 
the infection group and the remaining were controls) the quality of DNA was not of 
adequate quality in the 100 whereas the remaining did not consent to give DNA for 
genetic screening. There were no differences in the clinical characteristics of the 281 
children compared to the rest of the cohort. Genotypic proportions were in Hardy- 
Weinberg equilibrium with the frequency of the O alleles being 33% similar to that 
observed in previous studies in Caucasians people. The frequencies of the genotypic 
groups according to infectious status are shown in (Table 6.3). Children in the AI and 
Conv group did not have an increased frequency of variant MBL allele. There were no 
significant differences in body size, birth weight or other clinical characteristics 
between genotypic groups (Table 6.4).
MBL genotype AI group Conv group Control
1 107 111 73756.02% 49.78% 56.48%
15 28 1622 7.85% 12.56% 12.41%
52 60 2713 27.23% 26.91% 20.77%
A 17 24 1354 8.90% 10.76% 10.34%
Table 6.3: Frequencies o f the MBL genotype according to infectious status.
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Variable Group 1 Group 2 Group 3 Group 4 P value
Sex (% male) 52.5 49.8 45.2 50 0.1
Soc/ class 
(% I/II) 55.1 57.1 54.3 62.5 0.4
BMI (kg/m2) 18.2(2.9) 18.3(3.2) 18.1(3.0) 17.8(2.7) 0.2
Tchol (mmol/L) 
at 7yrs 4.4(0.7) 4.5(0.7) 4.4(0.7) 4.4(0.6) 0.9
HDL (mmol/L) 
at 7yrs 1.5(0.3) 1.5(0.3) 1.5(0.3) 1.5(0.3) 0.7
LDL (mmol/L) 
at 7yrs 2.2(0.5) 2.3(0.6) 2.2(0.6) 2.3(0.5) 0.4
SBP (mmHg) 
at lOyrs 101.9(8.7) 101.7(9.1) 101.9(8.3) 102.3(8.2) 0.9
DBP(mmHg) 
at lOyrs 57.7(7.4) 58.0(7.1) 57.7(7.5) 58.3(7.8) 0.8
HR (beats/min) 71(10) 71(12) 72(11) 71(11) 0.9
Infection score 
Not seen doctor 3.6(0.9) 3.5(0.9) 3.7(0.9) 3.7(0.9) 0.08
Infection score 
Seen the doctor 1.2(0.8) 1.2(0.8) 1.3(0.9) 1.3(0.9) 0.6
Antibiotic score 0.7(0.5) 0.7(0.5) 0.7(0.5) 0.8(0.5) 0.7
Hygiene score 9.8(1.8) 9.8(1.7) 9.8(1.7) 9.7(1.7) 0.8
Table 6.4: Baseline characteristics in the whole cohort according to MBL 
polymorphisms.
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6.5.4 Infection and endothelial function
Baseline diameter, baseline flow, reactive hyperaemia flow and absolute 
flow were similar in the three groups (Table 6.5). FMD was lower in the AI 
in the Conv group compared with the Control children (p<0.001 for both) 
with our finding in chapter 4 (Figure 6.2).
p < 0 .0 0 1
p < 0 .0 0 1
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Figure 6.2: FMD according to infectious status.
A Igroup Conv group Control group p value
Baseline
diameter(mm) 2.7(0.4) 2.6(0.4) 2.7(0.4) 0.3
% FMD 7.5(3.2) 7.9(3.1) 8.5(3.1) <0.001
Baseline flow 
ml/m in 7.2(3.5) 7.2(3.4) 7.4(4.2) 0.5
% Reactive 
hyperemia flow 553.6(156.6) 553.6(149.1) 569.5(250.7) 0.4
Table 6.5: Vascular characteristics according to infectious status.
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6.5.5 MBL influences endothelial response to infection
MBL polymorphisms did not have an overall influence on endothelial function in this 
group of children (p=0.6, linear regression). The impact of acute and recent infection 
on endothelial function was investigated separately in the different genotypic groups.
• In group 1 (N= 955), FMD was lower in the children who presented with infection 
(AI, N=107 and Conv group, N=111) compared with the Control children (p=0.05, 
ANOVA). However this did not reach conventional statistical significance in 
individual comparisons (Bonferonni correction) (Table 6.6, Figure 6.3).
p = 0 .0 5
In fection  C ontrol
Figure 6.3: The impact o f  infection on FMD in MBL group 1.
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In MBL groups 2 and 3, FMD was lower in children with infection (AI and 
Conv) compared to controls but this difference did not reach conventional 
statistical significance (p=NS for both) (Table 6.6, Figure 6.4).
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Figure 6.4: The impact o f  infection on FMD in MBL group 2 and 3.
a) FMD in children with infection and controls in MBL group 2.
b) FMD in children with infection and controls in MBL group 3.
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• In MBL group 4, FMD was significantly reduced in children with infection 
(AI and Conv group) compared to Controls (p<0.01, ANOVA) (Table 6.6, Figure 
6.5).
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Figure 6.5: The impact o f  infection on FMD in MBL group 4.
FMD was lower in the children who presented with infection (N=41) compared to 
controls (N=135). Individual comparisons with Bonferroni correction demonstrated 
that FMD in the Conv group (N=24) was significantly impaired compared to 
Controls.
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In children with infection, a range of endothelial responses were noted. To investigate 
whether MBL modulates endothelial response to infection we divided the children 
with infection in 4 groups on the basis of their FMD responses (cut off being 5.4% for 
the lowest quartile of FMD). Following logistic regression analysis we identified that 
MBL group 4 was an independent determinant of reduced FMD in these children 
(Odds ratio 4.0 (1.35, 11.96); p<0.01) as shown in (Table 6.7). In multivariate 
analysis, adjusting for age, sex, social class, body mass index, systolic and diastolic 
blood pressure, cholesterol, infection and hygiene score, homozygosity for the MBL 
polymorphisms (group 4) remained the only independent predictor of the low FMD in 
children with infection (AI and Conv group).
Acute Conv Controls P value
Group 1 7.8±3.4
N=107
7.7±3.0 
N=111
8.5±3.0
N=737
0.05*
Group 2 7.5±2.4
N=15
7.6±2.7
N=28
8.4±3.2
N=162
0.2
Group 3 7.5±2.8
N=52
8.3±3.5
N=60
8.4±3.1
N=271
0.1
Group 4 7.2±3.2
N=17
6.9±3.3
N=24
8.9±2.9
N=135
0.002
Table 6.6: % FMD according to infectious status and MBL genotype.
Differences in FMD between the groups were compared with AN OVA. *: Individual 
comparisons between the groups did not reveal any significance (Bonferroni 
correction).
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Odds ratio [95% Cl] P value
Arterial diameter 2.2 [0.8, 6.7] 0.2
Group 2vs group 1 0.5 [0.1, 2.6] 0.4
Group3 vs group 1 1.0 [0.5, 2.4] 0.9
Group 4 vs group 1 4.0 [1.4, 11.9] 0.01
Table 6.7: MBL genotype and %FMD in the children with infection.
Odds ratio expresses the likelihood to present in the lowest quartile o f %FMD (cutoff 
5.37%) vs the rest.
6.6 DISCUSSION
In this study I found no overall influence of the MBL polymorphisms on endothelial 
function as assessed by FMD in a large cohort of healthy children. However, I was 
able to demonstrate that MBL polymorphisms appear to modulate the vascular 
response to infection with homozygosity for the variant allele being predictive of 
worse endothelial function during a mild infectious illness.
Mutations in exon 1 and promoter polymorphisms of the MBL gene are common and 
one third of the population presents with a variant allele resulting in decreased levels 
of MBL in the serum [340]. Although deficiency in MBL has been associated with 
increased frequency and severity of bacterial, viral, and fungal infections in both 
children and adults, I was not able to confirm this association in this large cohort of
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children[341;507;508]. These children’s infectious history was obtained from 
questionnaires filled by parents reporting the number and type of infection without 
having any serological or clinical documentation. It is thus possible that incorrect 
estimation of number of infections reported by parents may have confounded these 
infectious scores. Deficiency in MBL has also been associated with increased duration 
of inflammatory infections [509;510]. In this study I did not have the opportunity to 
assess inflammatory markers or serological evidence of infection, thus I was unable to 
determine whether the effect of MBL is mediated by alterations in inflammatory 
markers or by interactions with specific infectious agents.
Studies in adults have implicated MBL genotype as an independent risk factor for 
coronary artery disease both in the presence and in the absence of serological 
evidence of infection [503]. To date no data exist for the role of MBL in the early 
phase of atherogenesis. In this study, I presented evidence for a modifying role of 
MBL on the vascular biology of atherosclerosis in the presence of a mild non-specific 
infection. Homozygotes for the MBL variant allele had pronounced endothelial 
dysfunction in response to infection when compared to both the wild type and 
heterozygotes suggesting the presence of a gene/environment interaction in the early 
phase of atherosclerotic process. In particular, this apparent modulatory effect of 
MBL was more evident in the recent infection group.
In this study, heterozygotes for the MBL variant allele did not show an aggravated 
endothelial response to infection. This finding is suggestive of a threshold effect of 
MBL in early atherogenesis which may have significant clinical implications. No 
interaction between MBL and common cardiovascular risk factors was noted in our 
cohort. Of note, the children in this study were invariably at low cardiovascular risk
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and thus our findings cannot be extrapolated to “at risk populations” and do not refute 
earlier published interactions suggested to be relevant in adult populations ie in 
diabetics [503].
6.7 CONCLUSION
This study provides evidence that variability in the genetic make up can alter the 
response of the vasculature to common environmental influences and thus has the 
potential to modulate the risk for later development of clinical atherosclerosis. 
Prospective studies are needed to explore the long-term impact of MBL genotype on 
progression of arterial disease in the context of recognised cardiovascular risk factors 
and in the presence of increased pathogen burden.
If our results are confirmed in prospective designed studies, MBL and possibly other 
modifying inflammatory genes may provide a genetic rationale for the apparent 
variable influence of infection on clinical presentation of atherosclerotic 
cardiovascular disease.
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CHAPTER 7
MANNOSE BINDING LECTIN 
DOWNREGULATES ADHESION MOLECULE
EXPRESSION
7.1 INTRODUCTION
Vascular endothelial pathology is central to atherosclerosis and culture of primary 
endothelial cells has been widely used to study a range of important 
pathophysiological processes including immune-endothelial interactions[511;512]. 
Endothelial cell activation has been demonstrated in vitro following stimulation by a 
number of bacteria and viruses [513;514]. These experimental findings suggest an 
explanation for a pathophysiological link between infection and atherosclerosis.
C. pneumoniae are amongst the well studied bacteria for their role in atherosclerosis. 
Experimental evidence demonstrate that they can replicate in 
monocytes/macrophages, in epithelial and endothelial cells [515]. Moreover Krull et 
al demonstrated that infection of endothelial cells by C.pneumoniae activates signal 
transduction pathways in endothelial cells that lead to endothelial activation, 
inflammation and thrombosis, which may result or promote atherosclerosis [516].
I have previously demonstrated in chapter 6 that MBL polymorphisms, predictive of 
serum MBL levels, may influence the endothelial response to a non-specific 
infectious stimulus. However, the underlying mechanism of this response is unknown. 
MBL is known to recognize and bind to a variety of microorganisms including 
C.pneumoniae. Swanson et al demonstrated that MBL can inhibit infection of HeLa 
cells by impeding entry of C.pneumoniae into the host cell and subsequent infection 
[517]. It remains unknown whether the same findings apply to cells relevant to 
atherosclerosis, endothelial cells.
I therefore initiated this study to investigate whether MBL can influence endothelial 
activation induced by C.pneumoniae.
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7.2 AIMS OF CHAPTER
The aims of this chapter were:
• To determine C. pneumoniae-dependent changes in surface expression of 
adhesion molecules on HUVEC.
• To investigate the role of MBL as a modulator of endothelial activation during 
C. pneumoniae infection.
7.3 METHODS
7.3.1 HUVEC culture
Isolation of endothelial cells from umbilical cords, cell culture and maintenance of 
HUVEC was performed as described in Chapter 2, section 2.7. Once HUVEC reached 
95% confluence on T25-flasks, they were subcultured onto 24 well tissue culture 
plates coated with attachment factor, and grown until confluent.
7.3.2 Meningococcal Lipopolvsaccharide (LPS)
Meningococcal LPS from N. meningitidis serogroup B strain H44/76 was used as a 
positive control to ensure stimulation of HUVEC. LPS was prepared by Dr. Liana 
Steeghs (University Medical Centre, Utrecht, The Netherlands). LPS concentrations 
ranging from 0.1-100ng/ml were used to activate HUVEC, to establish a potent 
positive control.
7.3.3 C.pneumoniae propagation
C. pneumoniae TW183 strain was kindly provided by Mr Simon Stevenson (chief lab 
technician) at the University College Hospital Chlamydia laboratory. Culture of
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C.pneumoniae was established in McCoy fibroblasts cells as previously described in 
chapter 2 section and aliquots stocks of 1.8x10s IFU/ml C.pneumoniae were stored at 
-80°C. All experiments described in this chapter were performed from the same 
bacterial stock.
7.3.4 HUVEC infection protocol
C.pneumoniae suspensions were thawed at room temperature. The suspension was 
sonicated for 30 seconds and cellular debris was removed by centrifugation at 500xg 
for 10 min at 4°C. Bacterial supernatant was diluted in RPMI to create concentrations 
104-106 IFU of elementary bodies (EBs). C.pneumoniae EBs (104-107) were added to 
HUVEC media and inoculated on the endothelial monolayer without centrifugation. 
Cells were incubated at 37°C in 5% CO2 in air. Activation of HUVEC was assessed 
following 5 hours incubation, the optimal time to assess maximum E-selectin 
expression as previously established [298].
7.3.5 HUVEC immunostaining
HUVEC immunostaining was performed as previously described in Chapter 2. 
Briefly, following 5 hours incubation of HUVECs with C.pneumoniae, cells were 
detached with Puck’s A saline and collected by centrifugation. Cells were incubated 
with primary antibodies: E-selectin (5pg/ml), ICAM-1 (5pg/ml), VCAM-1 (20pg/ml) 
and mouse IgG2b (20pg/ml) as negative control. Excess antibody was removed with 
FACS wash. 20pl fluorescently labelled Goat anti-mouse IgG (F(ab)2)-PE was used 
as secondary antibody at a 1:20 dilution. Adhesion molecule expression levels were 
detected using FACs acquisition as described in Chapter 2. Both % gated cells and
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mean fluorescence intensity (MFI) were used to assess adhesion molecule expression 
from HUVEC.
7.3.6 Mannose binding lectin preparation
MBL was purified from human serum as described in section 2.9. The column flow­
through fractions were pooled and then stored at 4°C until required. Aliquots of 
230pg/ml of MBL were used for the experiments described in this chapter.
7.4 STATISTICS
Data are expressed as mean±SD. Normality of the data was assessed with the 
Kolmogorov-Smimov test. For multiple comparisons (more than 3 groups), p values 
by ANOVA were Bonferroni adjusted. The effect of MBL on C.pneumoniae 
stimulated endothelial cells was assessed by two-way ANOVA with Bonferroni 
correction. In all cases, p<0.05 was considered statistically significant.
7.5 RESULTS
7.5.1 LPS stimulates HUVEC in a dose dependent manner
Meningococcal LPS was used to demonstrate adhesion molecule surface expression 
on HUVEC (Figure 7.1). Unstimulated HUVEC showed no E-selectin expression. 
LPS at O.lng/ml and lng/ml induced minimal E-selectin expression. lOng/ml LPS 
concentration induced significant expression of E-selectin compared to unstimulated 
cells (p=0.001). No further increase in E-selectin expression was noted with 
concentrations above lOng/ml (Figure 7.2).
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ICAM-1 was constitutively expressed in unstimulated HUVEC at low levels (Figure 
7.1). LPS stimulation at O.lng/ml did not enhance ICAM-1 expression. ICAM-1 
expression was increased at lng/ml rising to a maximum at lOng/ml (p=0.001). No 
further increase in ICAM-1 expression was noted at lOOng/ml (Figure 7.2).
VCAM-1 was also constitutively expressed in unstimulated cells (Figure 7.1). No 
change in VCAM-1 expression was noted when cells were activated with O.lng/ml 
LPS. VCAM-1 expression was higher at lng/ml LPS (p=NS) rising to a maximum at 
lOng/ml (p=0.001). No further increase in VCAM-1 expression was noted at 
lOOng/ml (Figure 7.2).
From these experiments the concentration of lOng/ml of purified meningococcal LPS 
was established as the positive control to achieve maximal stimulation of endothelial 
cells.
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Figure 7.1: Adhesion molecule expression on HUVEC in response to increasing 
doses o f Neisseria LPS.
A representative experiment o f  HUVEC stimulated fo r  5 hours in response to 
increasing concentrations o f purified meningococcal LPS or with medium alone
a) E-selectin, h) ICAM-1 and c) VCAM-1.
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Figure 7.2: Adhesion molecule surface expression o f HUVEC 5 hours post 
stimulation with Neisseria LPS.
The adhesion molecule expression was increased dose dependently up to lOng/ml 
both in a) % o f gated cells and b) in MFI (N=6). *: p<0.05 (ANOVA) compared to 
control, **: p<0.001 (ANOVA) compared to control. MFI: mean fluorescence 
intensity.
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7.5.2 C. pneumoniae stimulates HUVEC in a dose dependent manner
To explore the activation of HUVEC in response to C.pneumoniae a dose response 
experiment was performed. HUVEC were infected with 104-107 IFU of C.pneumoniae 
and lOng/ml of LPS was used as a positive control. To exclude the possibility of 
endotoxin contamination, HUVECs treated with lysates of McCoy cells were 
processed in the same way as infected cells (mock cells).
C. pneumoniae (TW183 strain) was a weak stimulator of HUVECs compared to 
Neisseria LPS. Following C. pneumoniae infection, E-selectin, ICAM-1 and VCAM- 
1 expression in HUVECs increased in a dose dependent manner from 104-107 IFUs 
(Figure 7.3, Figure 7.4).
No constitutive E-selectin expression was noted in the unstimulated (media-control) 
and the mock infected cells (Figure 7.3). E-selectin expression was increased at 
concentration of 104 IFU of C.pneumoniae and reached its maximum at 107 (Figure 
7.4).
ICAM-1 was constitutively expressed at low levels in unstimulated HUVEC and in 
mock infected cells (Figure 7.3). The ICAM-1 expression was increased at 104 IFU
n
and reached its maximum at 10 (Figure 7.4).
VCAM-1 was also constitutively expressed at low levels in unstimulated and mock 
stimulated HUVEC. Concentrations 104 IFU of C.pneumoniae increased VCAM-1 
expression (Figure 7.3). Concentrations of 106 and 107 IFU significantly increased 
VCAM-1 expression in HUVEC when compared to unstimulated cells (Figure 7.4).
267
E-selectin ICAM-1 VCAM-1
Control-
media
Mock-
infected
C.pneumoniae 
ltf* IFU
C.pneumoniae
105IFU
M-
C.pneumoniae 
106 IFU
C.pneumoniae 
107 IFU
u .
u
u
10° 101 102 103 104 10P 101 10? 10? 10* 1(P 1C? 1<? 1C? 1C?
Li
10° 101 102 103 104 10P 101 10? 103 10* 1C? 1C? 1C? 1C? 1C?
10P 101 102 103 10* 10P 101 102 103 10* 1<? 1C? 1C? 1(?
10°  101 102 103 10* 10P 101 102 103 10* 1cP 101 1C? 1C? 1(?
10° 101 10? 103 10* 10P 101 10? 103 10* 1C? 1C? 1C? 1C?
10° 101 10? 10? 10* 1CP 101 10? 103 10* 1 (? 101 1C? 1C? 1C?
Figure 7.3: Adhesion molecule expression on HUVEC in response to increasing 
doses o f C. pneumoniae (TW183).
A representative experiment o f  HUVEC stimulated fo r  5 hours in response to 
increasing concentrations o f  C.pneumoniae (TW183) EBs or with medium alone and 
lOng/ml Neisseria LPS A) E-selectin, B) ICAM-1 and C) VCAM-1.
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Figure 7.4: Adhesion molecule expression on HUVEC in response to different doses 
o f C.pneumoniae.
HUVEC were stimulated with media (control), remnants o f McCoy cells (mock) and 
with C.pneumoniae TW183 strain (104-107 IFU). Adhesion molecule expression (E- 
selectin, ICAM-1 and VCAM-1) was concentration dependent o f C.pneumoniae (N=6 
experiments). The effect was apparent both in a) % gated cells and b) in MFI. **; 
p<0.001 (ANOVA) compared to control **: p<0.01 and *: p<0.05 (ANOVA with 
Bonferroni correction) compared to control.
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7.5.3 MBL downregulates E-selectin and VCAM-1 expression
The influence of MBL on the activation of HUVEC by C.pneumoniae was assessed. 
5pg/ml of MBL and C.pneumoniae at concentrations 104-107 were added to HUVEC 
medium. This concentration corresponds to the one found normally in the serum in 
the absence of MBL immunodeficiency.
MBL did not have any effect on unstimulated endothelial cells. In the presence of 
MBL, there was a 15-30% reduction in E-selectin surface expression on HUVEC at 
different bacteria concentrations (104-107) (Figure 7.6). Cells activated with the 107 
IFU had the greatest reduction (p<0.05) (Figure 7.5, Figure 7.6).
VCAM-1 expression from HUVECs was also significantly reduced in the presence of 
5 pg/ml of MBL when endothelial cells were activated with concentrations of 
elementary bodies higher than 104 (Figure 7.6). The response was more apparent (35- 
45% reduction) when cells were activated with higher concentrations of elementary 
bodies (106-107 IFU) (Figure 7.5, Figure 7.6).
There was a trend towards reduction in ICAM-1 surface expression on HUVEC in 
the presence of 5pg/ml of MBL, when cells were activated with 107 IFU of 
C.pneumoniae (p=0.06) (Figure 7.6). Activated HUVEC (104- 106 IFU) had similar 
surface expression of ICAM-1 in the presence or absence of MBL (Figure 7.5, Figure 
7.6).
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Figure 7.5: The effect o f  MBL on E-selectin and VCAM-1 expression.
A representative experiment to show the difference in E-selectin and VCAM-1 
expression when cells were activated with 107 IFU o f C.pneumoniae with (green line) 
or without (orange line) the presence o f  5 jug/ml o f  MBL (N=5).
60 
"3 50d
^30-0s
s
1 2°- 6
"5s  io  u
- C.pneumoniae C.pneumoniae +5ng/ml MBL
control 104 10 106 10'
10-
s
1I
control 104 105 106
C.pneumoniae (IFU)
C. pneumoniae (IFU)
■ C.pneumoniae Cpneumoniae + 5jig/ml MBL
 1 1 1 1—
control 104 1° 5 1° 6
Cpneumoniae (IFU)
107
17.5-1
15.0-
-  12.5-
10.0-
25 -
control
C.pneumoniae (IFU)
■Cpneumoniae Cpneumoniae +5jig/ml MBL
70-|
«  50-
_  40-
*  30-
C.pneumoniae (IFU)
20-1
15-
i  10-
<
control io4 1° 5 1°6
Cpneumoniae (IFU)
Figure 7.6: MBL downregulates E-selectin and VCAM-1 expression.
HUVEC were activated with different concentrations o f C.pneumoniae (104-107 IFU) 
with or without the presence o f  5jug/ml o f MBL. Comparisons were made with 
C.pneumoniae alone *:p<0.05, **: p<0.01 ***: p<0.001.
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7.5.4 Optimization of MBL concentration
To assess whether MBL reduces E-selectin and VCAM-1 expression in a 
concentration dependent manner concentrations of MBL ranging from 0.5-lOpg/ml 
were tested whilst HUVEC were activated with 107 IFU of C.pneumoniae. The 
concentrations of MBL were chosen to cover the range found in serum with or 
without MBL deficiency.
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Figure 7.7: MBL downregulates E-selectin and VCAM-1 expression.
HUVEC were activated with C.pneumoniae 107 IFU (0) with and without MBL (0.5- 
10 pig/ml). MBL downregulated E-selectin and VCAM-1 at 5 and 10 pg/ml. **:p<0.01 
and ***: p<0.001 (ANOVA) when compared with cells activated without MBL(N=5).
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MBL at concentrations 0.5-lpg/ml did not alter E-selectin, VCAM-1 and ICAM-1 
expression. E-selectin and VCAM-1 were significantly reduced in the presence of 
5pg/ml of MBL as previously shown. No significant difference in ICAM-1 expression 
was noted.
Higher concentrations of MBL (lOpg/ml) did not reduce further E-selectin and 
VCAM-1 expression in HUVEC. No change in ICAM-1 expression on HUVEC was 
noted at lOpg/ml MBL concentration (data not shown).
7.6 DISCUSSION
In this study I confirmed previous reports that demonstrated that C.pneumoniae can 
induce the expression of adhesion molecules on HUVEC in a dose-dependent manner, 
but also showed for the first time that MBL is a modulator of this response [298]. At 
concentrations relevant to those found normally in serum, MBL decreased E-selectin 
and VCAM-1 expression on HUVEC. These results may provide a pathophysiologic 
link explaining the association between deficiency in MBL and increased 
atherosclerotic risk.
The endothelium has a key role in the initiation of atherosclerosis [18]. One of the 
earliest changes noted in atherogenesis is activation of endothelial cells and 
measurement of adhesion molecule expression in vitro serves as a useful model of an 
early step in atherogenesis [167]. A number of cardiovascular risk factors and a 
variety of infectious agents have been shown to initiate this response [167]. In this 
study I focused on the role of C.pneumoniae. Previous studies have demonstrated that 
C. pneumoniae is linked to atherogenesis by its ability to replicate and persist within 
vascular cells and by its proinflammatory and angiogenic effects [518]. However, the 
clinical evidence for the role of this bacterium in atherosclerosis remains controversial
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[519]. Consistent with previous studies I demonstrated that C.pneumoniae can 
activate endothelial cells in a dose- dependent manner [298]. The magnitude of 
HUVEC activation in our experiment was less compared to previously published 
studies and to potent endothelial stimulators such as LPS [516]. In contrast to other 
studies, infection of endothelial cells in this study was performed without 
centrifugation as recent studies demonstrated that C.pneumoniae attachment is 
sufficient to initiate endothelial cell response and that bacterial uptake may not be 
required [515]. This difference may explain the noted discrepancy as it is well known 
that centrifugation activates unstimulated endothelial cells.
In addition I showed that endothelial activation could be modulated by the presence of 
MBL. This effect was noted only for E-selectin and VCAM-1 but not ICAM-1 
expression. The magnitude of the response was higher in the presence of enhanced 
endothelial activation supporting a role of MBL as a modulator of the increased 
inflammatory response. The mechanism was not assessed in this experiment. It is 
possible that MBL binds to the bacterium and restricts its infectivity. Indeed, Swanson 
et al demonstrated that MBL binding to C.pneumoniae abolished infection of 
epithelial cells[517]. Moreover one could speculate that the effect of MBL could be 
downstream of a receptor ligand interaction in activated endothelial cells, affecting 
transcription pathways. Furthermore, it remains unclear from this study whether the 
effect of MBL will result in reduction in monocyte adhesion to activated endothelial 
cells. Further studies using a flow system will need to confirm that.
Another interesting finding of the experiments presented in this chapter was the 
threshold effect of MBL. Values of MBL equal or higher than 5 pg/ml induced a 
protective effect as far as endothelial activation is concerned. Lower tested
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concentrations did not have a beneficial modulator effect. However further studies 
need to assess whether the same threshold effect applies in the clinical setting.
7.7 CONCLUSION
In this series of experiments I have shown that C.pneumoniae activates endothelial 
cells and that MBL downregulates E-selectin and VCAM-1 expression on cultured 
activated HUVEC. Further studies are required to explore whether this finding is 
specific for C.pneumoniae or it applies to other infectious agents.
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CHAPTER 8
GENERAL DISCUSSION-CONCLUSIONS
8.1 OVERVIEW OF THIS THESIS
Atherosclerosis is an inflammatory disease and infections are among the most 
common inflammatory stimuli. To date, numerous studies have been performed to 
explore the impact of different infectious agents in the late phases of the disease 
process in humans and have provided mostly conflicting results. In this thesis I have 
focused on childhood to explore the role of infection and its modifiers on early 
vascular changes relevant to atherosclerosis.
Studies in the young require the use of non-invasive methods. Therefore, I established 
the reproducibility of three non-invasive techniques, which have previously been 
shown to assess NO-dependent endothelial vasomotion in children and in young 
adults to cover the wide range of the preclinical phase of atherosclerosis. In addition, 
since the interest of this thesis is on infection I determined the sensitivity of these 
techniques to measure acute well documented pertubations in endothelial function 
induced by a low grade inflammatory stimulus (typhoid vaccination).
The role of common acute infections on endothelial function was assessed in a large 
number of children nested within the ALSPAC cohort. The long-term effect of these 
non-specific infections was established in a subgroup of these children, one year after 
the reported insult. Moreover I stratified these children according to genotypic 
variations in MBL to assess the role of host immunity as modulator of the vascular 
consequences of infection both in vivo and in vitro. Finally the role of chronic 
infection in early atherosclerosis was assessed by studying HIV-infected children.
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8.2 ASSESSMENT OF ENDOTHELIAL FUNCTION IN THE YOUNG
It is well documented that the atherosclerotic process begins early in life even by the 
first decade, hence intermediate disease phenotypes are necessary to measure the 
impact of preventive strategies implemented in preclinical disease [7]. Disturbance of 
endothelial function is an early event in the atherosclerotic process and clinical studies 
have demonstrated its predictive power for later cardiovascular events [18;153;520]. 
To date, FMD is the most widely used non-invasive method for NO-mediated 
endothelial function assessement. However inherent difficulties, related both to the 
cost of ultrasound machine and software in addition to the paucity of expertise has 
hitherto restricted its use to the clinical research setting. Thus, the identification of 
other non-invasive, operator friendly and preferably portable techniques would be of 
value to extend endothelial function testing beyond the specialized vascular labs in the 
community. Salbutamol-mediated changes measured by PAIx and RI may fulfil these 
criteria, however their reproducibility was largely unknown in particularly in children.
In chapter 3 I documented, consistent with previous published reports, that 
endothelial function assessed by FMD and by salbutamol mediated changes in PAIx is 
reproducible in adults but also in children [136; 146]. In contrast, endothelial function 
assessed by salbutamol mediated changes in RI was the least reproducible method in 
adults and even less so in children. It is possible that variations in the finger arterial 
pulse dependent on the sympathetic tone can account for the reduced reproducibility 
noted when the DVP was used. However, this hypothesis was not addressed in this 
thesis. In children, FMD had better reproducibility compared to the two other 
techniques. Of note, all studied children were of school age as good cooperation is 
needed to obtain accurate measurements with all tested methods.
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Apart from reproducibility, the sensitivity of a method is also important. To address 
this issue in chapter 3 I assessed the sensitivity of these 3 non-invasive techniques to 
detect acute short lived perturbation in endothelial function induced by typhoid 
vaccination. The latter is known to be a good model for low grade inflammation 
which has been shown consistently to induce a short lived detrimental effect in NO- 
dependent endothelial vasodilatation. In our hands, both FMD and PWA were 
sensitive to detect pronounced differences in endothelial physiology in adults. In 
contrast, this effect was not detectable by DVP measurements. It is possible that the 
latter technique is less sensitive to detect inflammatory associated changes compared 
to the two others or that the measured response is regulated by different biological 
determinants.
8.3 ACUTE INFECTION IN CHILDREN AND EARLY ARTERIAL 
DISEASE
8.3.1 Clinical studies
Previous studies have documented that acute infections in children, severe enough to 
require hospitalization, are accompanied by enhanced oxidative modification of LDL 
and by decrease in HDL cholesterol. These lipid changes, induced by infection, were 
also associated with thickening of carotid intima media [213].
In chapter 4 I assessed the impact of acute non-specific infections on endothelial 
function. These infections are likely to represent the majority of insults mostly upper 
respiratory in origin (ie common cold) encountered in childhood. In this study I 
demonstrated that these acute common infections are associated with endothelial 
dysfunction. The noted effect was sustained for at least two weeks as children who 
were convalescing from a recent infection presented with marked endothelial
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dysfunction compared to controls. However, this type of infection does not seem to 
induce long-term vascular consequences. In this study I was able to demonstrate that 
endothelial responses recovered in the vast majority of infected children at follow-up 
in the absence of recurrent infections.
A number of different mechanisms, including direct effect of the virus on the vascular 
endothelium or indirect effects related to host response (ie lipid changes, 
inflammatory and immune responses) may explain the noted results. In this thesis 
(chapter 6), however, my interest concentrated on the role of a host immune factor, 
MBL as a determinant of infectivity and of the endothelial response to infection.
8.3.2 MBL modifier of endothelial response to acute infection
MBL deficiency is one of the commonest genetically determined immunodeficiencies, 
which has been associated with increased incidence and severity of 
infection[342;508;510]. It is of interest that this deficiency is found relatively 
frequently in the general population. Indeed almost 30% of the ALSPAC population 
as described in chapter 6 had one variant allele and almost 4% presented with 
deficiency in MBL. In this thesis we addressed whether MBL can be a modifier of the 
endothelial response to infection both in vivo and in vitro.
• In vivo study
In the study described in chapter 6, I stratified children, nested within the ALSPAC 
cohort, in four genotypic groups which reflect well characterised differences in MBL 
levels found in serum and examined the effect of infection on endothelial vasomotor 
responses in each of these groups. I demonstrated that children with genotype that 
result in very low or absent MBL levels had greater and possibly more sustained 
endothelial impairment in response to infection. In contrast, I showed that MBL was
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not a determinant of FMD in the wider cohort. Furthermore, in children with acute 
infection or recent history of infection, homozygosity for the variant MBL allele was 
independently predictive of endothelial dysfunction. My results suggest the presence 
of an important gene-environment interaction, which may have long-term 
consequences.
Indeed, a number of studies have demonstrated that deficiency in MBL is associated 
with increased atherosclerosis and its complications[344;345]. More recently 
Saevarsdottir et al documented that MBL could be an adjunct to risk assessment for 
myocardial infarction especially for individuals with enhanced atherosclerotic 
risk[503]. But how can MBL modulate atherosclerotic risk? Unfortunately, the 
implicated mechanism is largely unknown. It is possible that MBL can exert its effect 
by modulating infectivity but also by modulating inflammatory response to both 
infectious and non-infectious stimuli.
• In vitro study
To investigate the role of MBL further I set up an in vitro experiment in chapter 7. 
Endothelial response was studied in human primary endothelial cells derived from 
umbilical veins and I used C.pneumoniae as the infectious stimulus. The latter was 
chosen as it binds to MBL, infects endothelial cells and may be relevant to 
atherosclerosis [298;340;516;521]. In this study, C.pneumoniae activated endothelial 
cells in a dose-dependent fashion. However, the activation was modest in comparison 
to other potent stimulators of endothelial cells {Neisseria LPS). In the series of 
experiments described in chapter 7, I demonstrated that MBL at high concentrations, 
equivalent to the ones found clinically in people without variant MBL allele, 
attenuated the expression of E-selectin and VCAM-1 on activated HUVEC. This 
effect was not observed in the lower MBL concentrations. These preliminary results
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require further investigation, since they suggest that MBL is a potential modifier of 
the inflammatory response to infection.
Critically assessing the results from chapter 4 and chapter 6 and 7, one could 
speculate that alterations in endothelial function can be a consequence of a normal 
host defence mechanism against infection and only in genetically predisposed people 
this response is aggravated and thus more likely to induce a long-term effect.
8.4 CHRONIC INFECTION AND EARLY ARTERIAL DISEASE
In recent years, the incidence of HIV disease is increasing rapidly in both developing 
and developed countries. In addition, with the introduction of ART, life expectancy 
has increased considerably among HIV-infected people, so that HIV is now regarded 
as a chronic infection. However, with this increase in lifespan cardiovascular 
atherosclerotic disease has emerged as a long-term concern among HIV-infected 
patients and both the virus itself and metabolic abnormalities related to the use of 
combination therapy have been implicated [522;523].
The long-term consequences of HIV infection are particularly important for young 
individuals. Therefore, I decided to study the vascular consequences of chronic HIV 
infection in childhood where the confounding effect of exposure to classical 
cardiovascular risk factors is minimal.
In chapter 5, consistent with previously published reports, I was able to demonstrate 
functional and structural arterial changes in HIV-infected children compared to 
controls[524]. This effect was noted in untreated children and in those treated with 
ART. In addition, I identified age, a marker of disease duration, and ART as
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independent predictors of increased progression in carotid IMT. In this study, the 
most pronounced functional and structural changes were noted in HIV-infected 
children who were receiving antiretroviral therapy. Although interesting, we have to 
interpret these results with caution. Further longitudinal studies are needed to clarify 
the aetiology of vascular disease in HIV-infected children and particularly ascertain 
the contribution of different ART regimens.
8.5 FURTHER W ORK
In this thesis I demonstrated a biological rationale for a key role of infection during 
the early phase of the atherosclerotic process. However further studies are needed for 
causality to be confirmed or refuted. Understanding the possible interactions between 
infection and known cardiovascular risk factors and/or host responses will also be 
critical in this process. In addition, carefully designed studies will help us understand 
the importance of severity, persistence of infection and the consequences of 
interrupting the infectious and inflammatory pathologic processes in the vasculature.
Further to the work presented in this thesis, I am planning to assess interactions 
between infections and metabolic and environmental factors in the ALSPAC 
population. We will also investigate the long-term impact of infection and its 
modifiers by studying these children through their puberty and early adulthood. This 
longitudinal assessment will allow us to characterise the contribution of individual 
risk factors in the progression of arterial disease. Further to my findings we will 
investigate the impact of MBL deficiency on atherogenesis in greater detail both in 
the clinical and experimental setting.
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We are fortunate to have access to the ALSPAC children, a well characterized 
population, which gives us adequate power to explore the long-term vascular 
consequences of infectious and non-infectious stimuli in MBL deficient children. In 
vitro we are currently investigating whether the reported MBL effect on activated 
endothelial cells is specific to selected bacteria species. Finally we have set up a flow 
system to investigate leukocyte interactions with infected endothelium in the presence 
or absence of MBL.
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APPENDIX A
SUMMARY OF STUDIES INVESTIGATING SEROLOGICAL 
EVIDENCE OF BACTERIAL AND VIRAL INFECTIONS 
AND ATHEROSCLEROTIC DISEASE
Author Study population Type of study Method used Outcome
Sharma et a l [525] 98 healthy m en and 
w om en( 18-49 years old ) C ross-sectional
M icroim m unofluorescence for  
IgA and IgG
IgA (not IgG )antibodies and CRP  
w ere associated w ith reduced flo w -  
m ediated and nitroglycerin-induced  
vasodilatation
Schm idt et a l  [526] 113 patients w ith treated  hypertension and at high risk 
for coronary heart d isease
C ross sectional
MIF for IgG , IgA and IgM  for  
C.pneumoniae and circulating  
im m une com plex
Seropositiv ity  for C.pneumoniae 
w as associated with increased IM T  
in the com m on carotid artery but not 
plaque status
M arkus et a l [527] 983 subjects w ith no past history o f  stroke or transient 
ischaem ic attack
C ross-sectional M IF for IgA  and IgG for  
C.pneumoniae
N o  association betw een  
seropositivity for C.pneumoniae  and 
early atherosclerosis (IM T )
Altm an et a l [528]
159 patients w ith C A D  or 
P A O D  and 203 patients with  
m echanical heart valve  
prostheses w ithout C A D
C ross-sectional Indirect M IF for IgG  for 
C.pneumoniae
N o  association  betw een  
C.pneumoniae and acute or chronic  
arterial d isease
M itusch et a l [529] 1032 healthy participants from  the study o f  H ealth in 
Pom erania
C ross-sectional C.pneumoniae D N A  PB M C s determ ined by nested PCR
Circulating C.pneumoniae  D N A  is 
associated w ith asym ptom atic  
atherosclerosis (IM T)
M cD onald  et a l[530] 23 7  adults from an Australian  Aboriginal com m unity C ross-sectional
IgG for C.pneumoniae 
m easured w ith ELISA
N o  association w as found betw een  
C.pneumoniae and carotid IM T
L inares-Palom ino et al 
[531]
64 patients w ith peripheral 
artery o cc lu siv e  d isease and 50  
controls w ho underwent 
varicose vein  surgery
C ross-sectional
M IF for IgG and E LISA for 
IgG and IgA  for 
C.pneumoniae and hem i- 
nested PCR for C.pneumoniae 
D N A  from  biopsies
C.pneumoniae seropositiv ity  is 
associated w ith peripheral artery 
occlu sive  d isease
Table Al: Associations between serological evidence o f C.pneumoniae infection and arterial vascular disease
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Authors Patients Type of study Method used Outcome
Pitiriga et a l[532]
90  hypertensives, 60  w h ite coat 
hypertensives and 45  
norm otensives
C ross-sectional M IF for IgA and IgG for 
C.pneumoniae
N o  association  betw een  
C.pneumoniae and IMT  
m easurem ents
S essa  et a l[533]
18 patients w ith sym ptom atic  
carotid atherosclerotic d isease  
and 33 w ith asym ptom atic  
atherosclerotic d isease
C ross-sectional M IF for IgG and IgA for
C.pneumoniae
C.pneumoniae  is associated w ith  
sym ptom atic atherosclerotic
disease  j
Khairy et a l [302] 65 healthy m ale subjects C ross-sectional M IF for IgG and IgM  for  
C.pneumoniae
N o  association  betw een C. 
pm eum oniae  and endothelial 
function
Tsirpanlis et a l [ 534] 130 haem odialysis patients C ross-sectional
M IF for IgG for C.pneumoniae 
and PCR and cell culture for 
detection o f  C.pneumoniae in 
PB M C s
N o  association  betw een  
C.pneumoniae  seropositivity and 
atherosclerosis, how ever positive  
association  betw een viable  
C.pneumoniae and 
atherosclerosis
M alm qvist et a l[535]
137 patients with ischem ic heart 
disease  and 88 without ischem ic  
heart d isease
C ross-sectional M IF for IgA  and IgG for
C.pneumoniae
P ositive  association betw een  
C.pneumoniae seropositivity and 
ischem ic heart d isease , how ever  
no association betw een  
C.pneumoniae and FM D
G erdes et a l [536]
273  patients (90  w ith recent 
ischem ic stroke, 87 w ith recent 
MI and 96 w ith peripheral artery 
disease)
Prospective E L ISA  for IgA  and IgG for C.pneumoniae
N o  association  betw een  
C.pneumoniae  and IM T
Table A2: Associations between serological evidence o f  C.pneumoniae infection and arterial vascular disease
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Author Study population Type of study Method used Outcome
Kawamoto et al [537] 147 in-patients in a medicine ward Cross-sectional
IgG specific antibody level (IgG 
index) using enzyme-linked 
immunosorbent assay (ELISA)
Antibodies against C. 
pneumoniae were associated 
with increased common carotid 
IMT
Coles et al [538]
1034 subjects from the 1989 
Australian National Heart 
Foundation Perth Risk Factor 
Prevalence survey
Cross-sectional MIF for IgG and IgA for C.pneumoniae
No association was found 
between seroprevalence to 
C.pneumoniae and carotid 
atherosclerosis (measured by 
IMT)
Oshima et al [539] 81 japanese healthy men Cross-sectional ELISA for IgG for C.pneumoniae
No association between 
C.pneumoniae and inflammatory 
markers or endothelial 
dysfunction
Tasaki et a l [540] 102 healthy young m ales C ross-sectional ELISA for IgA and IgG for 
C.pneumoniae
N o  association  betw een  
C.pneumoniae and PW V
Table A3: Associations between serological evidence o f C.pneumoniae infection and arterial vascular disease
289
Author Study population Type of study Method used Outcome
Cook et al[541] 1874 patients :11.8% unstable angina, 10%AMI, 9% acute stroke or transient cerebral ischemia and 69.2% 
acute noncardiovascular, nonpulmonary disease
Retrospective MIF for IgA, IgG and IgM
Positive association between 
C.pneumoniae and acute arterial 
thrombotic disease
Thomas et al[542]
83 patients with CAD, MI or undergoing cardiac 
catheterization 
157 hospiatlized patients with respiratory disease and 
93 patients hospitalized for other reasons
Cross-sectional MIF Positive association between antibody prevalence and CHD
Gabriel et al[543]
282 ischaemic heart disease and 102 controls
Retrospective/ 
cross- sectional
PCR from pharyngeal 
specimens and MIF for 
IgA, IgG and IgM
Positive association between 
C.pneumoniae and ischaemic heart 
disease
Lanza et al[544] 55 patients with cardiac syndrome X(effort angina pectoris, positive exercise test, normal coronary 
angiogram), 49 patients with long term angina
Cross-sectional MIF for IgG for C.pneumoniae
No association between C.pneumoniae 
and cardiac syndrome X
Glader et a/[545] 78 patients with MI and 156 controls with mean age 
54.9 years Cross sectional
MIF for IgG antibodies 
for C.pneumoniae and 
ELISa for IgA 
antibodies
No difference was seen in 
C.pneumoniae between patients and 
controls
Ammann et al[546] 21 patients with normal coronary arteries and regional hypoakinesia and 21 healthy blood donors Retrospective MIF for IgG and IgA antibodies
Positive association between 
C.pneumoniae and MINC and CAD
Nobel et al[547]
58 patients with MI or proven unstable angina and 58 
controls Cross sectional
MIF for IgG, IgA and 
IgM for C.pneumoniae
No association between C.pneumoniae 
and acute coronary event
Komer et al[548] 275 patients with significant stenosis (>70%) in one of 
the peripheral arteries, carotid arteries or coronary 
arteries and 65 patients without significant stenosis
Cross sectional
IgG and IgA-ELISA 
for chlamydial 
lipopolysaccharide 
antibodies and MIF for 
IgG for C.pneumoniae
Association between C.pneumoniae 
and atherosclerosis irrespective o f the 
severity o f atherosclerosis and with no 
predisposition to any particular 
vascular region
Table A4.: Studies investigating the serological evidence of C.pneumoniae infection in CAD.
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Authors Study population Type of study Methods Outcome
Cellesi et al[549]
150 angiography patients with a stenotic lesion 
>50% o f  at least one principal coronary artery, 49 
controls with no angiographic evidence o f coronary 
lesions and 56 controls without any history o f  
cardiac disease
Cross sectional Indirect MIF for IgG and IgA for C.pneumoniae
N o association between C.pneumoniae 
infection and coronary disease
Leowattana et 
al[550] 243 patients with CAD admitted for coronary angiography and 115 blood donors Cross-sectional ELISA for IgG and IgA for C.pneumoniae
Chronic C.pneumoniae infection was 
more common in CAD patients than in 
blood donors
Kontula etal[551] 28 patients with familial hypercholesterolemia(FH) with MI or coronary artery bypass grafting and 68 
FH patients without CAD
Cross -sectional MIF for IgG and IgA forC.pneumoniae
Significant association between 
combination o f  high IgG and IgA titres 
o f  C.pneumoniae and established CHD
Wong et al[552] 669 men and 244 women with CAD found by coronary arteriography and 135 men and 157 
women without CAD
Cross-sectional
PCR for Blood mononuclear 
cells and a time-resolved 
fluoroscopic immunoassay for 
serology
Circulating C.pneumoniae nDNA is a 
predictor o f  CAD in men
Sessa et al[533] 98 patients with acute MI, 80 patients with CHD 
and 50 controls Cross-sectional
MIF for IgG, IgA and IgM for 
C.pneumoniae
Positive association between chronic 
C.pneumoniae and atherosclerotic 
coronary disease
Kaykov et al[553] 130 patients with CAD and 98 blood donors Cross-sectional ELISA for IgG for C.pneumoniae
Positive association between chronic 
C.pneumoniae infection and CAD
Adiloglu et a/[554]
From patients who underwent coronary 
angiography for suspected ischemic heart disease 88 
patients with 3 or more obstructive vessels, 65 had 
ecstatic vessels without atherosclerosis and 91 
controls
Cross-sectional ELISA for IgG and IgM for C.pneumoniae
C.pneumoniae infection is associated 
with atherosclerosis and ectasia
Zibaeenezhad et 
al[555] 109 patients with coronary event and 58 controls Cross-sectional ELISA for IgG and IgA antibodies for C.pneumoniae
N o association between C.pneumoniae 
and angiographically documented CAD
Sun et al[556] 1422 hospitalised patients with angiographically 
demonstrated CAD and 297 controls Cross-sectional
ELISA for IgG for 
C.pneumoniae
No association between C.pneumoniae 
and CAD
Table A5: Studies investigating the serological evidence o f  C.pneumoniae infection in CAD
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Authors Study population Type of study Methods Outcome
Meza-Junco et a/[557] 89 patients with scintigraphic evidence o f  CAD and 
105 controls
Cross-sectional
Indirect solid-phase enzyme 
immunoassay (EIA) for IgG, IgA 
and IgM for C.pneumoniae
No association between ! 
C.pneumoniae seropositivity and 
CAD
Momiyama et al[558] 396 patients with CAD and 153 controls without 
CAD Cross-sectional
ELISA for IgG for C.pneumoniae
No association between 
C.pneumoniae seropositivity and 
CAD
M iyaef a/[559] 268 patients with ischemic heart disease and 178 
controls
Cross-sectional ELISA for IgG for C.pneumoniae
Association between 
C.pneumoniae and ischemic heart 
disease
Romano et o/[560] 64 patients with unstable angina, 56 patients with 
exertional angina and 74 controls
Cross-sectional
MIF for Ig G , IgA and IgM for 
C.pneumoniae
Positive association between 
C.pneumoniae and CAD
Heltai et al[561] 40 patients after MI,
43 patients with stable effort angina and 46 controls Cross-sectional MIF for IgG for C.pneumoniae
Positive association between 
C.pneumoniae and MI
Perumal et al[562] 149 patients undergoing coronary angiography for 
chest pain (99 with (stenosis>50% and 50 without 
significant stenosis) and 60 healthy blood donors
Cross-sectional MIF for IgG for C.pneumoniae
Positive association between 
C.pneumoniae and CAD
Chaudhury et a/[563] 117 patients with unstable angina, 16 patients with 
chronic stable angina and 90 healthy blood donors Cross-sectional
ELISA for IgG for C.pneumoniae
No association between 
C.pneumoniae seropositivity and 
coronary heart disease
M uller et al[564]
194 patients with diabetes mellitus, 50 patients with 
acute coronary syndrome, 102 hypertensive 
patients, 193 patients having suffered a stroke and 
in 368 healthy subject
Cross-sectional
Nested PCR in the DNA o f  white 
blood cells from the peripheral 
blood
No association between 
C.pneumoniae and CAD or other 
disease tested
Koh et al [565] 34 patients with ischemic heart disease nad 680 
patients without ischemic heart disease Cross-sectional
Indirect MIF for IgG for
C.pneumoniae
No association between 
C.pneumoniae and ischemic heart 
disease
Sirmatel et al[566]
36 patients with peripheral vascular disease (PVD), 
29 patients with acute myocardial infection(AMI), 
25 patients with late onset asthma (LOA) and 28 
controls
Cross-sectional
MIF for IgG, IgA and IgM for 
C.pneumoniae
Positive association between 
C.pneumoniae and PVD, AMI 
and LOA
Table A6: Studies investigating the serological evidence o f C.pneumoniae infection in CAD 
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Authors Study population Type of study Methods Outcome
Georges et al [567] 991 patients with CAD and 333 controls Cross-sectional Indirect MIF for IgA for C pneumoniae
Positive association between 
C.pneumoniae and CAD
Kinjo et al[568] 618 patients with acute MI and 967 controls Cross-sectional ELISA for IgG and IgA for C pneumoniae
Positive association between IgA o f  
C.pneumoniae and acute MI
Altannavch et al 
[569] 140 patients with unstable angina (52 with type II diabetes) and controls Cross -sectional
Indirect MIFfor IgA and IgG for
C.pneumoniae
Positive association between 
C.pneumoniae and cardiovascular 
heart disease
Fraser et al [570] 334 patients with MI 820 controls Cross-sectional MIF for IgG for C.pneumoniae
N o significant association between 
C.pneumoniae and MI
Biasucci et al 
[571] 179 patients with unstable angina, 40 with acute MI, 40 with unstable angina and 100 controls
Cross-sectional 
and prospective 
for 41 patients
MIF for IgG for C.pneumoniae and 
ELISA for chlamydial heat shock 
protein 60(CpHSP60)
Association between C.pneumoniae 
HSP60 and 
Acute coronary syndromes
Krausse et al[572] 67 patients who underwent angiography after PTCA and 180 controls Cross-sectional
MIF and ELISA for IgG and IgA for
C.pneumoniae
No association between 
C.pneumoniae and restenosis
Badiaga et al [573]
296 patients with at least one coronary artery lesion 
occupying at least 50% o f  the luminal diameter on 
angiography and 170 controls
Cross-sectional MIF for IgG for C.pneumoniae j
Positive association between 
C.pneumoniae and coronary heart 
disease
Choi e ta l  [574] 391 with CAD and 97 controls Cross sectional IgA and IgG antibodies ELISA
Chlamydia antibodies were 
increased in patients with CAD and 
especially in those without 
additional CV risk factors
Table A7: Studies investigating the serological evidence o f C.pneumoniae infection in CAD
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Author Study population Type of study H.pylori detection Conclusion
Mendall et al[248] 111 consecutive patients with CHD 74 controls aged 45-65 yrs Cross-sectional IgG for H.pylori ELISA
Increased incidence o f  H.pylori in 
patients with CHD
Danesh e ta l [ 575]
288 patients with incident or prevalent 
CHD
704 age and sex matched controls
Cross-sectional IgG for H.pylori ELISA
H.pylori seropositivity was not 
associated with increased incidence o f  
CHD
Alkout e ta l  [576]
171 men who survived one MI 
175 men matched for age and 
socioeconomic class 
125 Individuals who died suddenly of 
IHD
50 accidental deaths without IHD
Cross-sectional IgG for H.pylori ELISA
Antibodies higher in those who died 
from IHD
Higher for survivors than the controls
Pellicano e ta l [511] 44 male age 40-65 admitted for MI 310 volunteer blood donors Cross-sectional IgG ELISA serum
Positive association with myocardial 
infarction
Pietroiusti e t a l [518]
138 patients with large vessel stroke 
61 patients with cardioembolic stroke 
151 healthy control
Cross-sectional IgG for H pylori CagA protein (ELISA)
Association between ischemic stroke 
and H.pylori is due to increased 
prevalence o f more virulent H.pylori 
infection in patients with 
atherosclerotic stroke
Majka et al[579]
80 patients (60-75yrs) with ischemic 
stroke
80 age matched controls
H.pylori positive patients and controls
received one week H.pylori therapy
Cross-sectional
Interventional
1.C-Urea Breath Test
2. Anti -H.pylori and anti CagA 
IgG
3. PCR detection o f  H.pylori 
DNA in atherosclerotic plaques
•  H.pylori CagA+ infection seems to 
be more prevalent in stroke patients.
•  Chronic H.pylori infection may 
raise TChol and LDL-C. enhances 
plasma fibrinogen and is associated 
with increased IL8 levels
•  Anti- H.pylori therapy has 
beneficial effect on atherogenic and 
inflammatory plasma biochemical 
factors
•  H.pylori infection within the 
arterial wall may be directly implicated 
in the atherosclerotic process
Table A8: Associations between atherosclerosis and H.pylori infection (serological evidence)
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Authors Study population Type of study Methods Results
Danesh e ta l [ 249]
1122 survivors o f  suspected acute MI 30- 
49yrs
1122 age and sex matched controls without 
history o f  CHD
510 age and sex matched pair o f  siblings 
mean age 59 yrs (one had survived o f  MI and 
the other no history o f CHD)
Cross sectional
IgG antibodies in
plasma
ELISA
Moderate association between CHD and H.pylori 
seropositivity which cannot be fully accounted by 
other risk factors
Gunn e /a /[5 8 0 ]
342 cases o f  acute MI
214 population based controls with no history 
o f CHD
Cross sectional
CagA seropositivity
H.pylori
seropositivity
CagA strain is associated with increased risk o f  
MI. The association is age dependent and stronger 
in younger subjects
Kowalski etal[250]
Group A: 100 patients with CAD and 100 
controls
Group B: 40 patients with significant single 
vessel disease and confirmed H.pylori 
infection had PTC A and 6 months course o f  
triple H.pylori therapy
Cross sectional
H.pylori IgG and 
anti CagA IgG
Significant link between CAD and infection with 
H.pylori (CagA strain). H.pylori eradication 
attenuates reduction in coronary artery lumen after 
PTCA
Pienazek e ta l [ 581] 76 patients with CAD and 81 healthy controls Cross sectional H.pylori IgG and CagA IgG
Significant link between CAD and H.pylori (in 
particular when both antibodies are positive) 
Cytotoxic H.pylori strain may induce low grade 
inflammatory response in arterial wall + increase 
in acute phase reactants
Pasceri e ta l [ 582]
88 patients with ischemic heart disease 
88 age and sex matched controls Cross sectional H.pylori IgG and CagA IgG
Association between H.pylori and ischemic heart 
disease is due to higher incidence o f  more virulent 
H.pylori strains in patients
Singh e t a l [583]
201 subjects who developed coronary event 
414 controls who remained event free 
Study nested in WOSCOP study
Prospective H.pylori IgG and CagA IgG
Association between H.pylori infection (in 
particular the CagA strain) and CHD
Gabrielli e /a /[5 8 4 ]
105 consecutive patients with atherosclerotic 
stroke
130 age and sex and social background 
matched controls
Cross sectional H.pylori IgG and CagA IgG
Association between CagA IgG and carotid 
plaque instability
Table A9: Associations between atherosclerosis and H.pylori infection (serological evidence)
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Authors Study population Type of study Methods Results
Zito et al [585] 101 patients with MI 101 controls Cross sectional H.pylori IgG ELISA
H.pylori infection is associated with increased risk 
o f  MI
H.pylori infection is associated with higher levels 
o f  fibrinogen in patients and controls 
H.pylori had a stronger effect on the risk for MI in 
patients with genetically increased fibrinogen 
levels
Hoffimeister et al[586] 470 healthy controls238 patients with angiographically proven CHD Cross sectional [13C] Urea breath test
Current infection with H.pylori was associated 
with an atherogenic modified lipid profile
Schumacher e ta l 
[587]
193 patients with CHD and 193 age and sex 
matched controls Cross sectional
IgA and IgG for 
Chlamydia (MIF) 
IgA and IgG ELISA 
for C.pneumoniae 
IgA and IgG for 
H.PYLORI
Serology for C.pneumoniae LPS may contribute 
to increased vascular inflammation (TNF-alpha, 
IL6, CRP, fibrinogen) even more pronounced 
when present in combination with H.pylori 
seropositivity
Kowalski e ta l [250]
1. 96 patients with CAD & 96 patients without 
CAD
2 .135  patients (3 4  patients with H.pylori IgG 
(+) and CagA (+), 37 patients H.pylori IgG (+) 
but IgGCagA(-), 64 patients with H.pylori (-) 
and IgGCagA(-)[control group]) who 
underwent PTCA
3. 40 patients with significantly single vessel 
CAD and H.pylori infection (+)
1.Cross sectional
2. Prospective
3. Randomised 
placebo controlled 
trial
AnO-H.pylori and 
antiCagA IgG ELISA 
and Western blot 
Urea breath test
1 .Significant link between CAD and H.pylori 
infection in particular CagA (+)
2. Patients CagA(+) show significantly greater 
coronary artery lumen loss and arterial re-stenosis 
following PTCA with stent implantation
3. H.pylori eradication attenuates the reduction in 
coronary artery lumen in CAD patients after 
PTCA. This effect was attributed to reduction in 
chronic inflammation and decline in pro- 
inflammatory cytokine release
Schumacher e ta l 
[588]
193 CHD patients and 193 age and sex matched 
controls Cross sectional
MIF for 
C.pneumoniae 
IgA and IgG for 
C.pneumoniae 
(ELISA) and IgA and 
IgG for H pylori
Seropositivity to C.pneumoniae in combination 
with seropositivity for H.pylori is associated with 
increased inflammatory markers (sICAM-1, E 
selectin) whereas H.pylori seropositivity only 
was not associated with increased inflammation
Table A10: Associations between atherosclerosis and H.pylori infection (serological evidence)
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Authors Study population Type of study Methods Results
Zhu et al [589]
1.391 patients evaluated with coronary 
angiography for CAD  
2 .9 2 9  patients angiographically 
documented CAD
Cross sectional 
Prospective IgG H.pylori ELISA
N o association between H.pylori infection and 
CAD, frequency o f CAD or death
Crea e t a / [590]
129 participants in the 4S (pre 
randomisation) who died 
129 matched controls who were alive 
during 5 yr follow up
Retrospective IgG H.pylori, C.pneumoniae
Seropositivity does not predict the risk o f  death in 
patients with stable ischemic heart disease
Brenner e ta l [ 591] 1834 population based sample Cross sectional IgG H.pylori, CagA (ELISA)
H.pylori seropositivity was unrelated to 
inflammatory status as assessed by CRP, leukocyte 
count
Schweeger e ta l [ 592]
100 patients with H.pylori (+) followed 
eradication therapy with pantoprazole and 
clarithromycin and metronidazole
Clinical trial 13C-urea breath test Eradication o f  H.pylori infection does not alter the levels o f  acute phase response markers
Yusuf e ta l  [593] 44 patients with symptomatic IHD 21 age matched controls Cross sectional 14C-Urea breath test
The presence o f  H.pylori infection did not 
correlate with the presence o f  IHD
Parente et al [594] 494 asymptomatic blood donors Cross sectional IgG H.pylori and CagA ELISA
CagA seropositivity is not associated with 
increased systemic inflammation or with raised 
concentrations o f  haemostatic factors
Rothenbacher et al 
[595]
312 patients who underwent coronary 
angiography and had a coronary stenosis o f  
>50%
479 age and sex matched controls
Cross sectional
H.pylori HSP60 (ELISA) 
H.pylori antigens 
(immunoblot)
Antibodies for H.pylori heat shock proteins are 
not associated with CHD
Leung e ta l [ 596] 49 dyspeptic patients Cross sectional Urease test for H.pylori No association between H.pylori infection and homocysteine levels
Bimie e ta l[  194]
100 patients with CAD and confirmed 
active H.pylori infection randomised to 
placebo and Rx for H p y lo r i^
Randomised trial IgG H.pylori (ELISA)
Eradication o f  H.pylori led to a significant fall in 
anti-HSP65 titres suggesting that H.pylori may 
increase risk o f CAD by autoimmune process
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Roivainen e ta l  [253]
241 patients who suffered either 
MI or coronary death during the 
8.5 year trial in the Helsinki 
Heart Study and 241 controls
Retrospective
H.pylori specific IgG antibodies 
(EIA)
C.pneumoniae IgG and IgA MIF 
CMV, Adenovirus and enterovirus 
antibodies with EIA
H.pylori antibodies were not associated 
with increased risk for CHD whereas 
HSV-1 and C.pneumoniae were 
associated with increased risk
Danesh e ta l  [597]
18 epidemiological studies 
involving a total o f  10,000 
patients
Meta-analysis
(1994-1998)
Serum antibody concentrations for 
H.pylori
No strong correlation between 
H.pylori seropositivity and vascular 
risk factors
Mayr e ta l [25\] 684 subjects were assessed prospectively from 1995-2000 Prospective IgG H.pylori and CagA (ELISA)
Dose dependent relation between anti- 
CagA antibodies and IMT and 
atherosclerotic risk. The risk was 
amplified by elevated levels o f  CRP
Laurila e ta l [59%] 880 males in North Finland Cross sectional IgG and IgA antibody titers for H.pylori
Seropositivity was associated with 
increased TChol and triglycerides
Bielanski etal[599] 328 patient with CAD and 897 sex and age matched controls Prospective
Urea breath test with capsulated low  
dose 13C-UBT
No positive association exists between 
H.pylori and CAD
Quinn etal[600]
488 patients undergoing elective 
coronary angiography form 
April 1996-March 1997
Cross sectional Serum H.pylori status was determined with ELISA
No association between H.pylori 
infection and coronary artery disease
Tsai CJ e ta l [601]
165 patients with at least one 
coronary lesion 
127 with normal coronary 
angiography
Cross sectional IgG H.pylori antibody with ELISA No increase was found in H.pylori seropositivity in subjects with CAD
Stollberger et a/[602]
50 patients with CAD and 62 
with normal coronary 
angiograms
Cross sectional IgG H.pylori antibody ELISA
N o difference in seropositivity between 
patients with CAD and normal 
angiograms
Carlsson et al [603]
148 patients undergoing 
percutaneous transluminal 
coronary angioplasty
Prospective IgG and IgA for H.pylori with ELISA
No association between seropositivity 
and risk o f  stenosis immediately after 
PTC A or 6 months after.
Schiele e ta l [604] 180 patients who had stent implantation Prospective IgG for H.pylori with ELISA
H.pylori was not a contributing factor 
in the process o f  restenosis after stent 
implantation
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Ridker e ta l [605]
445 men who subsequently had a MI 
445 men who did not developed arterial 
disease for 8.9yrs o f  follow-up Retrospective
IgG for H.pylori 
ELISA
Limited evidence o f  association between 
H.pylori exposure and risk for future MI
Wald et al [606]
648 men who died from ischaemic heart 
disease
1296 age matched controls
Prospective IgG H.pylori ELISA
No association between H.pylori infection 
and ischaemic heart disease
Harvey e ta l [601] 10537 subjects (Bristol helicobacter project) Cross sectional 13C urea breath test
H.pylori infection had little effect on blood 
pressure in the general population
Murray e fa /[6 0 8 ] 259 patients who had MI 259 population based controls Retrospective
IgG H.pylori and 
CagA ELISA
N o association between MI and H.pylori was 
found after adjusting for potential 
confounders
Stone e ta l [252]
312 men who died o f  IHD or developed 
non-fatal MI (172 were serum available) 
and 205 age matched controls
Retrospective
Western blot analysis 
and ELISA to 
determine H.pylori 
and CagA strains
N o evidence o f  an association between CagA 
seropositivity and incident heart disease or 
ischaemic heart disease
Pellicano etal[609] 223 patients admitted for AMI and 223 age matched controls Cross sectional
IgG H.pylori 
antibodies and CagA
Higher prevalence o f  anti- H.pylori in patients 
compared to controls which was not restricted 
to virulent strain
Koenig et al [610] 312 patients with stable CHD and 479 controls Cross sectional
IgG H.pylori anc 
CagA
N o association between H.pylori 
seropositivity and CHD after adjusting for 
potential confounders.
Whincup e ta l [254] 505 CHD cases and 1025 age-matched controls Cross sectional
IgG to mixed H.pylori 
antigens (ELISA) and 
to CagA
There is no association between H.pylori 
seropositivity and incidence o f  CHD in late- 
middle aged men.
Pellicano etal[611]
212 consecutive male patients admitted 
for AMI
volunteer blood donors
Cross sectional
13C-Urea breath test 
IgG antibodies 
H.pylori
Increased prevalence o f  H.pylori infection 
than the general population
De Backer et al [612]
446 subjects who had had MI, CABG, 
PTCA or had prominent Q/QS waves on 
their resting ECG 892 healthy controls
Cross sectional
IgG and IgA H.pylori 
and IgG Cpn, CMV 
ELISA
No association between seropositivity and 
CHD.
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Muller et al [613]
109 patients who underwent surgery 
forICA
Asymptomatic N=40 
Symptomatic N=36
prospective IgG and IgM with ELISA
No difference in the levels o f  antibodies 
between symptomatic and asymptomatic 
patients
Rothenbacher et al[ 614] 300 patients with angiographically defined CAD mean age 57.9years Prospective
IgG antibodies with ELISA 
borderline zone 0.35-0.45 U/ml)
CMV is not related to the incidence o f  
secondary cardiovascular events and is 
not associated with inflammatory 
markers
Eryol et al [615] 179 patients evaluated for CAD suspicion (58 f, 121m) Cross sectional
IgM and IgG antibodies with 
ELISA
Positive IgG >lU /m L  
Positive IgM >8U/mL
CMV seropositivity is independent risk 
factor for CAD
Sun e t a l [616]
463 patients with CAD and 125 
controls without evidence for CAD in 
coronary angiography
Cross sectional IgG for CMV detected with ELISA
• Seropositivity for CMV was not 
significant different between patients 
and controls
• Seropositivity was associated with 
increased levels o f  IL10 in patients but 
not in controls
Gabrylewicz et al [617]
158 subjects divided into three groups: 
group I - 70 patients with acute MI, 
group II - 40 patients with stable 
angina, and group III - 48 healthy 
controls
Cross sectional IgG and IgM antibodies assessed by ELISA
* Patients with symptomatic coronary 
irtery disease have a significantly higher 
mti-CMV antibody titre than healthy 
iubjects.
► The active form o f  infection is 
.ignificantly more prevalent in patients 
vith acute MI than in patients with stable 
m g in ^ _
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Tim oteoef al [618]
60 patients with ACS.
30 patients with stable coronary 
disease
Prospective 30 days 
follow-up
Serologic markers (IgM and 
IgG) for CMV
* Higher prevalence o f  serologic markers for 
DMVin patients with ACS than in patients 
>vith stable coronary disease.
* An elevation in IgG titer for CMV was 
issociated with a worse outcome at 30 days 
md six months.
Grahame-Clarke e ta l  [301] 400 subjects 199 non diabetic and 201 diabetics Cross sectional
IgG and IgM measured by 
ELISA
CMV-seropositive individuals have 
endothelial dysfunction and impaired 
responses to NO
Khairy e ta l  [302] 65 male subjects free o f  CAD Cross-sectional study IgG antibodies measured by ELISA Lack o f  association with endothelial function
Witherell e ta l [  619] Cases o f  first MI (N = 121) Controls without MI (N = 204)
Nested case-control 
design
IgG antibodies measured 
with ELISA
No association between CMV seropositivity 
and MI was detected
Auer et al [620] 218 consecutive patients 
undergoing coronary 
angiography
Cross sectional IgG antibodies measured with ELISA
N o association o f  anti-CMV seropositivity 
and increased risk o f  CAD assessed by 
coronary angiography
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Espinola-Klein et al 
[621]
504 patients (74.9% men; age, 62.9+/-10 
years)
Prospective follow up 
in 2.5 years IgA and IgG measured by ELISA
N o independent association 
between CMV and IMT
Hu e ta l  [622]
210 patients with atherosclerostic 
cerebral infarction (Grade III)
100 healthy people
Cross sectional study CMV nucleic acid by PCR In blood and arterial wall
Increased prevalence o f  CMV 
nucleic acid in the arterial wall 
o f  people with Grade III 
atherosclerosis
Burian e ta l  [198]
405 subjects (aged 35 to 77 years)
Group 1: 248 patients with severe CAD 
Group 2 :28 patients with mild CAD 
stenosis (<50% occlusion).
Group 3: 53 control patients with clinical 
symptoms o f  stable angina pectoris and 
no coronary alterations 
Group 4: 76 blood donors without 
history o f CAD
Cross sectional 
Case control study
Serum IgG antibodies to CMV-IE1 
antigen were determined by in-house- 
developed ELISA"low" at a calculated OD 
<1.00 and "high"at OD^l.OO
Higher anti-CMV-IEl levels in 
patients compared to controls
Hoffmeister et al [586]
470 healthy blood donors and 238 
patients with angiographically proven 
coronary heart disease (CHD), aged 40 to 
68 years
Cross sectional 
Case-control
IgG, IgA, and IgMagainst CMV, was 
measured by ELISA The cutoff was 
defined as the mean optical density o f  
negative control, +0.14 for IgG and IgM 
and +0.09 for IgA. The "gray zone" was 
defined as the cutoff ±10%.
Seropositivity to CMV was not 
associated with atherogenic 
modified lipid profile
Mayr et al [623] 919 individuals Prospective IgG measured by ELISA
Antibody titers against 
cytomegalovirus were not 
predictive o f  IMT
Sorlie et a l [267]
People nested in the ARIC study who 
developed CHD (n=221) during follow- 
up o f up to 5 years and a random sample 
o f  515 partici£ants_
nested case-cohort Antibodies for CMV measured by solid- phase radioimmunoassay
High levels o f  CMV antibodies 
are significantly associated with 
incident CHD.
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Espinola-Klein e ta l 
[624]
504 patients (75% men; mean age 62.9 [SD  
10] years Cross- sectional
IgG antibodies (positive: cutoff point o f  20 
RU/mL)and IgA(positive ratio o f  >1 .0)
Significant association between 
IgG antibodies and IMT 
measurements and carotid artery 
stenosis
Carlsson et al [603] 148 patients with coronary artery disease prospective anti-CMV IgG with ELISA
CMV seropositivity was not 
associated with the risk o f  
restenosis after coronary 
intervention
Zhu e ta l  [336] 238 individuals evaluated for CAD by coronary angiography Cross- sectional
anti-CMV IgG antibodies by ELISA 
an ELISA value <0.25 units was 
considered a negative result, and a value 
o f  >0.25 unit was considered positive, 
indicating prior exposure to CMV
individuals with an 
inflammatory response appear 
susceptible to the atherogenic 
effects o f  CMV, whereas those 
without appear resistant
Manegold et al 
[274] 92 patients with CAD and PTCA prospective
IgG measured by ELISA 
positive for CMV antibodies if  the optical 
density at 405 nm exceeded 0.2 after 
subtraction o f  the reactivity with the 
control antigen o f uninfected cell lysates
Prior CMV infection, is not 
associated with chronic 
restenosis after conventional 
coronary balloon angioplasty
Carlsson et al [625] 148 patients with CAD had PTCA nested in the VERA trial prospective IgG antibodies measured with ELISA
N o association between CMV 
seropositivity and risk o f  
restenosis
Blum A et al [626]
50 men and 15 women, aged 40 to 75 
years) with symptomatic ischemic coronary 
disease
prospective Anti-CMV IgG antibodies were measured with ELISA
High antibody titers against 
CMV (IgG) may be a strong 
marker for coronary artery 
disease, and might predict post­
coronary angioplasty restenosis
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Lindberg et al [627] 267 patients with atherosclerosis as measured by IMT and 267 controls Cross-sectional
Positive or negative by solid phase 
radioimmunoassay
Weak association between 
CMV and carotid 
atherosclerosis
Stiegler et al [628] 900 successive nontransplant patients undergoing coronary angiography Cross-sectional
CMV seropositivity IgG antibodies to 
CMV whole cell antigen or the levels o f  
IgG antibodies to CMV glycoprotein B
CMV infection is not a major 
risk factor for the development 
o f  primary CAD in adults.
Zhou et a l [273]
75 consecutive patients undergoing 
directional coronary atherectomy for 
symptomatic coronary artery disease nested 
in the Optimal Atherectomy Restenosis 
Study
prospective
anti-CMV IgG and IgM antibodies 
measured by ELISA
prior exposure to CMV, as 
indicated by the presence o f  
anti-CMV IgG antibodies at the 
time o f coronary atherectomy, is 
a strong independent risk factor 
for restenosis.
Nieto et a l [269]
150 participants with the highest overall 
mean IMT were included in the case group. 
Control subjects were the participants with 
the lowest mean IMT within 10-year age 
and sex strata nested in ARIC study
Cross-sectional
solid-phase radioimmunoassay was used 
for the detection o f  antibodies, solid-phase 
radioimmunoassay was used for the 
detection o f  antibodies.
a graded relation between the 
odds ofintimal-medial 
thickening and the levels o f  
CMV antibodies that remained 
significant after adjustment for 
the main cardiovascular risk 
factors
Kol e ta l  [629]
20 patients with unstable angina (12 men 
and 8 women; mean age, 62 years; range, 
44 to 89 years) and 20 patients with stable 
angina (16 men and 4 women; mean age, 
62 years; range, 43 to 81 years) who 
underwent successful directional coronary 
atherectomy were enrolled in the study.
Cross sectional
Reverse transcription and thermal cycling  
amplification o f  a 145-bp CMV cDNA  
segment o f the major immediate early 
geneMIE
CMV MIE gene mRNA was not 
detected in coronary 
atherectomy specimens 
obtained from patients with 
either unstable or stable angina.
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Sorlie et a\ [630]
340 matched case-control pairs from the Atherosclerosis Risk 
in Communities (ARIC) Study. Cases were defined as 
persons with thickened carotid artery walls but without a 
history o f cardiovascular disease. Controls were defined as 
persons without thickened walls or history o f  cardiovascular 
disease.
Cross sectional IgG and IgM antibody Measured by ELISA
Modest association between 
CMV and asymptomatic carotid 
wall thickening consistent with 
early atherosclerosis
Loebe et al [631] 38 long-term survivors o f  orthotopic heart transplantation Cross sectional IgG and IgM antibody Measured by ELISA
Cytomegalovirus infection 
seems to be an important factor 
in the development o f  
accelerated graft arteriosclerosis 
in the transplanted heart.
Adam et al [632]
157 Caucasian male patients undergoing vascular surgery for 
atherosclerosis and a matched control group o f  patients with 
high cholesterol levels
Cross sectional IgG and IgM antibody Measured by ELISA
N o correlation between 
antibody titre and blood levels 
o f  total cholesterol or 
triglycerides.
Grattan MT et al 
[633]. 301 cardiac transplant recipients Retrospective
IgG and IgM antibody 
Measured by ELISA
CMV infection in cardiac 
transplant recipients is 
associated with more frequent 
rejection, graft atherosclerosis, 
and death.
Schiele F et al 
[604]
180 patients who had stent implantation in a native coronary 
artery with systematic angiographic and intravascular 
ultrasound (IVUS) follow up at six months
prospective IgG and IgM antibody Measured by ELISA
Previous infection with CMV 
was not a contributing factor in 
the process o f  restenosis after 
stent implantation.
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Unit of P aed ia tric  & Perinata l
Epidemiology
University o f Bristol
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W e s t o n  G e n e r a l  H o s p i t a l  
G r a n g e  R o a d ,  Uphi l l  
W e s t o n - s u p e r - M a r e  
S o m e r s e t  
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24 Tyndall A venue  
BRISTOL BS8 1TQ
Dear Professor Golding *
Re: E283 ( R ) - Genetic and Environmental Influences on the Atherogenic Phenotype 
in the Young: A Population Based Study
Many thanks for sending us your application, which has recently received approval from the UBHT 
Ethics Committee.
We have a reciprocal arrangement with UBHT so that any study that has been agreed by them can 
occur within Weston Area Health Trust as long as the Ethics Committee is suitably informed.
Therefore approval is granted.
Yours sincerely,
Mr D Pack
Chairman. W eston  LREC
Chairman: M artha Perriam  Chief Executive: Roger Moyse
An a s s n r in t -p d  Tenchina H osnital o f  the Universitu o f Bristol
N orth  Bristol E JL
NHS Trus t
fS
Clinical Governance Directorate
24 August 2001 Beaufort House Southmead Hospital 
Westbury-on-T rym 
Bristol BS10 5NB 
 
Professor J Deanfield
Vascular Physiology Unit
Great Ormond Street Hospital NHS Trust
Great Ormond Street
LONDON W C 1 N 3 J H
Dear. Professor Deanfieid
PROJECT : GENETIC AND ENVIRONMENTAL INFLUENCES ON THE ATHEROGENIC  
PHENOTYPE IN THE YOUNG - A POPULATION BASED STUDY
I am pleased to inform you that the Southmead Local Research Ethics Committee has approved 
your application in respect of the above project.
Approval is given on the understanding that:-
a) Any ethical problems arising in the course of the project will be reported to the Ethics 
Committee;
b) Any change in protocol will be reported to the Ethics Committee;^
c) An annual progress report will be submitted and a brief final report on completion.
Yours sincerely
Mrs S B Bowman 
Administrator
Southmead Local Research Ethics Committee
Copy: Prof. J Golding
10 Guilford Street, London, W C1N 1EH. Telephone: 02 0  724 2  9789  Fax: 020 7813 8234
19 December 2002 
Dr N Klein
nfectious Diseases &
Microbiology Unit 
CH
Dear Dr Klein,
ritle: Infectious diseases in children and vascular fuction-
potential risk for later atherosclerosis 
*&D registration number:  
’rotocol number/version: N/A
Notification of ethical approval
'he above research has been given ethical approval after review by the Great 
)rmond Street Hospital for Children NHS Trust / Institute of Child Health Research 
ithics Committee subject to the following conditions.
Your research must commence within twelve months of the date of this letter 
and ethical approval is given for a period of 12 months from the 
commencement of the project. If you wish to start the research more than 
twelve months from the date o f this letter or extend the duration of your 
approval you should seek Chairman’s approval.
You must seek Chairman’s approval for proposed amendments to the research 
for which this approval has been given. Ethical approval is specific to this 
project and must not be treated as applicable to research of a similar nature, 
eg. using the same procedure(s) or medicinal product(s). Each research 
project is reviewed separately and if there are significant changes to the 
research protocol, for example in response to a grant giving body’s 
requirements you should seek confirmation of continued ethical approval. 
Researchers are reminded that REC approval does not imply approval by the 
GOS Trust. Researchers should confirm with the R&D office that all necessary 
permissions have been obtained before proceeding.
1 It is your responsibility to notify the Committee immediately of any information
which would raise questions about the safety and continued conduct of the 
research.
5. On completion of the research, you must submit a report of your findings to the 
Research Ethics Committee.
6. Specific conditions pertaining to the approval of this project are:
• The use of the enclosed standard consent forms for the research. A copy of
the signed consent form must be placed in the patient’s clinical records and a 
copy must be kept by you with the research records.
Yours sincerely
Orlagh Sheils
Administrator to the Research Ethics Committee
Cc: Dr M Charakida, Vascular Physiology, GOS
4. It is your responsibility to notify the Committee immediately of any information 
which would raise questions about the safety and continued conduct of the 
research.
5. On completion of the research, you must submit a report of your findings to the 
Research Ethics Committee.
6 Specific conditions pertaining to the approval of this project are:
• The use of the enclosed standard consent forms for the research. A copy of
the signed consent form must be placed in the patient’s clinical records and a 
copy must be kept by you with the research records.
Yours sincerely
Orlagh Sheils
Administrator to the Research Ethics Committee
Cc: Dr M Charakida, Vascular Physiology, GOS
GreafrOrmond Street Hospital 
for Children NHS Trust I The 
Institute of Child Health 
Local Research Ethics Committee
Institute of Child Health 
30 Guilford Street 
London 
WC1N1EH
 
 
Email: l.howe@ich.ucl.ac.uk
27th November 2003
Dr J Halcox 
Vascular Physiology 
ICH
Dear Dr Halcox,
Title: Validation of a new technique for measuring
endothelial function in the clinical setting
R&D registration number: 
Protocol number/version: N/A
Notification of ethical approval
The above research has been given ethical approval after review by the Great
Ormond Street Hospital for Children NHS Trust / Institute of Child Health Research
Ethics Committee subject to the following conditions.
1. Your research must commence within twelve months of the date of this letter
and ethical approval is given for a period of twelve months from the 
commencement of the project. If you wish to start the research more than 
twelve months from the date of this letter or extend the duration of your 
approval you should seek Chairman’s approval.
2 You must seek Chairman’s approval for proposed amendments to the research
for which this approval has been given. Ethical approval is specific to this 
project and must not be treated as applicable to research of a similar nature, 
eg. using the same procedure(s) or medicinal product(s). Each research 
project is reviewed separately and if there are significant changes to the 
research protocol, for example in response to a grant giving body’s 
requirements you should seek confirmation of continued ethical approval.
An advisory co m m i t t ee  to  North Central  London  Strategic Heal th Author i ty
3. Researchers are reminded that REC approval does not imply approval by the
GOS Trust. Researchers should confirm with the R&D office that all necessary 
%
permissions have been obtained before proceeding.
4. It is your responsibility to notify the Committee immediately of any information 
which would raise questions about the safety and continued conduct of the 
research.
5 On completion of the research, you must submit a report of your findings to the
Research Ethics Committee. You may also be required to submit annual 
reports.
6. Specific conditions pertaining to the approval of this project are:
• The use of the enclosed standard consent forms for the research. A copy of 
the signed consent form must be placed in the patient’s clinical records and a 
copy must be kept by you with the research records as our insurers may 
demand access to them. r
Yours sincerely
Laura Howe
Research Ethics Coordinator
cc. Marietta Charakida, Vascular Physiology
An advisory co m m i t t ee  t o  North Central  London Strategic Health Author i ty
Great Ormond Street Hospital 
for Children NHS Trust I The 
Institute of Child Health 
Local Research Ethics Committee
Institute of Child Health 
30 Guilford Street 
London 
WC1N 1 EH
 
Email: l.how e@ ich .uc l.ac .uk
13th January 2004
Marietta Charakida , 
Vascular Physiology 
ICH
Dear Marietta,
Title: Validation of a new technique for measuring
endothelial function in the clinical setting 
R&D registration number: 
Protocol number/version: N/A
Thank you for your letter dated 13th January 2004. The Chairman of the Research Ethics 
Committee, Dr Victor Larcher, has on behalf of the Committee, approved the amendment 
to the above study as detailed in your letter and summarised below:
• Measurement of endothelial function in 12 young healthy adult volunteers after 
administration of typhoid vaccine in order to determine whether PWA after 
salbutamol inhalation is able to detect the transient endothelial dysfunction 
associated with vaccination
The decision will be ratified at the full Committee meeting that will take place on 
W ednesday 4th February 2004 (Please note that you will not receive a letter confirming the 
above ratification).
Yours sincerely
Laura Howe
Research Ethics Coordinator
An advisory commi t t ee  to  Nor th Central  London  Strategic Heal th Author i ty
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Endothelial Dysfunction in Childhood Infection
Marietta Charakida, MD; Ann E. Donald, AVS; Mari Terese, BSc (Hons), AVS; Sam Leary, PhD;
Julian P. Halcox, MB, MA, MRCP; Andy Ness, PhD, MFPH;
George Davey Smith, MD, DSc, FFPH; Jean Golding, PhD, DSc, FMedSci;
Peter Friberg, MD, PhD; Nigel J. Klein, PhD, FRCPCH; John E. Deanfield, BA, BCh, MB, FRCP;
for the ALSPAC (Avon Longitudinal Study of Parents 
and Children) Study Team
B a c k g ro u n d — A th e r o s c le r o s is  b e g in s  in ea r ly  l if e ,  and e n d o th e lia l d y s fu n c t io n  is r e c o g n iz e d  as a key in it ia tin g  e v e n t  
in the d e v e lo p m e n t  o f  a th e r o sc le r o s is .  A lth o u g h  in fe c t io n  h as b een  im p lic a te d  in e n d o th e lia l d y s fu n c tio n  and  
a th e r o g e n e s is ,  the im p a ct o f  a cu te  c o m m o n  c h ild h o o d  in fe c t io n s  on  th e  v a sc u la r  e n d o th e liu m  is u n k n o w n .
M ethods a n d  R e su lts— W e stu d ied  6 0 0  ch ild ren  aged  10 years draw n from  the A v o n  L ong itu d ina l Study o f  Parents and 
C h ild ren . T he ch ild ren  w ere d iv id ed  in to  3 groups: th o se  w ith  current acute in fectio n  (A l;  n =  135; 73  b o y s and 62  g irls); 
a c o n v a le sc e n t  group  w ith  in fec tio n  in the past 2 w e e k s  (n =  166; 78  b o y s  and 8 8  g ir ls), and a healthy control group  
t n - 2 9 9 ;  131 b o y s  and 168 g ir ls). E n d o th e lia l fun ction  w as determ ined  in all su b jects by h ig h -reso lu tion  ultrasound to  
m easure brach ial artery flo w -m ed ia te d  d ila tio n  (F M D ) and w as e x p ressed  as the percen tage  ch ange in d iam eter from  
b a se lin e  after rea ctiv e  h y p erem ia . F M D  w a s rep eated  in 4 0  ch ild ren  in the A l group and 5 0  in the control group after  
a m ean  interval o f  1 year. F M D  w a s lo w e r  in both  the A l group ( 6 .3 ± 2 .7 % , m e a n ± S D )  and the co n v a lescen t group  
(8.1 ± 3 .1 % ) than in the contro l group (9 .7 ± 2 .5 % ;  P < 0 .0 0 1  for  both ). T h e o b serv ed  d ifferen ces  in F M D  rem ained after  
adju stm ent for p o ten tia l c o n fo u n d in g  variab les. A t the repeat v isit, F M D  w as u n ch an ged  in contro ls ( P = 0 .8 5 )  but 
im p roved  in the A l group  ( P < 0 .0 0 1 ).
C o n c lu sio n s— A c u te  in fec tio n  in c h ild h o o d  is a sso c ia ted  w ith  im paired  en d o th eliu m -d ep en d en t vasod ila tion . T h e se  
fin d in g s support a poten tia l role for p r e v io u sly  u n su sp ected  ex tr in s ic  in flam m atory  stim u li in the p a th o g en esis o f  early  
a th ero sc lero s is . (C ircu la tio n . 2005; 111:1660-1665.)
Key Words: in fec tio n  ■ en d o th eliu m  ■ risk factors ■ pop u lation
A th e r o sc le ro s is  as a c lin ic a l d ise a se  usually  presents in m id d le  and late adu lth ood , but the p a th o g en esis  o f  
this d ise a se  starts very early , o ften  from  the first d ecade o f  
l if e .1 C la ss ic  risk factors, in c lu d in g  h y p erch o lestero lem ia , 
obesity , and d ia b etes, have been a sso c ia ted  w ith a cce ler ­
ated a th ero sc lero s is  in ch ild ren , w h ich  has been linked to 
cardtovascu lar m orbid ity  and m ortality  in later l i f e .2 ' It is 
likely, h o w ev er , that other in flu en ces  m ay be im portant for 
initiation and p ro g ressio n  o f  early d isea se .
See p 1568
Experimental and clinical studies have led to a dramatic 
change in our understanding o f  the pathophysiology o f  athero­
sclerosis. providing robust evidence o f  the importance o f  vascu­
lar inflammation throughout disease developm ent.4-' The endo­
thelium plays a key role as the signal transducer that regulates 
this process. Although classic risk factors may induce inflam­
mation and endothelial dysfunction, our group has recently 
shown that even a low-grade inflammatory stimulus such as 
typhoid vaccination can cause profound, reversible impairment 
o f  endothelial function in young healthy subjects.6
Infection is the m ost com m on inflammatory insult in early 
life. T o date, m ost clinical studies have focused on the contri­
bution o f  infection on the advanced stages o f  atherosclerotic 
disease in adults, with conflicting results7- 10; however, the 
greatest burden o f infection occurs in childhood, which raises the 
possibility that infection may play a more important role during 
the preclinical phase o f  atherosclerosis. There has been limited  
clinical investigation into the role o f infection in children; 
however, a provocative study suggested that a severe infection 
can accelerate the early progression o f  structural arterial d is­
ea se .11 In the present study, we investigated the effect o f  
com m on mild childhood infections on endothelial function in a 
large cohort o f  children.
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Methods 
The ALSPAC Population
The A .on  Longitudinal Study of Parents and Children (ALSPAC) is 
a population-based study designed to investigate environmental and 
genetic influences that may affect the health and development of 
children. The study methods are described in detail elsewhere12 and 
on the study ’s World Wide Web site (http://www.alspac.bris.ac.uk). 
Brieflv, 15 541 pregnant women with an expected delivery date 
between the start of April 1991 and the end of December 1992 were 
enrolled, which represented 859?- of the eligible total general popu­
lation in 3 health authorities in the Bristol, United Kingdom, area. 
The cohort of 14 062 livebom children has been followed up 
p ro tec t iv e ly . Detailed information about the children has been 
collected from questionnaires administered through childhood, and 
clinic measurements have been performed on the entire cohort 
annually since the age of 7 years.
The Vascular Study Population
Our study population consisted of 600 children aged 10 years. These 
represented consecutive children bom between February 2002 and 
June 2002 who were participating in a vascular study of the entire 
ALSPAC cohort, provided they did not have asthma or chronic 
infections and were not taking antibiotics or antiinflammatory drugs. 
The protocols were approved by the ALSPAC Law and Ethics 
committee and by the local research ethics committees. Written 
informed consent was sought from the parent/guardian, and assent 
from the child was obtained at the time of the study.
Definition of Infection
Information on the nature, timing, and treatment of  the children with 
acute infection was obtained by questionnaires completed by the 
parents/guardians of the children at the time of the vascular function 
measures Acute infection was defined by clinical symptoms. The 
commonest were cough, cold, fever, and sore throat. These were 
reported by the parents in the questionnaires and not confirmed by 
formal clinical examination or serological evidence. No blood tests 
were undertaken to document infectious agents or state. The ques­
tionnaires inquired about the type and severity of infection and 
details of any medication or supplement taken at the time of their 
assessment, or regularly, by the children. Children were then 
classified into 3 different groups: (1) children who reported acute 
infection at the time of the study (Al group), (2) children who were 
convalescing from an infection in the previous 2 weeks but were well 
at the time of the study (convalescent group), and (3) children 
without recent illness (controls). None of the illnesses were consid­
ered severe enough to warrant medical consultation or prescription of 
antibiotics.
Endothelial Function
Eiach child underwent measurement of endothelium-dependent vas­
cular responses of the right brachial artery by high-resolution 
ultrasound imaging (Aloka 5500, Japan; 7-MHz linear probe and 
automated v essel-diameter measurements. Brachial Tools, MIA) in a 
temperature-controlled vascular room in Bristol.13 The child lay 
supine on a couch in a temperature-controlled room (24°C to 26°C), 
and after 10 minutes’ rest, a straight, nonbranching segment of the 
brachial artery above the antecubital fossa was identified and 
scanned in a longitudinal fashion. Once depth and gain settings were 
adjusted, brachial artery diameter was recorded (baseline) for I 
minute A pneumatic cuff was then inflated to 200 mm Hg on the 
forearm for 5 minutes, and the segment of the brachial artery was 
recorded continuously for another 5 minutes. We recorded end-dia- 
stolic images at 3-second intervals throughout. Brachial artery 
diameter was measured offline by an automatic cdge-detection 
system and expressed as a percent change from the baseline 
d iam e te r"  Doppler-derived flow measurements (using a pulsed- 
wave Doppler signal at a 70° angle) were also obtained continuously. 
The increase in blood flow after the release of the cuff was expressed 
as a percentage of the baseline flow.
Potential Confounding Factors 
Measures o f Social Position
The occupation of both the mother and her partner were recorded in 
the 32-week antenatal questionnaire. These were used to allocate 
each to a social class group (which ranged from V = unskilled to 
I = professional) with the United Kingdom Registrar General’s occu­
pational coding. A combined variable was derived that was the 
highest socioeconomic class of the mother and her partner.
Measures o f Cardiovascular Risk Factors
At 10 years, systolic and diastolic blood pressures were measured as 
the average of the last 2 seated readings with an automated 
oscillometric device (Dinamap 9301 vital signs monitor) in the left 
arm. A pediatric cuff was used when arm circumference was < 2 5  cm 
and a regular adult cuff when arm circumference was > 25  cm. Heart 
rate was measured as the average of the last 2 readings as recorded 
by the same (Dinamap 9301 vital signs monitor) device. Weight was 
measured to the nearest 0.1 kg with SECA scales while the child was 
wearing underwear, and height was measured to the nearest 0.1 cm 
w ith a Leicester height meter. From these measurements, body mass 
index values were calculated (weight/height2, with weight in kilo­
grams and height in meters). Nonfasting venous blood samples were 
collected from each child at age 7 years and analyzed for total 
cholesterol, HDL, and LDL.
Measures o f Previous Infection and Hygiene Practice
Mothers reported, in 4 different questionnaires at 15 months, 15 to 24 
months, 24 to 38 months, and 54 months, how often in a normal day 
their child’s face and hands were wiped and also how often hands 
were wiped before meals. Responses ranged from “not at all" to "5 
or more times per day.” Mothers were also asked how often their 
child was given a bath or shower, brushed their teeth, and cleaned 
their ears. Responses ranged from “hardly ever” to “more than once 
a day.” The score at each time point was the sum of 6 questions that 
gave values of 0 to 18, with higher values indicating greater hygiene. 
From these responses, the child’s mean hygiene score was derived 
(ranging from least hygienic to most hygienic).15 Similarly, a mean 
infection score was created from questionnaires for the age periods 
< 6  months, 6 to 18 months, 18 to 30 months, 30 to 42 months, and 
59 to 81 months, which gave values from 0 to 7. The infection score 
at each time point was the number of infections (diarrhea, vomiting, 
cough, high temperature, cold, earache, and ear discharge) reported. 
In addition an "infection seen by the doctor” score was also derived 
with individual questions recoded as having visited a doctor with 
infections versus not having visited a doctor with infection/no 
infection. With the same time points, a mean antibiotic score was 
calculated, for which the score at each time point was "0” for no 
antibiotic use, “ 1” for only 1 episode of use, and “2” for 2 or more 
episodes of antibiotic use. For all variables, mean values were only 
calculated if values were recorded for at least 2 time points.
Follow-Up Study Methods
To assess the long-term effect of the infectious illness on endothelial 
function, we performed repeat measures. We calculated that 40 
children from the Al group would have the power to demonstrate a 
25% improvement in the flow-mediated dilation (FMD) response 
relative to their baseline measurement in the Al group with 90% 
power and at the 5% significance level. To ensure adequate partic­
ipation, we invited by letter all 135 children of the Al group and 150 
randomly selected control children to attend for an additional 
vascular assessment (1 2 ± 6  months after the initial evaluation).
Data Analysis
The data were analyzed with the Stata analysis package, version 8. 
All vascular function data were normally distributed and are present­
ed as mean and SD for continuous variables or percentages for 
categorical variables. We examined the effect of infection on 
endothelial function by linear regression analysis. Multivariable 
analysis was performed to adjust for other potential confounders. At
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TABLE 1. Demographic Characteristics and Clinical Parameters According to 
Infection Status in Children
Al G r o u p  
(n  =  1 3 5 )
C o n v a l e s c e n t  G r o u p  
(n  =  1 6 6 )
C o n t ro l  G r o u p  
(n  =  2 8 2 ) P
M a le ,  % 5 4 .1 4 7 .0 4 0 .4 0 .0 1
S o c ia l  c l a s s  1 a n d  II, % 6 7 .2 5 9 .7 5 4 .1 0 .0 2
B o d y  m a s s  in d e x  @ 1 0  y e a r s ,  k g / m 2 1 6 .1  (1 .8 ) 1 5 . 8 ( 1 . 6 ) 1 6 .2  ( 2 .2 ) 0 .4
T o ta l  c h o l e s t e r o l  @ 7  y e a r s ,  m m o l /L 4 .4  (0 .7 ) 4 . 4  (0 .7 ) 4 . 4  ( 0 .7 ) 0 .9
H D L  @ 7  y e a r s ,  m m o l /L 1 .5  ( 0 .3 ) 1 .6  ( 0 .4 ) 1 . 5 ( 0 3 ) 0 .1
LD L  @ 7  y e a r s ,  m m o l /L 2 .2  (0 .6 ) 2 .3  (0 .5 ) 2 .3  (0 .6 ) 0 .5
S B P  @ 1 0  y e a r s ,  m m  H g 1 0 2 . 2 ( 8 . 2 ) 1 0 1 . 5 ( 8 . 9 ) 1 0 0 . 7  (8 .4 ) 0 .1
D B P  @ 1 0  y e a r s ,  m m  H g 5 7 .1  (6 .8 ) 5 7 .1  (7 .2 ) 5 6 .9  (7 .1 ) 0 .8
H e a r t  r a t e  @ 1 0  y e a r s ,  b p m 7 1 . 2 ( 1 1 . 9 ) 7 3 . 0  ( 1 1 .5 ) 7 1 .0  ( 1 1 .3 ) 0 .6
I n f e c t io n  s c o r e :  n o t  s e e n  b y  d o c to r * 3 .7  (0 .9 ) 3 . 6  (0 .9 ) 3 .5  (0 .9 ) 0 .1
I n f e c t io n  s c o r e :  s e e n  b y  d o c to r * 1 .4  ( 0 .9 ) 1 .3  (0 .9 ) 1 .3  (0 .9 ) 0 .3
A n t ib io t ic  s c o r e t 0 . 8  ( 0 .5 ) 0 . 7  (0 .5 ) 0 . 7  (0 .5 ) 0 .1
H y g ie n e  s c o r e ! 9 .8  ( 1 .8 ) 9 .7  (1 .8 ) 9 . 8  ( 2 .0 ) 0 .8
S B P  i n d i c a t e s  s y s t o l i c  b lo o d  p r e s s u r e ;  D B P , d i a s t o l i c  b lo o d  p r e s s u r e .
’ M e a n  n u m b e r  o f  i n f e c t i o n s  ( d i a r r h e a ,  v o m i t in g ,  c o u g h ,  h ig h  t e m p e r a t u r e ,  c o l d ,  e a r a c h e ,  a n d  e a r  
d i s c h a r g e )  r e p o r t e d  a t  5  d i f f e r e n t  t i m e  p o i n t s .  In d iv id u a l  q u e s t i o n s  w e r e  r e c o d e d  a s  “ s e e n  d o c t o r  w i th  
i n f e c t io n "  v s  “ n o t  s e e n  d o c t o r  w i th  i n f e c t io n /n o  i n f e c t io n ."
t M e a n  n u m b e r  o f  a n t i b i o t i c s  u s e d  a t  5  d i f f e r e n t  t i m e  p o i n t s .
T M e a n  o f  h y g i e n e  s c o r e s  a t  4  t i m e  p o i n t s .  H y g ie n e  s c o r e  a t  e a c h  t i m e  p o in t  w a s  t h e  s u m  o f  f a c e
w a s h i n g ,  h a n d  w a s h i n g ,  h a n d  c l e a n i n g  b e f o r e  m e a l s ,  b a t h / s h o w e r ,  a n d  e a r  h o l e  c l e a n i n g  v a l u e s .
H i g h e r  v a l u e s  i n d i c a t e  g r e a t e r  h y g ie n e .
V a lu e s  a r e  p e r c e n t  o r  m e a n  (S O ).
the follow-up study, / tests were used to compare the differences in 
endothelial function measures.
Results 
Population C haracteristics
Of the 6(X) subjects, 301 children had either an acute infection 
at the time o f the study (A l group, n = 135) or were conva­
lescing from an infection in the previous 2 weeks but were 
well at the time o f  study. The 299 controls were healthy 
children w ithout recent illness. The majority o f children in
both the Al and convalescent groups presented with upper
respiratory tract infections (93% and 94%, respectively). The 
remainder had either ear infections (2% and 2%) or urinary 
tract infections (5% and 4%). Seventeen children from the 
control group were excluded from the analysis because their 
vascular measures could not be linked to the main database.
None of the children in the present study had infectious 
illnesses deemed sufficiently severe to warrant prescription of
TABLE 2. Vascular Characteristics According to Infection Status
Al G r o u p  
(n  -■= 1 3 5 )
C o n v a l e s c e n t  G r o u p  
( n - 1 6 6 )
C o n t ro l  G r o u p  
(n  -  2 8 2 ) P
B a s e l i n e  d i a m e t e r ,  m m 2 .7  (0 .3 ) 2 .7  (0 .3 ) 2 .7  (0 .5 ) 0 .9
%  FM D 6 . 3  ( 2 .7 ) 8 .1  (3 .1 ) 9 .7  (2 .5 ) 0 .0 0 1
B a s e l i n e  f l o w ,  m l i m i n 8 .6  (3 .7 ) 8 .7  (4 .1 ) 9 . 2  ( 5 .7 ) 0 .6
%  R e a c t i v e  h y p e r e m i a  f lo w 4 9 2 . 2 ( 1 3 9 . 1 ) 5 2 3 . 2  ( 1 3 8 .2 ) 4 8 6 . 0 ( 1 4 0 . 9 ) 0 .6
A b s o l u t e  c h a n g e  in  f l o w , m L /m in 3 1 .0  (9 .4 ) 3 1 . 3  ( 1 6 .2 3 ) 3 2 . 4  ( 1 7 .6 ) 0 .8
V a lu e s  a r e  m e a n  (S D ); P  v a l u e s  w e r e  f r o m  1 - w a y  A N O V A  t e s t i n g  t h e  m e a n s  a c r o s s  t h e  3  g r o u p s .
antibiotics. The clinical characteristics and risk factor profiles 
o f the children are shown in Table 1.
In the follow-up study, all 43 children who replied from the 
Al group were studied, but 3 were excluded because they 
presented with acute infection or with a history o f recent 
infection within the last 2 weeks. Fifty control children had a 
repeat study performed in an identical manner. None o f those 
children had experienced another infection during the period 
between the 2 studies.
Associations Between Acute Infection and 
Clinical C haracteristics
Higher socioeconom ic position was associated with increased 
incidence o f infection, and there were more boys than girls in 
the Al group. No other factors were associated with infectious 
status (Table 1).
Infection and  Endothelial Function
Baseline brachial artery diameter, baseline flow, reactive 
hyperemia flow, and absolute change in flow were similar in
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Figure 1. Impact of infection on endothelial function. This figure 
demonstrates differences in endothelial function (% FMD) 
between Al group, convalescent (Conv) group, and controls. 
Values expressed as mean±SD. *P<0.001 vs control group.
the 3 infec tion  g ro u p s  (Tab le  2). E n d o th e l iu m -d ep e n d e n t  
FM D  w as low er  in the A l g ro u p  than in e i th e r  the c o n v a le s ­
cent or  the con tro l  ch i ld ren  ( P < 0 .0 0 1  for both; F igure  1). In 
addition.  F M D  w as a lso  lo w er  in the c o n v a lescen t  children  
than in the c on tro ls  (P<0.001).
N one  o f  the facto rs  m en t io n ed  in T ab le  1, including 
hygiene  and  p r io r  in fec t ion  score,  were  assoc ia ted  with  F M D  
in this cohor t  (P  =  0.3 to P = 0.9).  H o w ev e r ,  g iven  the da ta  
from the literature,  w e  co n s id e red  these  factors as potential  
c o n fo u n d ers  and ad ju s ted  for th em  in the analysis .  T h e  im pact  
o f AI on F M D  w as una lte red  a f te r  m ult ivar iab le  ad jus tm en t  
for gender ,  b ase l ine  b rach ia l  artery d iam ete r ,  total c h o le s te r ­
ol, systolic  b lood  p ressu re ,  so c io ec o n o m ic  status, body  m ass 
index, infec tion ,  and  hy g ien e  score  (T ab le  3).
Follow-Up Study
The d if fe rences  in v a scu la r  func tion  b e tw een  the A l and 
control ch i ld ren  w h o  par t ic ipa ted  in the fo l low -up  study were  
similar to the f ind ings  for the entire  cohort.  B ase line  vessel 
s i /e  was s im ila r  in bo th  the A l  and the con tro l  g ro u p  at the 2 
\is i ts .  B ase l ine  and  reac tive  h y p e rem ia  f low m easu rem en ts  
were s im ila r  in the con tro l  g roup  at the 2 visi ts (Table  4). 
FM D  w as u n c h an g e d  in the con tro l  ch i ld ren  in the 2 visits.  In 
contrast ,  F M D  im p ro v e d  subs tan t ia l ly  in the ch ild ren  in the 
Al g ro u p  (F igure  2; T ab le  4).  At fo l low -up  study, F M D  was 
lower in the Al g ro u p  than  in con tro ls ,  but this d id  not reach 
conven t ional  s ta tist ical s ign if icance  (P  =  0 .06).  Th ir ty -six  o f  
the ch ild ren  in the A l  g ro u p  had endothe l ia l  function  values 
within the no rm al  range  at fo l low -up .  T h e  F M D  values o f  4 
Al ch ild ren  re m a in e d  2 SD s be low  the m ean  value for the 
control ch ild ren .  In the con tro l  g roup,  2 ch ild ren  had F M D
TABLE 3. Associations Between FMD and Acute Infection
%  F M D  U n a d j u s t e d %  F M D , A d ju s te d *
Al g r o u p
C o n v a l e s c e n t  g r o u p
- 3 . 4  ( -  
- 1 . 7  ( -
3 .9 ,  - 2 . 8 )  
2 .2 ,  - 1 . 1 )
- 3 . 1  ( - 3 . 9 ,  - 2 . 3 )  
- 1 . 7  ( - 2 . 4 ,  - 0 . 7 )
• A d iu s t e d  f o r  g e n d e r ,  b a s e l i n e  b r a c h i a l  a r t e r y  d i a m e t e r ,  in f e c t io n  s c o r e ,  
hygiene s c o r e ,  t o t a l  c h o l e s t e r o l ,  b o d y  m a s s  in d e x ,  s o c i a l  c l a s s ,  a n d  s y s to l i c  
blood p r e s s u r e .
fi (Cl) v a l u e s  a r e  f r o m  r e g r e s s i o n s  in  c o m p a r i s o n s  w i th  c o n t r o l s .
values 2 S D s  be low  the m ean  both  at baseline  and at restudy. 
T h ere  w ere  no d e m o g ra p h ic  or  c linical features that d isc r im ­
inated this sm all  g roup  o f  A l  or  control child ren  from  the 
rem a in in g  children .  B ase line  flow m easu rem en ts  in the Al 
g ro u p  were  h ig h er  in the fo l low -up  study than in their  index 
visit.  A lth o u g h  this base line  d ifference  in flow resulted  in 
lo w er  reac tive  hype rem ic  f low expressed  as a pe rcen tage ,  the 
abso lu te  increase  in hyp e rem ic  flow w as sim ila r  to that seen 
at the first visi t (Table  4).
Discussion
T his  study sh o w s  that m in o r  infectious illnesses are a sso c i­
ated with  im p a irm en t  in endothe lia l  function in o therw ise  
well children .  V ascu la r  function  recovered  in m ost  but not all 
ch i ld ren  at fo l low -up  study 1 year  later. T hese  findings 
support  a potential  role for prev ious ly  unsuspec ted  extrinsic  
i n f l a m m a t o r y  s t i m u l i  in th e  p a t h o g e n e s i s  o f  e a r ly  
a therosc lerosis .
M ost  s tudies  o f  infec tion  and  a therosc lerosis  have e x a m ­
ined the late c linical phase  o f  the disease.  Infectious agents 
have  been  found  in a therosc lero t ic  p laques and linked to 
v ascu la r  i n f la m m a t io n .16 Ind iv idual  p a thogens  and total 
p a thogen  bu rd en  have  been  assoc ia ted  with structural and 
func tional  arterial  wall abnorm ali t ie s  and ou tcom e,  but  no 
c ausal  re la tionsh ip  has been  e s tab l i sh ed .17 19 Large  antibiotic  
tria ls targe ting  specific  infec tious agents  to treat the e s tab ­
lished a therosc lero t ic  d isease  have reported  conflic t ing  and 
m ostly  d isappo in t ing  resu lts ,20 which  suggests  at m ost  a 
l im ited  benefi t  o f  trea tm en t  in patients  with advanced  a th e ro ­
sclero tic  d isease.
E x per im en ta l  work ,  h ow ever ,  has suggested  that infection 
m ay  play a m ore  im portan t  role in the early  phase  o f  
a the rogenesis  and m ay  be am enab le  to intervention  at this 
s tage .21-23 W e  have p rev ious ly  show n that a specific  vascu- 
litic d isease ,  K aw asak i  d isease ,  can  cause  long-term  vascu lar  
d ysfunc t ion  in the y o u n g .24 W e  now  ex tend  these f ind ings to 
d em o n s tra te  an acute  vascu la r  effect o f  m inor  c o m m o n  
infec tious illnesses exper ienced  by the m ajority  o f  children.  
By study ing  children ,  it is poss ib le  to m in im ize  the potential  
c o n fo u n d in g  but less easily  quan tif iab le  e ffects o f  life time 
risk factor burden.
W e chose  to s tudy the effect o f  these  i llnesses on e n d o th e ­
lial func tion  in condu it  arteries because  endo the l ium  plays a 
key role in regu la ting  m any  o f  the vascu lar  changes  involved  
in the init iation and progress ion  o f  early  disease.  W e  m e a ­
sured  F M D , a techn ique  deve lo p ed  by ou r  group,  because  this 
has been  show n  to be accurate ,  to be reproducible ,  to corre late  
with endothe lia l  function  in the coronaries ,  and to reflect 
ni tric ox ide  b io av a i lab il i ty .13-25-26 Furtherm ore ,  endothe lia l  
function  m easu red  by F M D  has been show n  to predic t  
c a rd io v ascu la r  o u tco m e  in recent reports and to respond  to 
in te rven t ions .27-28
W e have  show n  that even  m ild ch ildhood  infections that do 
not require  a visit to the d o c to r  o r  antib io tic  therapy  are 
assoc ia ted  with  m arked  endothe lia l  dysfunction .  T he  impact  
on F M D  was c o m p arab le  to that seen in p rev ious  s tudies  in 
y ou n g  adults  with risk factors such as d iabe tes  and family 
h is tory  o f  co ronary  artery d isease .29-30 W ith in  this large 
represen ta t ive  cohort,  there was a range o f  vascu la r  responses
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TABLE 4. Vascular C haracteristics of Children in Follow-Up Study
Al G r o u p  (n  =  4 0 ) C o n t r o l  G r o u p  ( n = 5 0 )
P \V is i t  1 V is i t 2 F V isi t 1 V is i t 2 F
B a s e l i n e  d i a m e t e r ,  m m 2 .8  ( 0 .3 ) 2 .7  ( 0 .3 ) 0 .2 2 . 8  (0 .9 ) 2 .7  ( 0 .4 ) 0 .5 0 .9
%  F M D 5 .0  ( 2 .3 ) 8 . 2  ( 2 .5 ) 0 .0 0 1 9 . 3  ( 2 .4 ) 9 . 2  (2 .3 ) 0 .8 0 .0 6
B a s e l i n e  f l o w ,  m lV m in 8 . 5  ( 2 .8 ) 1 1 .6  ( 6 .9 ) 0 .0 1 1 0 .3  (8 .7 ) 1 0 . 3 ( 4 . 9 ) 0 .9 0 .3
%  R e a c t i v e  h y p e r e m i a  f l o w 4 9 9 . 1  ( 1 4 3 .2 ) 4 3 2 . 7  ( 1 4 0 .2 ) 0 . 0 5 4 7 6 . 8  ( 1 4 0 .5 ) 4 7 7 . 8 ( 1 6 2 . 4 ) 0 .9 0 .2
A b s o l u t e  c h a n g e  in  f l o w , m U m i n 3 1 . 6  ( 8 .9 ) 3 3 .1  ( 1 3 .5 ) 0 .8 3 4 . 5 ( 1 3 . 9 ) 3 3 . 9 ( 1 2 . 5 ) 0 .6 0 .8
V a lu e s  a r e  m e a n  (S D ).
• V is i t  1 v s  v i s i t  2 ,  t v i s i t  2  o f  Al g r o u p  v s  v i s i t  2  o f  c o n t r o l  g r o u p .
to acute infection . T his is unlikely to have been due to 
variation in cardiovascular risk factor profile in the present 
study population, because there were sim ilarly low leve ls o f  
risk factors in all 3 groups. In addition, ow ing to size  and tim e 
limitations o f  the study, blood was not taken at the tim e o f  the 
study. W e were therefore unable to define w hether sp ecific  
infectious agents are m ore likely  to produce vascular e ffects. 
It was a lso  not possib le  to quantify the m agnitude o f  the 
vascular inflam m atory response by m easuring b lood  markers 
of endothelial activation, w hich have been identified  in adult 
subjects at risk o f  coronary artery' d isease . Further studies are 
required to exam in e the contribution o f  sp ec ific  in fectious  
agents and the potential contribution o f  parental risk factors, 
le. sm oking.31 32
A number o f  potential m echanism s by w hich infection  may 
damage the arterial w all have been proposed. A direct e ffect  
of the virus on the endothelium  has been su g g ested .33 
Alternatively, indirect dam age m ay result from inflam m atory  
cytokines on constitu tive endothelial nitric o x id e  synthase, as 
well as lip id  m o d if ic a t io n s  o f  both  H D L  and L D L  
cholesterol." 34-*•
Animal studies have show n that repeated adm inistration o f  
infectious organism s can lead to progressive endothelial 
damage.3' ■'* In the present study, w e were able to exam ine  
changes in FM D  over an average fo llo w -u p  o f  1 year. 
Endothelial responses in m ost but not all the children in the 
Al group returned to w ithin the normal range. Thus, the 
effects o f A l at this age m ay be transient and recoverable. W e 
are unable, how ever, to determ ine the potential im pact o f
V isit 1 
V isit 2 
V isit 1 
V isit 2
p = 0 .8 520
■J„ EMI)
C ontrol
Figure 2. Follow-up study. FMD was reassessed in 40 children 
m Al group and 50 controls at mean interval of 1 2 i6  months 
after their initial evaluation. Horizontal lines represent mean val­
ues for each group.
recurrent infections, w hich m ight be cum ulative, as in the 
anim al studies, on the initiation and progression o f  early 
atherosclerosis. The A l, convalescent, and control children all 
had sim ilar reported histories o f  early childhood infections  
and h ygiene practices. N one o f  the children experienced an 
infection in the interval betw een the 2 studies. There were 
on ly  4 children from the A l group in whom  vascular function  
rem ained abnormal at fo llow -up . This did not allow  us to 
study the factors that m ight predispose a child to persistent 
endothelial dysfunction  after acute infection. It rem ains 
p ossib le  that genetic or environm ental factors may influence  
the long-term  vascular e ffects o f  infection that may take years 
to b ecom e clin ica lly  apparent.
Conclusions
W e have show n that a m inor infectious stim ulus in childhood  
relevant to normal daily life is associated with endothelial 
dysfunction . T his raises the possib ility  that infection may 
contribute to m echanism s relevant to the developm ent o f  
atherosclerosis. H ow ever, the cum ulative impact o f  ind ivid­
ual in fectious agents and the interaction with genetic, pheno­
typic, and other environm ental predisposing factors requires 
prospective evaluation .
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Early Structural and Functional Changes of the Vasculature
in HIV-Infected Children
Im pact o f Disease and Antiretroviral Therapy
Marietta Charakida, MD; Ann E. Donald, AVS; Hannah Green, MSc; Clare Storry, BSc, AVS;
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B ackground— Premature cardiovascular disease is increasingly recognized in HIV-infected patients, but the mechanisms 
involved are unclear. The purpose of this study was to determine the impact of HIV infection and antiretroviral therapy 
(ART) on markers of early vascular disease in children.
M ethods an d  R esu lts— We studied 83 HIV-infected children (56 had taken ART, of whom 31 received a regimen containing 
protease inhibitors [PIsJ; 27 were never treated) and a control group of 59 healthy children. Carotid intima-media thickness 
(IMT) and brachial artery flow-mediated dilatation (FMD) were measured. IMT was significantly greater in HIV-infected 
children compared with the control subjects (P<0.001). Among the HIV-infected children, age and treatment were 
significantly associated with increased IMT. Children exposed to Pis had greater IMT compared with both non-PI-treated 
children and untreated children (P=0.02). FMD was also significantly reduced in the HIV-infected children compared with 
control subjects (P = 0.02). Pairwise comparisons of different treatment exposure groups revealed that FMD was impaired by 
a mean of 3.6% (95% Cl, 1.8 to 5.3; /5<0.001) for children exposed to Pis compared with untreated children and by a mean 
of 1.8% (95% Cl, 0.01 to 3.5; P=0.05) compared with non-PI-treated children. HIV-infected children had lipid abnormalities, 
but they did not account for the observed differences in either FMD or IMT.
C onclusions— HIV infection in childhood is associated with adverse structural and functional vascular changes that are 
most pronounced in children exposed to PI therapy. Longitudinal studies are required to differentiate the relative impact 
of HIV disease and ART and to assess the potential for prevention. (C irculation . 2005;112:103-109.)
Key Words: endothelium ■ HIV ■ protease inhibitors
Human im m unodeficiency virus (HIV) infection is a major cause o f  morbidity and mortality worldwide. In developed  
countries, life expectancy has increased considerably as a result 
of antiretroviral therapy (AR T), and cardiovascular disease has 
emerged as an important late concern.1-2 Recent studies have 
shown a 26% increase in myocardial infarction in HIV-infected 
adults per year exposure to ART and that metabolic abnormal­
ities related to the use o f  com bination therapy may contribute.v5 
Protease inhibitors (Pis), in particular, are associated with 
dyslipidem ia, insulin resistance, and lipodystrophic phenotype, 
vs hich may be due to hepatic overproduction o f  VLDL and, to a 
lesser extent, impaired clearance.56 It has been difficult, how- 
e \ er. to separate the effects o f  HIV disease itself, drug treatment, 
metabolic consequences, or interactions with the exposure to 
classic risk factors for atherosclerosis.
A lthough clin ical m anifestations o f  atherosclerosis do not 
tvpically present until m iddle and late adulthood, the process
o f  atherogenesis begins earlier.7 Num erous cardiovascular  
risk factors have been show n to affect both endothelial 
vascular function and early structural arterial wall changes 
from the first decade o f  life .8 9
W e therefore studied children who acquired HIV through 
mother-to-child transmission to exam ine the potential effect o f  
chronic HIV infection and ART on measures o f  vascular 
structure and function. This population provides the opportunity 
not only to investigate the impact o f  HIV infection and AR T on 
the vasculature but to do so without the confounding effect o f  the 
cumulative risk factor burden present by adulthood.
Methods 
Study Population and Design
We studied HIV-infected children attending Great Ormond Street 
Hospital (GOSH) NHS Trust (London, UK). Children with current
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opportunistic infections or cardiovascular risk factors, including 
hypertension, diabetes, and renal failure, were excluded. Of the 96 
HIV-infected children identified as eligible for the study, 83 agreed 
to participate Fifty-nine healthy volunteer children were recruited as 
control subjects from healthy siblings of the HIV-infected children 
and children of staff working at the hospital. No formal matching 
seas used in selecting the control children (apart from siblings). None 
had a current or recent infectious illness, nor were they receiving any 
medication or vitamin supplementation.
All children had a clinical examination, including blood pressure 
measurements, blood sampling, anthropometry, and vascular mea­
surements. Details of past clinical and ART history were extracted 
from the UK Collaborative HIV Pediatric Study (CHIPS) database.10 
The HIV clinic at GOSH does not use rigid criteria for initiating 
ART However, ART is usually started for persistently low or 
declining CD4% counts and/or clinical deterioration. The nature of 
the ART regime was not based on measures of disease severity.
Fthnicity data were obtained from the National Study of HIV in 
Pregnancy and Childhood (NSHPC).
Institutional Review Board approval was received, and all parents 
or caregivers and children, when appropriate, gave written informed 
consent to participate in the study at the time of the visit.
Anthropometric Measurements
Weight and height were recorded, and body mass index (BMI; 
kg 'n ri  was calculated. Values were converted to age- and sex- 
adjusted z scores with the use of UK reference curves." Blood 
pressure was measured as the average of 3 seated readings with an 
automated oscillometric dev ice (Omron). A pediatric cuff was used 
when the arm circumference was < 25  cm and an adult cuff when the 
arm circumference was > 25  cm.
Blood Sample Analysis
Nonfasting blood was taken from all children in heparinized tubes, 
and 1 mL of plasma was stored at -8 0 ° C .  Lipid levels and 
inflammatory markers (see below) were measured in all subjects, and 
markers of disease activity were assessed in the HIV-infected
children
Markers of HIV Severity and Inflammation
HIV RNA viral load was measured by branched DNA assay (Chiron 
Diagnostics) with a lower limit of detection of 50 copies per 1 mL. 
CD-Vr was measured by flow cytometry. For viral load and CD4% 
measurements, the closest measurements (within 3 months before the 
study visit) were used if available. High-sensitivity C-reactive 
protein (hsCRP) was analyzed with an in-house ELISA method.12
Lipoprotein Analysis
Total cholesterol was measured by enzymatic colorimetry; HDL was 
measured directly in plasma after precipitation with polyethylene 
glycol (Roche Diagnostics) Apolipoprotein B (apoB) and lipopro­
tein (a) [Lp<a)J were measured by immunoturbimetry kits from 
WAKO and Diasys Diagnostic Systems, respectively. LDL peak and 
mean particle diameters were determined by PAGE, as described in 
detail elsewhere.1’
Vascular Measurements
All vascular measurements were undertaken by 2 experienced 
investigators Measurement on a random sample of 10 HIV-infected 
and 10 control children performed by both investigators showed no 
evidence of systematic observer bias (mean difference in intima- 
media thickness [IMT], 0.003 [P = 0.80, paired t test]; mean differ­
ence in flow-mediated dilation [FMD], 0.25 [/4 = 0.40, paired t test]).
IMT Study
The right and left common carotid arteries were scanned with a 5- to 
10 .MHz linear-array transducer (Acuson). The carotid bulb was 
identified, and longitudinal 2D ultrasonographic images of the 
common carotid artery 1 to 2 cm proximal to the carotid bulb were
obtained. The optimal longitudinal image was acquired on the R 
wave of the ECG and continuously recorded on videotape for 5 
seconds. Measurements of the posterior wall of the artery were made 
from stored images with electronic calipers. IMT was calculated as 
the distance between the first bright line (lumen-intima interface) and 
the leading edge of the second bright line (media-adventitia inter­
face). Six measurements, the 3 maximum measurements of the right 
common carotid artery in 3 different frames and the 3 maximum 
measurements of the left common carotid artery in 3 different 
frames, were averaged.
FMD Study
Each child underwent measurement of endothelium-dependent vas­
cular responses of the right brachial artery by high-resolution 
ultrasound imaging with an Acuson 5- to 10-MHz linear probe as 
previously reported.8 Brachial artery diameter was measured offline 
by an automatic edge detection system (Brachial Tools) and ex­
pressed as a percentage change from baseline diameter.14 Doppler- 
derived flow measurements (using a pulsed-wave Doppler signal at 
a 70° angle) were also obtained continuously. The increase in blood 
flow after the release of the cuff was expressed as a percentage 
change from the baseline flow. Endothelium-independent response 
to glyceryl trinitrate (GTN) was also calculated as a percentage 
change from the baseline diameter after sublingual administration of 
25 ix g GTN in the HIV-infected children only.
Statistical Analysis
In descriptive analyses, parametric summary statistics and signifi­
cance tests were used when the data were approximately normally 
distributed; otherwise, nonparametric methods were used. All FMD 
and GTN analyses were adjusted for baseline diameter; GTN 
analyses were adjusted for weight. Multivariate regression analysis 
was used to examine relationships between vascular measurements 
and HIV infection status and ART exposure with adjustment for 
potential confounders. Confounders included age, sex, ethnicity. 
Centers for Disease Control (CDC) stage, hsCRP, glucose, and 
selected lipid parameters. Variables that were not normally distrib­
uted were log,0 transformed to reduce the influence of outlying 
observations.
Results
Study Population
T he 83 H IV -infected children had a mean age o f 11.0 years 
(range, 5 .4  to 17.7 years); 70% were black; and all had 
acquired HIV from m other-to-child transm ission. The control 
children were 1 year older than the H IV -infected children; 
80% were w hite and had sim ilar age-adjusted BMI scores 
(Table 1).
T w enty-seven  H IV -infected children had never received  
AR T. The rem aining 56 children had taken AR T for a median 
o f  5 years (range, 0 .2  to 14 years). O f these 56, 31 had 
received regim ens containing a PI (Table 2). At the tim e o f  
the study, 48  children were taking AR T (23 including a PI), 
and 35 children were not receiving any ART. O f the 31 
P i-exposed  children, 8 were on com bination therapy that did 
not include a PI at the tim e o f  the study visit (m edian duration 
since a PI w as taken, 1.3 years; range, 0.5 to 2.8 years). 
T w enty H IV -infected children (24% ) had previously experi­
enced a C D C  stage C d isea se15; all 20 had been treated with 
A R T  (15 exposed  to PI therapy) (Table 2).
Lipoprotein Parameters
T riglycerides, non-H D L  cholesterol, apoB, and Lp(a) were 
sign ificantly  higher in H IV -infected children com pared with 
control subjects. In addition, H IV -infected children had
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TABLE 1. Demographic Data, Clinical Param eters, Lipid Results, and Vascular 
M easurements in HIV-Infected Children and Control Subjects
H I V - I n f e c te d  C h i ld r e n  
(n  =  8 3 )
C o n t r o l  S u b j e c t s  
(n  =  5 9 ) P
D e m o g r a p h i c  d a t a
A g e ,  y 1 1 . 0 ( 3 . 1 ) 1 2 . 2 ( 2 . 8 ) 0 . 0 1 4
M a le ,  % 5 7 4 7 0 .3 1
H e ig h t  z  s c o r e  (IQ R ) - 0 . 3 1  ( - 1 . 2 6 - 0 . 2 7 ) 0 . 3 0  ( - 0 . 1 5 - 0 . 9 4 ) 0 . 0 0 0 2
B M I z  s c o r e  (IQ R ) 0 . 0 4  ( - 0 . 7 8 - 0 . 8 7 ) 0 . 2 0  ( - 0 . 4 6 - 1 . 0 4 ) 0 . 3 9
C l in ic a l  p a r a m e t e r s
S y s to l i c  b lo o d  p r e s s u r e ,  m m  H g 1 0 4  (1 0 ) 1 1 0 ( 1 2 ) 0 . 0 0 0 9
D i a s to l i c  b lo o d  p r e s s u r e ,  m m  H g 6 1  (9 ) 6 3  (8 ) 0 . 0 9
H e a r t  r a t e ,  b p m 8 0  (1 3 ) 7 2 ( 1 2 ) 0 . 0 0 0 3
G l u c o s e ,  m m o l /L 4 . 4  ( 0 . 7 ) 5 .1  ( 0 .3 ) < 0 . 0 0 0 1
h s C R P , m e d i a n  (IQ R ), m g / l 0 . 6  ( 0 . 2 - 2  3 ) 0 . 2  ( 0 . 1 - 0 . 6 ) < 0 . 0 0 0 1
L ip id /b lo o d  r e s u l t s
T o ta l  c h o l e s t e r o l ,  m m o l /L 4 .1  ( 0 .9 ) 3 . 8  ( 0 .7 ) 0 . 0 6
H D L  c h o l e s t e r o l ,  m m o l /L 1 .2  ( 0 .5 ) 1 .4  ( 0 .3 ) 0 . 0 2
N o n -H D L  c h o l e s t e r o l ,  m m o l /L 2 . 9  ( 0 .8 ) 2 . 4  ( 0 .6 ) 0 . 0 0 0 7
M e a n  p a r t i c l e  d i a m e t e r ,  n m 2 8 . 2  ( 1 .0 ) 2 9 . 0  ( 1 .1 ) < 0 . 0 0 0 1
P e a k  p a r t i c l e  d i a m e t e r ,  n m 2 7 . 8 ( 1 . 2 ) 2 8 . 6  ( 1 .4 ) 0 . 0 0 0 9
A p o B , m g /d L 7 5 ( 1 7 ) 6 4  (1 1 ) 0 .0 0 0 1
L p ( a ) ,  m e d i a n  (IQ R ), m g / d L 4 2  ( 2 3 - 6 9 ) 2 3  ( 1 4 - 5 1 ) 0 . 0 2
T n g l y c e n d e s ,  m e d i a n  (IQ R ), m m o l / L 1 .0  ( 0 . 7 - 1 . 3 ) 0 . 6  ( 0 . 5 - 0 . 8 ) < 0 . 0 0 1
V a s c u l a r  m e a s u r e m e n t s
IM T , m m 0 . 6  ( 0 . 0 7 ) 0 . 4 7  ( 0 . 0 6 ) < 0 . 0 0 0 1
F M D . t  % 7 . 9  ( 4 .9 ) 9 . 4  ( 5 .8 ) 0 . 0 2
G N T - m e d i a t e d  d i l a t i o n .^  % 1 5 .1  ( 5 .3 )
IQ R i n d i c a t e s  i n t e r q u a r t i l e  r a n g e .  H e ig h t ,  B M I, b lo o d  p r e s s u r e ,  h e a r t  r a t e ,  a n d  l ip id  m e a s u r e m e n t s  
o n ly  w e r e  a v a i l a b l e  fo r  5 6 ,  5 6 ,  5 5 ,  5 5 ,  a n d  4 3  c o n t r o l  c h i l d r e n ,  r e s p e c t i v e l y .  V a lu e s  a r e  g iv e n  a s
m e a n  (S O ) u n l e s s  o t h e r w i s e  s t a t e d .
' B a s e d  o n  t h e  2 - s a m p l e  t t e s t  o r  W i lc o x o n  2 - s a m p l e  t e s t  w h e n  a p p r o p r i a t e .  
t A d i u s t e d  fo r  b a s e l i n e  d i a m e t e r ;  e s t i m a t e s  g i v e n  f o r  m e a n  b a s e l i n e  d i a m e t e r  o f  2 .8 6  m m .  
^ A d j u s t e d  fo r  b a s e l i n e  d i a m e t e r  a n d  w e i g h t ;  e s t i m a t e s  g i v e n  f o r  m e a n  b a s e l i n e  d i a m e t e r  o f  
2  8 1  m m  a n d  m e a n  w e i g h t  o f  3 6 . 9  k g .
significantly low er H D L  cholesterol lev e ls  and m ean and 
peak LDL particle s izes  (Table 1).
Within the HIV cohort, d ifferences in lipid param eters 
were observed betw een  those receiv ing  d ifferent treatm ent 
regimens (Table 2). T otal cholestero l w as higher in children  
receiving ART (both w ith and w ithout PI) com pared with  
untreated H IV -infected  children. Lp(a), apoB , and tr ig lycer­
ide levels were higher in Pi-treated children com pared with  
non-PI-treated and untreated H IV -in fected  children. H D L  
cholesterol leve ls were low er in the untreated H IV -in fected  
children compared w ith treated children, and the latter had 
levels similar to those in the control children.
CRP Measurement
hsCRP was sign ificantly  higher in the H IV -in fected  children  
compared with control subjects (T able 1). L ight H IV -in fected  
children had m arkedly increased hsC R P values (C R P  > 1 0  
rog/L); although they did not have c lin ica l ev id en ce  o f  acute  
infection, these CRP lev e ls  are com patib le  w ith acute in flam ­
mation. H owever, the d ifference in C R P values betw een  
control subjects and H IV -in fected  children rem ained w hen  
the analysis was perform ed w ith these 8 children om itted .
Vascular Measurements 
IM T  A ssessm en t
IM T m easurem ents w ere availab le for 77 o f  the 83 HIV- 
in fected  children and 45  o f  the 53 control subjects. IM T w as 
higher in the H IV -in fected  children com pared with the 
control subjects (P < 0 .0 0 0 1 ;  Table 1) in both unadjusted and 
adjusted analyses. There w as a significant association be­
tw een  IM T and age in the H IV -infected  children that w as not 
observed  in the control subjects (Figure 1A); for every year 
increase in age , IM T w as increased on average by 0 .005  mm  
(959c C l, 0 .0 0 0 3  to 0 .0 1 ). There was no association betw een  
ethnicity  and IM T in either H IV -infected or control children.
T here was ev id en ce  o f  a treatment effect when the HIV- 
in fected  children w ere categorized as ever exposed  to P is, 
non -P I-trcated , and untreated (P = 0.03; Table 2). Exposure to 
P is w as associated  w ith a higher mean IM T com pared with  
both those untreated (P  =  0 .0 4 ) and the non-PI-treated group 
(F  =  0 .01 ; Figure IB ). Sim ilar results were found when the 
children w ere categorized according to their treatment regi­
m en at the tim e o f  the test (data not show n). There w as no 
associa tion  betw een  IM T and CD4%  or viral load at the time 
o f  the study, but m ore advanced CD C stage was associated
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TABLE 2. Comparison of ART Exposure in HIV-Infected Children
PI T r e a t e d  
(n  =  3 1 )
N o n - P I  T r e a t e d  
( n = 2 5 )
U n t r e a t e d
( n = 2 7 ) P*
D e m o g r a p h i c  d a t a
A g e ,  y 1 1 .1  ( 3 .5 ) 1 1 .5  ( 3 .0 ) 1 0 . 3 ( 2 . 5 ) 0 .3 9
M a le .  % 6 2 4 4 6 3 0 .7 2
H e ig h t  z  s c o r e ,  m e d i a n  (IQ R) - 0 . 5 9  ( - 1 . 3 5 - 0 . 1 8 ) - 0 . 4 0  ( - 0 . 9 4 - 0 . 0 6 ) - 0 . 2 4  ( - 1 . 3 2 - 0 . 3 8 ) 0 .7 5
B M I z  s c o r e ,  m e d i a n  (IQ R ) - 0 . 2 0  ( - 0 . 8 1 - 0 . 7 5 ) 0 . 0 4  ( - 0 . 9 3 - 0 . 5 6 ) 0 . 6 2  ( - 0 . 2 5 - 1 . 1 9 ) 0 .1 3
C l in ic a l  p a r a m e t e r s
S y s t o l i c  b lo o d  p r e s s u r e ,  m m  H g 1 0 3 ( 1 0 ) 1 0 3  (8 ) 1 0 6 ( 1 0 ) 0 .3 7
D i a s to l i c  b l o o d  p r e s s u r e ,  m m  H g 6 1  (1 2 ) 6 0 ( 7 ) 6 1  (6 ) 0 .9 0
H e a r t  r a t e ,  b p m 7 9 ( 1 1 ) 7 9  ( 1 2 ) 8 3 ( 1 5 ) 0 .3 7
G l u c o s e ,  m m o l /L 4 . 4  ( 0 .8 ) 4 . 3  ( 0 .6 ) 4 . 4  (0 .7 ) 0 .7 9
h s C R P , m e d i a n  (IQ R ), m g /L 1 .1  ( 0 . 2 —2 .0 ) 1 .2  ( 0 . 4 - 6 . 7 ) 0 . 4  ( 0 . 4 - 2 . 0 ) 0 .1 4
C lin ic a l  p a r a m e t e r s  r e l a t e d  to  HIV a n d  A R T
C D C  s t a g e  C , % 4 8 2 0 0 < 0 . 0 0 0 1
C D 4 % , m e d i a n  (IQ R) 2 6  ( 2 1 - 3 4 ) 2 6 ( 1 4 - 2 9 ) 2 2 ( 1 9 - 2 4 ) 0 .1 8
h iv  R N A , l o g !0 c o p i e s / m L 2 . 3 0  ( 0 . 9 8 ) 2 . 6 8  ( 1 . 1 1 ) 4 . 0 8  ( 0 .7 0 ) < 0 . 0 0 0 1
E x p o s u r e  t o  A R T , m e d i a n  (IQ R ), y 5 . 3  ( 4 . 7 —6 .8 ) 3 . 8  ( 2 . 3 - 6 . 0 )
E x p o s u r e  t o  P i s ,  m e d i a n  (IQ R ), y 4 . 2  ( 2 . 7 - 5 . 1 )
L ip id /b lo o d  r e s u l t s
T o ta l  c h o l e s t e r o l ,  m m o l /L 4 . 6  ( 0 .9 ) 4 . 0  ( 0 .8 ) 3 . 6  ( 0 .8 ) 0 . 0 0 2
H D L  c h o l e s t e r o l ,  m m o l /L 1 .4  ( 0 .5 ) 1 .3  ( 0 .5 ) 1 .0  ( 0 .3 ) 0 . 0 0 0 7
N o n -H D L  c h o l e s t e r o l ,  m m o l /L 3 . 2  ( 1 .0 ) 2 . 7  ( 0 .7 ) 2 .7  ( 0 .7 ) 0 .0 2
A p o B , m g /d L 8 0  ( 2 0 ) 7 3  ( 1 5 ) 7 2 ( 1 5 ) 0 .1 3
M e a n  p a r t i c l e  d i a m e t e r ,  n m 2 8 . 0 ( 1 . 1 ) 2 8 . 3  ( 0 .7 ) 2 8 . 3 ( 1 . 2 ) 0 .5 2
P e a k  p a r t i c l e  d i a m e t e r ,  n m 2 7 . 7  ( 1 .2 ) 2 7 . 0  ( 1 .3 ) 2 7 . 8  ( 1 .3 ) 0 .7 4
L p (a ) , m e d i a n  (IQ R ), m g /d L 5 0 ( 3 8 - 8 6 ) 3 3  ( 1 7 - 4 5 ) 3 4  ( 2 1 - 6 3 ) 0 .0 1
T n g l y c e n d e s .  m e d i a n  (IQ R ), m m o l /L 1 .1  ( 0 . 8 - 1 . 4 ) 0 . 9  ( 0 . 8 - 1 . 2 ) 0 . 9  ( 0 . 6 - 1 . 4 ) 0 .3 1
V a s c u l a r  m e a s u r e m e n t s
IM T , m m 0 . 6 2  ( 0 . 0 7 ) 0 . 5 8  ( 0 .0 6 ) 0 . 5 8  ( 0 .0 6 ) 0 .0 3
F M D . t  % 6 3 ( 5 . 4 ) 8 .1  ( 5 .9 ) 9 . 9  ( 5 .7 ) 0 . 0 0 0 5
G T N - m e d i a t e d  d i l a t i o n , J  % 1 4 . 5 ( 8 . 4 ) 1 4 .0  ( 9 .5 ) 1 7 . 2 ( 8 . 9 ) 0 .0 8
IQ R i n d i c a t e s  i n t e r q u a r t i l e  r a n g e .  E ig h t  o f  t h e  P l - t r e a t e d  c h i l d r e n  w e r e  o n  c o m b i n a t i o n  t h e r a p y  t h a t  d id  n o t  i n c l u d e  a  PI a t  t h e  t i m e  
o f  t h e  s t u d y  v i s i t .  E ig h t  c h i l d r e n  in  t h e  n o n - P I  g r o u p  w e r e  o f f  a l l  t r e a t m e n t  a t  t h e  t i m e  o f  t h e  s t u d y  v i s i t .  C D 4 %  a n d  HIV R N A : c l o s e s t  
m e a s u r e m e n t  w i th in  3  m o n t h s  b e f o r e  t h e  t i m e  o f  t h e  s t u d y  v i s i t  (n  =  7 8  f o r  C D 4 % , n = 7 7  f o r  HIV R N A ). T h e r e  a r e  4  C D C  s t a g e s  t h a t  
r e f l e c t  t h e  e x t e n t  o f  HIV d i s e a s e  p r o g r e s s i o n :  N s i g n i f i e s  n o  s i g n s  o r  s y m p t o m s ;  A , B , a n d  C , i n c r e a s i n g l y  s e v e r e  d i s e a s e ;  a n d  C , A ID S ). 
V a lu e s  a r e  g i v e n  a s  m e a n  (S D ) u n l e s s  o t h e r w i s e  s t a t e d .
• G lo b a l  p r o b a b i l i t y  v a l u e s  a r e  b a s e d  o n  A N O V A  o r  t h e  K r u s k a l - W a l l i s  t e s t  w h e n  a p p r o p r i a t e .
t A d j u s t e d  f o r  b a s e l i n e  d i a m e t e r ;  e s t i m a t e s  g iv e n  f o r  m e a n  b a s e l i n e  d i a m e t e r  o f  2 . 8 0  m m .
^ A d ju s te d  fo r  b a s e l i n e  d i a m e t e r  a n d  w e ig h t ;  e s t i m a t e s  g iv e n  fo r  m e a n  b a s e l i n e  d i a m e t e r  o f 2 .8 0  m m  a n d  m e a n  w e ig h t  o f  3 6 .9  k g .
with greater IMT. H ow ever, in m ultivariate analyses, the 
higher IMT in children with exposure to P is could  not be 
accounted for by C D C  stage or other potential confounders. 
Notably, there w as no association  betw een  IM T and duration  
of PI therapy.
FMD Assessment
FMD m easurem ents w ere availab le for 82 o f  the 83 HIV- 
infected children and 57 o f  the 59 control children. R esting  
vessel s i /e ,  b lood How. and reactive hyperem ia were sim ilar  
in both groups. FM D  w as low er in the H IV -in fected  children  
than in the control subjects after adjustment for baseline diam ­
eter (P =0.02; Table 1 and Figure 2A). The relationship re­
mained after adjustment for age, sex, and other potential con­
founders. There was no evidence o f  an association between age, 
sex, ethnicity, lipids, and hsCRP in the w hole cohort.
A m ong the H IV -infected children, there were no d iffer­
en ces in baseline vesse l diam eter, baseline flow , or reactive 
hyperem ia in the different treatment groups. FM D was 
sign ifican tly  low er in those exposed  to P is com pared with 
non-PI-treated (F ^ O .0 5 ) and untreated (P C 0 .0 0 1 ) children. 
Sim ilar results were obtained when the analysis was per­
form ed by current therapy (Figure 2B ). The response to GTN  
w as not associated  w ith exposure to AR T (Table 2). A s for 
IM T, C D C  stage C was associated with low er FM D. FM D  
w as also inversely related to hsCRP, and this relationship  
rem ained after the 8 H IV -infected children w hose hsCRP was 
> 1 0  m g/L  were excluded . H ow ever, the relationship betw een  
F M D  and A R T  exposure rem ained after adjustment for CD C  
stage, hsC R P, and other potential confounders in m ultivariate 
analysis.
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Figure 1. IMT in HIV-infected children and control subjects. A, 
IMT and age. IMT was increased on average by 0.005 mm/y 
(95% Cl, 0.0003 to 0.01; P = 0.04) (solid line) in HIV-infected chil­
dren, whereas no association with age was found in control 
subjects (dotted line). B, IMT according to exposure to treat­
ment. IMT was significantly higher in children who had received 
Pis. *P = 0.04, ■*P = 0.01.
Discussion
This s tudy  d e m o n s t r a t e s  tha t  s t ru c tu ra l  and  func tional  
changes o f  the v ascu la tu re  are a lready  p resen t  dur ing  c h i ld ­
hood in H IV -in fec ted  ch ild ren .  T h ese  c h an g es  w ere  most 
p ronounced  in ch ild ren  rece iv ing  P is  but w ere  also obse rved  
in n o n -P I - t r e a te d  and  un trea ted  ch ild ren .  O u r  f ind ings su p ­
port a role for bo th  H IV  in fec tion  i tse lf  and A R T ,  particularly  
Pis, in the p a th o g e n es is  o f  ear ly  vascu la r  d isease ,  likely to be 
relevant to future c lin ica l  a the rosc le ros is .
Several  s tudies  have  ra ised  c o n ce rn s  abou t  the effect o f  
HIV and A R T  on bo th  p rog ress ion  o f  a therosc leros is  and 
c a rd iovascu la r  ev en ts  in adu lts .4 16 P is  in particular  are 
associated  with m etab o lic  a b n o rm a li t ie s  and l ipodystrophic  
pheno type  in adults ,  w h ich  m ay add to the backg ro u n d  risk 
factor p ro f i le . '  H o w ev e r ,  the re la tive  impact  o f  d isease,  
t reatment,  and  u n d e r ly in g  risk factor profile  rem ains  unclear.  
T hese factors are par t icu la r ly  hard to d isen tangle  in adults 
because the t im ing  o f  H IV  infection  is of ten  u n k n o w n  and 
there m ay  be an in te rac t ion  b e tw een  the p resence  o f  c lassic 
risk factors for a the rosc le ro t ic  d isease  and ART.
The long- te rm  c o n se q u e n c e s  o f  HIV  infection are p a r t icu ­
larly im por tan t  for y o u n g  individuals .  W ith  n e w er  antiretro- 
\ ira l  r e e im e n s ,  H IV  has now  b eco m e  a chron ic  illness in
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Figure 2. Endothelial function in HIV-infected children and con­
trol subjects. A, FMD was significantly reduced in HIV-infected 
children. *P=0.02. B, FMD according to ART received at time of 
study visit. FMD was reduced in children receiving Pis.
*P=0.006, **P<0.0001.
d ev e lo p ed  countries .  T hus ,  H IV -infec ted  children  have  the 
potential  to surv ive  even  to the third or fourth decade  o f  life. 
B ecause  ca rd iovascu la r  disease  is em erg ing  as an im portan t  
health  concern  at these  ages, it is crit ically im portan t  to 
de te rm in e  the ear ly  impact  o f  bo th  the HIV infection and  its 
t rea tm en t  on the arterial wall in these children.
In o u r  s tudy, we m easured  carot id  IM T  to assess structural 
d isease  o f  the arterial wall.  IM T  represents  the cum ula t ive  
b u rden  o f  adverse  in f luences  opera t ing  from the earliest  
s tages o f  d isease.  Increased IM T , show n  to reflect c o n v e n ­
t ional risk factor burden  in ch ild ren  as young  as 10 years  o f  
age,  is an independen t  p red ic to r  o f  adverse  card iovascu la r  
o u t c o m e .17 W e  also assessed  endothe lia l  function, wh ich  is 
k n o w n  to be a key event  in the init iation and progress ion  o f  
precl in ical  a th e ro sc le ro s is .18 In particular,  reduction in local 
nitric ox ide  bioavailabil i ty ,  reflected by the m agn i tude  of 
F M D  response ,  is assoc ia ted  with a p ro inf lam m atory ,  p ro l if ­
e rat ive ,  and p rocoagu lan t  pheno type  that establishes a locally 
a the rogen ic  en v ironm en t .  F M D  is a dynam ic  m easure  of 
arterial function  that can be used to assess the impact o f  both 
r isk facto rs  and  in te rv en t io n s .19 20 Using  these  2 well- 
va lida ted  m easu rem en ts  o f  arterial structure  and function , we 
have  desc r ibed  the im pact  o f  disease  and treatment,  m in im iz ­
ing the e ffec ts  o f  e xposu re  to con fo u n d in g  risk factors usually  
p resen t  in adults.
On ly  1 o ther  study has ex am in ed  the vascu la r  c h an g es  o f  
long- te rm  e xposu re  to H IV  in children. F M D  was impaired ,
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as in ou r  study, bu t  IM T  w as not inc reased .21 T he  m ore  
ex tensive  vascu la r  ch an g e s  in o u r  popula t ion  m ay  be due  to 
o lder  age and  w o rse  d isease .  IM T  was re la ted  to both  age (a 
surrogate  for d u ra t io n  o f  H IV ) and  C D C  stage. T h e  obse rved  
d if fe rences  b e tw ee n  H IV -in fec ted  ch ild ren  and  control su b ­
jec ts  rem a in ed  a f te r  d i f fe rences  in the base line  characteris tics  
be tw een  the g ro u p s  were  acco u n ted  for, suggest ing  that these 
chan g es  m ay  be re la ted  to HIV  disease.  O u r  s tudy also raised 
the poss ib i l i ty  that v a scu la r  function  m ay  be re la ted  to A R T . 
Both IM T  and F M D  w ere  im paired  in ch ild ren  rece iv ing 
A R T ; this was m o s t  p ro n o u n c ed  in the P i-trea ted  children. 
H ow ev e r ,  these  f ind ings  m us t  be v iew ed  with som e caution. 
A l though  Pis w o u ld  not have  been  included o r  exc luded  on 
the basis o f  d isease  severi ty ,  there  have  been changes  in the 
A R T  reg im en s  since  tr iple  therapy  b eca m e  available  for 
ch ild ren  in 1997. Pe rh ap s  m os t  im portan t  is that trip le therapy 
at that t im e w o u ld  likely have  included  a PI. In recent  years, 
how ever ,  there  has b een  a t rend tow ard  the use o f  a n o n ­
nuc leoside  reverse - t ranscr ip ta se  inh ib ito r  as f irst-line therapy. 
W e h a \ e  a t tem p ted  to con tro l  for  var iab les  such as age that 
may have in f luenced  o u r  analyses ,  but  m ore  studies  are 
requ ired  to c larify  the role  o f  A R T  on vascu la r  dysfunction .
It is a lso unc lea r  w h e th e r  the obse rv ed  vascu la r  changes  
that ap p ea r  to be a s so c ia ted  with  A R T  are  d r iven  by changes  
in the m etabolic  prof i le  o f  these  children .  Insulin  resistance 
and m etabo lic  sy n d ro m e  have  been  independen t ly  associated  
with vascu la r  d isease  and  acce le ra ted  ca rd io v ascu la r  d isease  
in H IV -in fec ted  adults .  Insulin  res is tance  and the full m e ta ­
bolic  sy n d ro m e  are p reva len t  in o v e rw eig h t  you th ,  and it has 
been suggested  that they are increas ing ly  p revalen t  in high- 
risk H IV -in fec ted  y o u n g  people ,  e specia l ly  b lacks .22 In the 
present  s tudy,  we did  not find m ajo r  d i f fe rences  in B M I z 
scores be tw een  cases  and  con tro ls  and be tw een  H IV -infected  
ch ild ren  rece iv ing  d if fe ren t  antire trov ira l  reg im ens .  Further 
studies are requ ired  to ascer ta in  the vascu la r  e ffects  o f  A R T  
m c h i ld h o o d  and  to p rov ide  insight into the m echan ism s  
con tr ibu t ing  to v ascu la r  d isease.
HIV m ay  p ro m o te  a the rosc le ros is  by act ivat ing  the v asc u ­
lar e n d o th e l iu m  d irec tly  or  indirectly  by sys tem ic  cytokine  
s t im ula tion  by the v iru s .2' In add it ion ,  opportun is tic  agents 
such as c y to m e g a lo v iru s  o r  he rpesv irus ,  often  present  in HIV 
may con tr ibu te  to endothe l ia l  d a m a g e .24 25 In this study, 
H IV -in fec ted  c h ild ren  had  e leva ted  total cho lestero l  and 
choles tero l  subfract ions .  In particular ,  it is in teres ting  to note 
that L p ta )  levels, w h ich  are h igh ly  genetica lly  de term ined ,  
also were  e leva ted  in H IV -in fec ted  ch ild ren  c o m p ared  with 
control subjects.  Th is  finding, h ow ever ,  must be interpreted 
with caution .  T h e  averag e  Lp(a) level is h igher  in black than 
in white  ch ild ren ,  so e thn ic  d ifferences  m ay  contr ibute  to the
I.p ta)  variabili ty .  Fu r the rm ore ,  within the HIV cohort,  the 
most p ro n o u n c ed  c h an g e s  in Lp(a)  w ere  noted in children  
rece iv ing PI therapy .  It is poss ib le  that increased synthesis  or 
c learance  o f  the partic le  re la ted  to H IV  infection and  PI 
therapy can acco u n t  for o u r  o bse rved  d ifferences.  The  d is tu r ­
bances  o f  lipids [ increased  total cho lestero l  and Lp(a) and a 
sm alle r  L D L  particle  size] in o u r  ch ild ren  receiv ing P is  are 
sim ilar  to those  reported  in adu lts  but d id  not account  for the 
obse rv ed  vascu la r  ab n o rm a l i t ie s .26 N everthe less ,  the impact 
o f  lipid a b n o rm a li t ie s  on vascu la r  d isease  progression  in HIV
certain ly  w arran ts  further p rospec t ive  exp lora tion .  O th e r  
m ec h an ism s  m ay  also  contr ibute  to the adverse  e ffec t  o f  H IV  
and  A R T  on  vascu la r  d isease,  including enhanced  express ion  
o f  m a c r o p h a g e  s c a v e n g e r  rece p to rs  a n d  m i to c h o n d r ia l  
tox ic i ty .23-27
H IV  infection and  A R T  are associated  w ith  an a the rogen ic  
structural and  functional arteria l phenotype  from ear ly  c h i ld ­
hood .  Because  death  rates a m o n g  H IV -in fec ted  children  have  
decreased  5-fo ld  since  the in troduction  o f  the h ighly  act ive  
antiretroviral  trea tm ent,  careful  long-term  m onito r ing  appears  
w arran ted  to detect em erg in g  card iovascu la r  disease. L o n g i ­
tudina l  studies  are needed  to unders tand  the cause  o f  vascu lar  
d isease  and  to ascertain the con tr ibu tion  o f  d ifferent A R T  
reg im ens .  P ha rm aco log ica l  o r  physio log ica l  in te rven tions 
m ay  be required  to prevent  future vascular  events  in H IV - 
infec ted  children.
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